



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>C07H 21/04, C07K 14/435, C12N 1/20,</b> <b>C12P 21/02, A61K 38/00</b>	<b>A1</b>	<b>(11) International Publication Number:      WO 99/55721</b>  <b>(43) International Publication Date:      4 November 1999 (04.11.99)</b>		
<table style="width: 100%; border: none;"> <tr> <td style="width: 50%; vertical-align: top; padding: 5px;"> <b>(21) International Application Number:</b>      PCT/US99/08504   <b>(22) International Filing Date:</b>      23 April 1999 (23.04.99)   <b>(30) Priority Data:</b>  <div style="display: flex; justify-content: space-between; margin-top: 5px;"> <div style="width: 60%;"> 60/082,904      24 April 1998 (24.04.98)  60/088,994      11 June 1998 (11.06.98)  60/089,278      12 June 1998 (12.06.98)  60/091,647      2 July 1998 (02.07.98)  60/097,639      24 August 1998 (24.08.98)  Not furnished      22 April 1999 (22.04.99) </div> <div style="width: 35%; text-align: center;"> US US US US US US </div> </div>   <b>(71) Applicant:</b> ALPHAGENE, INC. [US/US]; 260 West Cummings Park, Woburn, MA 01801 (US).   <b>(72) Inventors:</b> VALENZUELA, Dario; 260 West Cummings Park, Woburn, MA 01801 (US). YUAN, Olive; 260 West Cummings Park, Woburn, MA 01801 (US). HOFFMAN, Heidi; 260 West Cummings Park, Woburn, MA 01801 (US). HALL, Jeff; 260 West Cummings Park, Woburn, MA 01801 (US). RAPIEJKO, Peter; 260 West Cummings Park, Woburn, MA 01801 (US).   <b>(74) Agent:</b> SPRUNGER, Suzanne, A.; American Home Products Corporation, Patent &amp; Trademark Dept.-2B (Kay E. Brady), One Campus Drive, Parsippany, NJ 07054 (US). </td> <td style="width: 50%; vertical-align: top; padding: 5px;"> <b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).   <b>Published</b>  <i>With international search report.</i>  <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i> </td> </tr> </table>			<b>(21) International Application Number:</b> PCT/US99/08504  <b>(22) International Filing Date:</b> 23 April 1999 (23.04.99)  <b>(30) Priority Data:</b> <div style="display: flex; justify-content: space-between; margin-top: 5px;"> <div style="width: 60%;"> 60/082,904      24 April 1998 (24.04.98)  60/088,994      11 June 1998 (11.06.98)  60/089,278      12 June 1998 (12.06.98)  60/091,647      2 July 1998 (02.07.98)  60/097,639      24 August 1998 (24.08.98)  Not furnished      22 April 1999 (22.04.99) </div> <div style="width: 35%; text-align: center;"> US US US US US US </div> </div> <b>(71) Applicant:</b> ALPHAGENE, INC. [US/US]; 260 West Cummings Park, Woburn, MA 01801 (US).  <b>(72) Inventors:</b> VALENZUELA, Dario; 260 West Cummings Park, Woburn, MA 01801 (US). YUAN, Olive; 260 West Cummings Park, Woburn, MA 01801 (US). HOFFMAN, Heidi; 260 West Cummings Park, Woburn, MA 01801 (US). HALL, Jeff; 260 West Cummings Park, Woburn, MA 01801 (US). RAPIEJKO, Peter; 260 West Cummings Park, Woburn, MA 01801 (US).  <b>(74) Agent:</b> SPRUNGER, Suzanne, A.; American Home Products Corporation, Patent & Trademark Dept.-2B (Kay E. Brady), One Campus Drive, Parsippany, NJ 07054 (US).	<b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
<b>(21) International Application Number:</b> PCT/US99/08504  <b>(22) International Filing Date:</b> 23 April 1999 (23.04.99)  <b>(30) Priority Data:</b> <div style="display: flex; justify-content: space-between; margin-top: 5px;"> <div style="width: 60%;"> 60/082,904      24 April 1998 (24.04.98)  60/088,994      11 June 1998 (11.06.98)  60/089,278      12 June 1998 (12.06.98)  60/091,647      2 July 1998 (02.07.98)  60/097,639      24 August 1998 (24.08.98)  Not furnished      22 April 1999 (22.04.99) </div> <div style="width: 35%; text-align: center;"> US US US US US US </div> </div> <b>(71) Applicant:</b> ALPHAGENE, INC. [US/US]; 260 West Cummings Park, Woburn, MA 01801 (US).  <b>(72) Inventors:</b> VALENZUELA, Dario; 260 West Cummings Park, Woburn, MA 01801 (US). YUAN, Olive; 260 West Cummings Park, Woburn, MA 01801 (US). HOFFMAN, Heidi; 260 West Cummings Park, Woburn, MA 01801 (US). HALL, Jeff; 260 West Cummings Park, Woburn, MA 01801 (US). RAPIEJKO, Peter; 260 West Cummings Park, Woburn, MA 01801 (US).  <b>(74) Agent:</b> SPRUNGER, Suzanne, A.; American Home Products Corporation, Patent & Trademark Dept.-2B (Kay E. Brady), One Campus Drive, Parsippany, NJ 07054 (US).	<b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>			
<b>(54) Title:</b> SECRETED PROTEINS AND POLYNUCLEOTIDES ENCODING THEM				
<b>(57) Abstract</b>  Novel polynucleotides and the proteins encoded thereby are disclosed.				

***FOR THE PURPOSES OF INFORMATION ONLY***

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

## 5           SECRETED PROTEINS AND POLYNUCLEOTIDES ENCODING THEM

10

15

FIELD OF THE INVENTION

The present invention provides novel polynucleotides and proteins encoded by such polynucleotides, along with therapeutic, diagnostic and research utilities for these polynucleotides and proteins.

20

BACKGROUND OF THE INVENTION

Technology aimed at the discovery of protein factors (including e.g., cytokines, such as lymphokines, interferons, CSFs and interleukins) has matured rapidly over the past decade. The now routine hybridization cloning and expression cloning techniques  
25 clone novel polynucleotides "directly" in the sense that they rely on information directly related to the discovered protein (i.e., partial DNA/amino acid sequence of the protein in the case of hybridization cloning; activity of the protein in the case of expression cloning). More recent "indirect" cloning techniques such as signal sequence cloning, which isolates DNA sequences based on the presence of a now well-recognized secretory leader  
30 sequence motif, as well as various PCR-based or low stringency hybridization cloning techniques, have advanced the state of the art by making available large numbers of DNA/amino acid sequences for proteins that are known to have biological activity by virtue of their secreted nature in the case of leader sequence cloning, or by virtue of the cell or tissue source in the case of PCR-based techniques. It is to these proteins and the  
35 polynucleotides encoding them that the present invention is directed.

SUMMARY OF THE INVENTION

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- 5 (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:1;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:1 from nucleotide 126 to nucleotide 485;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:1 from nucleotide 207 to nucleotide 485;
- 10 (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone vb2\_1 deposited under accession number ATCC 98804;
- (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vb2\_1 deposited under accession number ATCC 98804;
- 15 (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vb2\_1 deposited under accession number ATCC 98804;
- (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone vb2\_1 deposited under accession number ATCC 98804;
- 20 (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:2;
- (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:2 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:2;
- 25 (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
- (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ;
- (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and
- 30 (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:1.



Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:1 from nucleotide 126 to nucleotide 485; the nucleotide sequence of SEQ ID NO:1 from nucleotide 207 to nucleotide 485; the nucleotide sequence of the full-length protein coding sequence of clone vb2\_1 deposited under accession number ATCC 98804; or the  
5 nucleotide sequence of a mature protein coding sequence of clone vb2\_1 deposited under accession number ATCC 98804. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vb2\_1 deposited under accession number ATCC 98804. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment  
10 of the amino acid sequence of SEQ ID NO:2 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:2, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:2 having biological activity, the fragment comprising the amino acid sequence from amino acid 55 to amino acid 64 of SEQ  
15 ID NO:2.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:1.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

- 20 (a) a process comprising the steps of:
- (i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
    - (aa) SEQ ID NO:1, but excluding the poly(A) tail at the  
25 3' end of SEQ ID NO:1; and
    - (ab) the nucleotide sequence of the cDNA insert of clone vb2\_1 deposited under accession number ATCC 98804;
  - (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and
  - 30 (iii) isolating the DNA polynucleotides detected with the probe(s);

and

- (b) a process comprising the steps of:

(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

- 5 (ba) SEQ ID NO:1, but excluding the poly(A) tail at the 3' end of SEQ ID NO:1; and
- (bb) the nucleotide sequence of the cDNA insert of clone vb2\_1 deposited under accession number ATCC 98804;
- (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;
- 10 (iii) amplifying human DNA sequences; and
- (iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:1, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:1 to

15 a nucleotide sequence corresponding to the 3' end of SEQ ID NO:1, but excluding the poly(A) tail at the 3' end of SEQ ID NO:1. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:1 from nucleotide 126 to nucleotide 485, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of

20 SEQ ID NO:1 from nucleotide 126 to nucleotide 485, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:1 from nucleotide 126 to nucleotide 485. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:1 from nucleotide 207 to nucleotide 485, and extending contiguously from a

25 nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:1 from nucleotide 207 to nucleotide 485, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:1 from nucleotide 207 to nucleotide 485.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group

30 consisting of:

- (a) the amino acid sequence of SEQ ID NO:2;
- (b) a fragment of the amino acid sequence of SEQ ID NO:2, the fragment comprising eight contiguous amino acids of SEQ ID NO:2; and

(c) the amino acid sequence encoded by the cDNA insert of clone vb2\_1 deposited under accession number ATCC 98804;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:2. In further preferred  
5 embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:2 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:2, or a protein comprising a fragment of the amino acid sequence of SEQ  
ID NO:2 having biological activity, the fragment comprising the amino acid sequence from  
10 amino acid 55 to amino acid 64 of SEQ ID NO:2.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:3;
- 15 (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:3 from nucleotide 130 to nucleotide 2286;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:3 from nucleotide 214 to nucleotide 2286;
- (d) a polynucleotide comprising the nucleotide sequence of the full-  
20 length protein coding sequence of clone vb3\_1 deposited under accession number ATCC 98804;
- (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vb3\_1 deposited under accession number ATCC 98804;
- (f) a polynucleotide comprising the nucleotide sequence of a mature  
25 protein coding sequence of clone vb3\_1 deposited under accession number ATCC 98804;
- (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone vb3\_1 deposited under accession number ATCC 98804;
- (h) a polynucleotide encoding a protein comprising the amino acid  
30 sequence of SEQ ID NO:4;
- (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:4 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:4;

(j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;

(k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ;

5 (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and

(m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:3.

10 Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:3 from nucleotide 130 to nucleotide 2286; the nucleotide sequence of SEQ ID NO:3 from nucleotide 214 to nucleotide 2286; the nucleotide sequence of the full-length protein coding sequence of clone vb3\_1 deposited under accession number ATCC 98804; or the nucleotide sequence of a mature protein coding sequence of clone vb3\_1 deposited under  
15 accession number ATCC 98804. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vb3\_1 deposited under accession number ATCC 98804. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:4 having biological activity, the fragment  
20 preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:4, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:4 having biological activity, the fragment comprising the amino acid sequence from amino acid 354 to amino acid 363 of SEQ ID NO:4.

25 Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:3.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

(a) a process comprising the steps of:

30 (i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(aa) SEQ ID NO:3, but excluding the poly(A) tail at the 3' end of SEQ ID NO:3; and

- (ab) the nucleotide sequence of the cDNA insert of clone vb3\_1 deposited under accession number ATCC 98804;
- (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and
- 5 (iii) isolating the DNA polynucleotides detected with the probe(s);

and

- (b) a process comprising the steps of:
  - (i) preparing one or more polynucleotide primers that
  - 10 hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
    - (ba) SEQ ID NO:3, but excluding the poly(A) tail at the 3' end of SEQ ID NO:3; and
    - (bb) the nucleotide sequence of the cDNA insert of clone
    - 15 vb3\_1 deposited under accession number ATCC 98804;
  - (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;
  - (iii) amplifying human DNA sequences; and
  - (iv) isolating the polynucleotide products of step (b)(iii).

- 20 Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:3, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:3 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:3 , but excluding the poly(A) tail at the 3' end of SEQ ID NO:3. Also preferably the polynucleotide isolated
- 25 according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:3 from nucleotide 130 to nucleotide 2286, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:3 from nucleotide 130 to nucleotide 2286, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:3 from nucleotide 130 to
- 30 nucleotide 2286. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:3 from nucleotide 214 to nucleotide 2286, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:3 from

nucleotide 214 to nucleotide 2286, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:3 from nucleotide 214 to nucleotide 2286.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group

5 consisting of:

(a) the amino acid sequence of SEQ ID NO:4;

(b) a fragment of the amino acid sequence of SEQ ID NO:4, the fragment comprising eight contiguous amino acids of SEQ ID NO:4; and

(c) the amino acid sequence encoded by the cDNA insert of clone  
10 vb3\_1 deposited under accession number ATCC 98804;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:4. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:4 having biological activity, the fragment preferably  
15 comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:4, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:4 having biological activity, the fragment comprising the amino acid sequence from amino acid 354 to amino acid 363 of SEQ ID NO:4.

In one embodiment, the present invention provides a composition comprising an  
20 isolated polynucleotide selected from the group consisting of:

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:5;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:5 from nucleotide 172 to nucleotide 522;

25 (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:5 from nucleotide 214 to nucleotide 522;

(d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone vb4\_1 deposited under accession number ATCC 98804;

30 (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vb4\_1 deposited under accession number ATCC 98804;

(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vb4\_1 deposited under accession number ATCC 98804;

(g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone vb4\_1 deposited under accession number ATCC 98804;

(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:6;

5 (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:6 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:6;

(j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;

10 (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ;

(l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and

15 (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:5.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:5 from nucleotide 172 to nucleotide 522; the nucleotide sequence of SEQ ID NO:5 from nucleotide 214 to nucleotide 522; the nucleotide sequence of the full-length protein coding  
20 sequence of clone vb4\_1 deposited under accession number ATCC 98804; or the nucleotide sequence of a mature protein coding sequence of clone vb4\_1 deposited under accession number ATCC 98804. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vb4\_1 deposited under accession number ATCC 98804. In further preferred embodiments, the  
25 present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:6 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:6, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:6 having biological activity, the  
30 fragment comprising the amino acid sequence from amino acid 53 to amino acid 62 of SEQ ID NO:6.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:5.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

(a) a process comprising the steps of:

(i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(aa) SEQ ID NO:5, but excluding the poly(A) tail at the 3' end of SEQ ID NO:5; and

(ab) the nucleotide sequence of the cDNA insert of clone vb4\_1 deposited under accession number ATCC 98804;

(ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and

(iii) isolating the DNA polynucleotides detected with the probe(s);

and

(b) a process comprising the steps of:

(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(ba) SEQ ID NO:5, but excluding the poly(A) tail at the 3' end of SEQ ID NO:5; and

(bb) the nucleotide sequence of the cDNA insert of clone vb4\_1 deposited under accession number ATCC 98804;

(ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:5, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:5 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:5, but excluding the poly(A) tail at the 3' end of SEQ ID NO:5. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:5 from nucleotide 172 to nucleotide 522, and extending



contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:5 from nucleotide 172 to nucleotide 522, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:5 from nucleotide 172 to nucleotide 522. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:5 from nucleotide 214 to nucleotide 522, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:5 from nucleotide 214 to nucleotide 522, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:5 from nucleotide 214 to nucleotide 522.

10 In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:6;
- (b) a fragment of the amino acid sequence of SEQ ID NO:6, the  
15 fragment comprising eight contiguous amino acids of SEQ ID NO:6; and
- (c) the amino acid sequence encoded by the cDNA insert of clone vb4\_1 deposited under accession number ATCC 98804;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:6. In further preferred  
20 embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:6 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:6, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:6 having biological activity, the fragment comprising the amino acid sequence from  
25 amino acid 53 to amino acid 62 of SEQ ID NO:6.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:7;
- 30 (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:7 from nucleotide 119 to nucleotide 502;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:7 from nucleotide 176 to nucleotide 502;

(d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone vb5\_1 deposited under accession number ATCC 98804;

5 (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vb5\_1 deposited under accession number ATCC 98804;

(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vb5\_1 deposited under accession number ATCC 98804;

10 (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone vb5\_1 deposited under accession number ATCC 98804;

(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:8;

15 (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:8 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:8;

(j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;

(k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ;

20 (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and

(m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:7.

25 Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:7 from nucleotide 119 to nucleotide 502; the nucleotide sequence of SEQ ID NO:7 from nucleotide 176 to nucleotide 502; the nucleotide sequence of the full-length protein coding sequence of clone vb5\_1 deposited under accession number ATCC 98804; or the nucleotide sequence of a mature protein coding sequence of clone vb5\_1 deposited under  
30 accession number ATCC 98804. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vb5\_1 deposited under accession number ATCC 98804. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:8 having biological activity, the fragment

preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:8, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:8 having biological activity, the fragment comprising the amino acid sequence from amino acid 59 to amino acid 68 of SEQ ID NO:8.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:7.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

- 10 (a) a process comprising the steps of:
  - (i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
    - 15 (aa) SEQ ID NO:7, but excluding the poly(A) tail at the 3' end of SEQ ID NO:7; and
    - (ab) the nucleotide sequence of the cDNA insert of clone vb5\_1 deposited under accession number ATCC 98804;
  - (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and
  - 20 (iii) isolating the DNA polynucleotides detected with the probe(s);
- and
- (b) a process comprising the steps of:
  - 25 (i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
    - (ba) SEQ ID NO:7, but excluding the poly(A) tail at the 3' end of SEQ ID NO:7; and
    - (bb) the nucleotide sequence of the cDNA insert of clone vb5\_1 deposited under accession number ATCC 98804;
  - 30 (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;
  - (iii) amplifying human DNA sequences; and
  - (iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:7, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:7 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:7, but excluding the poly(A) tail at the 3' end of SEQ ID NO:7. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:7 from nucleotide 119 to nucleotide 502, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:7 from nucleotide 119 to nucleotide 502, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:7 from nucleotide 119 to nucleotide 502. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:7 from nucleotide 176 to nucleotide 502, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:7 from nucleotide 176 to nucleotide 502, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:7 from nucleotide 176 to nucleotide 502.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:8;
- (b) a fragment of the amino acid sequence of SEQ ID NO:8, the fragment comprising eight contiguous amino acids of SEQ ID NO:8; and
- (c) the amino acid sequence encoded by the cDNA insert of clone vb5\_1 deposited under accession number ATCC 98804;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:8. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:8 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:8, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:8 having biological activity, the fragment comprising the amino acid sequence from amino acid 59 to amino acid 68 of SEQ ID NO:8.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:9;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:9 from nucleotide 128 to nucleotide 436;
- 5 (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:9 from nucleotide 203 to nucleotide 436;
- (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone vb6\_1 deposited under accession number ATCC 98804;
- 10 (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vb6\_1 deposited under accession number ATCC 98804;
- (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vb6\_1 deposited under accession number ATCC 98804;
- 15 (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone vb6\_1 deposited under accession number ATCC 98804;
- (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:10;
- (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:10 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:10;
- 20 (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
- (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ;
- 25 (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and
- (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least
- 30 25% of the length of SEQ ID NO:9.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:9 from nucleotide 128 to nucleotide 436; the nucleotide sequence of SEQ ID NO:9 from nucleotide 203 to nucleotide 436; the nucleotide sequence of the full-length protein coding sequence of clone vb6\_1 deposited under accession number ATCC 98804; or the

nucleotide sequence of a mature protein coding sequence of clone vb6\_1 deposited under accession number ATCC 98804. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vb6\_1 deposited under accession number ATCC 98804. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:10 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:10, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:10 having biological activity, the fragment comprising the amino acid sequence from amino acid 46 to amino acid 55 of SEQ ID NO:10.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:9.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

- (a) a process comprising the steps of:
  - (i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
    - (aa) SEQ ID NO:9, but excluding the poly(A) tail at the 3' end of SEQ ID NO:9; and
    - (ab) the nucleotide sequence of the cDNA insert of clone vb6\_1 deposited under accession number ATCC 98804;
  - (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and
  - (iii) isolating the DNA polynucleotides detected with the probe(s);

and

- (b) a process comprising the steps of:
  - (i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
    - (ba) SEQ ID NO:9, but excluding the poly(A) tail at the 3' end of SEQ ID NO:9; and

- (bb) the nucleotide sequence of the cDNA insert of clone vb6\_1 deposited under accession number ATCC 98804;
- (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;
- 5 (iii) amplifying human DNA sequences; and
- (iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:9, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:9 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:9, but excluding the poly(A) tail at the 3' end of SEQ ID NO:9. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:9 from nucleotide 128 to nucleotide 436, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:9 from nucleotide 128 to nucleotide 436, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:9 from nucleotide 128 to nucleotide 436. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:9 from nucleotide 203 to nucleotide 436, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:9 from nucleotide 203 to nucleotide 436, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:9 from nucleotide 203 to nucleotide 436.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:10;
- (b) a fragment of the amino acid sequence of SEQ ID NO:10, the fragment comprising eight contiguous amino acids of SEQ ID NO:10; and
- (c) the amino acid sequence encoded by the cDNA insert of clone vb6\_1 deposited under accession number ATCC 98804;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:10. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:10 having biological activity, the fragment preferably

comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:10, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:10 having biological activity, the fragment comprising the amino acid sequence from amino acid 46 to amino acid 55 of SEQ ID NO:10.

5           In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a)     a polynucleotide comprising the nucleotide sequence of SEQ ID NO:11;
- (b)     a polynucleotide comprising the nucleotide sequence of SEQ ID  
10     NO:11 from nucleotide 138 to nucleotide 1250;
- (c)     a polynucleotide comprising the nucleotide sequence of SEQ ID NO:11 from nucleotide 279 to nucleotide 1250;
- (d)     a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone vb7\_1 deposited under accession number  
15     ATCC 98804;
- (e)     a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vb7\_1 deposited under accession number ATCC 98804;
- (f)     a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vb7\_1 deposited under accession number ATCC  
20     98804;
- (g)     a polynucleotide encoding a mature protein encoded by the cDNA insert of clone vb7\_1 deposited under accession number ATCC 98804;
- (h)     a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:12;
- (i)     a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:12 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:12;
- (j)     a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
- (k)     a polynucleotide which encodes a species homologue of the protein  
30     of (h) or (i) above ;
- (l)     a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and



(m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:11.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:11 from nucleotide 138 to nucleotide 1250; the nucleotide sequence of SEQ ID NO:11 from nucleotide 279 to nucleotide 1250; the nucleotide sequence of the full-length protein coding sequence of clone vb7\_1 deposited under accession number ATCC 98804; or the nucleotide sequence of a mature protein coding sequence of clone vb7\_1 deposited under accession number ATCC 98804. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vb7\_1 deposited under accession number ATCC 98804. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:12 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:12, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:12 having biological activity, the fragment comprising the amino acid sequence from amino acid 180 to amino acid 189 of SEQ ID NO:12.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:11.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

- (a) a process comprising the steps of:
  - (i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
    - (aa) SEQ ID NO:11, but excluding the poly(A) tail at the 3' end of SEQ ID NO:11; and
    - (ab) the nucleotide sequence of the cDNA insert of clone vb7\_1 deposited under accession number ATCC 98804;
  - (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and
  - (iii) isolating the DNA polynucleotides detected with the probe(s);

and

(b) a process comprising the steps of:

(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(ba) SEQ ID NO:11, but excluding the poly(A) tail at the 3' end of SEQ ID NO:11; and

(bb) the nucleotide sequence of the cDNA insert of clone vb7\_1 deposited under accession number ATCC 98804;

(ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:11, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:11 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:11, but excluding the poly(A) tail at the 3' end of SEQ ID NO:11. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:11 from nucleotide 138 to nucleotide 1250, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:11 from nucleotide 138 to nucleotide 1250, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:11 from nucleotide 138 to nucleotide 1250. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:11 from nucleotide 279 to nucleotide 1250, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:11 from nucleotide 279 to nucleotide 1250, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:11 from nucleotide 279 to nucleotide 1250.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO:12;

(b) a fragment of the amino acid sequence of SEQ ID NO:12, the fragment comprising eight contiguous amino acids of SEQ ID NO:12; and

(c) the amino acid sequence encoded by the cDNA insert of clone vb7\_1 deposited under accession number ATCC 98804;

5 the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:12. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:12 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids  
10 of SEQ ID NO:12, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:12 having biological activity, the fragment comprising the amino acid sequence from amino acid 180 to amino acid 189 of SEQ ID NO:12.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

15 (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:13;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:13 from nucleotide 615 to nucleotide 869;

(c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone vb8\_1 deposited under accession number  
20 ATCC 98804;

(d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vb8\_1 deposited under accession number ATCC 98804;

(e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vb8\_1 deposited under accession number ATCC  
25 98804;

(f) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone vb8\_1 deposited under accession number ATCC 98804;

(g) a polynucleotide encoding a protein comprising the amino acid  
30 sequence of SEQ ID NO:14;

(h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:14 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:14;

(i) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above;

(j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above ;

5 (k) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h); and

(l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:13.

10 Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:13 from nucleotide 615 to nucleotide 869; the nucleotide sequence of the full-length protein coding sequence of clone vb8\_1 deposited under accession number ATCC 98804; or the nucleotide sequence of a mature protein coding sequence of clone vb8\_1 deposited under accession number ATCC 98804. In other preferred embodiments, the  
15 polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vb8\_1 deposited under accession number ATCC 98804. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:14 having biological activity, the fragment preferably comprising eight (more preferably twenty, most  
20 preferably thirty) contiguous amino acids of SEQ ID NO:14, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:14 having biological activity, the fragment comprising the amino acid sequence from amino acid 37 to amino acid 46 of SEQ ID NO:14.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ  
25 ID NO:13.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

(a) a process comprising the steps of:

30 (i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(aa) SEQ ID NO:13, but excluding the poly(A) tail at the 3' end of SEQ ID NO:13; and

- (ab) the nucleotide sequence of the cDNA insert of clone vb8\_1 deposited under accession number ATCC 98804;
- (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and
- 5 (iii) isolating the DNA polynucleotides detected with the probe(s);

and

- (b) a process comprising the steps of:
  - (i) preparing one or more polynucleotide primers that
  - 10 hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
    - (ba) SEQ ID NO:13, but excluding the poly(A) tail at the 3' end of SEQ ID NO:13; and
    - (bb) the nucleotide sequence of the cDNA insert of clone
    - 15 vb8\_1 deposited under accession number ATCC 98804;
  - (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;
  - (iii) amplifying human DNA sequences; and
  - (iv) isolating the polynucleotide products of step (b)(iii).

- 20 Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:13, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:13 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:13, but excluding the poly(A) tail at the 3' end of SEQ ID NO:13. Also preferably the
- 25 polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:13 from nucleotide 615 to nucleotide 869, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:13 from nucleotide 615 to nucleotide 869, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:13 from nucleotide
- 30 615 to nucleotide 869.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:14;

(b) a fragment of the amino acid sequence of SEQ ID NO:14, the fragment comprising eight contiguous amino acids of SEQ ID NO:14; and

(c) the amino acid sequence encoded by the cDNA insert of clone vb8\_1 deposited under accession number ATCC 98804;

5 the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:14. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:14 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids  
10 of SEQ ID NO:14, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:14 having biological activity, the fragment comprising the amino acid sequence from amino acid 37 to amino acid 46 of SEQ ID NO:14.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

15 (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:15;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:15 from nucleotide 148 to nucleotide 1470;

20 (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:15 from nucleotide 193 to nucleotide 1470;

(d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone vb9\_1 deposited under accession number ATCC 98804;

25 (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vb9\_1 deposited under accession number ATCC 98804;

(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vb9\_1 deposited under accession number ATCC 98804;

30 (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone vb9\_1 deposited under accession number ATCC 98804;

(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:16;

(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:16 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:16;

(j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;

(k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ;

(l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and

(m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:15.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:15 from nucleotide 148 to nucleotide 1470; the nucleotide sequence of SEQ ID NO:15 from nucleotide 193 to nucleotide 1470; the nucleotide sequence of the full-length protein coding sequence of clone vb9\_1 deposited under accession number ATCC 98804; or the nucleotide sequence of a mature protein coding sequence of clone vb9\_1 deposited under accession number ATCC 98804. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vb9\_1 deposited under accession number ATCC 98804. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:16 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:16, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:16 having biological activity, the fragment comprising the amino acid sequence from amino acid 215 to amino acid 224 of SEQ ID NO:16.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:15.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

(a) a process comprising the steps of:

(i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(aa) SEQ ID NO:15, but excluding the poly(A) tail at the 3' end of SEQ ID NO:15; and

(ab) the nucleotide sequence of the cDNA insert of clone vb9\_1 deposited under accession number ATCC 98804;

(ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and

(iii) isolating the DNA polynucleotides detected with the probe(s);

and

(b) a process comprising the steps of:

(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(ba) SEQ ID NO:15, but excluding the poly(A) tail at the 3' end of SEQ ID NO:15; and

(bb) the nucleotide sequence of the cDNA insert of clone vb9\_1 deposited under accession number ATCC 98804;

(ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:15, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:15 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:15, but excluding the poly(A) tail at the 3' end of SEQ ID NO:15. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:15 from nucleotide 148 to nucleotide 1470, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:15 from nucleotide 148 to nucleotide 1470, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:15 from nucleotide



148 to nucleotide 1470. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:15 from nucleotide 193 to nucleotide 1470, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:15 from nucleotide 193 to nucleotide 1470, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:15 from nucleotide 193 to nucleotide 1470.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- 10 (a) the amino acid sequence of SEQ ID NO:16;
  - (b) a fragment of the amino acid sequence of SEQ ID NO:16, the fragment comprising eight contiguous amino acids of SEQ ID NO:16; and
  - (c) the amino acid sequence encoded by the cDNA insert of clone vb9\_1 deposited under accession number ATCC 98804;
- 15 the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:16. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:16 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids
- 20 of SEQ ID NO:16, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:16 having biological activity, the fragment comprising the amino acid sequence from amino acid 215 to amino acid 224 of SEQ ID NO:16.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- 25 (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:17;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:17 from nucleotide 109 to nucleotide 414;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID
- 30 NO:17 from nucleotide 217 to nucleotide 414;
- (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone vc3\_1 deposited under accession number ATCC 98748;

(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vc3\_1 deposited under accession number ATCC 98748;

(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vc3\_1 deposited under accession number ATCC 98748;

(g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone vc3\_1 deposited under accession number ATCC 98748;

(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:18;

(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:18 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:18;

(j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;

(k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ;

(l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and

(m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:17.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:17 from nucleotide 109 to nucleotide 414; the nucleotide sequence of SEQ ID NO:17 from nucleotide 217 to nucleotide 414; the nucleotide sequence of the full-length protein coding sequence of clone vc3\_1 deposited under accession number ATCC 98748; or the nucleotide sequence of a mature protein coding sequence of clone vc3\_1 deposited under accession number ATCC 98748. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vc3\_1 deposited under accession number ATCC 98748. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:18 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:18, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:18 having biological activity, the

fragment comprising the amino acid sequence from amino acid 46 to amino acid 55 of SEQ ID NO:18.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:17.

5 Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

(a) a process comprising the steps of:

(i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

10

(aa) SEQ ID NO:17, but excluding the poly(A) tail at the 3' end of SEQ ID NO:17; and

(ab) the nucleotide sequence of the cDNA insert of clone vc3\_1 deposited under accession number ATCC 98748;

15

(ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and

(iii) isolating the DNA polynucleotides detected with the probe(s);

and

20

(b) a process comprising the steps of:

(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

25

(ba) SEQ ID NO:17, but excluding the poly(A) tail at the 3' end of SEQ ID NO:17; and

(bb) the nucleotide sequence of the cDNA insert of clone vc3\_1 deposited under accession number ATCC 98748;

(ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;

30

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:17, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ

ID NO:17 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:17, but excluding the poly(A) tail at the 3' end of SEQ ID NO:17. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:17 from nucleotide 109 to nucleotide 414, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:17 from nucleotide 109 to nucleotide 414, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:17 from nucleotide 109 to nucleotide 414. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:17 from nucleotide 217 to nucleotide 414, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:17 from nucleotide 217 to nucleotide 414, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:17 from nucleotide 217 to nucleotide 414.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:18;
- (b) a fragment of the amino acid sequence of SEQ ID NO:18, the fragment comprising eight contiguous amino acids of SEQ ID NO:18; and
- (c) the amino acid sequence encoded by the cDNA insert of clone vc3\_1 deposited under accession number ATCC 98748;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:18. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:18 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:18, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:18 having biological activity, the fragment comprising the amino acid sequence from amino acid 46 to amino acid 55 of SEQ ID NO:18.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:19;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:19 from nucleotide 169 to nucleotide 840;

(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:19 from nucleotide 211 to nucleotide 840;

5 (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone vc4\_1 deposited under accession number ATCC 98748;

(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vc4\_1 deposited under accession number ATCC 98748;

10 (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vc4\_1 deposited under accession number ATCC 98748;

(g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone vc4\_1 deposited under accession number ATCC 98748;

15 (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:20;

(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:20 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:20;

20 (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;

(k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ;

25 (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and

(m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:19.

30 Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:19 from nucleotide 169 to nucleotide 840; the nucleotide sequence of SEQ ID NO:19 from nucleotide 211 to nucleotide 840; the nucleotide sequence of the full-length protein coding sequence of clone vc4\_1 deposited under accession number ATCC 98748; or the nucleotide sequence of a mature protein coding sequence of clone vc4\_1 deposited under accession number ATCC 98748. In other preferred embodiments, the polynucleotide

encodes the full-length or a mature protein encoded by the cDNA insert of clone vc4\_1 deposited under accession number ATCC 98748. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:20 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:20, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:20 having biological activity, the fragment comprising the amino acid sequence from amino acid 107 to amino acid 116 of SEQ ID NO:20.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:19.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

- (a) a process comprising the steps of:
    - (i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
      - (aa) SEQ ID NO:19, but excluding the poly(A) tail at the 3' end of SEQ ID NO:19; and
      - (ab) the nucleotide sequence of the cDNA insert of clone vc4\_1 deposited under accession number ATCC 98748;
    - (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and
    - (iii) isolating the DNA polynucleotides detected with the probe(s);
- and
- (b) a process comprising the steps of:
    - (i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
      - (ba) SEQ ID NO:19, but excluding the poly(A) tail at the 3' end of SEQ ID NO:19; and
      - (bb) the nucleotide sequence of the cDNA insert of clone vc4\_1 deposited under accession number ATCC 98748;

- (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;
- (iii) amplifying human DNA sequences; and
- (iv) isolating the polynucleotide products of step (b)(iii).

5 Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:19, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:19 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:19, but excluding the poly(A) tail at the 3' end of SEQ ID NO:19. Also preferably the  
10 polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:19 from nucleotide 169 to nucleotide 840, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:19 from nucleotide 169 to nucleotide 840, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:19 from nucleotide  
15 169 to nucleotide 840. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:19 from nucleotide 211 to nucleotide 840, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:19 from nucleotide 211 to nucleotide 840, to a nucleotide sequence corresponding to the 3' end of  
20 said sequence of SEQ ID NO:19 from nucleotide 211 to nucleotide 840.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:20;
- 25 (b) a fragment of the amino acid sequence of SEQ ID NO:20, the fragment comprising eight contiguous amino acids of SEQ ID NO:20; and
- (c) the amino acid sequence encoded by the cDNA insert of clone vc4\_1 deposited under accession number ATCC 98748;

the protein being substantially free from other mammalian proteins. Preferably such  
30 protein comprises the amino acid sequence of SEQ ID NO:20. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:20 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:20, or a protein comprising a fragment of the amino acid sequence of SEQ

ID NO:20 having biological activity, the fragment comprising the amino acid sequence from amino acid 107 to amino acid 116 of SEQ ID NO:20.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- 5 (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:21;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:21 from nucleotide 508 to nucleotide 951;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID  
10 NO:21 from nucleotide 733 to nucleotide 951;
- (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone vc5\_1 deposited under accession number ATCC 98748;
- (e) a polynucleotide encoding the full-length protein encoded by the  
15 cDNA insert of clone vc5\_1 deposited under accession number ATCC 98748;
- (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vc5\_1 deposited under accession number ATCC 98748;
- (g) a polynucleotide encoding a mature protein encoded by the cDNA  
20 insert of clone vc5\_1 deposited under accession number ATCC 98748;
- (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:22;
- (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:22 having biological activity, the fragment  
25 comprising eight contiguous amino acids of SEQ ID NO:22;
- (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
- (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ;
- 30 (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and
- (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:21.



Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:21 from nucleotide 508 to nucleotide 951; the nucleotide sequence of SEQ ID NO:21 from nucleotide 733 to nucleotide 951; the nucleotide sequence of the full-length protein coding sequence of clone vc5\_1 deposited under accession number ATCC 98748; or the  
5 nucleotide sequence of a mature protein coding sequence of clone vc5\_1 deposited under accession number ATCC 98748. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vc5\_1 deposited under accession number ATCC 98748. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment  
10 of the amino acid sequence of SEQ ID NO:22 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:22, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:22 having biological activity, the fragment comprising the amino acid sequence from amino acid 69 to amino acid 78 of SEQ  
15 ID NO:22.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:21.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

- 20 (a) a process comprising the steps of:
- (i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
    - (aa) SEQ ID NO:21, but excluding the poly(A) tail at the  
25 3' end of SEQ ID NO:21; and
    - (ab) the nucleotide sequence of the cDNA insert of clone vc5\_1 deposited under accession number ATCC 98748;
  - (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and
  - 30 (iii) isolating the DNA polynucleotides detected with the probe(s);
- and
- (b) a process comprising the steps of:

(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(ba) SEQ ID NO:21, but excluding the poly(A) tail at the 3' end of SEQ ID NO:21; and

(bb) the nucleotide sequence of the cDNA insert of clone vc5\_1 deposited under accession number ATCC 98748;

(ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:21, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:21 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:21, but excluding the poly(A) tail at the 3' end of SEQ ID NO:21. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:21 from nucleotide 508 to nucleotide 951, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:21 from nucleotide 508 to nucleotide 951, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:21 from nucleotide 508 to nucleotide 951. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:21 from nucleotide 733 to nucleotide 951, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:21 from nucleotide 733 to nucleotide 951, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:21 from nucleotide 733 to nucleotide 951.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO:22;

(b) a fragment of the amino acid sequence of SEQ ID NO:22, the fragment comprising eight contiguous amino acids of SEQ ID NO:22; and

(c) the amino acid sequence encoded by the cDNA insert of clone vc5\_1 deposited under accession number ATCC 98748; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:22. In further preferred  
5 embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:22 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:22, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:22 having biological activity, the fragment comprising the amino acid sequence  
10 from amino acid 69 to amino acid 78 of SEQ ID NO:22.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:23;
- 15 (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:23 from nucleotide 125 to nucleotide 493;
- (c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone vc7\_1 deposited under accession number ATCC 98748;
- 20 (d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vc7\_1 deposited under accession number ATCC 98748;
- (e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vc7\_1 deposited under accession number ATCC 98748;
- 25 (f) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone vc7\_1 deposited under accession number ATCC 98748;
- (g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:24;
- (h) a polynucleotide encoding a protein comprising a fragment of the  
30 amino acid sequence of SEQ ID NO:24 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:24;
- (i) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above;

(j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above ;

(k) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h); and

5 (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:23.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:23 from nucleotide 125 to nucleotide 493; the nucleotide sequence of the full-length  
10 protein coding sequence of clone vc7\_1 deposited under accession number ATCC 98748; or the nucleotide sequence of a mature protein coding sequence of clone vc7\_1 deposited under accession number ATCC 98748. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vc7\_1 deposited under accession number ATCC 98748. In further preferred  
15 embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:24 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:24, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:24 having  
20 biological activity, the fragment comprising the amino acid sequence from amino acid 56 to amino acid 65 of SEQ ID NO:24.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:23.

Further embodiments of the invention provide isolated polynucleotides produced  
25 according to a process selected from the group consisting of:

(a) a process comprising the steps of:

(i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

30 (aa) SEQ ID NO:23, but excluding the poly(A) tail at the 3' end of SEQ ID NO:23; and

(ab) the nucleotide sequence of the cDNA insert of clone vc7\_1 deposited under accession number ATCC 98748;

(ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and

(iii) isolating the DNA polynucleotides detected with the probe(s);

5 and

(b) a process comprising the steps of:

(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

10 (ba) SEQ ID NO:23, but excluding the poly(A) tail at the 3' end of SEQ ID NO:23; and

(bb) the nucleotide sequence of the cDNA insert of clone vc7\_1 deposited under accession number ATCC 98748;

15 (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:23, and  
20 extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:23 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:23, but excluding the poly(A) tail at the 3' end of SEQ ID NO:23. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:23 from nucleotide 125 to nucleotide  
25 493, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:23 from nucleotide 125 to nucleotide 493, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:23 from nucleotide 125 to nucleotide 493.

In other embodiments, the present invention provides a composition comprising  
30 a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO:24;

(b) a fragment of the amino acid sequence of SEQ ID NO:24, the fragment comprising eight contiguous amino acids of SEQ ID NO:24; and

(c) the amino acid sequence encoded by the cDNA insert of clone vc7\_1 deposited under accession number ATCC 98748; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:24. In further preferred  
5 embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:24 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:24, or a protein comprising a fragment of the amino acid sequence of SEQ  
10 ID NO:24 having biological activity, the fragment comprising the amino acid sequence from amino acid 56 to amino acid 65 of SEQ ID NO:24.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:25;
- 15 (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:25 from nucleotide 33 to nucleotide 407;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:25 from nucleotide 99 to nucleotide 407;
- (d) a polynucleotide comprising the nucleotide sequence of the full-  
20 length protein coding sequence of clone vc9\_1 deposited under accession number ATCC 98748;
- (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vc9\_1 deposited under accession number ATCC 98748;
- (f) a polynucleotide comprising the nucleotide sequence of a mature  
25 protein coding sequence of clone vc9\_1 deposited under accession number ATCC 98748;
- (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone vc9\_1 deposited under accession number ATCC 98748;
- (h) a polynucleotide encoding a protein comprising the amino acid  
30 sequence of SEQ ID NO:26;
- (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:26 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:26;

(j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;

(k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ;

5 (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and

(m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:25.

10 Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:25 from nucleotide 33 to nucleotide 407; the nucleotide sequence of SEQ ID NO:25 from nucleotide 99 to nucleotide 407; the nucleotide sequence of the full-length protein coding sequence of clone vc9\_1 deposited under accession number ATCC 98748; or the nucleotide sequence of a mature protein coding sequence of clone vc9\_1 deposited under  
15 accession number ATCC 98748. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vc9\_1 deposited under accession number ATCC 98748. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:26 having biological activity, the fragment  
20 preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:26, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:26 having biological activity, the fragment comprising the amino acid sequence from amino acid 57 to amino acid 66 of SEQ ID NO:26.

25 Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:25.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

(a) a process comprising the steps of:

30 (i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(aa) SEQ ID NO:25, but excluding the poly(A) tail at the 3' end of SEQ ID NO:25; and

- (ab) the nucleotide sequence of the cDNA insert of clone vc9\_1 deposited under accession number ATCC 98748;
- (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and
- 5 (iii) isolating the DNA polynucleotides detected with the probe(s);
- and
- (b) a process comprising the steps of:
- (i) preparing one or more polynucleotide primers that
- 10 hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
- (ba) SEQ ID NO:25, but excluding the poly(A) tail at the 3' end of SEQ ID NO:25; and
- (bb) the nucleotide sequence of the cDNA insert of clone
- 15 vc9\_1 deposited under accession number ATCC 98748;
- (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;
- (iii) amplifying human DNA sequences; and
- (iv) isolating the polynucleotide products of step (b)(iii).
- 20 Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:25, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:25 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:25, but excluding the poly(A) tail at the 3' end of SEQ ID NO:25. Also preferably the
- 25 polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:25 from nucleotide 33 to nucleotide 407, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:25 from nucleotide 33 to nucleotide 407, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:25 from nucleotide
- 30 33 to nucleotide 407. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:25 from nucleotide 99 to nucleotide 407, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:25 from



nucleotide 99 to nucleotide 407, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:25 from nucleotide 99 to nucleotide 407.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:26;
  - (b) a fragment of the amino acid sequence of SEQ ID NO:26, the fragment comprising eight contiguous amino acids of SEQ ID NO:26; and
  - (c) the amino acid sequence encoded by the cDNA insert of clone vc9\_1 deposited under accession number ATCC 98748;
- the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:26. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:26 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:26, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:26 having biological activity, the fragment comprising the amino acid sequence from amino acid 57 to amino acid 66 of SEQ ID NO:26.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:27;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:27 from nucleotide 176 to nucleotide 871;
- (c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone vc10\_1 deposited under accession number ATCC 98748;
- (d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vc10\_1 deposited under accession number ATCC 98748;
- (e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vc10\_1 deposited under accession number ATCC 98748;
- (f) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone vc10\_1 deposited under accession number ATCC 98748;

(g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:28;

(h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:28 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:28;

(i) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above;

(j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above ;

(k) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h); and

(l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:27.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:27 from nucleotide 176 to nucleotide 871; the nucleotide sequence of the full-length protein coding sequence of clone vc10\_1 deposited under accession number ATCC 98748; or the nucleotide sequence of a mature protein coding sequence of clone vc10\_1 deposited under accession number ATCC 98748. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vc10\_1 deposited under accession number ATCC 98748. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:28 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:28, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:28 having biological activity, the fragment comprising the amino acid sequence from amino acid 111 to amino acid 120 of SEQ ID NO:28.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:27.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

(a) a process comprising the steps of:

(i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(aa) SEQ ID NO:27, but excluding the poly(A) tail at the 3' end of SEQ ID NO:27; and

(ab) the nucleotide sequence of the cDNA insert of clone vc10\_1 deposited under accession number ATCC 98748;

(ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and

(iii) isolating the DNA polynucleotides detected with the probe(s);

and

(b) a process comprising the steps of:

(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(ba) SEQ ID NO:27, but excluding the poly(A) tail at the 3' end of SEQ ID NO:27; and

(bb) the nucleotide sequence of the cDNA insert of clone vc10\_1 deposited under accession number ATCC 98748;

(ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:27, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:27 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:27, but excluding the poly(A) tail at the 3' end of SEQ ID NO:27. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:27 from nucleotide 176 to nucleotide 871, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:27 from nucleotide 176 to nucleotide 871, to a nucleotide

sequence corresponding to the 3' end of said sequence of SEQ ID NO:27 from nucleotide 176 to nucleotide 871.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group

5 consisting of:

- (a) the amino acid sequence of SEQ ID NO:28;
- (b) a fragment of the amino acid sequence of SEQ ID NO:28, the fragment comprising eight contiguous amino acids of SEQ ID NO:28; and
- (c) the amino acid sequence encoded by the cDNA insert of clone

10 vc10\_1 deposited under accession number ATCC 98748;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:28. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:28 having biological activity, the fragment preferably

15 comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:28, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:28 having biological activity, the fragment comprising the amino acid sequence from amino acid 111 to amino acid 120 of SEQ ID NO:28.

In one embodiment, the present invention provides a composition comprising an

20 isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:29;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:29 from nucleotide 160 to nucleotide 657;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:29 from nucleotide 214 to nucleotide 657;
- (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone vc11\_1 deposited under accession number ATCC 98748;

25 (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vc11\_1 deposited under accession number ATCC 98748;

(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vc11\_1 deposited under accession number ATCC 98748;

(g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone vc11\_1 deposited under accession number ATCC 98748;

(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:30;

5 (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:30 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:30;

(j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;

10 (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ;

(l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and

15 (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:29.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:29 from nucleotide 160 to nucleotide 657; the nucleotide sequence of SEQ ID NO:29 from nucleotide 214 to nucleotide 657; the nucleotide sequence of the full-length protein coding sequence of clone vc11\_1 deposited under accession number ATCC 98748; or the  
20 nucleotide sequence of a mature protein coding sequence of clone vc11\_1 deposited under accession number ATCC 98748. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vc11\_1 deposited under accession number ATCC 98748. In further preferred embodiments, the  
25 present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:30 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:30, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:30 having biological activity, the  
30 fragment comprising the amino acid sequence from amino acid 78 to amino acid 87 of SEQ ID NO:30.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:29.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

(a) a process comprising the steps of:

(i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(aa) SEQ ID NO:29, but excluding the poly(A) tail at the 3' end of SEQ ID NO:29; and

(ab) the nucleotide sequence of the cDNA insert of clone vc11\_1 deposited under accession number ATCC 98748;

(ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and

(iii) isolating the DNA polynucleotides detected with the probe(s);

and

(b) a process comprising the steps of:

(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(ba) SEQ ID NO:29, but excluding the poly(A) tail at the 3' end of SEQ ID NO:29; and

(bb) the nucleotide sequence of the cDNA insert of clone vc11\_1 deposited under accession number ATCC 98748;

(ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:29, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:29 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:29, but excluding the poly(A) tail at the 3' end of SEQ ID NO:29. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:29 from nucleotide 160 to nucleotide

657, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:29 from nucleotide 160 to nucleotide 657, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:29 from nucleotide 160 to nucleotide 657. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:29 from nucleotide 214 to nucleotide 657, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:29 from nucleotide 214 to nucleotide 657, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:29 from nucleotide 214 to nucleotide 657.

10 In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:30;
- (b) a fragment of the amino acid sequence of SEQ ID NO:30, the  
15 fragment comprising eight contiguous amino acids of SEQ ID NO:30; and
- (c) the amino acid sequence encoded by the cDNA insert of clone vc11\_1 deposited under accession number ATCC 98748;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:30. In further preferred  
20 embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:30 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:30, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:30 having biological activity, the fragment comprising the amino acid sequence  
25 from amino acid 78 to amino acid 87 of SEQ ID NO:30.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:31;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:31 from nucleotide 228 to nucleotide 662;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:31 from nucleotide 327 to nucleotide 662;

(d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone vc14\_1 deposited under accession number ATCC 98748;

(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vc14\_1 deposited under accession number ATCC 98748;

(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vc14\_1 deposited under accession number ATCC 98748;

(g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone vc14\_1 deposited under accession number ATCC 98748;

(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:32;

(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:32 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:32;

(j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;

(k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ;

(l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and

(m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:31.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:31 from nucleotide 228 to nucleotide 662; the nucleotide sequence of SEQ ID NO:31 from nucleotide 327 to nucleotide 662; the nucleotide sequence of the full-length protein coding sequence of clone vc14\_1 deposited under accession number ATCC 98748; or the nucleotide sequence of a mature protein coding sequence of clone vc14\_1 deposited under accession number ATCC 98748. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vc14\_1 deposited under accession number ATCC 98748. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:32 having biological activity, the fragment



preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:32, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:32 having biological activity, the fragment comprising the amino acid sequence from amino acid 67 to amino acid 76 of SEQ ID NO:32.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:31.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

- 10 (a) a process comprising the steps of:
  - (i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
    - 15 (aa) SEQ ID NO:31, but excluding the poly(A) tail at the 3' end of SEQ ID NO:31; and
    - (ab) the nucleotide sequence of the cDNA insert of clone vc14\_1 deposited under accession number ATCC 98748;
  - (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and
  - 20 (iii) isolating the DNA polynucleotides detected with the probe(s);
- and
- (b) a process comprising the steps of:
  - (i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
    - 25 (ba) SEQ ID NO:31, but excluding the poly(A) tail at the 3' end of SEQ ID NO:31; and
    - (bb) the nucleotide sequence of the cDNA insert of clone vc14\_1 deposited under accession number ATCC 98748;
  - 30 (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;
  - (iii) amplifying human DNA sequences; and
  - (iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:31, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:31 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:31, but  
5 excluding the poly(A) tail at the 3' end of SEQ ID NO:31. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:31 from nucleotide 228 to nucleotide 662, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:31 from nucleotide 228 to nucleotide 662, to a nucleotide  
10 sequence corresponding to the 3' end of said sequence of SEQ ID NO:31 from nucleotide 228 to nucleotide 662. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:31 from nucleotide 327 to nucleotide 662, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:31 from  
15 nucleotide 327 to nucleotide 662, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:31 from nucleotide 327 to nucleotide 662.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- 20 (a) the amino acid sequence of SEQ ID NO:32;
  - (b) a fragment of the amino acid sequence of SEQ ID NO:32, the fragment comprising eight contiguous amino acids of SEQ ID NO:32; and
  - (c) the amino acid sequence encoded by the cDNA insert of clone vc14\_1 deposited under accession number ATCC 98748;
- 25 the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:32. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:32 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids  
30 of SEQ ID NO:32, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:32 having biological activity, the fragment comprising the amino acid sequence from amino acid 67 to amino acid 76 of SEQ ID NO:32.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:33;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:33 from nucleotide 101 to nucleotide 667;
- 5 (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:33 from nucleotide 182 to nucleotide 667;
- (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone vc16\_1 deposited under accession number ATCC 98784;
- 10 (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vc16\_1 deposited under accession number ATCC 98784;
- (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vc16\_1 deposited under accession number ATCC 98784;
- 15 (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone vc16\_1 deposited under accession number ATCC 98784;
- (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:34;
- (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:34 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:34;
- 20 (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
- (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ;
- 25 (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and
- (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least
- 30 25% of the length of SEQ ID NO:33.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:33 from nucleotide 101 to nucleotide 667; the nucleotide sequence of SEQ ID NO:33 from nucleotide 182 to nucleotide 667; the nucleotide sequence of the full-length protein coding sequence of clone vc16\_1 deposited under accession number ATCC 98784; or the

nucleotide sequence of a mature protein coding sequence of clone vc16\_1 deposited under accession number ATCC 98784. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vc16\_1 deposited under accession number ATCC 98784. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:34 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:34, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:34 having biological activity, the fragment comprising the amino acid sequence from amino acid 89 to amino acid 98 of SEQ ID NO:34.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:33.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

- (a) a process comprising the steps of:
  - (i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

- (aa) SEQ ID NO:33, but excluding the poly(A) tail at the 3' end of SEQ ID NO:33; and

- (ab) the nucleotide sequence of the cDNA insert of clone vc16\_1 deposited under accession number ATCC 98784;

- (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and

- (iii) isolating the DNA polynucleotides detected with the probe(s);

and

- (b) a process comprising the steps of:

- (i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

- (ba) SEQ ID NO:33, but excluding the poly(A) tail at the 3' end of SEQ ID NO:33; and

- (bb) the nucleotide sequence of the cDNA insert of clone vc16\_1 deposited under accession number ATCC 98784;
- (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;
- 5 (iii) amplifying human DNA sequences; and
- (iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:33, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:33 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:33, but excluding the poly(A) tail at the 3' end of SEQ ID NO:33. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:33 from nucleotide 101 to nucleotide 667, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:33 from nucleotide 101 to nucleotide 667, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:33 from nucleotide 101 to nucleotide 667. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:33 from nucleotide 182 to nucleotide 667, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:33 from nucleotide 182 to nucleotide 667, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:33 from nucleotide 182 to nucleotide 667.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:34;
- (b) a fragment of the amino acid sequence of SEQ ID NO:34, the fragment comprising eight contiguous amino acids of SEQ ID NO:34; and
- (c) the amino acid sequence encoded by the cDNA insert of clone vc16\_1 deposited under accession number ATCC 98784;
- 30

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:34. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:34 having biological activity, the fragment preferably

comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:34, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:34 having biological activity, the fragment comprising the amino acid sequence from amino acid 89 to amino acid 98 of SEQ ID NO:34.

5           In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a)     a polynucleotide comprising the nucleotide sequence of SEQ ID NO:35;
- (b)     a polynucleotide comprising the nucleotide sequence of SEQ ID  
10     NO:35 from nucleotide 8 to nucleotide 355;
- (c)     a polynucleotide comprising the nucleotide sequence of SEQ ID NO:35 from nucleotide 134 to nucleotide 355;
- (d)     a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone vc17\_1 deposited under accession number  
15     ATCC 98784;
- (e)     a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vc17\_1 deposited under accession number ATCC 98784;
- (f)     a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vc17\_1 deposited under accession number ATCC  
20     98784;
- (g)     a polynucleotide encoding a mature protein encoded by the cDNA insert of clone vc17\_1 deposited under accession number ATCC 98784;
- (h)     a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:36;
- (i)     a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:36 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:36;
- (j)     a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
- (k)     a polynucleotide which encodes a species homologue of the protein  
30     of (h) or (i) above ;
- (l)     a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and

(m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:35.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:35 from nucleotide 8 to nucleotide 355; the nucleotide sequence of SEQ ID NO:35 from nucleotide 134 to nucleotide 355; the nucleotide sequence of the full-length protein coding sequence of clone vc17\_1 deposited under accession number ATCC 98784; or the nucleotide sequence of a mature protein coding sequence of clone vc17\_1 deposited under accession number ATCC 98784. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vc17\_1 deposited under accession number ATCC 98784. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:36 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:36, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:36 having biological activity, the fragment comprising the amino acid sequence from amino acid 53 to amino acid 62 of SEQ ID NO:36.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:35.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

- (a) a process comprising the steps of:
  - (i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
    - (aa) SEQ ID NO:35, but excluding the poly(A) tail at the 3' end of SEQ ID NO:35; and
    - (ab) the nucleotide sequence of the cDNA insert of clone vc17\_1 deposited under accession number ATCC 98784;
  - (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and
  - (iii) isolating the DNA polynucleotides detected with the probe(s);

and

(b) a process comprising the steps of:

(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(ba) SEQ ID NO:35, but excluding the poly(A) tail at the 3' end of SEQ ID NO:35; and

(bb) the nucleotide sequence of the cDNA insert of clone vc17\_1 deposited under accession number ATCC 98784;

(ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:35, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:35 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:35, but excluding the poly(A) tail at the 3' end of SEQ ID NO:35. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:35 from nucleotide 8 to nucleotide 355, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:35 from nucleotide 8 to nucleotide 355, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:35 from nucleotide 8 to nucleotide 355. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:35 from nucleotide 134 to nucleotide 355, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:35 from nucleotide 134 to nucleotide 355, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:35 from nucleotide 134 to nucleotide 355.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO:36;



(b) a fragment of the amino acid sequence of SEQ ID NO:36, the fragment comprising eight contiguous amino acids of SEQ ID NO:36; and

(c) the amino acid sequence encoded by the cDNA insert of clone vc17\_1 deposited under accession number ATCC 98784;

5 the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:36. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:36 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids  
10 of SEQ ID NO:36, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:36 having biological activity, the fragment comprising the amino acid sequence from amino acid 53 to amino acid 62 of SEQ ID NO:36.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

15 (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:37;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:37 from nucleotide 1031 to nucleotide 1252;

(c) a polynucleotide comprising the nucleotide sequence of SEQ ID  
20 NO:37 from nucleotide 1100 to nucleotide 1252;

(d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone vc21\_1 deposited under accession number ATCC 98785;

(e) a polynucleotide encoding the full-length protein encoded by the  
25 cDNA insert of clone vc21\_1 deposited under accession number ATCC 98785;

(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vc21\_1 deposited under accession number ATCC 98785;

(g) a polynucleotide encoding a mature protein encoded by the cDNA  
30 insert of clone vc21\_1 deposited under accession number ATCC 98785;

(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:38;

(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:38 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:38;

(j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;

(k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ;

(l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and

(m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:37.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:37 from nucleotide 1031 to nucleotide 1252; the nucleotide sequence of SEQ ID NO:37 from nucleotide 1100 to nucleotide 1252; the nucleotide sequence of the full-length protein coding sequence of clone vc21\_1 deposited under accession number ATCC 98785; or the nucleotide sequence of a mature protein coding sequence of clone vc21\_1 deposited under accession number ATCC 98785. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vc21\_1 deposited under accession number ATCC 98785. In yet other preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:38 from amino acid 29 to amino acid 74. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:38 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:38, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:38 having biological activity, the fragment comprising the amino acid sequence from amino acid 32 to amino acid 41 of SEQ ID NO:38.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:37.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

(a) a process comprising the steps of:

(i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(aa) SEQ ID NO:37, but excluding the poly(A) tail at the 3' end of SEQ ID NO:37; and

(ab) the nucleotide sequence of the cDNA insert of clone vc21\_1 deposited under accession number ATCC 98785;

(ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and

(iii) isolating the DNA polynucleotides detected with the probe(s);

and

(b) a process comprising the steps of:

(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(ba) SEQ ID NO:37, but excluding the poly(A) tail at the 3' end of SEQ ID NO:37; and

(bb) the nucleotide sequence of the cDNA insert of clone vc21\_1 deposited under accession number ATCC 98785;

(ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:37, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:37 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:37, but excluding the poly(A) tail at the 3' end of SEQ ID NO:37. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:37 from nucleotide 1031 to nucleotide 1252, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:37 from nucleotide 1031 to nucleotide 1252, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:37 from nucleotide

1031 to nucleotide 1252. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:37 from nucleotide 1100 to nucleotide 1252, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:37 from  
5 nucleotide 1100 to nucleotide 1252, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:37 from nucleotide 1100 to nucleotide 1252.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- 10 (a) the amino acid sequence of SEQ ID NO:38;
- (b) the amino acid sequence of SEQ ID NO:38 from amino acid 29 to amino acid 74;
- (c) a fragment of the amino acid sequence of SEQ ID NO:38, the fragment comprising eight contiguous amino acids of SEQ ID NO:38; and
- 15 (d) the amino acid sequence encoded by the cDNA insert of clone vc21\_1 deposited under accession number ATCC 98785;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:38 or the amino acid sequence of SEQ ID NO:38 from amino acid 29 to amino acid 74. In further preferred embodiments,  
20 the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:38 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:38, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:38 having biological activity, the fragment comprising the amino acid sequence from amino  
25 acid 32 to amino acid 41 of SEQ ID NO:38.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:39;
- 30 (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:39 from nucleotide 94 to nucleotide 1482;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:39 from nucleotide 214 to nucleotide 1482;

(d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone vc23\_1 deposited under accession number ATCC 98784;

(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vc23\_1 deposited under accession number ATCC 98784;

(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vc23\_1 deposited under accession number ATCC 98784;

(g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone vc23\_1 deposited under accession number ATCC 98784;

(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:40;

(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:40 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:40;

(j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;

(k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ;

(l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and

(m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:39.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:39 from nucleotide 94 to nucleotide 1482; the nucleotide sequence of SEQ ID NO:39 from nucleotide 214 to nucleotide 1482; the nucleotide sequence of the full-length protein coding sequence of clone vc23\_1 deposited under accession number ATCC 98784; or the nucleotide sequence of a mature protein coding sequence of clone vc23\_1 deposited under accession number ATCC 98784. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vc23\_1 deposited under accession number ATCC 98784. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:40 having biological activity, the fragment

preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:40, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:40 having biological activity, the fragment comprising the amino acid sequence from amino acid 226 to amino acid 235 of  
5 SEQ ID NO:40.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:39.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

- 10 (a) a process comprising the steps of:
- (i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
    - (aa) SEQ ID NO:39, but excluding the poly(A) tail at the  
15 3' end of SEQ ID NO:39; and
    - (ab) the nucleotide sequence of the cDNA insert of clone vc23\_1 deposited under accession number ATCC 98784;
  - (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and
  - 20 (iii) isolating the DNA polynucleotides detected with the probe(s);

and

- (b) a process comprising the steps of:
- (i) preparing one or more polynucleotide primers that  
25 hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
    - (ba) SEQ ID NO:39, but excluding the poly(A) tail at the 3' end of SEQ ID NO:39; and
    - (bb) the nucleotide sequence of the cDNA insert of clone  
30 vc23\_1 deposited under accession number ATCC 98784;
  - (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;
  - (iii) amplifying human DNA sequences; and
  - (iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:39, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:39 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:39, but  
5 excluding the poly(A) tail at the 3' end of SEQ ID NO:39. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:39 from nucleotide 94 to nucleotide 1482, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:39 from nucleotide 94 to nucleotide 1482, to a nucleotide  
10 sequence corresponding to the 3' end of said sequence of SEQ ID NO:39 from nucleotide 94 to nucleotide 1482. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:39 from nucleotide 214 to nucleotide 1482, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:39 from  
15 nucleotide 214 to nucleotide 1482, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:39 from nucleotide 214 to nucleotide 1482.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- 20 (a) the amino acid sequence of SEQ ID NO:40;
- (b) a fragment of the amino acid sequence of SEQ ID NO:40, the fragment comprising eight contiguous amino acids of SEQ ID NO:40; and
- (c) the amino acid sequence encoded by the cDNA insert of clone vc23\_1 deposited under accession number ATCC 98784;

25 the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:40. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:40 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids  
30 of SEQ ID NO:40, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:40 having biological activity, the fragment comprising the amino acid sequence from amino acid 226 to amino acid 235 of SEQ ID NO:40.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:41;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:41 from nucleotide 153 to nucleotide 413;
- 5 (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:41 from nucleotide 264 to nucleotide 413;
- (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone vc25\_1 deposited under accession number ATCC 98784;
- 10 (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vc25\_1 deposited under accession number ATCC 98784;
- (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vc25\_1 deposited under accession number ATCC 98784;
- 15 (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone vc25\_1 deposited under accession number ATCC 98784;
- (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:42;
- (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:42 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:42;
- 20 (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
- (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ;
- 25 (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and
- (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least
- 30 25% of the length of SEQ ID NO:41.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:41 from nucleotide 153 to nucleotide 413; the nucleotide sequence of SEQ ID NO:41 from nucleotide 264 to nucleotide 413; the nucleotide sequence of the full-length protein coding sequence of clone vc25\_1 deposited under accession number ATCC 98784; or the



nucleotide sequence of a mature protein coding sequence of clone vc25\_1 deposited under accession number ATCC 98784. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vc25\_1 deposited under accession number ATCC 98784. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:42 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:42, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:42 having biological activity, the fragment comprising the amino acid sequence from amino acid 38 to amino acid 47 of SEQ ID NO:42.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:41.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

- (a) a process comprising the steps of:
  - (i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

- (aa) SEQ ID NO:41, but excluding the poly(A) tail at the 3' end of SEQ ID NO:41; and

- (ab) the nucleotide sequence of the cDNA insert of clone vc25\_1 deposited under accession number ATCC 98784;

- (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and

- (iii) isolating the DNA polynucleotides detected with the probe(s);

and

- (b) a process comprising the steps of:
  - (i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

- (ba) SEQ ID NO:41, but excluding the poly(A) tail at the 3' end of SEQ ID NO:41; and

- (bb) the nucleotide sequence of the cDNA insert of clone vc25\_1 deposited under accession number ATCC 98784;
- (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;
- 5 (iii) amplifying human DNA sequences; and
- (iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:41, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:41 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:41, but excluding the poly(A) tail at the 3' end of SEQ ID NO:41. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:41 from nucleotide 153 to nucleotide 413, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:41 from nucleotide 153 to nucleotide 413, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:41 from nucleotide 153 to nucleotide 413. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:41 from nucleotide 264 to nucleotide 413, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:41 from nucleotide 264 to nucleotide 413, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:41 from nucleotide 264 to nucleotide 413.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:42;
- (b) a fragment of the amino acid sequence of SEQ ID NO:42, the fragment comprising eight contiguous amino acids of SEQ ID NO:42; and
- (c) the amino acid sequence encoded by the cDNA insert of clone vc25\_1 deposited under accession number ATCC 98784;
- 30

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:42. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:42 having biological activity, the fragment preferably

comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:42, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:42 having biological activity, the fragment comprising the amino acid sequence from amino acid 38 to amino acid 47 of SEQ ID NO:42.

5           In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a)     a polynucleotide comprising the nucleotide sequence of SEQ ID NO:43;
- (b)     a polynucleotide comprising the nucleotide sequence of SEQ ID  
10     NO:43 from nucleotide 87 to nucleotide 1409;
- (c)     a polynucleotide comprising the nucleotide sequence of SEQ ID NO:43 from nucleotide 156 to nucleotide 1409;
- (d)     a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone vc26\_1 deposited under accession number  
15     ATCC 98784;
- (e)     a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vc26\_1 deposited under accession number ATCC 98784;
- (f)     a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vc26\_1 deposited under accession number ATCC  
20     98784;
- (g)     a polynucleotide encoding a mature protein encoded by the cDNA insert of clone vc26\_1 deposited under accession number ATCC 98784;
- (h)     a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:44;
- (i)     a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:44 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:44;
- (j)     a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
- (k)     a polynucleotide which encodes a species homologue of the protein  
30     of (h) or (i) above ;
- (l)     a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and

(m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:43.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:43 from nucleotide 87 to nucleotide 1409; the nucleotide sequence of SEQ ID NO:43 from nucleotide 156 to nucleotide 1409; the nucleotide sequence of the full-length protein coding sequence of clone vc26\_1 deposited under accession number ATCC 98784; or the nucleotide sequence of a mature protein coding sequence of clone vc26\_1 deposited under accession number ATCC 98784. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vc26\_1 deposited under accession number ATCC 98784. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:44 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:44, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:44 having biological activity, the fragment comprising the amino acid sequence from amino acid 215 to amino acid 224 of SEQ ID NO:44.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:43.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

- (a) a process comprising the steps of:
  - (i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
    - (aa) SEQ ID NO:43, but excluding the poly(A) tail at the 3' end of SEQ ID NO:43; and
    - (ab) the nucleotide sequence of the cDNA insert of clone vc26\_1 deposited under accession number ATCC 98784;
  - (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and
  - (iii) isolating the DNA polynucleotides detected with the probe(s);

and

(b) a process comprising the steps of:

(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(ba) SEQ ID NO:43, but excluding the poly(A) tail at the 3' end of SEQ ID NO:43; and

(bb) the nucleotide sequence of the cDNA insert of clone vc26\_1 deposited under accession number ATCC 98784;

(ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:43, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:43 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:43, but excluding the poly(A) tail at the 3' end of SEQ ID NO:43. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:43 from nucleotide 87 to nucleotide 1409, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:43 from nucleotide 87 to nucleotide 1409, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:43 from nucleotide 87 to nucleotide 1409. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:43 from nucleotide 156 to nucleotide 1409, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:43 from nucleotide 156 to nucleotide 1409, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:43 from nucleotide 156 to nucleotide 1409.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO:44;

(b) a fragment of the amino acid sequence of SEQ ID NO:44, the fragment comprising eight contiguous amino acids of SEQ ID NO:44; and

(c) the amino acid sequence encoded by the cDNA insert of clone vc26\_1 deposited under accession number ATCC 98784;

5 the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:44. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:44 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids  
10 of SEQ ID NO:44, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:44 having biological activity, the fragment comprising the amino acid sequence from amino acid 215 to amino acid 224 of SEQ ID NO:44.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

15 (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:45;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:45 from nucleotide 63 to nucleotide 428;

20 (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:45 from nucleotide 156 to nucleotide 428;

(d) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:45 from nucleotide 356 to nucleotide 1773;

25 (e) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone vc30\_1 deposited under accession number ATCC 98804;

(f) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vc30\_1 deposited under accession number ATCC 98804;

30 (g) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vc30\_1 deposited under accession number ATCC 98804;

(h) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone vc30\_1 deposited under accession number ATCC 98804;

(i) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:46;

(j) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:46 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:46;

(k) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(h) above;

(l) a polynucleotide which encodes a species homologue of the protein of (i) or (j) above ;

(m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(j); and

(n) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(j) and that has a length that is at least 25% of the length of SEQ ID NO:45.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:45 from nucleotide 63 to nucleotide 428; the nucleotide sequence of SEQ ID NO:45 from nucleotide 156 to nucleotide 428; the nucleotide sequence of SEQ ID NO:45 from nucleotide 356 to nucleotide 1773; the nucleotide sequence of the full-length protein coding sequence of clone vc30\_1 deposited under accession number ATCC 98804; or the nucleotide sequence of a mature protein coding sequence of clone vc30\_1 deposited under accession number ATCC 98804. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vc30\_1 deposited under accession number ATCC 98804. In yet other preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:46 from amino acid 1 to amino acid 97. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:46 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:46, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:46 having biological activity, the fragment comprising the amino acid sequence from amino acid 56 to amino acid 65 of SEQ ID NO:46.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:45.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

(a) a process comprising the steps of:

(i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

5 (aa) SEQ ID NO:45, but excluding the poly(A) tail at the 3' end of SEQ ID NO:45; and

(ab) the nucleotide sequence of the cDNA insert of clone vc30\_1 deposited under accession number ATCC 98804;

10 (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and

(iii) isolating the DNA polynucleotides detected with the probe(s);

and

(b) a process comprising the steps of:

15 (i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(ba) SEQ ID NO:45, but excluding the poly(A) tail at the 3' end of SEQ ID NO:45; and

20 (bb) the nucleotide sequence of the cDNA insert of clone vc30\_1 deposited under accession number ATCC 98804;

(ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;

(iii) amplifying human DNA sequences; and

25 (iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:45, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:45 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:45, but  
30 excluding the poly(A) tail at the 3' end of SEQ ID NO:45. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:45 from nucleotide 63 to nucleotide 428, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:45 from nucleotide 63 to nucleotide 428, to a nucleotide



sequence corresponding to the 3' end of said sequence of SEQ ID NO:45 from nucleotide 63 to nucleotide 428. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:45 from nucleotide 156 to nucleotide 428, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:45 from nucleotide 156 to nucleotide 428, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:45 from nucleotide 156 to nucleotide 428. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:45 from nucleotide 356 to nucleotide 1773, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:45 from nucleotide 356 to nucleotide 1773, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:45 from nucleotide 356 to nucleotide 1773.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:46;
- (b) the amino acid sequence of SEQ ID NO:46 from amino acid 1 to amino acid 97;
- (c) a fragment of the amino acid sequence of SEQ ID NO:46, the fragment comprising eight contiguous amino acids of SEQ ID NO:46; and
- (d) the amino acid sequence encoded by the cDNA insert of clone vc30\_1 deposited under accession number ATCC 98804;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:46 or the amino acid sequence of SEQ ID NO:46 from amino acid 1 to amino acid 97. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:46 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:46, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:46 having biological activity, the fragment comprising the amino acid sequence from amino acid 56 to amino acid 65 of SEQ ID NO:46.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:47;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:47 from nucleotide 30 to nucleotide 1799;
- 5 (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:47 from nucleotide 90 to nucleotide 1799;
- (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone vd1\_1 deposited under accession number ATCC 98748;
- 10 (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vd1\_1 deposited under accession number ATCC 98748;
- (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vd1\_1 deposited under accession number ATCC 98748;
- 15 (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone vd1\_1 deposited under accession number ATCC 98748;
- (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:48;
- (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:48 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:48;
- 20 (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
- (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ;
- 25 (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and
- (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least
- 30 25% of the length of SEQ ID NO:47.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:47 from nucleotide 30 to nucleotide 1799; the nucleotide sequence of SEQ ID NO:47 from nucleotide 90 to nucleotide 1799; the nucleotide sequence of the full-length protein coding sequence of clone vd1\_1 deposited under accession number ATCC 98748; or the

nucleotide sequence of a mature protein coding sequence of clone vd1\_1 deposited under accession number ATCC 98748. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vd1\_1 deposited under accession number ATCC 98748. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:48 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:48, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:48 having biological activity, the fragment comprising the amino acid sequence from amino acid 290 to amino acid 299 of SEQ ID NO:48.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:47.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

- (a) a process comprising the steps of:
  - (i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
    - (aa) SEQ ID NO:47, but excluding the poly(A) tail at the 3' end of SEQ ID NO:47; and
    - (ab) the nucleotide sequence of the cDNA insert of clone vd1\_1 deposited under accession number ATCC 98748;
  - (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and
  - (iii) isolating the DNA polynucleotides detected with the probe(s);

and

- (b) a process comprising the steps of:
  - (i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
    - (ba) SEQ ID NO:47, but excluding the poly(A) tail at the 3' end of SEQ ID NO:47; and

- (bb) the nucleotide sequence of the cDNA insert of clone vd1\_1 deposited under accession number ATCC 98748;
- (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;
- 5 (iii) amplifying human DNA sequences; and
- (iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:47, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:47 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:47, but excluding the poly(A) tail at the 3' end of SEQ ID NO:47. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:47 from nucleotide 30 to nucleotide 1799, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:47 from nucleotide 30 to nucleotide 1799, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:47 from nucleotide 30 to nucleotide 1799. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:47 from nucleotide 90 to nucleotide 1799, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:47 from nucleotide 90 to nucleotide 1799, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:47 from nucleotide 90 to nucleotide 1799.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:48;
- (b) a fragment of the amino acid sequence of SEQ ID NO:48, the fragment comprising eight contiguous amino acids of SEQ ID NO:48; and
- (c) the amino acid sequence encoded by the cDNA insert of clone vd1\_1 deposited under accession number ATCC 98748;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:48. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:48 having biological activity, the fragment preferably

comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:48, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:48 having biological activity, the fragment comprising the amino acid sequence from amino acid 290 to amino acid 299 of SEQ ID NO:48.

5           In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a)     a polynucleotide comprising the nucleotide sequence of SEQ ID NO:49;
- (b)     a polynucleotide comprising the nucleotide sequence of SEQ ID  
10     NO:49 from nucleotide 69 to nucleotide 443;
- (c)     a polynucleotide comprising the nucleotide sequence of SEQ ID NO:49 from nucleotide 111 to nucleotide 443;
- (d)     a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone vd2\_1 deposited under accession number  
15     ATCC 98748;
- (e)     a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vd2\_1 deposited under accession number ATCC 98748;
- (f)     a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vd2\_1 deposited under accession number ATCC  
20     98748;
- (g)     a polynucleotide encoding a mature protein encoded by the cDNA insert of clone vd2\_1 deposited under accession number ATCC 98748;
- (h)     a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:50;
- (i)     a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:50 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:50;
- (j)     a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
- (k)     a polynucleotide which encodes a species homologue of the protein  
30     of (h) or (i) above ;
- (l)     a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and

(m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:49.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:49 from nucleotide 69 to nucleotide 443; the nucleotide sequence of SEQ ID NO:49 from nucleotide 111 to nucleotide 443; the nucleotide sequence of the full-length protein coding sequence of clone vd2\_1 deposited under accession number ATCC 98748; or the nucleotide sequence of a mature protein coding sequence of clone vd2\_1 deposited under accession number ATCC 98748. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vd2\_1 deposited under accession number ATCC 98748. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:50 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:50, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:50 having biological activity, the fragment comprising the amino acid sequence from amino acid 57 to amino acid 66 of SEQ ID NO:50.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:49.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

- (a) a process comprising the steps of:
  - (i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
    - (aa) SEQ ID NO:49, but excluding the poly(A) tail at the 3' end of SEQ ID NO:49; and
    - (ab) the nucleotide sequence of the cDNA insert of clone vd2\_1 deposited under accession number ATCC 98748;
  - (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and
  - (iii) isolating the DNA polynucleotides detected with the probe(s);

and

(b) a process comprising the steps of:

(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(ba) SEQ ID NO:49, but excluding the poly(A) tail at the 3' end of SEQ ID NO:49; and

(bb) the nucleotide sequence of the cDNA insert of clone vd2\_1 deposited under accession number ATCC 98748;

(ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:49, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:49 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:49, but excluding the poly(A) tail at the 3' end of SEQ ID NO:49. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:49 from nucleotide 69 to nucleotide 443, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:49 from nucleotide 69 to nucleotide 443, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:49 from nucleotide 69 to nucleotide 443. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:49 from nucleotide 111 to nucleotide 443, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:49 from nucleotide 111 to nucleotide 443, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:49 from nucleotide 111 to nucleotide 443.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO:50;

(b) a fragment of the amino acid sequence of SEQ ID NO:50, the fragment comprising eight contiguous amino acids of SEQ ID NO:50; and

(c) the amino acid sequence encoded by the cDNA insert of clone vd2\_1 deposited under accession number ATCC 98748;

5 the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:50. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:50 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids  
10 of SEQ ID NO:50, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:50 having biological activity, the fragment comprising the amino acid sequence from amino acid 57 to amino acid 66 of SEQ ID NO:50.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

15 (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:51;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:51 from nucleotide 176 to nucleotide 1249;

20 (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:51 from nucleotide 227 to nucleotide 1249;

(d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone vd3\_1 deposited under accession number ATCC 98804;

25 (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vd3\_1 deposited under accession number ATCC 98804;

(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vd3\_1 deposited under accession number ATCC 98804;

30 (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone vd3\_1 deposited under accession number ATCC 98804;

(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:52;



(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:52 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:52;

(j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;

(k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ;

(l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and

(m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:51.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:51 from nucleotide 176 to nucleotide 1249; the nucleotide sequence of SEQ ID NO:51 from nucleotide 227 to nucleotide 1249; the nucleotide sequence of the full-length protein coding sequence of clone vd3\_1 deposited under accession number ATCC 98804; or the nucleotide sequence of a mature protein coding sequence of clone vd3\_1 deposited under accession number ATCC 98804. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vd3\_1 deposited under accession number ATCC 98804. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:52 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:52, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:52 having biological activity, the fragment comprising the amino acid sequence from amino acid 174 to amino acid 183 of SEQ ID NO:52.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:51.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

(a) a process comprising the steps of:

(i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(aa) SEQ ID NO:51, but excluding the poly(A) tail at the 3' end of SEQ ID NO:51; and

(ab) the nucleotide sequence of the cDNA insert of clone vd3\_1 deposited under accession number ATCC 98804;

(ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and

(iii) isolating the DNA polynucleotides detected with the probe(s);

and

(b) a process comprising the steps of:

(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(ba) SEQ ID NO:51, but excluding the poly(A) tail at the 3' end of SEQ ID NO:51; and

(bb) the nucleotide sequence of the cDNA insert of clone vd3\_1 deposited under accession number ATCC 98804;

(ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:51, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:51 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:51, but excluding the poly(A) tail at the 3' end of SEQ ID NO:51. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:51 from nucleotide 176 to nucleotide 1249, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:51 from nucleotide 176 to nucleotide 1249, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:51 from nucleotide

176 to nucleotide 1249. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:51 from nucleotide 227 to nucleotide 1249, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:51 from  
5 nucleotide 227 to nucleotide 1249, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:51 from nucleotide 227 to nucleotide 1249.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- 10 (a) the amino acid sequence of SEQ ID NO:52;
  - (b) a fragment of the amino acid sequence of SEQ ID NO:52, the fragment comprising eight contiguous amino acids of SEQ ID NO:52; and
  - (c) the amino acid sequence encoded by the cDNA insert of clone vd3\_1 deposited under accession number ATCC 98804;
- 15 the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:52. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:52 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids  
20 of SEQ ID NO:52, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:52 having biological activity, the fragment comprising the amino acid sequence from amino acid 174 to amino acid 183 of SEQ ID NO:52.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- 25 (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:53;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:53 from nucleotide 94 to nucleotide 1530;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID  
30 NO:53 from nucleotide 145 to nucleotide 1530;
- (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone vd4\_1 deposited under accession number ATCC 98804;

(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vd4\_1 deposited under accession number ATCC 98804;

(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vd4\_1 deposited under accession number ATCC 98804;

(g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone vd4\_1 deposited under accession number ATCC 98804;

(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:54;

(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:54 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:54;

(j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;

(k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ;

(l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and

(m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:53.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:53 from nucleotide 94 to nucleotide 1530; the nucleotide sequence of SEQ ID NO:53 from nucleotide 145 to nucleotide 1530; the nucleotide sequence of the full-length protein coding sequence of clone vd4\_1 deposited under accession number ATCC 98804; or the nucleotide sequence of a mature protein coding sequence of clone vd4\_1 deposited under accession number ATCC 98804. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vd4\_1 deposited under accession number ATCC 98804. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:54 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:54, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:54 having biological activity, the

fragment comprising the amino acid sequence from amino acid 234 to amino acid 243 of SEQ ID NO:54.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:53.

5 Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

(a) a process comprising the steps of:

(i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

10

(aa) SEQ ID NO:53, but excluding the poly(A) tail at the 3' end of SEQ ID NO:53; and

(ab) the nucleotide sequence of the cDNA insert of clone vd4\_1 deposited under accession number ATCC 98804;

15

(ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and

(iii) isolating the DNA polynucleotides detected with the probe(s);

and

20

(b) a process comprising the steps of:

(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

25

(ba) SEQ ID NO:53, but excluding the poly(A) tail at the 3' end of SEQ ID NO:53; and

(bb) the nucleotide sequence of the cDNA insert of clone vd4\_1 deposited under accession number ATCC 98804;

(ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;

30

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:53, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ

ID NO:53 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:53, but excluding the poly(A) tail at the 3' end of SEQ ID NO:53. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:53 from nucleotide 94 to nucleotide 1530, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:53 from nucleotide 94 to nucleotide 1530, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:53 from nucleotide 94 to nucleotide 1530. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:53 from nucleotide 145 to nucleotide 1530, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:53 from nucleotide 145 to nucleotide 1530, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:53 from nucleotide 145 to nucleotide 1530.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:54;
- (b) a fragment of the amino acid sequence of SEQ ID NO:54, the fragment comprising eight contiguous amino acids of SEQ ID NO:54; and
- (c) the amino acid sequence encoded by the cDNA insert of clone vd4\_1 deposited under accession number ATCC 98804;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:54. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:54 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:54, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:54 having biological activity, the fragment comprising the amino acid sequence from amino acid 234 to amino acid 243 of SEQ ID NO:54.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:55;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:55 from nucleotide 71 to nucleotide 1300;

(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:55 from nucleotide 182 to nucleotide 1300;

5 (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone ve4\_1 deposited under accession number ATCC 98784;

(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone ve4\_1 deposited under accession number ATCC 98784;

10 (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone ve4\_1 deposited under accession number ATCC 98784;

(g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone ve4\_1 deposited under accession number ATCC 98784;

15 (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:56;

(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:56 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:56;

20 (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;

(k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ;

25 (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and

(m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:55.

30 Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:55 from nucleotide 71 to nucleotide 1300; the nucleotide sequence of SEQ ID NO:55 from nucleotide 182 to nucleotide 1300; the nucleotide sequence of the full-length protein coding sequence of clone ve4\_1 deposited under accession number ATCC 98784; or the nucleotide sequence of a mature protein coding sequence of clone ve4\_1 deposited under accession number ATCC 98784. In other preferred embodiments, the polynucleotide

encodes the full-length or a mature protein encoded by the cDNA insert of clone ve4\_1 deposited under accession number ATCC 98784. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:56 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:56, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:56 having biological activity, the fragment comprising the amino acid sequence from amino acid 200 to amino acid 209 of SEQ ID NO:56.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:55.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

- (a) a process comprising the steps of:
  - (i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
    - (aa) SEQ ID NO:55, but excluding the poly(A) tail at the 3' end of SEQ ID NO:55; and
    - (ab) the nucleotide sequence of the cDNA insert of clone ve4\_1 deposited under accession number ATCC 98784;
    - (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and
    - (iii) isolating the DNA polynucleotides detected with the probe(s);

and

- (b) a process comprising the steps of:
  - (i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
    - (ba) SEQ ID NO:55, but excluding the poly(A) tail at the 3' end of SEQ ID NO:55; and
    - (bb) the nucleotide sequence of the cDNA insert of clone ve4\_1 deposited under accession number ATCC 98784;



- (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;
- (iii) amplifying human DNA sequences; and
- (iv) isolating the polynucleotide products of step (b)(iii).

5 Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:55, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:55 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:55, but excluding the poly(A) tail at the 3' end of SEQ ID NO:55. Also preferably the  
10 polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:55 from nucleotide 71 to nucleotide 1300, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:55 from nucleotide 71 to nucleotide 1300, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:55 from nucleotide  
15 71 to nucleotide 1300. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:55 from nucleotide 182 to nucleotide 1300, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:55 from nucleotide 182 to nucleotide 1300, to a nucleotide sequence corresponding to the 3' end  
20 of said sequence of SEQ ID NO:55 from nucleotide 182 to nucleotide 1300.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:56;
- 25 (b) a fragment of the amino acid sequence of SEQ ID NO:56, the fragment comprising eight contiguous amino acids of SEQ ID NO:56; and
- (c) the amino acid sequence encoded by the cDNA insert of clone ve4\_1 deposited under accession number ATCC 98784;

the protein being substantially free from other mammalian proteins. Preferably such  
30 protein comprises the amino acid sequence of SEQ ID NO:56. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:56 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:56, or a protein comprising a fragment of the amino acid sequence of SEQ

ID NO:56 having biological activity, the fragment comprising the amino acid sequence from amino acid 200 to amino acid 209 of SEQ ID NO:56.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- 5                   (a)     a polynucleotide comprising the nucleotide sequence of SEQ ID NO:57;
- (b)     a polynucleotide comprising the nucleotide sequence of SEQ ID NO:57 from nucleotide 57 to nucleotide 785;
- (c)     a polynucleotide comprising the nucleotide sequence of SEQ ID  
10 NO:57 from nucleotide 147 to nucleotide 785;
- (d)     a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone ve8\_1 deposited under accession number ATCC 98804;
- (e)     a polynucleotide encoding the full-length protein encoded by the  
15 cDNA insert of clone ve8\_1 deposited under accession number ATCC 98804;
- (f)     a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone ve8\_1 deposited under accession number ATCC 98804;
- (g)     a polynucleotide encoding a mature protein encoded by the cDNA  
20 insert of clone ve8\_1 deposited under accession number ATCC 98804;
- (h)     a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:58;
- (i)     a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:58 having biological activity, the fragment  
25 comprising eight contiguous amino acids of SEQ ID NO:58;
- (j)     a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
- (k)     a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ;
- 30                  (l)     a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and
- (m)     a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:57.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:57 from nucleotide 57 to nucleotide 785; the nucleotide sequence of SEQ ID NO:57 from nucleotide 147 to nucleotide 785; the nucleotide sequence of the full-length protein coding sequence of clone ve8\_1 deposited under accession number ATCC 98804; or the  
5 nucleotide sequence of a mature protein coding sequence of clone ve8\_1 deposited under accession number ATCC 98804. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone ve8\_1 deposited under accession number ATCC 98804. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment  
10 of the amino acid sequence of SEQ ID NO:58 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:58, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:58 having biological activity, the fragment comprising the amino acid sequence from amino acid 116 to amino acid 125 of  
15 SEQ ID NO:58.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:57.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

- 20 (a) a process comprising the steps of:
- (i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
    - (aa) SEQ ID NO:57, but excluding the poly(A) tail at the  
25 3' end of SEQ ID NO:57; and
    - (ab) the nucleotide sequence of the cDNA insert of clone ve8\_1 deposited under accession number ATCC 98804;
  - (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and
  - 30 (iii) isolating the DNA polynucleotides detected with the probe(s);
- and
- (b) a process comprising the steps of:

(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(ba) SEQ ID NO:57, but excluding the poly(A) tail at the 3' end of SEQ ID NO:57; and

(bb) the nucleotide sequence of the cDNA insert of clone ve8\_1 deposited under accession number ATCC 98804;

(ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:57, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:57 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:57, but excluding the poly(A) tail at the 3' end of SEQ ID NO:57. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:57 from nucleotide 57 to nucleotide 785, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:57 from nucleotide 57 to nucleotide 785, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:57 from nucleotide 57 to nucleotide 785. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:57 from nucleotide 147 to nucleotide 785, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:57 from nucleotide 147 to nucleotide 785, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:57 from nucleotide 147 to nucleotide 785.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO:58;

(b) a fragment of the amino acid sequence of SEQ ID NO:58, the fragment comprising eight contiguous amino acids of SEQ ID NO:58; and

(c) the amino acid sequence encoded by the cDNA insert of clone ve8\_1 deposited under accession number ATCC 98804; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:58. In further preferred  
5       embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:58 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:58, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:58 having biological activity, the fragment comprising the amino acid sequence  
10       from amino acid 116 to amino acid 125 of SEQ ID NO:58.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:59;
- 15       (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:59 from nucleotide 64 to nucleotide 1002;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:59 from nucleotide 139 to nucleotide 1002;
- (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone vf1\_1 deposited under accession number  
20       ATCC 98784;
- (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vf1\_1 deposited under accession number ATCC 98784;
- (f) a polynucleotide comprising the nucleotide sequence of a mature  
25       protein coding sequence of clone vf1\_1 deposited under accession number ATCC 98784;
- (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone vf1\_1 deposited under accession number ATCC 98784;
- (h) a polynucleotide encoding a protein comprising the amino acid  
30       sequence of SEQ ID NO:60;
- (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:60 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:60;

(j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;

(k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ;

5 (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and

(m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:59.

10 Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:59 from nucleotide 64 to nucleotide 1002; the nucleotide sequence of SEQ ID NO:59 from nucleotide 139 to nucleotide 1002; the nucleotide sequence of the full-length protein coding sequence of clone vf1\_1 deposited under accession number ATCC 98784; or the nucleotide sequence of a mature protein coding sequence of clone vf1\_1 deposited under  
15 accession number ATCC 98784. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vf1\_1 deposited under accession number ATCC 98784. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:60 having biological activity, the fragment  
20 preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:60, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:60 having biological activity, the fragment comprising the amino acid sequence from amino acid 151 to amino acid 160 of SEQ ID NO:60.

25 Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:59.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

(a) a process comprising the steps of:

30 (i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(aa) SEQ ID NO:59, but excluding the poly(A) tail at the 3' end of SEQ ID NO:59; and

- (ab) the nucleotide sequence of the cDNA insert of clone vf1\_1 deposited under accession number ATCC 98784;
- (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and
- 5 (iii) isolating the DNA polynucleotides detected with the probe(s);
- and
- (b) a process comprising the steps of:
- (i) preparing one or more polynucleotide primers that
- 10 hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
- (ba) SEQ ID NO:59, but excluding the poly(A) tail at the 3' end of SEQ ID NO:59; and
- (bb) the nucleotide sequence of the cDNA insert of clone
- 15 vf1\_1 deposited under accession number ATCC 98784;
- (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;
- (iii) amplifying human DNA sequences; and
- (iv) isolating the polynucleotide products of step (b)(iii).
- 20 Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:59, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:59 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:59, but excluding the poly(A) tail at the 3' end of SEQ ID NO:59. Also preferably the
- 25 polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:59 from nucleotide 64 to nucleotide 1002, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:59 from nucleotide 64 to nucleotide 1002, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:59 from nucleotide
- 30 64 to nucleotide 1002. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:59 from nucleotide 139 to nucleotide 1002, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:59 from

nucleotide 139 to nucleotide 1002, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:59 from nucleotide 139 to nucleotide 1002.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:60;
- (b) a fragment of the amino acid sequence of SEQ ID NO:60, the fragment comprising eight contiguous amino acids of SEQ ID NO:60; and
- (c) the amino acid sequence encoded by the cDNA insert of clone vf1\_1 deposited under accession number ATCC 98784;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:60. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:60 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:60, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:60 having biological activity, the fragment comprising the amino acid sequence from amino acid 151 to amino acid 160 of SEQ ID NO:60.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:61;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:61 from nucleotide 588 to nucleotide 995;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:61 from nucleotide 750 to nucleotide 995;
- (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone vh1\_1 deposited under accession number ATCC 98804;
- (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vh1\_1 deposited under accession number ATCC 98804;
- (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vh1\_1 deposited under accession number ATCC 98804;



(g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone vh1\_1 deposited under accession number ATCC 98804;

(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:62;

5 (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:62 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:62;

(j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;

10 (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ;

(l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and

(m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:61.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:61 from nucleotide 588 to nucleotide 995; the nucleotide sequence of SEQ ID NO:61 from nucleotide 750 to nucleotide 995; the nucleotide sequence of the full-length protein coding sequence of clone vh1\_1 deposited under accession number ATCC 98804; or the nucleotide sequence of a mature protein coding sequence of clone vh1\_1 deposited under accession number ATCC 98804. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vh1\_1 deposited under accession number ATCC 98804. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:62 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:62, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:62 having biological activity, the fragment comprising the amino acid sequence from amino acid 63 to amino acid 72 of SEQ ID NO:62.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:61.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

(a) a process comprising the steps of:

(i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(aa) SEQ ID NO:61, but excluding the poly(A) tail at the 3' end of SEQ ID NO:61; and

(ab) the nucleotide sequence of the cDNA insert of clone vh1\_1 deposited under accession number ATCC 98804;

(ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and

(iii) isolating the DNA polynucleotides detected with the probe(s);

and

(b) a process comprising the steps of:

(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(ba) SEQ ID NO:61, but excluding the poly(A) tail at the 3' end of SEQ ID NO:61; and

(bb) the nucleotide sequence of the cDNA insert of clone vh1\_1 deposited under accession number ATCC 98804;

(ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:61, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:61 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:61, but excluding the poly(A) tail at the 3' end of SEQ ID NO:61. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:61 from nucleotide 588 to nucleotide

995, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:61 from nucleotide 588 to nucleotide 995, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:61 from nucleotide 588 to nucleotide 995. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:61 from nucleotide 750 to nucleotide 995, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:61 from nucleotide 750 to nucleotide 995, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:61 from nucleotide 750 to nucleotide 995.

10 In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:62;
- (b) a fragment of the amino acid sequence of SEQ ID NO:62, the  
15 fragment comprising eight contiguous amino acids of SEQ ID NO:62; and
- (c) the amino acid sequence encoded by the cDNA insert of clone  
vh1\_1 deposited under accession number ATCC 98804;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:62. In further preferred  
20 embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:62 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:62, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:62 having biological activity, the fragment comprising the amino acid sequence  
25 from amino acid 63 to amino acid 72 of SEQ ID NO:62.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:63;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:63 from nucleotide 29 to nucleotide 1369;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:63 from nucleotide 104 to nucleotide 1369;

(d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone vi1\_1 deposited under accession number ATCC 98804;

(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vi1\_1 deposited under accession number ATCC 98804;

(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vi1\_1 deposited under accession number ATCC 98804;

(g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone vi1\_1 deposited under accession number ATCC 98804;

(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:64;

(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:64 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:64;

(j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;

(k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ;

(l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and

(m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:63.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:63 from nucleotide 29 to nucleotide 1369; the nucleotide sequence of SEQ ID NO:63 from nucleotide 104 to nucleotide 1369; the nucleotide sequence of the full-length protein coding sequence of clone vi1\_1 deposited under accession number ATCC 98804; or the nucleotide sequence of a mature protein coding sequence of clone vi1\_1 deposited under accession number ATCC 98804. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vi1\_1 deposited under accession number ATCC 98804. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:64 having biological activity, the fragment

preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:64, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:64 having biological activity, the fragment comprising the amino acid sequence from amino acid 218 to amino acid 227 of  
5 SEQ ID NO:64.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:63.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

- 10 (a) a process comprising the steps of:
  - (i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
    - (aa) SEQ ID NO:63, but excluding the poly(A) tail at the  
15 3' end of SEQ ID NO:63; and
    - (ab) the nucleotide sequence of the cDNA insert of clone vi1\_1 deposited under accession number ATCC 98804;
  - (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and
  - 20 (iii) isolating the DNA polynucleotides detected with the probe(s);
- and
- (b) a process comprising the steps of:
  - (i) preparing one or more polynucleotide primers that  
25 hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
    - (ba) SEQ ID NO:63, but excluding the poly(A) tail at the  
3' end of SEQ ID NO:63; and
    - (bb) the nucleotide sequence of the cDNA insert of clone  
30 vi1\_1 deposited under accession number ATCC 98804;
  - (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;
  - (iii) amplifying human DNA sequences; and
  - (iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:63, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:63 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:63, but  
5 excluding the poly(A) tail at the 3' end of SEQ ID NO:63. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:63 from nucleotide 29 to nucleotide 1369, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:63 from nucleotide 29 to nucleotide 1369, to a nucleotide  
10 sequence corresponding to the 3' end of said sequence of SEQ ID NO:63 from nucleotide 29 to nucleotide 1369. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:63 from nucleotide 104 to nucleotide 1369, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:63 from  
15 nucleotide 104 to nucleotide 1369, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:63 from nucleotide 104 to nucleotide 1369.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- 20 (a) the amino acid sequence of SEQ ID NO:64;
- (b) a fragment of the amino acid sequence of SEQ ID NO:64, the fragment comprising eight contiguous amino acids of SEQ ID NO:64; and
- (c) the amino acid sequence encoded by the cDNA insert of clone vi1\_1 deposited under accession number ATCC 98804;

25 the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:64. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:64 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids  
30 of SEQ ID NO:64, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:64 having biological activity, the fragment comprising the amino acid sequence from amino acid 218 to amino acid 227 of SEQ ID NO:64.

In certain preferred embodiments, the polynucleotide is operably linked to an expression control sequence. The invention also provides a host cell, including bacterial,

yeast, insect and mammalian cells, transformed with such polynucleotide compositions. Also provided by the present invention are organisms that have enhanced, reduced, or modified expression of the gene(s) corresponding to the polynucleotide sequences disclosed herein.

5 Processes are also provided for producing a protein, which comprise:

(a) growing a culture of the host cell transformed with such polynucleotide compositions in a suitable culture medium; and

(b) purifying the protein from the culture.

The protein produced according to such methods is also provided by the present  
10 invention.

Protein compositions of the present invention may further comprise a pharmaceutically acceptable carrier. Compositions comprising an antibody which specifically reacts with such protein are also provided by the present invention.

15 Methods are also provided for preventing, treating or ameliorating a medical condition which comprises administering to a mammalian subject a therapeutically effective amount of a composition comprising a protein of the present invention and a pharmaceutically acceptable carrier.

#### BRIEF DESCRIPTION OF THE DRAWINGS

20 Figures 1A and 1B are schematic representations of the pED6 and pNOTs vectors, respectively, used for deposit of clones disclosed herein.

#### DETAILED DESCRIPTION

##### ISOLATED PROTEINS AND POLYNUCLEOTIDES

25 Nucleotide and amino acid sequences, as presently determined, are reported below for each clone and protein disclosed in the present application. The nucleotide sequence of each clone can readily be determined by sequencing of the deposited clone in accordance with known methods. The predicted amino acid sequence (both full-length and mature forms) can then be determined from such nucleotide sequence. The amino  
30 acid sequence of the protein encoded by a particular clone can also be determined by expression of the clone in a suitable host cell, collecting the protein and determining its sequence. For each disclosed protein applicants have identified what they have determined to be the reading frame best identifiable with sequence information available at the time of filing.

As used herein a "secreted" protein is one which, when expressed in a suitable host cell, is transported across or through a membrane, including transport as a result of signal sequences in its amino acid sequence. "Secreted" proteins include without limitation proteins secreted wholly (e.g., soluble proteins) or partially (e.g., receptors) from the cell in which they are expressed. "Secreted" proteins also include without limitation proteins which are transported across the membrane of the endoplasmic reticulum.

#### Clone "vb2\_1"

A polynucleotide of the present invention has been identified as clone "vb2\_1". vb2\_1 was isolated from a human fetal brain cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. vb2\_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "vb2\_1 protein").

The nucleotide sequence of vb2\_1 as presently determined is reported in SEQ ID NO:1, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the vb2\_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:2. Amino acids 15 to 27 of SEQ ID NO:2 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 28. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the vb2\_1 protein.

If a frameshift were introduced into the nucleotide sequence of SEQ ID NO:1 by deleting one of the adenine residues at positions 315 and 316, another potential vb2\_1 reading frame and predicted amino acid sequence could be encoded by basepairs 126 to 381 of SEQ ID NO:1 and is reported in SEQ ID NO:97. Amino acids 15 to 27 of SEQ ID NO:97 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 28 of SEQ ID NO:97, or are a transmembrane domain.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone vb2\_1 should be approximately 2342 bp.

The nucleotide sequence disclosed herein for vb2\_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vb2\_1 demonstrated at least some similarity with sequences identified as AA308563 (EST179381 HCC cell line (matatasis to liver in mouse) II Homo



sapiens cDNA 5' end, mRNA sequence). Based upon sequence similarity, vb2\_1 proteins and each similar protein or peptide may share at least some activity.

#### Clone "vb3\_1"

5 A polynucleotide of the present invention has been identified as clone "vb3\_1". vb3\_1 was isolated from a human fetal brain cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. vb3\_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "vb3\_1 protein").

10 The nucleotide sequence of vb3\_1 as presently determined is reported in SEQ ID NO:3, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the vb3\_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:4. Amino acids 16 to 28 of SEQ ID NO:4 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 29. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the vb3\_1 protein.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone vb3\_1 should be approximately 2498 bp.

20 The nucleotide sequence disclosed herein for vb3\_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vb3\_1 demonstrated at least some similarity with sequences identified as AA098874 (zn45f11.s1 Stratagene HeLa cell s3 937216 Homo sapiens cDNA clone 550413 3', mRNA sequence) and T26482 (Human gene signature HUMGS08724).

25 Based upon sequence similarity, vb3\_1 proteins and each similar protein or peptide may share at least some activity.

#### Clone "vb4\_1"

A polynucleotide of the present invention has been identified as clone "vb4\_1".  
30 vb4\_1 was isolated from a human fetal brain cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. vb4\_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "vb4\_1 protein").

The nucleotide sequence of vb4\_1 as presently determined is reported in SEQ ID NO:5, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the vb4\_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:6. Amino acids 2 to 14 of  
5 SEQ ID NO:6 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 15. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the vb4\_1 protein.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone  
10 vb4\_1 should be approximately 2161 bp.

The nucleotide sequence disclosed herein for vb4\_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vb4\_1 demonstrated at least some similarity with sequences identified as D88035 (Rat mRNA for glycoprotein specific UDP-glucuronyltransferase,  
15 complete cds), N49234 (yy83b10.s1 Homo sapiens cDNA clone 280123 3'), and Q59845 (Human brain Expressed Sequence Tag EST00765). Based upon sequence similarity, vb4\_1 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts two additional potential transmembrane domains within the vb4\_1 protein sequence, one centered around amino acid 40 and another  
20 around amino acid 80 of SEQ ID NO:6.

#### Clone "vb5\_1"

A polynucleotide of the present invention has been identified as clone "vb5\_1". vb5\_1 was isolated from a human fetal brain cDNA library and was identified as encoding  
25 a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. vb5\_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "vb5\_1 protein").

The nucleotide sequence of vb5\_1 as presently determined is reported in SEQ ID NO:7, and includes a poly(A) tail. What applicants presently believe to be the proper  
30 reading frame and the predicted amino acid sequence of the vb5\_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:8. Amino acids 7 to 19 of SEQ ID NO:8 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 20. Due to the hydrophobic nature of the predicted

leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the vb5\_1 protein.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone vb5\_1 should be approximately 724 bp.

5       The nucleotide sequence disclosed herein for vb5\_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vb5\_1 demonstrated at least some similarity with sequences identified as AA835218 (ak65a05.s1 Barstead pancreas HPLRB1 Homo sapiens cDNA clone IMAGE:1412720 3', mRNA sequence). Based upon sequence similarity, vb5\_1  
10       proteins and each similar protein or peptide may share at least some activity.

#### Clone "vb6\_1"

A polynucleotide of the present invention has been identified as clone "vb6\_1". vb6\_1 was isolated from a human fetal brain cDNA library and was identified as encoding  
15       a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. vb6\_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "vb6\_1 protein").

The nucleotide sequence of vb6\_1 as presently determined is reported in SEQ ID NO:9, and includes a poly(A) tail. What applicants presently believe to be the proper  
20       reading frame and the predicted amino acid sequence of the vb6\_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:10. Amino acids 13 to 25 of SEQ ID NO:10 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 26. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should  
25       the predicted leader/signal sequence not be separated from the remainder of the vb6\_1 protein.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone vb6\_1 should be approximately 2685 bp.

30       The nucleotide sequence disclosed herein for vb6\_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vb6\_1 demonstrated at least some similarity with sequences identified as AA478801 (zv20f05.s1 Soares NhHMPu S1 Homo sapiens cDNA clone

754209 3', mRNA sequence). Based upon sequence similarity, vb6\_1 proteins and each similar protein or peptide may share at least some activity.

Clone "vb7\_1"

5 A polynucleotide of the present invention has been identified as clone "vb7\_1". vb7\_1 was isolated from a human fetal brain cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. vb7\_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "vb7\_1 protein").

10 The nucleotide sequence of vb7\_1 as presently determined is reported in SEQ ID NO:11, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the vb7\_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:12. Amino acids 35 to 47 of SEQ ID NO:12 are a predicted leader/signal sequence, with the predicted mature  
15 amino acid sequence beginning at amino acid 48. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the vb7\_1 protein.

Another potential vb7\_1 reading frame and predicted amino acid sequence that  
20 could be encoded by basepairs 1093 to 1577 of SEQ ID NO:11 is reported in SEQ ID NO:98. Amino acids 11 to 23 of SEQ ID NO:98 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 24 of SEQ ID NO:98, or are a transmembrane domain. The TopPredII computer program predicts another potential transmembrane domain within the protein sequence of SEQ ID NO:98  
25 centered around amino acid 86 of SEQ ID NO:98. If a frameshift were introduced into the nucleotide sequence of SEQ ID NO:11 approximately between position 1090 and position 1253, the open reading frame of SEQ ID NO:12 could be joined to the open reading frame of SEQ ID NO:98.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone  
30 vb7\_1 should be approximately 1730 bp.

The nucleotide sequence disclosed herein for vb7\_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vb7\_1 demonstrated at least some similarity with sequences identified as D13748 (human eukaryotic initiation factor 4A1), M22873 (Mus musculus

protein synthesis initiation factor 4A (eIF-4A) gene, exon 1), and N36589 (yx86f08.r1 Homo sapiens cDNA clone 268647 5'). The predicted amino acid sequence disclosed herein for vb7\_1 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted vb7\_1 protein demonstrated  
5 at least some similarity to the sequence identified as AL021839 (hypothetical protein [Schizosaccharomyces pombe]). Based upon sequence similarity, vb7\_1 proteins and each similar protein or peptide may share at least some activity.

vb7\_1 protein was expressed in a COS cell expression system, and an expressed protein band of approximately 45 kDa was detected in membrane fractions using SDS  
10 polyacrylamide gel electrophoresis.

#### Clone "vb8\_1"

A polynucleotide of the present invention has been identified as clone "vb8\_1". vb8\_1 was isolated from a human fetal brain cDNA library and was identified as encoding  
15 a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. vb8\_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "vb8\_1 protein").

The nucleotide sequence of vb8\_1 as presently determined is reported in SEQ ID NO:13, and includes a poly(A) tail. What applicants presently believe to be the proper  
20 reading frame and the predicted amino acid sequence of the vb8\_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:14.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone vb8\_1 should be approximately 1363 bp.

The nucleotide sequence disclosed herein for vb8\_1 was searched against the  
25 GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vb8\_1 demonstrated at least some similarity with sequences identified as N57252 (yw93d11.r1 Homo sapiens cDNA clone 259797 5'). The predicted amino acid sequence disclosed herein for vb8\_1 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The  
30 predicted vb8\_1 protein demonstrated at least some similarity to sequences identified as AF51239 (probable ubiquitin activating enzyme 2 [Picea mariana]). Based upon sequence similarity, vb8\_1 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts a potential transmembrane domain

within the vb8\_1 protein sequence centered around amino acid 30 of SEQ ID NO:14. Both the CodonPreference and Testcode computer programs indicate that frameshifts in the nucleotide sequence of SEQ ID NO:13, resulting in the joining of the open reading frame of SEQ ID NO:14 with open reading frames that are more 5' to that of SEQ ID NO:14, are likely.

vb8\_1 protein was expressed in a COS cell expression system, and an expressed protein band of approximately 23 kDa was detected in conditioned medium using SDS polyacrylamide gel electrophoresis.

#### Clone "vb9\_1"

A polynucleotide of the present invention has been identified as clone "vb9\_1". vb9\_1 was isolated from a human fetal brain cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. vb9\_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "vb9\_1 protein").

The nucleotide sequence of vb9\_1 as presently determined is reported in SEQ ID NO:15, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the vb9\_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:16. Amino acids 3 to 15 of SEQ ID NO:16 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 16. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the vb9\_1 protein.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone vb9\_1 should be approximately 2996 bp.

The nucleotide sequence disclosed herein for vb9\_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vb9\_1 demonstrated at least some similarity with sequences identified as AA446380 (zw58b09.r1 Soares total fetus Nb2HF8 9w Homo sapiens cDNA clone 774233 5', mRNA sequence) and L48440 (Rattus norvegicus collagen type II mRNA, complete cds). The predicted amino acid sequence disclosed herein for vb9\_1 was searched against the GenPept and GeneSeq amino acid sequence databases using the

BLASTX search protocol. The predicted vb9\_1 protein demonstrated at least some similarity to the sequence identified as Z78279 (Collagen alpha1 [Rattus norvegicus]). Based upon sequence similarity, vb9\_1 proteins and each similar protein or peptide may share at least some activity.

- 5 vb9\_1 protein was expressed in a COS cell expression system, and an expressed protein band of approximately 58 kDa was detected in membrane fractions using SDS polyacrylamide gel electrophoresis.

Clone "vc3\_1"

- 10 A polynucleotide of the present invention has been identified as clone "vc3\_1". vc3\_1 was isolated from a human fetal brain cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. vc3\_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "vc3\_1 protein").

- 15 The nucleotide sequence of vc3\_1 as presently determined is reported in SEQ ID NO:17, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the vc3\_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:18. Amino acids 24 to 36 of SEQ ID NO:18 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 37. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the vc3\_1 protein.

- 25 Another potential vc3\_1 reading frame and predicted amino acid sequence is encoded by basepairs 227 to 703 of SEQ ID NO:17 and is reported in SEQ ID NO:99. Amino acids 83 to 95 of SEQ ID NO:99 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 96, or are a transmembrane domain, and the TopPredII computer program predicts two additional transmembrane domains within the SEQ ID NO:99 amino acid sequence. A frameshift in the nucleotide sequence of SEQ ID NO:17 between about nucleotide 109 to about nucleotide 417 could join together portions of the overlapping reading frames of SEQ ID NO:18 and SEQ ID NO:99.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone vc3\_1 should be approximately 950 bp.

The nucleotide sequence disclosed herein for vc3\_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vc3\_1 demonstrated at least some similarity with sequences identified as AA669665 (ac18h12.s1 Stratagene ovary (#937217) Homo sapiens cDNA clone 856871 3'). Based upon sequence similarity, vc3\_1 proteins and each similar protein or peptide may share at least some activity.

vc3\_1 protein was expressed in a COS cell expression system, and an expressed protein band of approximately 19 kDa was detected in membrane fractions using SDS polyacrylamide gel electrophoresis.

#### Clone "vc4\_1"

A polynucleotide of the present invention has been identified as clone "vc4\_1". vc4\_1 was isolated from a human fetal brain cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. vc4\_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "vc4\_1 protein").

The nucleotide sequence of vc4\_1 as presently determined is reported in SEQ ID NO:19, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the vc4\_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:20. Amino acids 2 to 14 of SEQ ID NO:20 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 15. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the vc4\_1 protein.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone vc4\_1 should be approximately 1200 bp.

The nucleotide sequence disclosed herein for vc4\_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vc4\_1 demonstrated at least some similarity with sequences identified as Q40970 (Human skeletal muscle ADP-ribosyltransferase gene), U60881 (Mus musculus Yac-2 NAD:arginine ADP-ribosyltransferase mRNA, complete cds), and



W12489 (ma57b11.r1 Soares mouse p3NMF19.5 Mus musculus cDNA clone 314781 5' similar to SW RT61\_RAT P17982 ALLOANTIGEN RT6.1 PRECURSOR). The predicted amino acid sequence disclosed herein for vc4\_1 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted vc4\_1 protein demonstrated at least some similarity to sequences identified as R37572 (Rabbit skeletal muscle ADP-ribosyltransferase) and U60881 (Yac-2 NAD arginine ADP-ribosyltransferase [Mus musculus]). ADP-ribosyltransferases are localized to the plasma membrane and are involved in "post-translational modification of proteins in which the ADP-ribose moiety of NAD is transferred to proteins", which is "responsible for the toxicity of some bacterial toxins (e.g. cholera toxin and pertussis toxin)". Based upon sequence similarity, vc4\_1 proteins and each similar protein or peptide may share at least some activity.

vc4\_1 protein was expressed in a COS cell expression system, and an expressed protein band of approximately 26 kDa was detected in membrane fractions using SDS polyacrylamide gel electrophoresis.

#### Clone "vc5\_1"

A polynucleotide of the present invention has been identified as clone "vc5\_1". vc5\_1 was isolated from a human fetal brain cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. vc5\_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "vc5\_1 protein").

The nucleotide sequence of vc5\_1 as presently determined is reported in SEQ ID NO:21, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the vc5\_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:22. Amino acids 63 to 75 of SEQ ID NO:22 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 76. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the vc5\_1 protein.

Another potential vc5\_1 reading frame and predicted amino acid sequence is encoded by basepairs 215-376 of SEQ ID NO:21 and is reported in SEQ ID NO:100. Amino

acids 4 to 16 of SEQ ID NO:100 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 17 of SEQ ID NO:100.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone vc5\_1 should be approximately 1650 bp.

5       The nucleotide sequence disclosed herein for vc5\_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vc5\_1 demonstrated at least some similarity with sequences identified as AA002211 (zh81h07.s1 Soares fetal liver spleen 1NFLS S1 Homo sapiens cDNA clone 427741 3'). Based upon sequence similarity, vc5\_1 proteins and each similar  
10   protein or peptide may share at least some activity.

vc5\_1 protein was expressed in a COS cell expression system, and an expressed protein band of approximately 28 kDa was detected in conditioned medium using SDS polyacrylamide gel electrophoresis.

15       Clone "vc7\_1"

A polynucleotide of the present invention has been identified as clone "vc7\_1". vc7\_1 was isolated from a human fetal brain cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. vc7\_1 is a full-length clone, including the entire coding  
20   sequence of a secreted protein (also referred to herein as "vc7\_1 protein").

The nucleotide sequence of vc7\_1 as presently determined is reported in SEQ ID NO:23, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the vc7\_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:24. Amino acids 11 to 23  
25   of SEQ ID NO:24 are a possible leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 24.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone vc7\_1 should be approximately 2600 bp.

30       The nucleotide sequence disclosed herein for vc7\_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. No hits were found in the database.

Clone "vc9\_1"

A polynucleotide of the present invention has been identified as clone "vc9\_1". vc9\_1 was isolated from a human fetal brain cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid  
5 sequence of the encoded protein. vc9\_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "vc9\_1 protein").

The nucleotide sequence of vc9\_1 as presently determined is reported in SEQ ID NO:25, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the vc9\_1 protein corresponding  
10 to the foregoing nucleotide sequence is reported in SEQ ID NO:26. Amino acids 10 to 22 of SEQ ID NO:26 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 23. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the vc9\_1  
15 protein.

Another potential vc9\_1 reading frame and predicted amino acid sequence is encoded by basepairs 1981 to 2619 of SEQ ID NO:25 and is reported in SEQ ID NO:101.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone vc9\_1 should be approximately 4500 bp.

20 The nucleotide sequence disclosed herein for vc9\_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vc9\_1 demonstrated at least some similarity with sequences identified as N66453 (yz41a08.s1 Homo sapiens cDNA clone 285590 3') and Z75407 (Human DNA sequence from cosmid N128A12 on chromosome 22q12-qter contains ESTs,  
25 CpG island). Based upon sequence similarity, vc9\_1 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts a potential transmembrane domain within the vc9\_1 protein sequence at the extreme C-terminus of SEQ ID NO:26.

30 Clone "vc10\_1"

A polynucleotide of the present invention has been identified as clone "vc10\_1". vc10\_1 was isolated from a human fetal brain cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the

amino acid sequence of the encoded protein. vc10\_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "vc10\_1 protein").

The nucleotide sequence of vc10\_1 as presently determined is reported in SEQ ID NO:27, and includes a poly(A) tail. What applicants presently believe to be the proper  
5 reading frame and the predicted amino acid sequence of the vc10\_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:28. Amino acids 21 to 33 of SEQ ID NO:28 are a possible leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 34.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone  
10 vc10\_1 should be approximately 2600 bp.

The nucleotide sequence disclosed herein for vc10\_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vc10\_1 demonstrated at least some similarity with sequences identified as AA398711 (zt75a05.s1 Soares testis NHT Homo sapiens cDNA clone 728144  
15 3') and T24621 (Human gene signature HUMGS06681). Based upon sequence similarity, vc10\_1 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts a potential transmembrane domain within the vc10\_1 protein sequence centered around amino acid 74 of SEQ ID NO:28. Nuclotides 1103 to 1191 of SEQ ID NO:27 represent a possible intron in the predicted 3' untranslated  
20 region of the vc10\_1 mRNA molecule.

#### Clone "vc11\_1"

A polynucleotide of the present invention has been identified as clone "vc11\_1". vc11\_1 was isolated from a human fetal brain cDNA library and was identified as  
25 encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. vc11\_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "vc11\_1 protein").

The nucleotide sequence of vc11\_1 as presently determined is reported in SEQ ID NO:29, and includes a poly(A) tail. What applicants presently believe to be the proper  
30 reading frame and the predicted amino acid sequence of the vc11\_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:30. Amino acids 6 to 18 of SEQ ID NO:30 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 19. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should

the predicted leader/signal sequence not be separated from the remainder of the vc11\_1 protein.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone vc11\_1 should be approximately 2600 bp.

5       The nucleotide sequence disclosed herein for vc11\_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vc11\_1 demonstrated at least some similarity with sequences identified as AA193348 (zr41c08.r1 Soares NhHMPu S1 Homo sapiens cDNA clone 665966 5') and T23590 (Human gene signature HUMGS05443). Based upon sequence similarity,  
10 vc11\_1 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts a potential transmembrane domain within the vc11\_1 protein sequence centered around amino acid 32 of SEQ ID NO:30.

Clone "vc14\_1"

15       A polynucleotide of the present invention has been identified as clone "vc14\_1". vc14\_1 was isolated from a human fetal brain cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. vc14\_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "vc14\_1 protein").

20       The nucleotide sequence of vc14\_1 as presently determined is reported in SEQ ID NO:31, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the vc14\_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:32. Amino acids 21 to 33 of SEQ ID NO:32 are a predicted leader/signal sequence, with the predicted mature  
25 amino acid sequence beginning at amino acid 34. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the vc14\_1 protein.

30       The EcoRI/NotI restriction fragment obtainable from the deposit containing clone vc14\_1 should be approximately 1300 bp.

The nucleotide sequence disclosed herein for vc14\_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vc14\_1 demonstrated at least some similarity with sequences identified as AA258182 (zs35f09.s1 NCI\_CGAP\_GCB1 Homo sapiens cDNA clone IMAGE

687209 3'). The predicted amino acid sequence disclosed herein for vc14\_1 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted vc14\_1 protein demonstrated at least some similarity to sequences identified as AC002339 (BAC T11A7 [Arabidopsis thaliana]) and Z71266 (R06C7.6 [Caenorhabditis elegans]). Based upon sequence similarity, vc14\_1 proteins and each similar protein or peptide may share at least some activity.

vc14\_1 protein was expressed in a COS cell expression system, and an expressed protein band of approximately 22 kDa was detected in membrane fractions using SDS polyacrylamide gel electrophoresis.

#### Clone "vc16\_1"

A polynucleotide of the present invention has been identified as clone "vc16\_1". vc16\_1 was isolated from a human fetal brain cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. vc16\_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "vc16\_1 protein").

The nucleotide sequence of vc16\_1 as presently determined is reported in SEQ ID NO:33, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the vc16\_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:34. Amino acids 15 to 27 of SEQ ID NO:34 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 28. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the vc16\_1 protein.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone vc16\_1 should be approximately 1256 bp.

The nucleotide sequence disclosed herein for vc16\_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vc16\_1 demonstrated at least some similarity with sequences identified as AA776882 (ac40a09.s1 Stratagene hNT neuron (#937233) Homo sapiens cDNA clone 858904 3' similar to SW XB3\_XENLA Q09004 STATHMIN-LIKE PROTEIN XB3, mRNA sequence), AF026528 (Rattus norvegicus stathmin-like-protein

RB3 mRNA, complete cds), and AF026529 (*Rattus norvegicus* stathmin-like-protein splice variant RB3' mRNA, complete cds). The predicted amino acid sequence disclosed herein for vc16\_1 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted vc16\_1 protein demonstrated at least  
5 some similarity to sequences identified as AF026528 (stathmin-like-protein RB3 [*Rattus norvegicus*]). While stathmin itself is intracellular, stathmin-related protein RB3 (as well as related proteins SCG10 in rat and XB3 in *Xenopus*) is membrane-associated and has been isolated in the membrane fraction from cell cultures. RB3 is expressed in neural tissue and may be involved in the expression of differentiated neuronal function. Based  
10 upon sequence similarity, vc16\_1 proteins and each similar protein or peptide may share at least some activity.

vc16\_1 protein was expressed in a COS cell expression system, and an expressed protein band of approximately 89 kDa was detected in conditioned medium using SDS polyacrylamide gel electrophoresis.

15

#### Clone "vc17\_1"

A polynucleotide of the present invention has been identified as clone "vc17\_1". vc17\_1 was isolated from a human fetal brain cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the  
20 amino acid sequence of the encoded protein. vc17\_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "vc17\_1 protein").

The nucleotide sequence of vc17\_1 as presently determined is reported in SEQ ID NO:35, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the vc17\_1 protein corresponding  
25 to the foregoing nucleotide sequence is reported in SEQ ID NO:36. Amino acids 30 to 42 of SEQ ID NO:36 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 43. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the vc17\_1  
30 protein.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone vc17\_1 should be approximately 1783 bp.

The nucleotide sequence disclosed herein for vc17\_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vc17\_1 demonstrated at least some similarity with sequences identified as N73805 (yz80g02.s1 Homo sapiens cDNA clone 289394 3'), and T24437 (Human gene signature HUMGS06471). Based upon sequence similarity, vc17\_1 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts an additional potential transmembrane domain within the vc17\_1 protein sequence centered around amino acid 60 of SEQ ID NO:36.

#### Clone "vc21\_1"

A polynucleotide of the present invention has been identified as clone "vc21\_1". vc21\_1 was isolated from a human fetal brain cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. vc21\_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "vc21\_1 protein").

The nucleotide sequence of vc21\_1 as presently determined is reported in SEQ ID NO:37, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the vc21\_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:38. Amino acids 11 to 23 of SEQ ID NO:38 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 24. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the vc21\_1 protein.

Another potential vc21\_1 reading frame and predicted amino acid sequence is encoded by basepairs 796 to 1014 of SEQ ID NO:37 and is reported in SEQ ID NO:102.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone vc21\_1 should be approximately 1773 bp.

The nucleotide sequence disclosed herein for vc21\_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vc21\_1 demonstrated at least some similarity with sequences identified as W85910 (zh52b10.s1 Soares fetal liver spleen 1NFLS S1 Homo sapiens cDNA clone 415675 3', mRNA sequence) and T24609 (Human gene signature



HUMGS06668). Based upon sequence similarity, vc21\_1 proteins and each similar protein or peptide may share at least some activity.

Clone "vc23\_1"

5 A polynucleotide of the present invention has been identified as clone "vc23\_1". vc23\_1 was isolated from a human fetal brain cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. vc23\_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "vc23\_1 protein").

10 The nucleotide sequence of vc23\_1 as presently determined is reported in SEQ ID NO:39, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the vc23\_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:40. Amino acids 28 to 40 of SEQ ID NO:40 are a predicted leader/signal sequence, with the predicted mature  
15 amino acid sequence beginning at amino acid 41. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the vc23\_1 protein.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone  
20 vc23\_1 should be approximately 1998 bp.

The nucleotide sequence disclosed herein for vc23\_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vc23\_1 demonstrated at least some similarity with sequences identified as AA580484 (nn22a05.s1 NCI\_CGAP\_Co12 Homo sapiens cDNA clone  
25 IMAGE:1084592 similar to TR:G1209718 G1209718 HYPOTHETICAL 50.1 KD PROTEIN, mRNA sequence), T25530 (Human gene signature HUMGS07700), U41293 (Saccharomyces cerevisiae putative serine/threonine protein kinase gene, putative ribosomal protein L25 gene, and malate dehydrogenase (MDH2) gene, complete cds), and Z74866 (S.cerevisiae chromosome XV reading frame ORF YOL124c). The predicted  
30 amino acid sequence disclosed herein for vc23\_1 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted vc23\_1 protein demonstrated at least some similarity to sequences identified as U41293 (unknown [Saccharomyces cerevisiae]) and Z74866 (ORF YOL124c [Saccharo-

myces cerevisiae]). Based upon sequence similarity, vc23\_1 proteins and each similar protein or peptide may share at least some activity. The vc23\_1 protein contains a "N-6 adenine-specific DNA methylases signature" motif. The TopPredII computer program predicts a potential transmembrane domain within the vc23\_1 protein sequence centered  
5 around amino acid 232 of SEQ ID NO:40.

vc23\_1 protein was expressed in a COS cell expression system, and an expressed protein band of approximately 51 kDa was detected in membrane fractions using SDS polyacrylamide gel electrophoresis.

10 Clone "vc25\_1"

A polynucleotide of the present invention has been identified as clone "vc25\_1". vc25\_1 was isolated from a human fetal brain cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. vc25\_1 is a full-length clone, including the  
15 entire coding sequence of a secreted protein (also referred to herein as "vc25\_1 protein").

The nucleotide sequence of vc25\_1 as presently determined is reported in SEQ ID NO:41, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the vc25\_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:42. Amino acids 25 to 37  
20 of SEQ ID NO:42 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 38. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the vc25\_1 protein.

25 The EcoRI/NotI restriction fragment obtainable from the deposit containing clone vc25\_1 should be approximately 1653 bp.

The nucleotide sequence disclosed herein for vc25\_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vc25\_1 demonstrated at least some similarity with sequences  
30 identified as N21690 (yx63h08.s1 Soares melanocyte 2NbHM Homo sapiens cDNA clone 266463 3', mRNA sequence) and T25257 (Human gene signature HUMGS07418). Based upon sequence similarity, vc25\_1 proteins and each similar protein or peptide may share at least some activity.

vc25\_1 protein was expressed in a COS cell expression system, and an expressed protein band of approximately 15 kDa was detected in membrane fractions using SDS polyacrylamide gel electrophoresis.

5           Clone "vc26\_1"

A polynucleotide of the present invention has been identified as clone "vc26\_1". vc26\_1 was isolated from a human fetal brain cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. vc26\_1 is a full-length clone, including the  
10   entire coding sequence of a secreted protein (also referred to herein as "vc26\_1 protein").

The nucleotide sequence of vc26\_1 as presently determined is reported in SEQ ID NO:43, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the vc26\_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:44. Amino acids 11 to 23  
15   of SEQ ID NO:44 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 24. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the vc26\_1 protein.

20           If the "G" residue at position 669 of SEQ ID NO:43 were deleted to create a frameshift, another potential vc26\_1 reading frame and predicted amino acid sequence could be encoded by what would then be basepairs 87 to 992 of the deletion-containing version of SEQ ID NO:43. This potential vc26\_1 reading frame and predicted amino acid sequence is reported in SEQ ID NO:103. Amino acids 11 to 23 of both SEQ ID NO:44 and  
25   SEQ ID NO:103 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 24, or are a transmembrane domain.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone vc26\_1 should be approximately 1982 bp.

The nucleotide sequence disclosed herein for vc26\_1 was searched against the  
30   GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vc26\_1 demonstrated at least some similarity with sequences identified as AA877534 (nr01g08.s1 NCI\_CGAP\_Co10 Homo sapiens cDNA clone IMAGE:1160606 3', mRNA sequence) and T25645 (Human gene signature HUMGS07835). The predicted vc26\_1 protein of SEQ ID NO:10 contains an immuno-

globulins and major histocompatibility complex proteins signature at amino acid 131. Based upon sequence similarity, vc26\_1 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts seven additional potential transmembrane domains within the vc26\_1 protein sequence, centered around  
5 amino acids 60, 100, 120, 160, 210, 250, and 290 of SEQ ID NO:44, respectively.

#### Clone "vc30\_1"

A polynucleotide of the present invention has been identified as clone "vc30\_1". vc30\_1 was isolated from a human fetal brain cDNA library and was identified as  
10 encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. vc30\_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "vc30\_1 protein").

The nucleotide sequence of vc30\_1 as presently determined is reported in SEQ ID NO:45, and includes a poly(A) tail. What applicants presently believe to be the proper  
15 reading frame and the predicted amino acid sequence of the vc30\_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:46. Amino acids 19 to 31 of SEQ ID NO:46 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 32. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should  
20 the predicted leader/signal sequence not be separated from the remainder of the vc30\_1 protein.

If a frameshift were introduced in the nucleotide sequence of SEQ ID NO:45 by deleting the cytosine residue at position 1393, another potential vc30\_1 reading frame and predicted amino acid sequence could be encoded by what would then be basepairs 1317  
25 to 1659 of SEQ ID NO:45 and is reported in SEQ ID NO:104.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone vc30\_1 should be approximately 1887 bp.

The nucleotide sequence disclosed herein for vc30\_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and  
30 FASTA search protocols. vc30\_1 demonstrated at least some similarity with sequences identified as AA496421 (zv37c04.r1 Soares ovary tumor NbHOT Homo sapiens cDNA clone 755814 5', mRNA sequence). The predicted amino acid sequence disclosed herein for vc30\_1 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted vc30\_1 protein demonstrated at least

some similarity to sequences identified as AF047760 (phosphatidic acid phosphohydrolase type 2c [Homo sapiens]). Based upon sequence similarity, vc30\_1 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts an additional potential transmembrane domain within the vc30\_1 protein sequence centered around amino acid 55 of SEQ ID NO:46.

#### Clone "vd1\_1"

A polynucleotide of the present invention has been identified as clone "vd1\_1". vd1\_1 was isolated from a human adult skin cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. vd1\_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "vd1\_1 protein").

The nucleotide sequence of vd1\_1 as presently determined is reported in SEQ ID NO:47, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the vd1\_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:48. Amino acids 8 to 20 of SEQ ID NO:48 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 21. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the vd1\_1 protein.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone vd1\_1 should be approximately 2000 bp.

The nucleotide sequence disclosed herein for vd1\_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vd1\_1 demonstrated at least some similarity with sequences identified as AA582963 (nr72e02.s1 NCI\_CGAP\_Lar1 Homo sapiens cDNA clone IMAGE 1089434) and AC002389 (Human DNA from chromosome 19 specific cosmid R28461, genomic sequence, complete sequence). Based upon sequence similarity, vd1\_1 proteins and each similar protein or peptide may share at least some activity. There is an 18-residue amino acid stretch (with an approximate consensus sequence shown in SEQ ID NO:105 (HHAAGQAGNEAGRFGQGV)) that is almost tandemly repeated 15 times in the vd1\_1 protein. Nucleotides 406-1668 of SEQ ID NO:47, which encode a region of SEQ ID

NO:48 that includes the 18-residue amino acid repeats, may represent an alternatively spliced region in mRNA molecules transcribed from the vd1\_1 gene.

vd1\_protein was expressed in a COS cell expression system, and an expressed protein band of approximately 55 kDa was detected in conditioned medium using SDS  
5 polyacrylamide gel electrophoresis.

#### Clone "vd2\_1"

A polynucleotide of the present invention has been identified as clone "vd2\_1".  
vd2\_1 was isolated from a human adult skin cDNA library and was identified as encoding  
10 a secreted or transmembrane protein on the basis of computer analysis of the amino acid  
sequence of the encoded protein. vd2\_1 is a full-length clone, including the entire coding  
sequence of a secreted protein (also referred to herein as "vd2\_1 protein").

The nucleotide sequence of vd2\_1 as presently determined is reported in SEQ ID  
NO:49, and includes a poly(A) tail. What applicants presently believe to be the proper  
15 reading frame and the predicted amino acid sequence of the vd2\_1 protein corresponding  
to the foregoing nucleotide sequence is reported in SEQ ID NO:50. Amino acids 2 to 14  
of SEQ ID NO:50 are a predicted leader/signal sequence, with the predicted mature  
amino acid sequence beginning at amino acid 15. Due to the hydrophobic nature of the  
predicted leader/signal sequence, it is likely to act as a transmembrane domain should  
20 the predicted leader/signal sequence not be separated from the remainder of the vd2\_1  
protein.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone  
vd2\_1 should be approximately 900 bp.

The nucleotide sequence disclosed herein for vd2\_1 was searched against the  
25 GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and  
FASTA search protocols. vd2\_1 demonstrated at least some similarity with sequences  
identified as H03945 (yj44c02.s1 Homo sapiens cDNA clone 151586 3'). Based upon  
sequence similarity, vd2\_1 proteins and each similar protein or peptide may share at least  
some activity. The TopPredII computer program predicts a potential transmembrane  
30 domain within the vd2\_1 protein sequence centered around amino acid 115 of SEQ ID  
NO:50.

Clone "vd3\_1"

A polynucleotide of the present invention has been identified as clone "vd3\_1". vd3\_1 was isolated from a human adult skin cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid  
5 sequence of the encoded protein. vd3\_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "vd3\_1 protein").

The nucleotide sequence of vd3\_1 as presently determined is reported in SEQ ID NO:51, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the vd3\_1 protein corresponding  
10 to the foregoing nucleotide sequence is reported in SEQ ID NO:52. Amino acids 5 to 17 of SEQ ID NO:52 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 18. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the vd3\_1  
15 protein.

If a frameshift were introduced into the nucleotide sequence of SEQ ID NO:19 by inserting an adenine or thymine residue at position 1132 or 1133, another potential vd3\_1 reading frame and predicted amino acid sequence could be encoded by basepairs 176 to 1281 of SEQ ID NO:51 and is reported in SEQ ID NO:106. Amino acids 5 to 17 of SEQ ID  
20 NO:106 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 18 of SEQ ID NO:106, or are a transmembrane domain.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone vd3\_1 should be approximately 1537 bp.

The nucleotide sequence disclosed herein for vd3\_1 was searched against the  
25 GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vd3\_1 demonstrated at least some similarity with sequences identified as AA873028 (ob11e05.s1 NCI\_CGAP\_Kid3 Homo sapiens cDNA clone IMAGE 1323392 3', mRNA sequence), AC002389 (Human DNA from chromosome 19 specific cosmid R28461, genomic sequence, complete sequence), and AD001502 (Homo  
30 sapiens DNA from chromosome 19-cosmid f21246, genomic sequence). Based upon sequence similarity, vd3\_1 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts an additional possible transmembrane domain within the vd3\_1 protein sequence centered around amino acid

290 of SEQ ID NO:52. The vd3\_1 protein is apparently a splice variant of the vd4\_1 protein described below.

vd3\_1 protein was expressed in a COS cell expression system, and an expressed protein band of approximately 42 kDa was detected in membrane fractions using SDS  
5 polyacrylamide gel electrophoresis.

#### Clone "vd4\_1"

A polynucleotide of the present invention has been identified as clone "vd4\_1". vd4\_1 was isolated from a human adult skin cDNA library and was identified as encoding  
10 a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. vd4\_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "vd4\_1 protein").

The nucleotide sequence of vd4\_1 as presently determined is reported in SEQ ID NO:53, and includes a poly(A) tail. What applicants presently believe to be the proper  
15 reading frame and the predicted amino acid sequence of the vd4\_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:54. Amino acids 5 to 17 of SEQ ID NO:54 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 18. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should  
20 the predicted leader/signal sequence not be separated from the remainder of the vd4\_1 protein.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone vd4\_1 should be approximately 1897 bp.

The nucleotide sequence disclosed herein for vd4\_1 was searched against the  
25 GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vd4\_1 demonstrated at least some similarity with sequences identified as AA706316 (ah28e11.s1 Soares parathyroid tumor NbHPA Homo sapiens cDNA clone 1240172 3', mRNA sequence), AC002389 (Human DNA from chromosome 19 specific cosmid R28461, genomic sequence, complete sequence), and AD001502  
30 (Homo sapiens DNA from chromosome 19-cosmid f21246, genomic sequence). Based upon sequence similarity, vd4\_1 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts an additional possible transmembrane domain within the vd4\_1 protein sequence centered around amino acid



290 of SEQ ID NO:54. The vd4\_1 protein is apparently a splice variant of the vd3\_1 protein described above.

vd4\_1 protein was expressed in a COS cell expression system, and an expressed protein band of approximately 54 kDa was detected in conditioned medium using SDS  
5 polyacrylamide gel electrophoresis.

#### Clone "ve4\_1"

A polynucleotide of the present invention has been identified as clone "ve4\_1". ve4\_1 was isolated from a human adult brain (Alzheimer's hippocampus level 7) cDNA  
10 library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. ve4\_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "ve4\_1 protein").

The nucleotide sequence of ve4\_1 as presently determined is reported in SEQ ID  
15 NO:55, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the ve4\_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:56. Amino acids 25 to 37 of SEQ ID NO:56 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 38. Due to the hydrophobic nature of the  
20 predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the ve4\_1 protein.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone ve4\_1 should be approximately 1578 bp.

25 The nucleotide sequence disclosed herein for ve4\_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. ve4\_1 demonstrated at least some similarity with sequences identified as AA707153 (zj33f10.s1 Soares fetal liver spleen 1NFLS S1 Homo sapiens cDNA clone 452107 3' similar to TR P70295 P70295 AUP1 PRECURSOR, mRNA  
30 sequence) and U41736 (Mus musculus ancient ubiquitous 46 kDa protein AUP1 precursor (Aup1) mRNA, complete cds). The predicted amino acid sequence disclosed herein for ve4\_1 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted ve4\_1 protein demonstrated at least

some similarity to the sequence identified as U41736 (ancient ubiquitous 46 kDa protein AUP46 precursor [Mus musculus]). Based upon sequence similarity, ve4\_1 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts two additional potential transmembrane domains within the ve4\_1 protein sequence, one centered around amino acid 110 and another around amino acid 210 of SEQ ID NO:56.

ve4\_1 protein was expressed in a COS cell expression system, and an expressed protein band of approximately 41 kDa was detected in membrane fractions using SDS polyacrylamide gel electrophoresis.

#### Clone "ve8\_1"

A polynucleotide of the present invention has been identified as clone "ve8\_1". ve8\_1 was isolated from a human adult brain (Alzheimer's hippocampus level 7) cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. ve8\_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "ve8\_1 protein").

The nucleotide sequence of ve8\_1 as presently determined is reported in SEQ ID NO:57, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the ve8\_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:58. Amino acids 18 to 30 of SEQ ID NO:58 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 31. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the ve8\_1 protein.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone ve8\_1 should be approximately 2093 bp.

The nucleotide sequence disclosed herein for ve8\_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. ve8\_1 demonstrated at least some similarity with sequences identified as AC004126 (Homo sapiens Chromosome 11q12 pac pDJ606g6; HTGS phase 1, 17 unordered pieces). Based upon sequence similarity, ve8\_1 proteins and each similar

protein or peptide may share at least some activity. The TopPredII computer program predicts four additional potential transmembrane domains within the ve8\_1 protein sequence, centered around amino acids 94, 147, 150, and 193 of SEQ ID NO:58, respectively.

5

Clone "vf1\_1"

A polynucleotide of the present invention has been identified as clone "vf1\_1". vf1\_1 was isolated from a human adult heart cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. vf1\_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "vf1\_1 protein").

The nucleotide sequence of vf1\_1 as presently determined is reported in SEQ ID NO:59, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the vf1\_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:60. Amino acids 13 to 25 of SEQ ID NO:60 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 26. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the vf1\_1 protein.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone vf1\_1 should be approximately 1382 bp.

The nucleotide sequence disclosed herein for vf1\_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vf1\_1 demonstrated at least some similarity with sequences identified as AA349531 (EST56314 Infant brain Homo sapiens cDNA 5' end, mRNA sequence) and AA532642 (nj17c07.s1 NCI\_CGAP\_Pr22 Homo sapiens cDNA clone IMAGE 986604, mRNA sequence). Based upon sequence similarity, vf1\_1 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts an additional potential transmembrane domain within the vf1\_1 protein sequence centered around amino acid 138 of SEQ ID NO:60.

vf1\_1 protein was expressed in a COS cell expression system, and an expressed protein band of approximately 40 kDa was detected in membrane fractions using SDS polyacrylamide gel electrophoresis.

5           Clone "vh1\_1"

A polynucleotide of the present invention has been identified as clone "vh1\_1". vh1\_1 was isolated from a human adult thymus cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. vh1\_1 is a full-length clone, including the  
10   entire coding sequence of a secreted protein (also referred to herein as "vh1\_1 protein").

The nucleotide sequence of vh1\_1 as presently determined is reported in SEQ ID NO:61, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the vh1\_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:62. Amino acids 42 to 54  
15   of SEQ ID NO:62 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 55. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the vh1\_1 protein.

20           Another potential vh1\_1 reading frame and predicted amino acid sequence that could be encoded by basepairs 833 to 1054 of SEQ ID NO:61 is reported in SEQ ID NO:107. Amino acids 22 to 34 of SEQ ID NO:107 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 35 of SEQ ID NO:107, or are a transmembrane domain. If a frameshift were introduced into the  
25   nucleotide sequence of SEQ ID NO:61 approximately between position 830 and position 998, the open reading frame of SEQ ID NO:62 could be joined to the open reading frame of SEQ ID NO:107.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone vh1\_1 should be approximately 1529 bp.

30           The nucleotide sequence disclosed herein for vh1\_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vh1\_1 demonstrated at least some similarity with sequences identified as AA927736 (om72h10.s1 NCI\_CGAP\_GC4 Homo sapiens cDNA clone

IMAGE:1552771 3', mRNA sequence). Based upon sequence similarity, vh1\_1 proteins and each similar protein or peptide may share at least some activity.

Clone "vi1\_1"

5 A polynucleotide of the present invention has been identified as clone "vi1\_1". vi1\_1 was isolated from a human adult aorta cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. vi1\_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "vi1\_1 protein").

10 The nucleotide sequence of vi1\_1 as presently determined is reported in SEQ ID NO:63, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the vi1\_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:64. Amino acids 13 to 25 of SEQ ID NO:64 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 26. Due to the hydrophobic nature of the  
15 predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the vi1\_1 protein.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone  
20 vi1\_1 should be approximately 2348 bp.

The nucleotide sequence disclosed herein for vi1\_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vi1\_1 demonstrated at least some similarity with sequences identified as AA411541 (zv30a03.r1 Soares ovary tumor NbHOT Homo sapiens cDNA  
25 clone 755116 5' similar to WP:F07H5.11 CE03160) and T21484 (Human gene signature HUMGS02856). The predicted amino acid sequence disclosed herein for vi1\_1 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted vi1\_1 protein demonstrated at least some similarity to the sequence identified as Z68314 (F46C5.9 [Caenorhabditis elegans]). The  
30 amino acid sequence of the predicted vi1\_1 protein indicates that it may contain a beta-transducin family Trp-Asp repeat signature (WD-40) motif centered around residue 300 of SEQ ID NO:28. The WD-40 motif is thought to be a widely distributed protein-protein interaction domain. Based upon sequence similarity, vi1\_1 proteins and each similar

protein or peptide may share at least some activity. The TopPredII computer program predicts two additional possible transmembrane domains within the vi1\_1 protein sequence, one centered around amino acid 200 and another around amino acid 340 of SEQ ID NO:64.

- 5 vi1\_1 protein was expressed in a COS cell expression system, and an expressed protein band of approximately 45 kDa was detected in membrane fractions using SDS polyacrylamide gel electrophoresis.

#### Deposit of Clones

- 10 Clones vc3\_1, vc4\_1, vc5\_1, vc7\_1, vc9\_1, vc10\_1, vc11\_1, vc14\_1, vd1\_1, and vd2\_1 were deposited on April 24, 1998 with the American Type Culture Collection (10801 University Boulevard, Manassas, Virginia 20110-2209 U.S.A.) as an original deposit under the Budapest Treaty and were given the accession number ATCC 98748, from which each clone comprising a particular polynucleotide is obtainable.

- 15 Clone vc21\_1 was deposited on June 10, 1998 with the American Type Culture Collection (10801 University Boulevard, Manassas, Virginia 20110-2209 U.S.A.) as an original deposit under the Budapest Treaty and was given the accession number ATCC 98785, from which each clone comprising a particular polynucleotide is obtainable.

- 20 Clones vc16\_1, vc17\_1, vc23\_1, vc25\_1, vc26\_1, ve4\_1, and vf1\_1 were deposited on June 10, 1998 with the American Type Culture Collection (10801 University Boulevard, Manassas, Virginia 20110-2209 U.S.A.) as an original deposit under the Budapest Treaty and were given the accession number ATCC 98784, from which each clone comprising a particular polynucleotide is obtainable.

- 25 Clones vb2\_1, vb3\_1, vb4\_1, vb5\_1, vb6\_1, vb7\_1, vb8\_1, vb9\_1, vc30\_1, vd3\_1, vd4\_1, ve8\_1, vh1\_1, and vi1\_1 were deposited on July 1, 1998 with the American Type Culture Collection (10801 University Boulevard, Manassas, Virginia 20110-2209 U.S.A.) as an original deposit under the Budapest Treaty and were given the accession number ATCC 98804, from which each clone comprising a particular polynucleotide is obtainable.

- 30 All restrictions on the availability to the public of the deposited material will be irrevocably removed upon the granting of the patent, except for the requirements specified in 37 C.F.R. § 1.808(b), and the term of the deposit will comply with 37 C.F.R. § 1.806.

Each clone has been transfected into separate bacterial cells (*E. coli*) in these composite deposits. Each clone can be removed from the vector in which it was deposited by performing an EcoRI/NotI digestion (5' site, EcoRI; 3' site, NotI) to produce the appropriate fragment for such clone. Each clone was deposited in either the pED6 or pNOTs vector depicted in Figures 1A and 1B, respectively. The pED6dpc2 vector ("pED6") was derived from pED6dpc1 by insertion of a new polylinker to facilitate cDNA cloning (Kaufman *et al.*, 1991, *Nucleic Acids Res.* 19: 4485-4490); the pNOTs vector was derived from pMT2 (Kaufman *et al.*, 1989, *Mol. Cell. Biol.* 9: 946-958) by deletion of the DHFR sequences, insertion of a new polylinker, and insertion of the M13 origin of replication in the ClaI site. In some instances, the deposited clone can become "flipped" (i.e., in the reverse orientation) in the deposited isolate. In such instances, the cDNA insert can still be isolated by digestion with EcoRI and NotI. However, NotI will then produce the 5' site and EcoRI will produce the 3' site for placement of the cDNA in proper orientation for expression in a suitable vector. The cDNA may also be expressed from the vectors in which they were deposited.

Bacterial cells containing a particular clone can be obtained from the composite deposit as follows:

An oligonucleotide probe or probes should be designed to the sequence that is known for that particular clone. This sequence can be derived from the sequences provided herein, or from a combination of those sequences. The sequence of an oligonucleotide probe that was used to isolate or to sequence each full-length clone is identified below, and should be most reliable in isolating the clone of interest.

<u>Clone</u>	<u>Probe Sequence</u>
vb2_1	SEQ ID NO:65
vb3_1	SEQ ID NO:66
vb4_1	SEQ ID NO:67
vb5_1	SEQ ID NO:68
vb6_1	SEQ ID NO:69
vb7_1	SEQ ID NO:70
vb8_1	SEQ ID NO:71
vb9_1	SEQ ID NO:72
vc3_1	SEQ ID NO:73
vc4_1	SEQ ID NO:74

	vc5_1	SEQ ID NO:75
	vc7_1	SEQ ID NO:76
	vc9_1	SEQ ID NO:77
	vc10_1	SEQ ID NO:78
5	vc11_1	SEQ ID NO:79
	vc14_1	SEQ ID NO:80
	vc16_1	SEQ ID NO:81
	vc17_1	SEQ ID NO:82
	vc21_1	SEQ ID NO:83
10	vc23_1	SEQ ID NO:84
	vc25_1	SEQ ID NO:85
	vc26_1	SEQ ID NO:86
	vc30_1	SEQ ID NO:87
	vd1_1	SEQ ID NO:88
15	vd2_1	SEQ ID NO:89
	vd3_1	SEQ ID NO:90
	vd4_1	SEQ ID NO:91
	ve4_1	SEQ ID NO:92
	ve8_1	SEQ ID NO:93
20	vf1_1	SEQ ID NO:94
	vh1_1	SEQ ID NO:95
	vi1_1	SEQ ID NO:96

In the sequences listed above which include an N at position 2, that position is occupied  
 25 in preferred probes/primers by a biotinylated phosphoramidite residue rather than a  
 nucleotide (such as, for example, that produced by use of biotin phosphoramidite (1-  
 dimethoxytrityloxy-2-(N-biotinyl-4-aminobutyl)-propyl-3-O-(2-cyanoethyl)-(N,N-  
 diisopropyl)-phosphoramidite) (Glen Research, cat. no. 10-1953)).

The design of the oligonucleotide probe should preferably follow these  
 30 parameters:

- (a) It should be designed to an area of the sequence which has the fewest  
 ambiguous bases ("N's"), if any;
- (b) It should be designed to have a  $T_m$  of approx. 80 ° C (assuming 2° for each  
 A or T and 4 degrees for each G or C).



The oligonucleotide should preferably be labeled with  $\gamma$ -<sup>32</sup>P ATP (specific activity 6000 Ci/mmol) and T4 polynucleotide kinase using commonly employed techniques for labeling oligonucleotides. Other labeling techniques can also be used. Unincorporated label should preferably be removed by gel filtration chromatography or other established methods. The amount of radioactivity incorporated into the probe should be quantitated by measurement in a scintillation counter. Preferably, specific activity of the resulting probe should be approximately 4e+6 dpm/pmol.

The bacterial culture containing the pool of full-length clones should preferably be thawed and 100  $\mu$ l of the stock used to inoculate a sterile culture flask containing 25 ml of sterile L-broth containing ampicillin at 100  $\mu$ g/ml. The culture should preferably be grown to saturation at 37°C, and the saturated culture should preferably be diluted in fresh L-broth. Aliquots of these dilutions should preferably be plated to determine the dilution and volume which will yield approximately 5000 distinct and well-separated colonies on solid bacteriological media containing L-broth containing ampicillin at 100  $\mu$ g/ml and agar at 1.5% in a 150 mm petri dish when grown overnight at 37°C. Other known methods of obtaining distinct, well-separated colonies can also be employed.

Standard colony hybridization procedures should then be used to transfer the colonies to nitrocellulose filters and lyse, denature and bake them.

The filter is then preferably incubated at 65°C for 1 hour with gentle agitation in 6X SSC (20X stock is 175.3 g NaCl/liter, 88.2 g Na citrate/liter, adjusted to pH 7.0 with NaOH) containing 0.5% SDS, 100  $\mu$ g/ml of yeast RNA, and 10 mM EDTA (approximately 10 mL per 150 mm filter). Preferably, the probe is then added to the hybridization mix at a concentration greater than or equal to 1e+6 dpm/mL. The filter is then preferably incubated at 65°C with gentle agitation overnight. The filter is then preferably washed in 500 mL of 2X SSC/0.5% SDS at room temperature without agitation, preferably followed by 500 mL of 2X SSC/0.1% SDS at room temperature with gentle shaking for 15 minutes. A third wash with 0.1X SSC/0.5% SDS at 65°C for 30 minutes to 1 hour is optional. The filter is then preferably dried and subjected to autoradiography for sufficient time to visualize the positives on the X-ray film. Other known hybridization methods can also be employed.

The positive colonies are picked, grown in culture, and plasmid DNA isolated using standard procedures. The clones can then be verified by restriction analysis, hybridization analysis, or DNA sequencing.

Fragments of the proteins of the present invention which are capable of exhibiting biological activity are also encompassed by the present invention. Fragments of the protein may be in linear form or they may be cyclized using known methods, for example, as described in H.U. Saragovi, *et al.*, Bio/Technology 10, 773-778 (1992) and in R.S. McDowell, *et al.*, J. Amer. Chem. Soc. 114, 9245-9253 (1992), both of which are incorporated herein by reference. Such fragments may be fused to carrier molecules such as immunoglobulins for many purposes, including increasing the valency of protein binding sites. For example, fragments of the protein may be fused through "linker" sequences to the Fc portion of an immunoglobulin. For a bivalent form of the protein, such a fusion could be to the Fc portion of an IgG molecule. Other immunoglobulin isotypes may also be used to generate such fusions. For example, a protein - IgM fusion would generate a decavalent form of the protein of the invention.

The present invention also provides both full-length and mature forms of the disclosed proteins. The full-length form of the such proteins is identified in the sequence listing by translation of the nucleotide sequence of each disclosed clone. The mature form(s) of such protein may be obtained by expression of the disclosed full-length polynucleotide (preferably those deposited with ATCC) in a suitable mammalian cell or other host cell. The sequence(s) of the mature form(s) of the protein may also be determinable from the amino acid sequence of the full-length form.

The present invention also provides genes corresponding to the polynucleotide sequences disclosed herein. "Corresponding genes" are the regions of the genome that are transcribed to produce the mRNAs from which cDNA polynucleotide sequences are derived and may include contiguous regions of the genome necessary for the regulated expression of such genes. Corresponding genes may therefore include but are not limited to coding sequences, 5' and 3' untranslated regions, alternatively spliced exons, introns, promoters, enhancers, and silencer or suppressor elements. The corresponding genes can be isolated in accordance with known methods using the sequence information disclosed herein. Such methods include the preparation of probes or primers from the disclosed sequence information for identification and/or amplification of genes in appropriate genomic libraries or other sources of genomic materials. An "isolated gene" is a gene that has been separated from the adjacent coding sequences, if any, present in the genome of the organism from which the gene was isolated.

The chromosomal location corresponding to the polynucleotide sequences disclosed herein may also be determined, for example by hybridizing appropriately

labeled polynucleotides of the present invention to chromosomes *in situ*. It may also be possible to determine the corresponding chromosomal location for a disclosed polynucleotide by identifying significantly similar nucleotide sequences in public databases, such as expressed sequence tags (ESTs), that have already been mapped to particular chromosomal locations. For at least some of the polynucleotide sequences disclosed herein, public database sequences having at least some similarity to the polynucleotide of the present invention have been listed by database accession number. Searches using the GenBank accession numbers of these public database sequences can then be performed at an Internet site provided by the National Center for Biotechnology Information having the address <http://www.ncbi.nlm.nih.gov/UniGene/>, in order to identify "UniGene clusters" of overlapping sequences. Many of the "UniGene clusters" so identified will already have been mapped to particular chromosomal sites.

Organisms that have enhanced, reduced, or modified expression of the gene(s) corresponding to the polynucleotide sequences disclosed herein are provided. The desired change in gene expression can be achieved through the use of antisense polynucleotides or ribozymes that bind and/or cleave the mRNA transcribed from the gene (Albert and Morris, 1994, *Trends Pharmacol. Sci.* **15**(7): 250-254; Lavarosky *et al.*, 1997, *Biochem. Mol. Med.* **62**(1): 11-22; and Hampel, 1998, *Prog. Nucleic Acid Res. Mol. Biol.* **58**: 1-39; all of which are incorporated by reference herein). Transgenic animals that have multiple copies of the gene(s) corresponding to the polynucleotide sequences disclosed herein, preferably produced by transformation of cells with genetic constructs that are stably maintained within the transformed cells and their progeny, are provided. Transgenic animals that have modified genetic control regions that increase or reduce gene expression levels, or that change temporal or spatial patterns of gene expression, are also provided (see European Patent No. 0 649 464 B1, incorporated by reference herein). In addition, organisms are provided in which the gene(s) corresponding to the polynucleotide sequences disclosed herein have been partially or completely inactivated, through insertion of extraneous sequences into the corresponding gene(s) or through deletion of all or part of the corresponding gene(s). Partial or complete gene inactivation can be accomplished through insertion, preferably followed by imprecise excision, of transposable elements (Plasterk, 1992, *Bioessays* **14**(9): 629-633; Zwaal *et al.*, 1993, *Proc. Natl. Acad. Sci. USA* **90**(16): 7431-7435; Clark *et al.*, 1994, *Proc. Natl. Acad. Sci. USA* **91**(2): 719-722; all of which are incorporated by reference herein), or through homologous recombination, preferably detected by positive/negative genetic selection strategies (Mansour *et al.*, 1988,

*Nature* 336: 348-352; U.S. Patent Nos. 5,464,764; 5,487,992; 5,627,059; 5,631,153; 5,614,396; 5,616,491; and 5,679,523; all of which are incorporated by reference herein). These organisms with altered gene expression are preferably eukaryotes and more preferably are mammals. Such organisms are useful for the development of non-human models for the study of disorders involving the corresponding gene(s), and for the development of assay systems for the identification of molecules that interact with the protein product(s) of the corresponding gene(s).

Where the protein of the present invention is membrane-bound (e.g., is a receptor), the present invention also provides for soluble forms of such protein. In such forms, part or all of the intracellular and transmembrane domains of the protein are deleted such that the protein is fully secreted from the cell in which it is expressed. The intracellular and transmembrane domains of proteins of the invention can be identified in accordance with known techniques for determination of such domains from sequence information. For example, the TopPredII computer program can be used to predict the location of transmembrane domains in an amino acid sequence, domains which are described by the location of the center of the transmembrane domain, with at least ten transmembrane amino acids on each side of the reported central residue(s).

Proteins and protein fragments of the present invention include proteins with amino acid sequence lengths that are at least 25% (more preferably at least 50%, and most preferably at least 75%) of the length of a disclosed protein and have at least 60% sequence identity (more preferably, at least 75% identity; most preferably at least 90% or 95% identity) with that disclosed protein, where sequence identity is determined by comparing the amino acid sequences of the proteins when aligned so as to maximize overlap and identity while minimizing sequence gaps. Also included in the present invention are proteins and protein fragments that contain a segment preferably comprising 8 or more (more preferably 20 or more, most preferably 30 or more) contiguous amino acids that shares at least 75% sequence identity (more preferably, at least 85% identity; most preferably at least 95% identity) with any such segment of any of the disclosed proteins.

In particular, sequence identity may be determined using WU-BLAST (Washington University BLAST) version 2.0 software, which builds upon WU-BLAST version 1.4, which in turn is based on the public domain NCBI-BLAST version 1.4 (Altschul and Gish, 1996, Local alignment statistics, Doolittle *ed.*, *Methods in Enzymology* 266: 460-480; Altschul *et al.*, 1990, Basic local alignment search tool, *Journal of*

*Molecular Biology* **215**: 403-410; Gish and States, 1993, Identification of protein coding regions by database similarity search, *Nature Genetics* **3**: 266-272; Karlin and Altschul, 1993, Applications and statistics for multiple high-scoring segments in molecular sequences, *Proc. Natl. Acad. Sci. USA* **90**: 5873-5877; all of which are incorporated by reference herein). WU-BLAST version 2.0 executable programs for several UNIX platforms can be downloaded from <ftp://blast.wustl.edu/blast/executables>. The complete suite of search programs (BLASTP, BLASTN, BLASTX, TBLASTN, and TBLASTX) is provided at that site, in addition to several support programs. WU-BLAST 2.0 is copyrighted and may not be sold or redistributed in any form or manner without the express written consent of the author; but the posted executables may otherwise be freely used for commercial, nonprofit, or academic purposes. In all search programs in the suite -- BLASTP, BLASTN, BLASTX, TBLASTN and TBLASTX -- the gapped alignment routines are integral to the database search itself, and thus yield much better sensitivity and selectivity while producing the more easily interpreted output. Gapping can optionally be turned off in all of these programs, if desired. The default penalty (Q) for a gap of length one is Q=9 for proteins and BLASTP, and Q=10 for BLASTN, but may be changed to any integer value including zero, one through eight, nine, ten, eleven, twelve through twenty, twenty-one through fifty, fifty-one through one hundred, etc. The default per-residue penalty for extending a gap (R) is R=2 for proteins and BLASTP, and R=10 for BLASTN, but may be changed to any integer value including zero, one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve through twenty, twenty-one through fifty, fifty-one through one hundred, etc. Any combination of values for Q and R can be used in order to align sequences so as to maximize overlap and identity while minimizing sequence gaps. The default amino acid comparison matrix is BLOSUM62, but other amino acid comparison matrices such as PAM can be utilized.

Species homologues of the disclosed polynucleotides and proteins are also provided by the present invention. As used herein, a "species homologue" is a protein or polynucleotide with a different species of origin from that of a given protein or polynucleotide, but with significant sequence similarity to the given protein or polynucleotide. Preferably, polynucleotide species homologues have at least 60% sequence identity (more preferably, at least 75% identity; most preferably at least 90% identity) with the given polynucleotide, and protein species homologues have at least 30% sequence

identity (more preferably, at least 45% identity; most preferably at least 60% identity) with the given protein, where sequence identity is determined by comparing the nucleotide sequences of the polynucleotides or the amino acid sequences of the proteins when aligned so as to maximize overlap and identity while minimizing sequence gaps. Species homologues may be isolated and identified by making suitable probes or primers from the sequences provided herein and screening a suitable nucleic acid source from the desired species. Preferably, species homologues are those isolated from mammalian species. Most preferably, species homologues are those isolated from certain mammalian species such as, for example, *Pan troglodytes*, *Gorilla gorilla*, *Pongo pygmaeus*, *Hylobates concolor*, *Macaca mulatta*, *Papio papio*, *Papio hamadryas*, *Cercopithecus aethiops*, *Cebus capucinus*, *Aotus trivirgatus*, *Sanguinus oedipus*, *Microcebus murinus*, *Mus musculus*, *Rattus norvegicus*, *Cricetulus griseus*, *Felis catus*, *Mustela vison*, *Canis familiaris*, *Oryctolagus cuniculus*, *Bos taurus*, *Ovis aries*, *Sus scrofa*, and *Equus caballus*, for which genetic maps have been created allowing the identification of syntenic relationships between the genomic organization of genes in one species and the genomic organization of the related genes in another species (O'Brien and Seuánez, 1988, *Ann. Rev. Genet.* **22**: 323-351; O'Brien *et al.*, 1993, *Nature Genetics* **3**:103-112; Johansson *et al.*, 1995, *Genomics* **25**: 682-690; Lyons *et al.*, 1997, *Nature Genetics* **15**: 47-56; O'Brien *et al.*, 1997, *Trends in Genetics* **13**(10): 393-399; Carver and Stubbs, 1997, *Genome Research* **7**:1123-1137; all of which are incorporated by reference herein).

The invention also encompasses allelic variants of the disclosed polynucleotides or proteins; that is, naturally-occurring alternative forms of the isolated polynucleotides which also encode proteins which are identical or have significantly similar sequences to those encoded by the disclosed polynucleotides. Preferably, allelic variants have at least 60% sequence identity (more preferably, at least 75% identity; most preferably at least 90% identity) with the given polynucleotide, where sequence identity is determined by comparing the nucleotide sequences of the polynucleotides when aligned so as to maximize overlap and identity while minimizing sequence gaps. Allelic variants may be isolated and identified by making suitable probes or primers from the sequences provided herein and screening a suitable nucleic acid source from individuals of the appropriate species.

The invention also includes polynucleotides with sequences complementary to those of the polynucleotides disclosed herein.

The present invention also includes polynucleotides that hybridize under reduced stringency conditions, more preferably stringent conditions, and most preferably highly

stringent conditions, to polynucleotides described herein. Examples of stringency conditions are shown in the table below: highly stringent conditions are those that are at least as stringent as, for example, conditions A-F; stringent conditions are at least as stringent as, for example, conditions G-L; and reduced stringency conditions are at least as stringent as, for example, conditions M-R.

Stringency Condition	Polynucleotide Hybrid	Hybrid Length (bp) <sup>‡</sup>	Hybridization Temperature and Buffer <sup>†</sup>	Wash Temperature and Buffer <sup>†</sup>
A	DNA:DNA	≥ 50	65°C; 1xSSC -or- 42°C; 1xSSC, 50% formamide	65°C; 0.3xSSC
B	DNA:DNA	<50	T <sub>B</sub> <sup>*</sup> ; 1xSSC	T <sub>B</sub> <sup>*</sup> ; 1xSSC
C	DNA:RNA	≥ 50	67°C; 1xSSC -or- 45°C; 1xSSC, 50% formamide	67°C; 0.3xSSC
D	DNA:RNA	<50	T <sub>D</sub> <sup>*</sup> ; 1xSSC	T <sub>D</sub> <sup>*</sup> ; 1xSSC
E	RNA:RNA	≥ 50	70°C; 1xSSC -or- 50°C; 1xSSC, 50% formamide	70°C; 0.3xSSC
F	RNA:RNA	<50	T <sub>F</sub> <sup>*</sup> ; 1xSSC	T <sub>F</sub> <sup>*</sup> ; 1xSSC
G	DNA:DNA	≥ 50	65°C; 4xSSC -or- 42°C; 4xSSC, 50% formamide	65°C; 1xSSC
H	DNA:DNA	<50	T <sub>H</sub> <sup>*</sup> ; 4xSSC	T <sub>H</sub> <sup>*</sup> ; 4xSSC
I	DNA:RNA	≥ 50	67°C; 4xSSC -or- 45°C; 4xSSC, 50% formamide	67°C; 1xSSC
J	DNA:RNA	<50	T <sub>J</sub> <sup>*</sup> ; 4xSSC	T <sub>J</sub> <sup>*</sup> ; 4xSSC
K	RNA:RNA	≥ 50	70°C; 4xSSC -or- 50°C; 4xSSC, 50% formamide	67°C; 1xSSC
L	RNA:RNA	<50	T <sub>L</sub> <sup>*</sup> ; 2xSSC	T <sub>L</sub> <sup>*</sup> ; 2xSSC
M	DNA:DNA	≥ 50	50°C; 4xSSC -or- 40°C; 6xSSC, 50% formamide	50°C; 2xSSC
N	DNA:DNA	<50	T <sub>N</sub> <sup>*</sup> ; 6xSSC	T <sub>N</sub> <sup>*</sup> ; 6xSSC
O	DNA:RNA	≥ 50	55°C; 4xSSC -or- 42°C; 6xSSC, 50% formamide	55°C; 2xSSC
P	DNA:RNA	<50	T <sub>P</sub> <sup>*</sup> ; 6xSSC	T <sub>P</sub> <sup>*</sup> ; 6xSSC
Q	RNA:RNA	≥ 50	60°C; 4xSSC -or- 45°C; 6xSSC, 50% formamide	60°C; 2xSSC
R	RNA:RNA	<50	T <sub>R</sub> <sup>*</sup> ; 4xSSC	T <sub>R</sub> <sup>*</sup> ; 4xSSC

<sup>‡</sup>: The hybrid length is that anticipated for the hybridized region(s) of the hybridizing polynucleotides. When hybridizing a polynucleotide to a target polynucleotide of unknown sequence, the hybrid length is assumed to be that of the hybridizing polynucleotide. When polynucleotides of known sequence are hybridized, the hybrid length can be determined by aligning the sequences of the polynucleotides and identifying the region or regions of optimal sequence complementarity.

<sup>†</sup>: SSPE (1xSSPE is 0.15M NaCl, 10mM NaH<sub>2</sub>PO<sub>4</sub>, and 1.25mM EDTA, pH 7.4) can be substituted for SSC (1xSSC is 0.15M NaCl and 15mM sodium citrate) in the hybridization and wash buffers; washes are performed for 15 minutes after hybridization is complete.

5 <sup>\*T<sub>B</sub> - T<sub>R</sub></sup>: The hybridization temperature for hybrids anticipated to be less than 50 base pairs in length should be 5-10°C less than the melting temperature (T<sub>m</sub>) of the hybrid, where T<sub>m</sub> is determined according to the following equations. For hybrids less than 18 base pairs in length,  $T_m(^{\circ}\text{C}) = 2(\# \text{ of A} + \text{T bases}) + 4(\# \text{ of G} + \text{C bases})$ . For hybrids between 18 and 49 base pairs in length,  $T_m(^{\circ}\text{C}) = 81.5 + 16.6(\log_{10}[\text{Na}^+]) + 0.41(\% \text{G+C}) - (600/\text{N})$ , where N is the number of bases in the hybrid, and [Na<sup>+</sup>] is the concentration of sodium ions in the hybridization buffer ([Na<sup>+</sup>] for 1xSSC = 0.165 M).

10

Additional examples of stringency conditions for polynucleotide hybridization are provided in Sambrook, J., E.F. Fritsch, and T. Maniatis, 1989, *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, chapters 9 and 11, and *Current Protocols in Molecular Biology*, 1995, F.M. Ausubel et al., eds.,  
15 John Wiley & Sons, Inc., sections 2.10 and 6.3-6.4, incorporated herein by reference.

Preferably, each such hybridizing polynucleotide has a length that is at least 25%(more preferably at least 50%, and most preferably at least 75%) of the length of the polynucleotide of the present invention to which it hybridizes, and has at least 60% sequence identity (more preferably, at least 75% identity; most preferably at least 90% or  
20 95% identity) with the polynucleotide of the present invention to which it hybridizes, where sequence identity is determined by comparing the sequences of the hybridizing polynucleotides when aligned so as to maximize overlap and identity while minimizing sequence gaps.

The isolated polynucleotide of the invention may be operably linked to an  
25 expression control sequence such as the pMT2 or pED expression vectors disclosed in Kaufman *et al.*, *Nucleic Acids Res.* 19, 4485-4490 (1991), in order to produce the protein recombinantly. Many suitable expression control sequences are known in the art. General methods of expressing recombinant proteins are also known and are exemplified in R. Kaufman, *Methods in Enzymology* 185, 537-566 (1990). As defined herein "operably  
30 linked" means that the isolated polynucleotide of the invention and an expression control sequence are situated within a vector or cell in such a way that the protein is expressed by a host cell which has been transformed (transfected) with the ligated polynucleotide/expression control sequence.

A number of types of cells may act as suitable host cells for expression of the  
35 protein. Mammalian host cells include, for example, monkey COS cells, Chinese Hamster Ovary (CHO) cells, human kidney 293 cells, human epidermal A431 cells, human Colo205 cells, 3T3 cells, CV-1 cells, other transformed primate cell lines, normal diploid cells, cell



strains derived from in vitro culture of primary tissue, primary explants, HeLa cells, mouse L cells, BHK, HL-60, U937, HaK or Jurkat cells.

Alternatively, it may be possible to produce the protein in lower eukaryotes such as yeast or in prokaryotes such as bacteria. Potentially suitable yeast strains include  
5 *Saccharomyces cerevisiae*, *Schizosaccharomyces pombe*, *Kluyveromyces* strains, *Candida*, or any yeast strain capable of expressing heterologous proteins. Potentially suitable bacterial strains include *Escherichia coli*, *Bacillus subtilis*, *Salmonella typhimurium*, or any bacterial strain capable of expressing heterologous proteins. If the protein is made in yeast or bacteria, it may be necessary to modify the protein produced therein, for example by  
10 phosphorylation or glycosylation of the appropriate sites, in order to obtain the functional protein. Such covalent attachments may be accomplished using known chemical or enzymatic methods.

The protein may also be produced by operably linking the isolated polynucleotide of the invention to suitable control sequences in one or more insect expression vectors,  
15 and employing an insect expression system. Materials and methods for baculovirus/insect cell expression systems are commercially available in kit form from, e.g., Invitrogen, San Diego, California, U.S.A. (the MaxBac® kit), and such methods are well known in the art, as described in Summers and Smith, Texas Agricultural Experiment Station Bulletin No. 1555 (1987), incorporated herein by reference. As used herein, an  
20 insect cell capable of expressing a polynucleotide of the present invention is "transformed."

The protein of the invention may be prepared by culturing transformed host cells under culture conditions suitable to express the recombinant protein. The resulting expressed protein may then be purified from such culture (i.e., from culture medium or  
25 cell extracts) using known purification processes, such as gel filtration and ion exchange chromatography. The purification of the protein may also include an affinity column containing agents which will bind to the protein; one or more column steps over such affinity resins as concanavalin A-agarose, heparin-toyopearl® or Cibacrom blue 3GA Sepharose®; one or more steps involving hydrophobic interaction chromatography using  
30 such resins as phenyl ether, butyl ether, or propyl ether; or immunoaffinity chromatography.

Alternatively, the protein of the invention may also be expressed in a form which will facilitate purification. For example, it may be expressed as a fusion protein, such as those of maltose binding protein (MBP), glutathione-S-transferase (GST) or thioredoxin

(TRX). Kits for expression and purification of such fusion proteins are commercially available from New England BioLabs (Beverly, MA), Pharmacia (Piscataway, NJ) and Invitrogen Corporation (Carlsbad, CA), respectively. The protein can also be tagged with an epitope and subsequently purified by using a specific antibody directed to such epitope. One such epitope ("Flag") is commercially available from the Eastman Kodak Company (New Haven, CT).

Finally, one or more reverse-phase high performance liquid chromatography (RP-HPLC) steps employing hydrophobic RP-HPLC media, e.g., silica gel having pendant methyl or other aliphatic groups, can be employed to further purify the protein. Some or all of the foregoing purification steps, in various combinations, can also be employed to provide a substantially homogeneous isolated recombinant protein. The protein thus purified is substantially free of other mammalian proteins and is defined in accordance with the present invention as an "isolated protein."

The protein of the invention may also be expressed as a product of transgenic animals, e.g., as a component of the milk of transgenic cows, goats, pigs, or sheep which are characterized by somatic or germ cells containing a nucleotide sequence encoding the protein.

The protein may also be produced by known conventional chemical synthesis. Methods for constructing the proteins of the present invention by synthetic means are known to those skilled in the art. The synthetically-constructed protein sequences, by virtue of sharing primary, secondary or tertiary structural and/or conformational characteristics with proteins may possess biological properties in common therewith, including protein activity. Thus, they may be employed as biologically active or immunological substitutes for natural, purified proteins in screening of therapeutic compounds and in immunological processes for the development of antibodies.

The proteins provided herein also include proteins characterized by amino acid sequences similar to those of purified proteins but into which modification are naturally provided or deliberately engineered. For example, modifications in the peptide or DNA sequences can be made by those skilled in the art using known techniques. Modifications of interest in the protein sequences may include the alteration, substitution, replacement, insertion or deletion of a selected amino acid residue in the coding sequence. For example, one or more of the cysteine residues may be deleted or replaced with another amino acid to alter the conformation of the molecule. Techniques for such alteration, substitution, replacement, insertion or deletion are well known to those skilled in the art

(see, e.g., U.S. Patent No. 4,518,584). Preferably, such alteration, substitution, replacement, insertion or deletion retains the desired activity of the protein.

Other fragments and derivatives of the sequences of proteins which would be expected to retain protein activity in whole or in part and may thus be useful for screening or other immunological methodologies may also be easily made by those skilled in the art given the disclosures herein. Such modifications are believed to be encompassed by the present invention.

### USES AND BIOLOGICAL ACTIVITY

The polynucleotides and proteins of the present invention are expected to exhibit one or more of the uses or biological activities (including those associated with assays cited herein) identified below. Uses or activities described for proteins of the present invention may be provided by administration or use of such proteins or by administration or use of polynucleotides encoding such proteins (such as, for example, in gene therapies or vectors suitable for introduction of DNA).

#### Research Uses and Utilities

The polynucleotides provided by the present invention can be used by the research community for various purposes. The polynucleotides can be used to express recombinant protein for analysis, characterization or therapeutic use; as markers for tissues in which the corresponding protein is preferentially expressed (either constitutively or at a particular stage of tissue differentiation or development or in disease states); as molecular weight markers on Southern gels; as chromosome markers or tags (when labeled) to identify chromosomes or to map related gene positions; to compare with endogenous DNA sequences in patients to identify potential genetic disorders; as probes to hybridize and thus discover novel, related DNA sequences; as a source of information to derive PCR primers for genetic fingerprinting; as a probe to "subtract-out" known sequences in the process of discovering other novel polynucleotides; for selecting and making oligomers for attachment to a "gene chip" or other support, including for examination of expression patterns; to raise anti-protein antibodies using DNA immunization techniques; and as an antigen to raise anti-DNA antibodies or elicit another immune response. Where the polynucleotide encodes a protein which binds or potentially binds to another protein (such as, for example, in a receptor-ligand interaction), the polynucleotide can also be used in interaction trap assays (such as, for example, those

described in Gyuris *et al.*, 1993, *Cell* 75: 791-803 and in Rossi *et al.*, 1997, *Proc. Natl. Acad. Sci. USA* 94: 8405-8410, all of which are incorporated by reference herein) to identify polynucleotides encoding the other protein with which binding occurs or to identify inhibitors of the binding interaction.

5           The proteins provided by the present invention can similarly be used in assay to determine biological activity, including in a panel of multiple proteins for high-throughput screening; to raise antibodies or to elicit another immune response; as a reagent (including the labeled reagent) in assays designed to quantitatively determine levels of the protein (or its receptor) in biological fluids; as markers for tissues in which  
10   the corresponding protein is preferentially expressed (either constitutively or at a particular stage of tissue differentiation or development or in a disease state); and, of course, to isolate correlative receptors or ligands. Where the protein binds or potentially binds to another protein (such as, for example, in a receptor-ligand interaction), the protein can be used to identify the other protein with which binding occurs or to identify  
15   inhibitors of the binding interaction. Proteins involved in these binding interactions can also be used to screen for peptide or small molecule inhibitors or agonists of the binding interaction.

Any or all of these research utilities are capable of being developed into reagent grade or kit format for commercialization as research products.

20           Methods for performing the uses listed above are well known to those skilled in the art. References disclosing such methods include without limitation "Molecular Cloning: A Laboratory Manual", 2d ed., Cold Spring Harbor Laboratory Press, Sambrook, J., E.F. Fritsch and T. Maniatis eds., 1989, and "Methods in Enzymology: Guide to Molecular Cloning Techniques", Academic Press, Berger, S.L. and A.R. Kimmel eds., 1987.

25

#### Nutritional Uses

Polynucleotides and proteins of the present invention can also be used as nutritional sources or supplements. Such uses include without limitation use as a protein or amino acid supplement, use as a carbon source, use as a nitrogen source and use as a  
30   source of carbohydrate. In such cases the protein or polynucleotide of the invention can be added to the feed of a particular organism or can be administered as a separate solid or liquid preparation, such as in the form of powder, pills, solutions, suspensions or capsules. In the case of microorganisms, the protein or polynucleotide of the invention can be added to the medium in or on which the microorganism is cultured.

Cytokine and Cell Proliferation/Differentiation Activity

A protein of the present invention may exhibit cytokine, cell proliferation (either inducing or inhibiting) or cell differentiation (either inducing or inhibiting) activity or may induce production of other cytokines in certain cell populations. Many protein factors discovered to date, including all known cytokines, have exhibited activity in one or more factor-dependent cell proliferation assays, and hence the assays serve as a convenient confirmation of cytokine activity. The activity of a protein of the present invention is evidenced by any one of a number of routine factor dependent cell proliferation assays for cell lines including, without limitation, 32D, DA2, DA1G, T10, B9, B9/11, BaF3, MC9/G, M+ (preB M+), 2E8, RB5, DA1, 123, T1165, HT2, CTLL2, TF-1, Mo7e and CMK.

The activity of a protein of the invention may, among other means, be measured by the following methods:

Assays for T-cell or thymocyte proliferation include without limitation those described in: *Current Protocols in Immunology*, Ed by J. E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, W Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 3, In Vitro assays for Mouse Lymphocyte Function 3.1-3.19; Chapter 7, Immunologic studies in Humans); Takai et al., *J. Immunol.* 137:3494-3500, 1986; Bertagnolli et al., *J. Immunol.* 145:1706-1712, 1990; Bertagnolli et al., *Cellular Immunology* 133:327-341, 1991; Bertagnolli, et al., *J. Immunol.* 149:3778-3783, 1992; Bowman et al., *J. Immunol.* 152: 1756-1761, 1994.

Assays for cytokine production and/or proliferation of spleen cells, lymph node cells or thymocytes include, without limitation, those described in: Polyclonal T cell stimulation, Kruisbeek, A.M. and Shevach, E.M. In *Current Protocols in Immunology*. J.E.e.a. Coligan eds. Vol 1 pp. 3.12.1-3.12.14, John Wiley and Sons, Toronto. 1994; and Measurement of mouse and human Interferon  $\gamma$ , Schreiber, R.D. In *Current Protocols in Immunology*. J.E.e.a. Coligan eds. Vol 1 pp. 6.8.1-6.8.8, John Wiley and Sons, Toronto. 1994.

Assays for proliferation and differentiation of hematopoietic and lymphopoietic cells include, without limitation, those described in: Measurement of Human and Murine Interleukin 2 and Interleukin 4, Bottomly, K., Davis, L.S. and Lipsky, P.E. In *Current Protocols in Immunology*. J.E.e.a. Coligan eds. Vol 1 pp. 6.3.1-6.3.12, John Wiley and Sons, Toronto. 1991; deVries et al., *J. Exp. Med.* 173:1205-1211, 1991; Moreau et al., *Nature* 336:690-692, 1988; Greenberger et al., *Proc. Natl. Acad. Sci. U.S.A.* 80:2931-2938, 1983; Measurement of mouse and human interleukin 6 - Nordan, R. In *Current Protocols in Immunology*. J.E.e.a. Coligan eds. Vol 1 pp. 6.6.1-6.6.5, John Wiley and Sons, Toronto. 1991;

Smith et al., Proc. Natl. Acad. Sci. U.S.A. 83:1857-1861, 1986; Measurement of human Interleukin 11 - Bennett, F., Giannotti, J., Clark, S.C. and Turner, K. J. In *Current Protocols in Immunology*. J.E.e.a. Coligan eds. Vol 1 pp. 6.15.1 John Wiley and Sons, Toronto. 1991; Measurement of mouse and human Interleukin 9 - Ciarletta, A., Giannotti, J., Clark, S.C. and Turner, K.J. In *Current Protocols in Immunology*. J.E.e.a. Coligan eds. Vol 1 pp. 6.13.1, John Wiley and Sons, Toronto. 1991.

Assays for T-cell clone responses to antigens (which will identify, among others, proteins that affect APC-T cell interactions as well as direct T-cell effects by measuring proliferation and cytokine production) include, without limitation, those described in: Current Protocols in Immunology, Ed by J. E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, W Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 3, In Vitro assays for Mouse Lymphocyte Function; Chapter 6, Cytokines and their cellular receptors; Chapter 7, Immunologic studies in Humans); Weinberger et al., Proc. Natl. Acad. Sci. USA 77:6091-6095, 1980; Weinberger et al., Eur. J. Immun. 11:405-411, 1981; Takai et al., J. Immunol. 137:3494-3500, 1986; Takai et al., J. Immunol. 140:508-512, 1988.

#### Immune Stimulating or Suppressing Activity

A protein of the present invention may also exhibit immune stimulating or immune suppressing activity, including without limitation the activities for which assays are described herein. A protein may be useful in the treatment of various immune deficiencies and disorders (including severe combined immunodeficiency (SCID)), e.g., in regulating (up or down) growth and proliferation of T and/or B lymphocytes, as well as effecting the cytolytic activity of NK cells and other cell populations. These immune deficiencies may be genetic or be caused by viral (e.g., HIV) as well as bacterial or fungal infections, or may result from autoimmune disorders. More specifically, infectious diseases caused by viral, bacterial, fungal or other infection may be treatable using a protein of the present invention, including infections by HIV, hepatitis viruses, herpesviruses, mycobacteria, Leishmania spp., malaria spp. and various fungal infections such as candidiasis. Of course, in this regard, a protein of the present invention may also be useful where a boost to the immune system generally may be desirable, i.e., in the treatment of cancer.

Autoimmune disorders which may be treated using a protein of the present invention include, for example, connective tissue disease, multiple sclerosis, systemic

lupus erythematosus, rheumatoid arthritis, autoimmune pulmonary inflammation, Guillain-Barre syndrome, autoimmune thyroiditis, insulin dependent diabetes mellitus, myasthenia gravis, graft-versus-host disease and autoimmune inflammatory eye disease. Such a protein of the present invention may also to be useful in the treatment of allergic reactions and conditions, such as asthma (particularly allergic asthma) or other respiratory problems. Other conditions, in which immune suppression is desired (including, for example, organ transplantation), may also be treatable using a protein of the present invention.

Using the proteins of the invention it may also be possible to regulate immune responses in a number of ways. Down regulation may be in the form of inhibiting or blocking an immune response already in progress or may involve preventing the induction of an immune response. The functions of activated T cells may be inhibited by suppressing T cell responses or by inducing specific tolerance in T cells, or both. Immunosuppression of T cell responses is generally an active, non-antigen-specific, process which requires continuous exposure of the T cells to the suppressive agent. Tolerance, which involves inducing non-responsiveness or anergy in T cells, is distinguishable from immunosuppression in that it is generally antigen-specific and persists after exposure to the tolerizing agent has ceased. Operationally, tolerance can be demonstrated by the lack of a T cell response upon reexposure to specific antigen in the absence of the tolerizing agent.

Down regulating or preventing one or more antigen functions (including without limitation B lymphocyte antigen functions (such as , for example, B7)), *e.g.*, preventing high level lymphokine synthesis by activated T cells, will be useful in situations of tissue, skin and organ transplantation and in graft-versus-host disease (GVHD). For example, blockage of T cell function should result in reduced tissue destruction in tissue transplantation. Typically, in tissue transplants, rejection of the transplant is initiated through its recognition as foreign by T cells, followed by an immune reaction that destroys the transplant. The administration of a molecule which inhibits or blocks interaction of a B7 lymphocyte antigen with its natural ligand(s) on immune cells (such as a soluble, monomeric form of a peptide having B7-2 activity alone or in conjunction with a monomeric form of a peptide having an activity of another B lymphocyte antigen (*e.g.*, B7-1, B7-3) or blocking antibody), prior to transplantation can lead to the binding of the molecule to the natural ligand(s) on the immune cells without transmitting the corresponding costimulatory signal. Blocking B lymphocyte antigen function in this

matter prevents cytokine synthesis by immune cells, such as T cells, and thus acts as an immunosuppressant. Moreover, the lack of costimulation may also be sufficient to anergize the T cells, thereby inducing tolerance in a subject. Induction of long-term tolerance by B lymphocyte antigen-blocking reagents may avoid the necessity of repeated  
5 administration of these blocking reagents. To achieve sufficient immunosuppression or tolerance in a subject, it may also be necessary to block the function of a combination of B lymphocyte antigens.

The efficacy of particular blocking reagents in preventing organ transplant rejection or GVHD can be assessed using animal models that are predictive of efficacy in  
10 humans. Examples of appropriate systems which can be used include allogeneic cardiac grafts in rats and xenogeneic pancreatic islet cell grafts in mice, both of which have been used to examine the immunosuppressive effects of CTLA4Ig fusion proteins *in vivo* as described in Lenschow *et al.*, Science 257:789-792 (1992) and Turka *et al.*, Proc. Natl. Acad. Sci USA, 89:11102-11105 (1992). In addition, murine models of GVHD (see Paul ed.,  
15 Fundamental Immunology, Raven Press, New York, 1989, pp. 846-847) can be used to determine the effect of blocking B lymphocyte antigen function *in vivo* on the development of that disease.

Blocking antigen function may also be therapeutically useful for treating autoimmune diseases. Many autoimmune disorders are the result of inappropriate  
20 activation of T cells that are reactive against self tissue and which promote the production of cytokines and autoantibodies involved in the pathology of the diseases. Preventing the activation of autoreactive T cells may reduce or eliminate disease symptoms. Administration of reagents which block costimulation of T cells by disrupting receptor:ligand interactions of B lymphocyte antigens can be used to inhibit T cell  
25 activation and prevent production of autoantibodies or T cell-derived cytokines which may be involved in the disease process. Additionally, blocking reagents may induce antigen-specific tolerance of autoreactive T cells which could lead to long-term relief from the disease. The efficacy of blocking reagents in preventing or alleviating autoimmune disorders can be determined using a number of well-characterized animal models of  
30 human autoimmune diseases. Examples include murine experimental autoimmune encephalitis, systemic lupus erythematosis in MRL/*lpr/lpr* mice or NZB hybrid mice, murine autoimmune collagen arthritis, diabetes mellitus in NOD mice and BB rats, and murine experimental myasthenia gravis (see Paul ed., Fundamental Immunology, Raven Press, New York, 1989, pp. 840-856).



Upregulation of an antigen function (preferably a B lymphocyte antigen function), as a means of up regulating immune responses, may also be useful in therapy. Upregulation of immune responses may be in the form of enhancing an existing immune response or eliciting an initial immune response. For example, enhancing an immune response through stimulating B lymphocyte antigen function may be useful in cases of viral infection. In addition, systemic viral diseases such as influenza, the common cold, and encephalitis might be alleviated by the administration of stimulatory forms of B lymphocyte antigens systemically.

Alternatively, anti-viral immune responses may be enhanced in an infected patient by removing T cells from the patient, costimulating the T cells *in vitro* with viral antigen-pulsed APCs either expressing a peptide of the present invention or together with a stimulatory form of a soluble peptide of the present invention and reintroducing the *in vitro* activated T cells into the patient. Another method of enhancing anti-viral immune responses would be to isolate infected cells from a patient, transfect them with a nucleic acid encoding a protein of the present invention as described herein such that the cells express all or a portion of the protein on their surface, and reintroduce the transfected cells into the patient. The infected cells would now be capable of delivering a costimulatory signal to, and thereby activate, T cells *in vivo*.

In another application, up regulation or enhancement of antigen function (preferably B lymphocyte antigen function) may be useful in the induction of tumor immunity. Tumor cells (*e.g.*, sarcoma, melanoma, lymphoma, leukemia, neuroblastoma, carcinoma) transfected with a nucleic acid encoding at least one peptide of the present invention can be administered to a subject to overcome tumor-specific tolerance in the subject. If desired, the tumor cell can be transfected to express a combination of peptides. For example, tumor cells obtained from a patient can be transfected *ex vivo* with an expression vector directing the expression of a peptide having B7-2-like activity alone, or in conjunction with a peptide having B7-1-like activity and/or B7-3-like activity. The transfected tumor cells are returned to the patient to result in expression of the peptides on the surface of the transfected cell. Alternatively, gene therapy techniques can be used to target a tumor cell for transfection *in vivo*.

The presence of the peptide of the present invention having the activity of a B lymphocyte antigen(s) on the surface of the tumor cell provides the necessary costimulation signal to T cells to induce a T cell mediated immune response against the transfected tumor cells. In addition, tumor cells which lack MHC class I or MHC class II

molecules, or which fail to reexpress sufficient amounts of MHC class I or MHC class II molecules, can be transfected with nucleic acid encoding all or a portion of (*e.g.*, a cytoplasmic-domain truncated portion) of an MHC class I  $\alpha$  chain protein and  $\beta_2$  microglobulin protein or an MHC class II  $\alpha$  chain protein and an MHC class II  $\beta$  chain protein to thereby express MHC class I or MHC class II proteins on the cell surface. Expression of the appropriate class I or class II MHC in conjunction with a peptide having the activity of a B lymphocyte antigen (*e.g.*, B7-1, B7-2, B7-3) induces a T cell mediated immune response against the transfected tumor cell. Optionally, a gene encoding an antisense construct which blocks expression of an MHC class II associated protein, such as the invariant chain, can also be cotransfected with a DNA encoding a peptide having the activity of a B lymphocyte antigen to promote presentation of tumor associated antigens and induce tumor specific immunity. Thus, the induction of a T cell mediated immune response in a human subject may be sufficient to overcome tumor-specific tolerance in the subject.

The activity of a protein of the invention may, among other means, be measured by the following methods:

Suitable assays for thymocyte or splenocyte cytotoxicity include, without limitation, those described in: *Current Protocols in Immunology*, Ed by J. E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, W Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 3, *In Vitro* assays for Mouse Lymphocyte Function 3.1-3.19; Chapter 7, *Immunologic studies in Humans*); Herrmann et al., *Proc. Natl. Acad. Sci. USA* 78:2488-2492, 1981; Herrmann et al., *J. Immunol.* 128:1968-1974, 1982; Handa et al., *J. Immunol.* 135:1564-1572, 1985; Takai et al., *J. Immunol.* 137:3494-3500, 1986; Takai et al., *J. Immunol.* 140:508-512, 1988; Herrmann et al., *Proc. Natl. Acad. Sci. USA* 78:2488-2492, 1981; Herrmann et al., *J. Immunol.* 128:1968-1974, 1982; Handa et al., *J. Immunol.* 135:1564-1572, 1985; Takai et al., *J. Immunol.* 137:3494-3500, 1986; Bowman et al., *J. Virology* 61:1992-1998; Takai et al., *J. Immunol.* 140:508-512, 1988; Bertagnolli et al., *Cellular Immunology* 133:327-341, 1991; Brown et al., *J. Immunol.* 153:3079-3092, 1994.

Assays for T-cell-dependent immunoglobulin responses and isotype switching (which will identify, among others, proteins that modulate T-cell dependent antibody responses and that affect Th1/Th2 profiles) include, without limitation, those described in: Maliszewski, *J. Immunol.* 144:3028-3033, 1990; and Assays for B cell function: *In vitro* antibody production, Mond, J.J. and Brunswick, M. In *Current Protocols in Immunology*. J.E.e.a. Coligan eds. Vol 1 pp. 3.8.1-3.8.16, John Wiley and Sons, Toronto. 1994.

Mixed lymphocyte reaction (MLR) assays (which will identify, among others, proteins that generate predominantly Th1 and CTL responses) include, without limitation, those described in: Current Protocols in Immunology, Ed by J. E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, W Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 3, In Vitro assays for Mouse Lymphocyte Function 3.1-3.19; Chapter 7, Immunologic studies in Humans); Takai et al., J. Immunol. 137:3494-3500, 1986; Takai et al., J. Immunol. 140:508-512, 1988; Bertagnolli et al., J. Immunol. 149:3778-3783, 1992.

Dendritic cell-dependent assays (which will identify, among others, proteins expressed by dendritic cells that activate naive T-cells) include, without limitation, those described in: Guery et al., J. Immunol. 134:536-544, 1995; Inaba et al., Journal of Experimental Medicine 173:549-559, 1991; Macatonia et al., Journal of Immunology 154:5071-5079, 1995; Porgador et al., Journal of Experimental Medicine 182:255-260, 1995; Nair et al., Journal of Virology 67:4062-4069, 1993; Huang et al., Science 264:961-965, 1994; Macatonia et al., Journal of Experimental Medicine 169:1255-1264, 1989; Bhardwaj et al., Journal of Clinical Investigation 94:797-807, 1994; and Inaba et al., Journal of Experimental Medicine 172:631-640, 1990.

Assays for lymphocyte survival/apoptosis (which will identify, among others, proteins that prevent apoptosis after superantigen induction and proteins that regulate lymphocyte homeostasis) include, without limitation, those described in: Darzynkiewicz et al., Cytometry 13:795-808, 1992; Gorczyca et al., Leukemia 7:659-670, 1993; Gorczyca et al., Cancer Research 53:1945-1951, 1993; Itoh et al., Cell 66:233-243, 1991; Zacharchuk, Journal of Immunology 145:4037-4045, 1990; Zamai et al., Cytometry 14:891-897, 1993; Gorczyca et al., International Journal of Oncology 1:639-648, 1992.

Assays for proteins that influence early steps of T-cell commitment and development include, without limitation, those described in: Antica et al., Blood 84:111-117, 1994; Fine et al., Cellular Immunology 155:111-122, 1994; Galy et al., Blood 85:2770-2778, 1995; Toki et al., Proc. Nat. Acad Sci. USA 88:7548-7551, 1991.

#### Hematopoiesis Regulating Activity

A protein of the present invention may be useful in regulation of hematopoiesis and, consequently, in the treatment of myeloid or lymphoid cell deficiencies. Even marginal biological activity in support of colony forming cells or of factor-dependent cell lines indicates involvement in regulating hematopoiesis, e.g. in supporting the growth and proliferation of erythroid progenitor cells alone or in combination with other cytokines,

thereby indicating utility, for example, in treating various anemias or for use in conjunction with irradiation/chemotherapy to stimulate the production of erythroid precursors and/or erythroid cells; in supporting the growth and proliferation of myeloid cells such as granulocytes and monocytes/macrophages (i.e., traditional CSF activity) 5 useful, for example, in conjunction with chemotherapy to prevent or treat consequent myelo-suppression; in supporting the growth and proliferation of megakaryocytes and consequently of platelets thereby allowing prevention or treatment of various platelet disorders such as thrombocytopenia, and generally for use in place of or complimentary to platelet transfusions; and/or in supporting the growth and proliferation of 10 hematopoietic stem cells which are capable of maturing to any and all of the above-mentioned hematopoietic cells and therefore find therapeutic utility in various stem cell disorders (such as those usually treated with transplantation, including, without limitation, aplastic anemia and paroxysmal nocturnal hemoglobinuria), as well as in repopulating the stem cell compartment post irradiation/chemotherapy, either *in-vivo* or 15 *ex-vivo* (i.e., in conjunction with bone marrow transplantation or with peripheral progenitor cell transplantation (homologous or heterologous)) as normal cells or genetically manipulated for gene therapy.

The activity of a protein of the invention may, among other means, be measured by the following methods:

20 Suitable assays for proliferation and differentiation of various hematopoietic lines are cited above.

Assays for embryonic stem cell differentiation (which will identify, among others, proteins that influence embryonic differentiation hematopoiesis) include, without limitation, those described in: Johansson et al. Cellular Biology 15:141-151, 1995; Keller et 25 al., Molecular and Cellular Biology 13:473-486, 1993; McClanahan et al., Blood 81:2903-2915, 1993.

Assays for stem cell survival and differentiation (which will identify, among others, proteins that regulate lympho-hematopoiesis) include, without limitation, those described in: Methylcellulose colony forming assays, Freshney, M.G. In *Culture of* 30 *Hematopoietic Cells*. R.I. Freshney, et al. eds. Vol pp. 265-268, Wiley-Liss, Inc., New York, NY. 1994; Hirayama et al., Proc. Natl. Acad. Sci. USA 89:5907-5911, 1992; Primitive hematopoietic colony forming cells with high proliferative potential, McNiece, I.K. and Briddell, R.A. In *Culture of Hematopoietic Cells*. R.I. Freshney, et al. eds. Vol pp. 23-39, Wiley-Liss, Inc., New York, NY. 1994; Neben et al., Experimental Hematology 22:353-359,

1994; Cobblestone area forming cell assay, Ploemacher, R.E. In *Culture of Hematopoietic Cells*. R.I. Freshney, *et al.* eds. Vol pp. 1-21, Wiley-Liss, Inc., New York, NY. 1994; Long term bone marrow cultures in the presence of stromal cells, Spooncer, E., Dexter, M. and Allen, T. In *Culture of Hematopoietic Cells*. R.I. Freshney, *et al.* eds. Vol pp. 163-179, 5 Wiley-Liss, Inc., New York, NY. 1994; Long term culture initiating cell assay, Sutherland, H.J. In *Culture of Hematopoietic Cells*. R.I. Freshney, *et al.* eds. Vol pp. 139-162, Wiley-Liss, Inc., New York, NY. 1994.

#### Tissue Growth Activity

10 A protein of the present invention also may have utility in compositions used for bone, cartilage, tendon, ligament and/or nerve tissue growth or regeneration, as well as for wound healing and tissue repair and replacement, and in the treatment of burns, incisions and ulcers.

A protein of the present invention, which induces cartilage and/or bone growth 15 in circumstances where bone is not normally formed, has application in the healing of bone fractures and cartilage damage or defects in humans and other animals. Such a preparation employing a protein of the invention may have prophylactic use in closed as well as open fracture reduction and also in the improved fixation of artificial joints. *De novo* bone formation induced by an osteogenic agent contributes to the repair of 20 congenital, trauma induced, or oncologic resection induced craniofacial defects, and also is useful in cosmetic plastic surgery.

A protein of this invention may also be used in the treatment of periodontal disease, and in other tooth repair processes. Such agents may provide an environment to attract bone-forming cells, stimulate growth of bone-forming cells or induce 25 differentiation of progenitors of bone-forming cells. A protein of the invention may also be useful in the treatment of osteoporosis or osteoarthritis, such as through stimulation of bone and/or cartilage repair or by blocking inflammation or processes of tissue destruction (collagenase activity, osteoclast activity, etc.) mediated by inflammatory processes.

30 Another category of tissue regeneration activity that may be attributable to the protein of the present invention is tendon/ligament formation. A protein of the present invention, which induces tendon/ligament-like tissue or other tissue formation in circumstances where such tissue is not normally formed, has application in the healing of tendon or ligament tears, deformities and other tendon or ligament defects in humans and

other animals. Such a preparation employing a tendon/ligament-like tissue inducing protein may have prophylactic use in preventing damage to tendon or ligament tissue, as well as use in the improved fixation of tendon or ligament to bone or other tissues, and in repairing defects to tendon or ligament tissue. De novo tendon/ligament-like tissue formation induced by a composition of the present invention contributes to the repair of congenital, trauma induced, or other tendon or ligament defects of other origin, and is also useful in cosmetic plastic surgery for attachment or repair of tendons or ligaments. The compositions of the present invention may provide an environment to attract tendon- or ligament-forming cells, stimulate growth of tendon- or ligament-forming cells, induce differentiation of progenitors of tendon- or ligament-forming cells, or induce growth of tendon/ligament cells or progenitors *ex vivo* for return *in vivo* to effect tissue repair. The compositions of the invention may also be useful in the treatment of tendinitis, carpal tunnel syndrome and other tendon or ligament defects. The compositions may also include an appropriate matrix and/or sequestering agent as a carrier as is well known in the art.

The protein of the present invention may also be useful for proliferation of neural cells and for regeneration of nerve and brain tissue, *i.e.* for the treatment of central and peripheral nervous system diseases and neuropathies, as well as mechanical and traumatic disorders, which involve degeneration, death or trauma to neural cells or nerve tissue. More specifically, a protein may be used in the treatment of diseases of the peripheral nervous system, such as peripheral nerve injuries, peripheral neuropathy and localized neuropathies, and central nervous system diseases, such as Alzheimer's, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, and Shy-Drager syndrome. Further conditions which may be treated in accordance with the present invention include mechanical and traumatic disorders, such as spinal cord disorders, head trauma and cerebrovascular diseases such as stroke. Peripheral neuropathies resulting from chemotherapy or other medical therapies may also be treatable using a protein of the invention.

Proteins of the invention may also be useful to promote better or faster closure of non-healing wounds, including without limitation pressure ulcers, ulcers associated with vascular insufficiency, surgical and traumatic wounds, and the like.

It is expected that a protein of the present invention may also exhibit activity for generation or regeneration of other tissues, such as organs (including, for example, pancreas, liver, intestine, kidney, skin, endothelium), muscle (smooth, skeletal or cardiac)

and vascular (including vascular endothelium) tissue, or for promoting the growth of cells comprising such tissues. Part of the desired effects may be by inhibition or modulation of fibrotic scarring to allow normal tissue to regenerate. A protein of the invention may also exhibit angiogenic activity.

5 A protein of the present invention may also be useful for gut protection or regeneration and treatment of lung or liver fibrosis, reperfusion injury in various tissues, and conditions resulting from systemic cytokine damage.

A protein of the present invention may also be useful for promoting or inhibiting differentiation of tissues described above from precursor tissues or cells; or for inhibiting  
10 the growth of tissues described above.

The activity of a protein of the invention may, among other means, be measured by the following methods:

Assays for tissue generation activity include, without limitation, those described in: International Patent Publication No. WO95/16035 (bone, cartilage, tendon);  
15 International Patent Publication No. WO95/05846 (nerve, neuronal); International Patent Publication No. WO91/07491 (skin, endothelium ).

Assays for wound healing activity include, without limitation, those described in: Winter, Epidermal Wound Healing, pps. 71-112 (Maibach, HI and Rovee, DT, eds.), Year Book Medical Publishers, Inc., Chicago, as modified by Eaglstein and Mertz, J. Invest.  
20 Dermatol 71:382-84 (1978).

#### Activin/Inhibin Activity

A protein of the present invention may also exhibit activin- or inhibin-related activities. Inhibins are characterized by their ability to inhibit the release of follicle stimulating hormone (FSH), while activins and are characterized by their ability to  
25 stimulate the release of follicle stimulating hormone (FSH). Thus, a protein of the present invention, alone or in heterodimers with a member of the inhibin  $\alpha$  family, may be useful as a contraceptive based on the ability of inhibins to decrease fertility in female mammals and decrease spermatogenesis in male mammals. Administration of sufficient amounts  
30 of other inhibins can induce infertility in these mammals. Alternatively, the protein of the invention, as a homodimer or as a heterodimer with other protein subunits of the inhibin- $\beta$  group, may be useful as a fertility inducing therapeutic, based upon the ability of activin molecules in stimulating FSH release from cells of the anterior pituitary. See, for example, United States Patent 4,798,885. A protein of the invention may also be useful for

advancement of the onset of fertility in sexually immature mammals, so as to increase the lifetime reproductive performance of domestic animals such as cows, sheep and pigs.

The activity of a protein of the invention may, among other means, be measured by the following methods:

5           Assays for activin/inhibin activity include, without limitation, those described in: Vale et al., Endocrinology 91:562-572, 1972; Ling et al., Nature 321:779-782, 1986; Vale et al., Nature 321:776-779, 1986; Mason et al., Nature 318:659-663, 1985; Forage et al., Proc. Natl. Acad. Sci. USA 83:3091-3095, 1986.

10           Chemotactic/Chemokinetic Activity

A protein of the present invention may have chemotactic or chemokinetic activity (e.g., act as a chemokine) for mammalian cells, including, for example, monocytes, fibroblasts, neutrophils, T-cells, mast cells, eosinophils, epithelial and/or endothelial cells. Chemotactic and chemokinetic proteins can be used to mobilize or attract a desired cell  
15   population to a desired site of action. Chemotactic or chemokinetic proteins provide particular advantages in treatment of wounds and other trauma to tissues, as well as in treatment of localized infections. For example, attraction of lymphocytes, monocytes or neutrophils to tumors or sites of infection may result in improved immune responses against the tumor or infecting agent.

20           A protein or peptide has chemotactic activity for a particular cell population if it can stimulate, directly or indirectly, the directed orientation or movement of such cell population. Preferably, the protein or peptide has the ability to directly stimulate directed movement of cells. Whether a particular protein has chemotactic activity for a population of cells can be readily determined by employing such protein or peptide in any known  
25   assay for cell chemotaxis.

The activity of a protein of the invention may, among other means, be measured by the following methods:

Assays for chemotactic activity (which will identify proteins that induce or prevent chemotaxis) consist of assays that measure the ability of a protein to induce the migration  
30   of cells across a membrane as well as the ability of a protein to induce the adhesion of one cell population to another cell population. Suitable assays for movement and adhesion include, without limitation, those described in: Current Protocols in Immunology, Ed by J.E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, W.Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 6.12, Measurement of alpha and



beta Chemokines 6.12.1-6.12.28; Taub et al. J. Clin. Invest. 95:1370-1376, 1995; Lind et al. APMIS 103:140-146, 1995; Muller et al Eur. J. Immunol. 25: 1744-1748; Gruber et al. J. of Immunol. 152:5860-5867, 1994; Johnston et al. J. of Immunol. 153: 1762-1768, 1994.

5           Hemostatic and Thrombolytic Activity

A protein of the invention may also exhibit hemostatic or thrombolytic activity. As a result, such a protein is expected to be useful in treatment of various coagulation disorders (including hereditary disorders, such as hemophilias) or to enhance coagulation and other hemostatic events in treating wounds resulting from trauma, surgery or other  
10 causes. A protein of the invention may also be useful for dissolving or inhibiting formation of thromboses and for treatment and prevention of conditions resulting therefrom (such as, for example, infarction of cardiac and central nervous system vessels (e.g., stroke).

The activity of a protein of the invention may, among other means, be measured  
15 by the following methods:

Assay for hemostatic and thrombolytic activity include, without limitation, those described in: Linet et al., J. Clin. Pharmacol. 26:131-140, 1986; Burdick et al., Thrombosis Res. 45:413-419, 1987; Humphrey et al., Fibrinolysis 5:71-79 (1991); Schaub, Prostaglandins 35:467-474, 1988.

20

Receptor/Ligand Activity

A protein of the present invention may also demonstrate activity as receptors, receptor ligands or inhibitors or agonists of receptor/ligand interactions. Examples of such receptors and ligands include, without limitation, cytokine receptors and their  
25 ligands, receptor kinases and their ligands, receptor phosphatases and their ligands, receptors involved in cell-cell interactions and their ligands (including without limitation, cellular adhesion molecules (such as selectins, integrins and their ligands) and receptor/ligand pairs involved in antigen presentation, antigen recognition and development of cellular and humoral immune responses). Receptors and ligands are also  
30 useful for screening of potential peptide or small molecule inhibitors of the relevant receptor/ligand interaction. A protein of the present invention (including, without limitation, fragments of receptors and ligands) may themselves be useful as inhibitors of receptor/ligand interactions.

The activity of a protein of the invention may, among other means, be measured by the following methods:

Suitable assays for receptor-ligand activity include without limitation those described in: Current Protocols in Immunology, Ed by J.E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, W. Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 7.28, Measurement of Cellular Adhesion under static conditions 7.28.1-7.28.22), Takai et al., Proc. Natl. Acad. Sci. USA 84:6864-6868, 1987; Bierer et al., J. Exp. Med. 168:1145-1156, 1988; Rosenstein et al., J. Exp. Med. 169:149-160, 1989; Stoltenborg et al., J. Immunol. Methods 175:59-68, 1994; Stitt et al., Cell 80:661-670, 1995.

#### Anti-Inflammatory Activity

Proteins of the present invention may also exhibit anti-inflammatory activity. The anti-inflammatory activity may be achieved by providing a stimulus to cells involved in the inflammatory response, by inhibiting or promoting cell-cell interactions (such as, for example, cell adhesion), by inhibiting or promoting chemotaxis of cells involved in the inflammatory process, inhibiting or promoting cell extravasation, or by stimulating or suppressing production of other factors which more directly inhibit or promote an inflammatory response. Proteins exhibiting such activities can be used to treat inflammatory conditions including chronic or acute conditions), including without limitation inflammation associated with infection (such as septic shock, sepsis or systemic inflammatory response syndrome (SIRS)), ischemia-reperfusion injury, endotoxin lethality, arthritis, complement-mediated hyperacute rejection, nephritis, cytokine or chemokine-induced lung injury, inflammatory bowel disease, Crohn's disease or resulting from over production of cytokines such as TNF or IL-1. Proteins of the invention may also be useful to treat anaphylaxis and hypersensitivity to an antigenic substance or material.

#### Cadherin/Tumor Invasion Suppressor Activity

Cadherins are calcium-dependent adhesion molecules that appear to play major roles during development, particularly in defining specific cell types. Loss or alteration of normal cadherin expression can lead to changes in cell adhesion properties linked to tumor growth and metastasis. Cadherin malfunction is also implicated in other human diseases, such as pemphigus vulgaris and pemphigus foliaceus (auto-immune blistering skin diseases), Crohn's disease, and some developmental abnormalities.

The cadherin superfamily includes well over forty members, each with a distinct pattern of expression. All members of the superfamily have in common conserved extracellular repeats (cadherin domains), but structural differences are found in other parts of the molecule. The cadherin domains bind calcium to form their tertiary structure and thus calcium is required to mediate their adhesion. Only a few amino acids in the first cadherin domain provide the basis for homophilic adhesion; modification of this recognition site can change the specificity of a cadherin so that instead of recognizing only itself, the mutant molecule can now also bind to a different cadherin. In addition, some cadherins engage in heterophilic adhesion with other cadherins.

E-cadherin, one member of the cadherin superfamily, is expressed in epithelial cell types. Pathologically, if E-cadherin expression is lost in a tumor, the malignant cells become invasive and the cancer metastasizes. Transfection of cancer cell lines with polynucleotides expressing E-cadherin has reversed cancer-associated changes by returning altered cell shapes to normal, restoring cells' adhesiveness to each other and to their substrate, decreasing the cell growth rate, and drastically reducing anchorage-independent cell growth. Thus, reintroducing E-cadherin expression reverts carcinomas to a less advanced stage. It is likely that other cadherins have the same invasion suppressor role in carcinomas derived from other tissue types. Therefore, proteins of the present invention with cadherin activity, and polynucleotides of the present invention encoding such proteins, can be used to treat cancer. Introducing such proteins or polynucleotides into cancer cells can reduce or eliminate the cancerous changes observed in these cells by providing normal cadherin expression.

Cancer cells have also been shown to express cadherins of a different tissue type than their origin, thus allowing these cells to invade and metastasize in a different tissue in the body. Proteins of the present invention with cadherin activity, and polynucleotides of the present invention encoding such proteins, can be substituted in these cells for the inappropriately expressed cadherins, restoring normal cell adhesive properties and reducing or eliminating the tendency of the cells to metastasize.

Additionally, proteins of the present invention with cadherin activity, and polynucleotides of the present invention encoding such proteins, can be used to generate antibodies recognizing and binding to cadherins. Such antibodies can be used to block the adhesion of inappropriately expressed tumor-cell cadherins, preventing the cells from forming a tumor elsewhere. Such an anti-cadherin antibody can also be used as a marker for the grade, pathological type, and prognosis of a cancer, i.e. the more progressed the

cancer, the less cadherin expression there will be, and this decrease in cadherin expression can be detected by the use of a cadherin-binding antibody.

Fragments of proteins of the present invention with cadherin activity, preferably a polypeptide comprising a decapeptide of the cadherin recognition site, and polynucleotides of the present invention encoding such protein fragments, can also be used to block cadherin function by binding to cadherins and preventing them from binding in ways that produce undesirable effects. Additionally, fragments of proteins of the present invention with cadherin activity, preferably truncated soluble cadherin fragments which have been found to be stable in the circulation of cancer patients, and polynucleotides encoding such protein fragments, can be used to disturb proper cell-cell adhesion.

Assays for cadherin adhesive and invasive suppressor activity include, without limitation, those described in: Hortsch et al. J Biol Chem 270 (32): 18809-18817, 1995; Miyaki et al. Oncogene 11: 2547-2552, 1995; Ozawa et al. Cell 63: 1033-1038, 1990.

#### Tumor Inhibition Activity

In addition to the activities described above for immunological treatment or prevention of tumors, a protein of the invention may exhibit other anti-tumor activities. A protein may inhibit tumor growth directly or indirectly (such as, for example, via antibody-dependent cell-mediated cytotoxicity (ADCC)). A protein may exhibit its tumor inhibitory activity by acting on tumor tissue or tumor precursor tissue, by inhibiting formation of tissues necessary to support tumor growth (such as, for example, by inhibiting angiogenesis), by causing production of other factors, agents or cell types which inhibit tumor growth, or by suppressing, eliminating or inhibiting factors, agents or cell types which promote tumor growth.

25

#### Other Activities

A protein of the invention may also exhibit one or more of the following additional activities or effects: inhibiting the growth, infection or function of, or killing, infectious agents, including, without limitation, bacteria, viruses, fungi and other parasites; effecting (suppressing or enhancing) bodily characteristics, including, without limitation, height, weight, hair color, eye color, skin, fat to lean ratio or other tissue pigmentation, or organ or body part size or shape (such as, for example, breast augmentation or diminution, change in bone form or shape); effecting biorhythms or circadian cycles or rhythms; effecting the fertility of male or female subjects; effecting the metabolism, catabolism,

anabolism, processing, utilization, storage or elimination of dietary fat, lipid, protein, carbohydrate, vitamins, minerals, cofactors or other nutritional factors or component(s); effecting behavioral characteristics, including, without limitation, appetite, libido, stress, cognition (including cognitive disorders), depression (including depressive disorders) and violent behaviors; providing analgesic effects or other pain reducing effects; promoting differentiation and growth of embryonic stem cells in lineages other than hematopoietic lineages; hormonal or endocrine activity; in the case of enzymes, correcting deficiencies of the enzyme and treating deficiency-related diseases; treatment of hyperproliferative disorders (such as, for example, psoriasis); immunoglobulin-like activity (such as, for example, the ability to bind antigens or complement); and the ability to act as an antigen in a vaccine composition to raise an immune response against such protein or another material or entity which is cross-reactive with such protein.

#### **ADMINISTRATION AND DOSING**

A protein of the present invention (from whatever source derived, including without limitation from recombinant and non-recombinant sources) may be used in a pharmaceutical composition when combined with a pharmaceutically acceptable carrier. Such a composition may also contain (in addition to protein and a carrier) diluents, fillers, salts, buffers, stabilizers, solubilizers, and other materials well known in the art. The term "pharmaceutically acceptable" means a non-toxic material that does not interfere with the effectiveness of the biological activity of the active ingredient(s). The characteristics of the carrier will depend on the route of administration. The pharmaceutical composition of the invention may also contain cytokines, lymphokines, or other hematopoietic factors such as M-CSF, GM-CSF, TNF, IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IFN, TNF0, TNF1, TNF2, G-CSF, Meg-CSF, thrombopoietin, stem cell factor, and erythropoietin. The pharmaceutical composition may further contain other agents which either enhance the activity of the protein or compliment its activity or use in treatment. Such additional factors and/or agents may be included in the pharmaceutical composition to produce a synergistic effect with protein of the invention, or to minimize side effects. Conversely, protein of the present invention may be included in formulations of the particular cytokine, lymphokine, other hematopoietic factor, thrombolytic or anti-thrombotic factor, or anti-inflammatory agent to minimize side effects of the cytokine, lymphokine, other hematopoietic factor, thrombolytic or anti-thrombotic factor, or anti-inflammatory agent.

A protein of the present invention may be active in multimers (e.g., heterodimers or homodimers) or complexes with itself or other proteins. As a result, pharmaceutical compositions of the invention may comprise a protein of the invention in such multimeric or complexed form.

5           The pharmaceutical composition of the invention may be in the form of a complex of the protein(s) of present invention along with protein or peptide antigens. The protein and/or peptide antigen will deliver a stimulatory signal to both B and T lymphocytes. B lymphocytes will respond to antigen through their surface immunoglobulin receptor. T lymphocytes will respond to antigen through the T cell receptor (TCR) following  
10 presentation of the antigen by MHC proteins. MHC and structurally related proteins including those encoded by class I and class II MHC genes on host cells will serve to present the peptide antigen(s) to T lymphocytes. The antigen components could also be supplied as purified MHC-peptide complexes alone or with co-stimulatory molecules that can directly signal T cells. Alternatively antibodies able to bind surface immunoglobulin  
15 and other molecules on B cells as well as antibodies able to bind the TCR and other molecules on T cells can be combined with the pharmaceutical composition of the invention.

          The pharmaceutical composition of the invention may be in the form of a liposome in which protein of the present invention is combined, in addition to other  
20 pharmaceutically acceptable carriers, with amphipathic agents such as lipids which exist in aggregated form as micelles, insoluble monolayers, liquid crystals, or lamellar layers in aqueous solution. Suitable lipids for liposomal formulation include, without limitation, monoglycerides, diglycerides, sulfatides, lysolecithin, phospholipids, saponin, bile acids, and the like. Preparation of such liposomal formulations is within the level of skill in the  
25 art, as disclosed, for example, in U.S. Patent No. 4,235,871; U.S. Patent No. 4,501,728; U.S. Patent No. 4,837,028; and U.S. Patent No. 4,737,323, all of which are incorporated herein by reference.

          As used herein, the term "therapeutically effective amount" means the total amount of each active component of the pharmaceutical composition or method that is  
30 sufficient to show a meaningful patient benefit, i.e., treatment, healing, prevention or amelioration of the relevant medical condition, or an increase in rate of treatment, healing, prevention or amelioration of such conditions. When applied to an individual active ingredient, administered alone, the term refers to that ingredient alone. When applied to

a combination, the term refers to combined amounts of the active ingredients that result in the therapeutic effect, whether administered in combination, serially or simultaneously.

In practicing the method of treatment or use of the present invention, a therapeutically effective amount of protein of the present invention is administered to a mammal having a condition to be treated. Protein of the present invention may be administered in accordance with the method of the invention either alone or in combination with other therapies such as treatments employing cytokines, lymphokines or other hematopoietic factors. When co-administered with one or more cytokines, lymphokines or other hematopoietic factors, protein of the present invention may be administered either simultaneously with the cytokine(s), lymphokine(s), other hematopoietic factor(s), thrombolytic or anti-thrombotic factors, or sequentially. If administered sequentially, the attending physician will decide on the appropriate sequence of administering protein of the present invention in combination with cytokine(s), lymphokine(s), other hematopoietic factor(s), thrombolytic or anti-thrombotic factors.

Administration of protein of the present invention used in the pharmaceutical composition or to practice the method of the present invention can be carried out in a variety of conventional ways, such as oral ingestion, inhalation, topical application or cutaneous, subcutaneous, intraperitoneal, parenteral or intravenous injection. Intravenous administration to the patient is preferred.

When a therapeutically effective amount of protein of the present invention is administered orally, protein of the present invention will be in the form of a tablet, capsule, powder, solution or elixir. When administered in tablet form, the pharmaceutical composition of the invention may additionally contain a solid carrier such as a gelatin or an adjuvant. The tablet, capsule, and powder contain from about 5 to 95% protein of the present invention, and preferably from about 25 to 90% protein of the present invention. When administered in liquid form, a liquid carrier such as water, petroleum, oils of animal or plant origin such as peanut oil, mineral oil, soybean oil, or sesame oil, or synthetic oils may be added. The liquid form of the pharmaceutical composition may further contain physiological saline solution, dextrose or other saccharide solution, or glycols such as ethylene glycol, propylene glycol or polyethylene glycol. When administered in liquid form, the pharmaceutical composition contains from about 0.5 to 90% by weight of protein of the present invention, and preferably from about 1 to 50% protein of the present invention.

When a therapeutically effective amount of protein of the present invention is administered by intravenous, cutaneous or subcutaneous injection, protein of the present invention will be in the form of a pyrogen-free, parenterally acceptable aqueous solution. The preparation of such parenterally acceptable protein solutions, having due regard to  
5 pH, isotonicity, stability, and the like, is within the skill in the art. A preferred pharmaceutical composition for intravenous, cutaneous, or subcutaneous injection should contain, in addition to protein of the present invention, an isotonic vehicle such as Sodium Chloride Injection, Ringer's Injection, Dextrose Injection, Dextrose and Sodium Chloride Injection, Lactated Ringer's Injection, or other vehicle as known in the art. The  
10 pharmaceutical composition of the present invention may also contain stabilizers, preservatives, buffers, antioxidants, or other additives known to those of skill in the art.

The amount of protein of the present invention in the pharmaceutical composition of the present invention will depend upon the nature and severity of the condition being treated, and on the nature of prior treatments which the patient has undergone.  
15 Ultimately, the attending physician will decide the amount of protein of the present invention with which to treat each individual patient. Initially, the attending physician will administer low doses of protein of the present invention and observe the patient's response. Larger doses of protein of the present invention may be administered until the optimal therapeutic effect is obtained for the patient, and at that point the dosage is not  
20 increased further. It is contemplated that the various pharmaceutical compositions used to practice the method of the present invention should contain about 0.01 µg to about 100 mg (preferably about 0.1mg to about 10 mg, more preferably about 0.1 µg to about 1 mg) of protein of the present invention per kg body weight.

The duration of intravenous therapy using the pharmaceutical composition of the  
25 present invention will vary, depending on the severity of the disease being treated and the condition and potential idiosyncratic response of each individual patient. It is contemplated that the duration of each application of the protein of the present invention will be in the range of 12 to 24 hours of continuous intravenous administration. Ultimately the attending physician will decide on the appropriate duration of intravenous  
30 therapy using the pharmaceutical composition of the present invention.

Protein of the invention may also be used to immunize animals to obtain polyclonal and monoclonal antibodies which specifically react with the protein. As used herein, the term "antibody" includes without limitation a polyclonal antibody, a monoclonal antibody, a chimeric antibody, a single-chain antibody, a CDR-grafted



antibody, a humanized antibody, or fragments thereof which bind to the indicated protein. Such term also includes any other species derived from an antibody or antibody sequence which is capable of binding the indicated protein.

Antibodies to a particular protein can be produced by methods well known to those skilled in the art. For example, monoclonal antibodies can be produced by generation of antibody-producing hybridomas in accordance with known methods (see for example, Goding, 1983, *Monoclonal antibodies: principles and practice*, Academic Press Inc., New York; and Yokoyama, 1992, "Production of Monoclonal Antibodies" in *Current Protocols in Immunology*, Unit 2.5, Greene Publishing Assoc. and John Wiley & Sons). Polyclonal sera and antibodies can be produced by inoculation of a mammalian subject with the relevant protein or fragments thereof in accordance with known methods. Fragments of antibodies, receptors, or other reactive peptides can be produced from the corresponding antibodies by cleavage of and collection of the desired fragments in accordance with known methods (see for example, Goding, *supra*; and Andrew et al., 1992, "Fragmentation of Immunoglobulins" in *Current Protocols in Immunology*, Unit 2.8, Greene Publishing Assoc. and John Wiley & Sons). Chimeric antibodies and single chain antibodies can also be produced in accordance with known recombinant methods (see for example, 5,169,939, 5,194,594, and 5,576,184). Humanized antibodies can also be made from corresponding murine antibodies in accordance with well known methods (see for example, U.S. Patent Nos. 5,530,101, 5,585,089, and 5,693,762). Additionally, human antibodies may be produced in non-human animals such as mice that have been genetically altered to express human antibody molecules (see for example Fishwild *et al.*, 1996, *Nature Biotechnology* **14**: 845-851; Mendez *et al.*, 1997, *Nature Genetics* **15**: 146-156 (erratum *Nature Genetics* **16**: 410); and U.S. Patents 5,877,397 and 5,625,126). Such antibodies may be obtained using either the entire protein or fragments thereof as an immunogen. The peptide immunogens additionally may contain a cysteine residue at the carboxyl terminus, and are conjugated to a hapten such as keyhole limpet hemocyanin (KLH). Methods for synthesizing such peptides are known in the art, for example, as in R.P. Merrifield, J. Amer.Chem.Soc. 85, 2149-2154 (1963); J.L. Krstenansky, *et al.*, *FEBS Lett.* 211, 10 (1987).

Monoclonal antibodies binding to the protein of the invention may be useful diagnostic agents for the immunodetection of the protein. Neutralizing monoclonal antibodies binding to the protein may also be useful therapeutics for both conditions

associated with the protein and also in the treatment of some forms of cancer where abnormal expression of the protein is involved. In the case of cancerous cells or leukemic cells, neutralizing monoclonal antibodies against the protein may be useful in detecting and preventing the metastatic spread of the cancerous cells, which may be mediated by the protein.

For compositions of the present invention which are useful for bone, cartilage, tendon or ligament regeneration, the therapeutic method includes administering the composition topically, systematically, or locally as an implant or device. When administered, the therapeutic composition for use in this invention is, of course, in a pyrogen-free, physiologically acceptable form. Further, the composition may desirably be encapsulated or injected in a viscous form for delivery to the site of bone, cartilage or tissue damage. Topical administration may be suitable for wound healing and tissue repair. Therapeutically useful agents other than a protein of the invention which may also optionally be included in the composition as described above, may alternatively or additionally, be administered simultaneously or sequentially with the composition in the methods of the invention. Preferably for bone and/or cartilage formation, the composition would include a matrix capable of delivering the protein-containing composition to the site of bone and/or cartilage damage, providing a structure for the developing bone and cartilage and optimally capable of being resorbed into the body. Such matrices may be formed of materials presently in use for other implanted medical applications.

The choice of matrix material is based on biocompatibility, biodegradability, mechanical properties, cosmetic appearance and interface properties. The particular application of the compositions will define the appropriate formulation. Potential matrices for the compositions may be biodegradable and chemically defined calcium sulfate, tricalciumphosphate, hydroxyapatite, polylactic acid, polyglycolic acid and polyanhydrides. Other potential materials are biodegradable and biologically well-defined, such as bone or dermal collagen. Further matrices are comprised of pure proteins or extracellular matrix components. Other potential matrices are nonbiodegradable and chemically defined, such as sintered hydroxapatite, bioglass, aluminates, or other ceramics. Matrices may be comprised of combinations of any of the above mentioned types of material, such as polylactic acid and hydroxyapatite or collagen and tricalciumphosphate. The bioceramics may be altered in composition, such as in calcium-

aluminate-phosphate and processing to alter pore size, particle size, particle shape, and biodegradability.

Presently preferred is a 50:50 (mole weight) copolymer of lactic acid and glycolic acid in the form of porous particles having diameters ranging from 150 to 800 microns.

- 5 In some applications, it will be useful to utilize a sequestering agent, such as carboxymethyl cellulose or autologous blood clot, to prevent the protein compositions from disassociating from the matrix.

A preferred family of sequestering agents is cellulosic materials such as alkylcelluloses (including hydroxyalkylcelluloses), including methylcellulose, 10 ethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, and carboxymethylcellulose, the most preferred being cationic salts of carboxymethylcellulose (CMC). Other preferred sequestering agents include hyaluronic acid, sodium alginate, poly(ethylene glycol), polyoxyethylene oxide, carboxyvinyl polymer and poly(vinyl alcohol). The amount of sequestering agent useful herein is 0.5-20 15 wt%, preferably 1-10 wt% based on total formulation weight, which represents the amount necessary to prevent desorption of the protein from the polymer matrix and to provide appropriate handling of the composition, yet not so much that the progenitor cells are prevented from infiltrating the matrix, thereby providing the protein the opportunity to assist the osteogenic activity of the progenitor cells.

20 In further compositions, proteins of the invention may be combined with other agents beneficial to the treatment of the bone and/or cartilage defect, wound, or tissue in question. These agents include various growth factors such as epidermal growth factor (EGF), platelet derived growth factor (PDGF), transforming growth factors (TGF- $\alpha$  and TGF- $\beta$ ), and insulin-like growth factor (IGF).

25 The therapeutic compositions are also presently valuable for veterinary applications. Particularly domestic animals and thoroughbred horses, in addition to humans, are desired patients for such treatment with proteins of the present invention.

The dosage regimen of a protein-containing pharmaceutical composition to be used in tissue regeneration will be determined by the attending physician considering 30 various factors which modify the action of the proteins, e.g., amount of tissue weight desired to be formed, the site of damage, the condition of the damaged tissue, the size of a wound, type of damaged tissue (e.g., bone), the patient's age, sex, and diet, the severity of any infection, time of administration and other clinical factors. The dosage may vary with the type of matrix used in the reconstitution and with inclusion of other proteins in

the pharmaceutical composition. For example, the addition of other known growth factors, such as IGF I (insulin like growth factor I), to the final composition, may also effect the dosage. Progress can be monitored by periodic assessment of tissue/bone growth and/or repair, for example, X-rays, histomorphometric determinations and tetracycline  
5 labeling.

Polynucleotides of the present invention can also be used for gene therapy. Such polynucleotides can be introduced either *in vivo* or *ex vivo* into cells for expression in a mammalian subject. Polynucleotides of the invention may also be administered by other known methods for introduction of nucleic acid into a cell or organism (including, without  
10 limitation, in the form of viral vectors or naked DNA).

Cells may also be cultured *ex vivo* in the presence of proteins of the present invention in order to proliferate or to produce a desired effect on or activity in such cells. Treated cells can then be introduced *in vivo* for therapeutic purposes.

15 Patent and literature references cited herein are incorporated by reference as if fully set forth.

What is claimed is:

1. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:
  - (a) the nucleotide sequence of SEQ ID NO:1;
  - (b) the nucleotide sequence of SEQ ID NO:1 from nucleotide 126 to nucleotide 485;
  - (c) the nucleotide sequence of SEQ ID NO:1 from nucleotide 207 to nucleotide 485;
  - (d) the nucleotide sequence of the full-length protein coding sequence of clone vb2\_1 deposited under accession number ATCC 98804;
  - (e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vb2\_1 deposited under accession number ATCC 98804;
  - (f) the nucleotide sequence of a mature protein coding sequence of clone vb2\_1 deposited under accession number ATCC 98804;
  - (g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vb2\_1 deposited under accession number ATCC 98804;
  - (h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:2;
  - (i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:2, the fragment comprising eight contiguous amino acids of SEQ ID NO:2;
  - (j) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g); and
  - (k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO:1.
2. The polynucleotide of claim 1 wherein said polynucleotide is operably linked to at least one expression control sequence.
3. A host cell transformed with the polynucleotide of claim 2.

4. The host cell of claim 3, wherein said cell is a mammalian cell.
5. A process for producing a protein encoded by the polynucleotide of claim 2, which process comprises:
  - (a) growing a culture of a host cell transformed with the polynucleotide of claim 2 in a suitable culture medium; and
  - (b) purifying said protein from the culture.
6. A protein produced according to the process of claim 5.
7. An isolated polynucleotide encoding the protein of claim 6.
8. The polynucleotide of claim 7, wherein the polynucleotide comprises the cDNA insert of clone vb2\_1 deposited under accession number ATCC 98804.
9. A protein comprising an amino acid sequence selected from the group consisting of:
  - (a) the amino acid sequence of SEQ ID NO:2;
  - (b) a fragment of the amino acid sequence of SEQ ID NO:2, the fragment comprising eight contiguous amino acids of SEQ ID NO:2; and
  - (c) the amino acid sequence encoded by the cDNA insert of clone vb2\_1 deposited under accession number ATCC 98804;the protein being substantially free from other mammalian proteins.
10. The protein of claim 9, wherein said protein comprises the amino acid sequence of SEQ ID NO:2.
11. A composition comprising the protein of claim 9 and a pharmaceutically acceptable carrier.
12. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:
  - (a) the nucleotide sequence of SEQ ID NO:3;

- (b) the nucleotide sequence of SEQ ID NO:3 from nucleotide 130 to nucleotide 2286;
- (c) the nucleotide sequence of SEQ ID NO:3 from nucleotide 214 to nucleotide 2286;
- (d) the nucleotide sequence of the full-length protein coding sequence of clone vb3\_1 deposited under accession number ATCC 98804;
- (e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vb3\_1 deposited under accession number ATCC 98804;
- (f) the nucleotide sequence of a mature protein coding sequence of clone vb3\_1 deposited under accession number ATCC 98804;
- (g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vb3\_1 deposited under accession number ATCC 98804;
- (h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:4;
- (i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:4, the fragment comprising eight contiguous amino acids of SEQ ID NO:4;
- (j) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g); and
- (k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO:3.

13. A protein comprising an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:4;
- (b) a fragment of the amino acid sequence of SEQ ID NO:4, the fragment comprising eight contiguous amino acids of SEQ ID NO:4; and
- (c) the amino acid sequence encoded by the cDNA insert of clone vb3\_1 deposited under accession number ATCC 98804;

the protein being substantially free from other mammalian proteins.

14. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:

- (a) the nucleotide sequence of SEQ ID NO:5;
- (b) the nucleotide sequence of SEQ ID NO:5 from nucleotide 172 to nucleotide 522;
- (c) the nucleotide sequence of SEQ ID NO:5 from nucleotide 214 to nucleotide 522;
- (d) the nucleotide sequence of the full-length protein coding sequence of clone vb4\_1 deposited under accession number ATCC 98804;
- (e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vb4\_1 deposited under accession number ATCC 98804;
- (f) the nucleotide sequence of a mature protein coding sequence of clone vb4\_1 deposited under accession number ATCC 98804;
- (g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vb4\_1 deposited under accession number ATCC 98804;
- (h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:6;
- (i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:6, the fragment comprising eight contiguous amino acids of SEQ ID NO:6;
- (j) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g); and
- (k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO:5.

15. A protein comprising an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:6;
- (b) a fragment of the amino acid sequence of SEQ ID NO:6, the fragment comprising eight contiguous amino acids of SEQ ID NO:6; and



(c) the amino acid sequence encoded by the cDNA insert of clone vb4\_1 deposited under accession number ATCC 98804; the protein being substantially free from other mammalian proteins.

16. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:

- (a) the nucleotide sequence of SEQ ID NO:7;
- (b) the nucleotide sequence of SEQ ID NO:7 from nucleotide 119 to nucleotide 502;
- (c) the nucleotide sequence of SEQ ID NO:7 from nucleotide 176 to nucleotide 502;
- (d) the nucleotide sequence of the full-length protein coding sequence of clone vb5\_1 deposited under accession number ATCC 98804;
- (e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vb5\_1 deposited under accession number ATCC 98804;
- (f) the nucleotide sequence of a mature protein coding sequence of clone vb5\_1 deposited under accession number ATCC 98804;
- (g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vb5\_1 deposited under accession number ATCC 98804;
- (h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:8;
- (i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:8, the fragment comprising eight contiguous amino acids of SEQ ID NO:8;
- (j) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g); and
- (k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO:7.

17. A protein comprising an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:8;
  - (b) a fragment of the amino acid sequence of SEQ ID NO:8, the fragment comprising eight contiguous amino acids of SEQ ID NO:8; and
  - (c) the amino acid sequence encoded by the cDNA insert of clone vb5\_1 deposited under accession number ATCC 98804;
- the protein being substantially free from other mammalian proteins.

18. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:

- (a) the nucleotide sequence of SEQ ID NO:9;
- (b) the nucleotide sequence of SEQ ID NO:9 from nucleotide 128 to nucleotide 436;
- (c) the nucleotide sequence of SEQ ID NO:9 from nucleotide 203 to nucleotide 436;
- (d) the nucleotide sequence of the full-length protein coding sequence of clone vb6\_1 deposited under accession number ATCC 98804;
- (e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vb6\_1 deposited under accession number ATCC 98804;
- (f) the nucleotide sequence of a mature protein coding sequence of clone vb6\_1 deposited under accession number ATCC 98804;
- (g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vb6\_1 deposited under accession number ATCC 98804;
- (h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:10;
- (i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:10, the fragment comprising eight contiguous amino acids of SEQ ID NO:10;
- (j) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g); and
- (k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO:9.

19. A protein comprising an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:10;
- (b) a fragment of the amino acid sequence of SEQ ID NO:10, the fragment comprising eight contiguous amino acids of SEQ ID NO:10; and
- (c) the amino acid sequence encoded by the cDNA insert of clone vb6\_1 deposited under accession number ATCC 98804;

the protein being substantially free from other mammalian proteins.

20. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:

- (a) the nucleotide sequence of SEQ ID NO:11;
- (b) the nucleotide sequence of SEQ ID NO:11 from nucleotide 138 to nucleotide 1250;
- (c) the nucleotide sequence of SEQ ID NO:11 from nucleotide 279 to nucleotide 1250;
- (d) the nucleotide sequence of the full-length protein coding sequence of clone vb7\_1 deposited under accession number ATCC 98804;
- (e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vb7\_1 deposited under accession number ATCC 98804;
- (f) the nucleotide sequence of a mature protein coding sequence of clone vb7\_1 deposited under accession number ATCC 98804;
- (g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vb7\_1 deposited under accession number ATCC 98804;
- (h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:12;
- (i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:12, the fragment comprising eight contiguous amino acids of SEQ ID NO:12;
- (j) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g); and
- (k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees

C with 50% formamide, to any one of the polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO:11.

21. A protein comprising an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:12;
  - (b) a fragment of the amino acid sequence of SEQ ID NO:12, the fragment comprising eight contiguous amino acids of SEQ ID NO:12; and
  - (c) the amino acid sequence encoded by the cDNA insert of clone vb7\_1 deposited under accession number ATCC 98804;
- the protein being substantially free from other mammalian proteins.

22. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:

- (a) the nucleotide sequence of SEQ ID NO:13;
- (b) the nucleotide sequence of SEQ ID NO:13 from nucleotide 615 to nucleotide 869;
- (c) the nucleotide sequence of the full-length protein coding sequence of clone vb8\_1 deposited under accession number ATCC 98804;
- (d) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vb8\_1 deposited under accession number ATCC 98804;
- (e) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:14;
- (f) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:14, the fragment comprising eight contiguous amino acids of SEQ ID NO:14;
- (g) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(d); and
- (h) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(d), and that has a length that is at least 25% of the length of SEQ ID NO:13.

23. A protein comprising an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:14;
- (b) a fragment of the amino acid sequence of SEQ ID NO:14, the fragment comprising eight contiguous amino acids of SEQ ID NO:14; and
- (c) the amino acid sequence encoded by the cDNA insert of clone vb8\_1 deposited under accession number ATCC 98804;

the protein being substantially free from other mammalian proteins.

24. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:

- (a) the nucleotide sequence of SEQ ID NO:15;
- (b) the nucleotide sequence of SEQ ID NO:15 from nucleotide 148 to nucleotide 1470;
- (c) the nucleotide sequence of SEQ ID NO:15 from nucleotide 193 to nucleotide 1470;
- (d) the nucleotide sequence of the full-length protein coding sequence of clone vb9\_1 deposited under accession number ATCC 98804;
- (e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vb9\_1 deposited under accession number ATCC 98804;
- (f) the nucleotide sequence of a mature protein coding sequence of clone vb9\_1 deposited under accession number ATCC 98804;
- (g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vb9\_1 deposited under accession number ATCC 98804;
- (h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:16;
- (i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:16, the fragment comprising eight contiguous amino acids of SEQ ID NO:16;
- (j) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g); and
- (k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees

C with 50% formamide, to any one of the polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO:15.

25. A protein comprising an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:16;
- (b) a fragment of the amino acid sequence of SEQ ID NO:16, the fragment comprising eight contiguous amino acids of SEQ ID NO:16; and
- (c) the amino acid sequence encoded by the cDNA insert of clone vb9\_1 deposited under accession number ATCC 98804;

the protein being substantially free from other mammalian proteins.

26. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:

- (a) the nucleotide sequence of SEQ ID NO:17;
- (b) the nucleotide sequence of SEQ ID NO:17 from nucleotide 109 to nucleotide 414;
- (c) the nucleotide sequence of SEQ ID NO:17 from nucleotide 217 to nucleotide 414;
- (d) the nucleotide sequence of the full-length protein coding sequence of clone vc3\_1 deposited under accession number ATCC 98748;
- (e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vc3\_1 deposited under accession number ATCC 98748;
- (f) the nucleotide sequence of a mature protein coding sequence of clone vc3\_1 deposited under accession number ATCC 98748;
- (g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vc3\_1 deposited under accession number ATCC 98748;
- (h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:18;
- (i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:18, the fragment comprising eight contiguous amino acids of SEQ ID NO:18;

(j) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g); and

(k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO:17.

27. A protein comprising an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO:18;

(b) a fragment of the amino acid sequence of SEQ ID NO:18, the fragment comprising eight contiguous amino acids of SEQ ID NO:18; and

(c) the amino acid sequence encoded by the cDNA insert of clone vc3\_1 deposited under accession number ATCC 98748;

the protein being substantially free from other mammalian proteins.

28. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:

(a) the nucleotide sequence of SEQ ID NO:19;

(b) the nucleotide sequence of SEQ ID NO:19 from nucleotide 169 to nucleotide 840;

(c) the nucleotide sequence of SEQ ID NO:19 from nucleotide 211 to nucleotide 840;

(d) the nucleotide sequence of the full-length protein coding sequence of clone vc4\_1 deposited under accession number ATCC 98748;

(e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vc4\_1 deposited under accession number ATCC 98748;

(f) the nucleotide sequence of a mature protein coding sequence of clone vc4\_1 deposited under accession number ATCC 98748;

(g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vc4\_1 deposited under accession number ATCC 98748;

(h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:20;

(i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:20, the fragment comprising eight contiguous amino acids of SEQ ID NO:20;

(j) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g); and

(k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO:19.

29. A protein comprising an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO:20;

(b) a fragment of the amino acid sequence of SEQ ID NO:20, the fragment comprising eight contiguous amino acids of SEQ ID NO:20; and

(c) the amino acid sequence encoded by the cDNA insert of clone vc4\_1 deposited under accession number ATCC 98748;

the protein being substantially free from other mammalian proteins.

30. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:

(a) the nucleotide sequence of SEQ ID NO:21;

(b) the nucleotide sequence of SEQ ID NO:21 from nucleotide 508 to nucleotide 951;

(c) the nucleotide sequence of SEQ ID NO:21 from nucleotide 733 to nucleotide 951;

(d) the nucleotide sequence of the full-length protein coding sequence of clone vc5\_1 deposited under accession number ATCC 98748;

(e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vc5\_1 deposited under accession number ATCC 98748;

(f) the nucleotide sequence of a mature protein coding sequence of clone vc5\_1 deposited under accession number ATCC 98748;



(g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vc5\_1 deposited under accession number ATCC 98748;

(h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:22;

(i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:22, the fragment comprising eight contiguous amino acids of SEQ ID NO:22;

(j) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g); and

(k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO:21.

31. A protein comprising an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO:22;

(b) a fragment of the amino acid sequence of SEQ ID NO:22, the fragment comprising eight contiguous amino acids of SEQ ID NO:22; and

(c) the amino acid sequence encoded by the cDNA insert of clone vc5\_1 deposited under accession number ATCC 98748;

the protein being substantially free from other mammalian proteins.

32. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:

(a) the nucleotide sequence of SEQ ID NO:23;

(b) the nucleotide sequence of SEQ ID NO:23 from nucleotide 125 to nucleotide 493;

(c) the nucleotide sequence of the full-length protein coding sequence of clone vc7\_1 deposited under accession number ATCC 98748;

(d) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vc7\_1 deposited under accession number ATCC 98748;

(e) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:24;

(f) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:24, the fragment comprising eight contiguous amino acids of SEQ ID NO:24;

(g) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(d); and

(h) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(d), and that has a length that is at least 25% of the length of SEQ ID NO:23.

33. A protein comprising an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO:24;

(b) a fragment of the amino acid sequence of SEQ ID NO:24, the fragment comprising eight contiguous amino acids of SEQ ID NO:24; and

(c) the amino acid sequence encoded by the cDNA insert of clone vc7\_1 deposited under accession number ATCC 98748;

the protein being substantially free from other mammalian proteins.

34. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:

(a) the nucleotide sequence of SEQ ID NO:25;

(b) the nucleotide sequence of SEQ ID NO:25 from nucleotide 33 to nucleotide 407;

(c) the nucleotide sequence of SEQ ID NO:25 from nucleotide 99 to nucleotide 407;

(d) the nucleotide sequence of the full-length protein coding sequence of clone vc9\_1 deposited under accession number ATCC 98748;

(e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vc9\_1 deposited under accession number ATCC 98748;

- (f) the nucleotide sequence of a mature protein coding sequence of clone vc9\_1 deposited under accession number ATCC 98748;
- (g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vc9\_1 deposited under accession number ATCC 98748;
- (h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:26;
- (i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:26, the fragment comprising eight contiguous amino acids of SEQ ID NO:26;
- (j) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g); and
- (k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO:25.

35. A protein comprising an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:26;
- (b) a fragment of the amino acid sequence of SEQ ID NO:26, the fragment comprising eight contiguous amino acids of SEQ ID NO:26; and
- (c) the amino acid sequence encoded by the cDNA insert of clone vc9\_1 deposited under accession number ATCC 98748;

the protein being substantially free from other mammalian proteins.

36. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:

- (a) the nucleotide sequence of SEQ ID NO:27;
- (b) the nucleotide sequence of SEQ ID NO:27 from nucleotide 176 to nucleotide 871;
- (c) the nucleotide sequence of the full-length protein coding sequence of clone vc10\_1 deposited under accession number ATCC 98748;

- (d) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vc10\_1 deposited under accession number ATCC 98748;
- (e) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:28;
- (f) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:28, the fragment comprising eight contiguous amino acids of SEQ ID NO:28;
- (g) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(d); and
- (h) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(d), and that has a length that is at least 25% of the length of SEQ ID NO:27.

37. A protein comprising an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:28;
- (b) a fragment of the amino acid sequence of SEQ ID NO:28, the fragment comprising eight contiguous amino acids of SEQ ID NO:28; and
- (c) the amino acid sequence encoded by the cDNA insert of clone vc10\_1 deposited under accession number ATCC 98748;

the protein being substantially free from other mammalian proteins.

38. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:

- (a) the nucleotide sequence of SEQ ID NO:29;
- (b) the nucleotide sequence of SEQ ID NO:29 from nucleotide 160 to nucleotide 657;
- (c) the nucleotide sequence of SEQ ID NO:29 from nucleotide 214 to nucleotide 657;
- (d) the nucleotide sequence of the full-length protein coding sequence of clone vc11\_1 deposited under accession number ATCC 98748;

- (e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vc11\_1 deposited under accession number ATCC 98748;
- (f) the nucleotide sequence of a mature protein coding sequence of clone vc11\_1 deposited under accession number ATCC 98748;
- (g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vc11\_1 deposited under accession number ATCC 98748;
- (h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:30;
- (i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:30, the fragment comprising eight contiguous amino acids of SEQ ID NO:30;
- (j) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g); and
- (k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO:29.

39. A protein comprising an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:30;
- (b) a fragment of the amino acid sequence of SEQ ID NO:30, the fragment comprising eight contiguous amino acids of SEQ ID NO:30; and
- (c) the amino acid sequence encoded by the cDNA insert of clone vc11\_1 deposited under accession number ATCC 98748;

the protein being substantially free from other mammalian proteins.

40. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:

- (a) the nucleotide sequence of SEQ ID NO:31;
- (b) the nucleotide sequence of SEQ ID NO:31 from nucleotide 228 to nucleotide 662;

- (c) the nucleotide sequence of SEQ ID NO:31 from nucleotide 327 to nucleotide 662;
- (d) the nucleotide sequence of the full-length protein coding sequence of clone vc14\_1 deposited under accession number ATCC 98748;
- (e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vc14\_1 deposited under accession number ATCC 98748;
- (f) the nucleotide sequence of a mature protein coding sequence of clone vc14\_1 deposited under accession number ATCC 98748;
- (g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vc14\_1 deposited under accession number ATCC 98748;
- (h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:32;
- (i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:32, the fragment comprising eight contiguous amino acids of SEQ ID NO:32;
- (j) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g); and
- (k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO:31.

41. A protein comprising an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:32;
- (b) a fragment of the amino acid sequence of SEQ ID NO:32, the fragment comprising eight contiguous amino acids of SEQ ID NO:32; and
- (c) the amino acid sequence encoded by the cDNA insert of clone vc14\_1 deposited under accession number ATCC 98748;

the protein being substantially free from other mammalian proteins.

42. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:

- (a) the nucleotide sequence of SEQ ID NO:33;
- (b) the nucleotide sequence of SEQ ID NO:33 from nucleotide 101 to nucleotide 667;
- (c) the nucleotide sequence of SEQ ID NO:33 from nucleotide 182 to nucleotide 667;
- (d) the nucleotide sequence of the full-length protein coding sequence of clone vc16\_1 deposited under accession number ATCC 98784;
- (e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vc16\_1 deposited under accession number ATCC 98784;
- (f) the nucleotide sequence of a mature protein coding sequence of clone vc16\_1 deposited under accession number ATCC 98784;
- (g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vc16\_1 deposited under accession number ATCC 98784;
- (h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:34;
- (i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:34, the fragment comprising eight contiguous amino acids of SEQ ID NO:34;
- (j) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g); and
- (k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO:33.

43. A protein comprising an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:34;
- (b) a fragment of the amino acid sequence of SEQ ID NO:34, the fragment comprising eight contiguous amino acids of SEQ ID NO:34; and
- (c) the amino acid sequence encoded by the cDNA insert of clone vc16\_1 deposited under accession number ATCC 98784;

the protein being substantially free from other mammalian proteins.

44. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:

- (a) the nucleotide sequence of SEQ ID NO:35;
- (b) the nucleotide sequence of SEQ ID NO:35 from nucleotide 8 to nucleotide 355;
- (c) the nucleotide sequence of SEQ ID NO:35 from nucleotide 134 to nucleotide 355;
- (d) the nucleotide sequence of the full-length protein coding sequence of clone vc17\_1 deposited under accession number ATCC 98784;
- (e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vc17\_1 deposited under accession number ATCC 98784;
- (f) the nucleotide sequence of a mature protein coding sequence of clone vc17\_1 deposited under accession number ATCC 98784;
- (g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vc17\_1 deposited under accession number ATCC 98784;
- (h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:36;
- (i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:36, the fragment comprising eight contiguous amino acids of SEQ ID NO:36;
- (j) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g); and
- (k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO:35.

45. A protein comprising an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:36;
- (b) a fragment of the amino acid sequence of SEQ ID NO:36, the fragment comprising eight contiguous amino acids of SEQ ID NO:36; and



(c) the amino acid sequence encoded by the cDNA insert of clone vc17\_1 deposited under accession number ATCC 98784;  
the protein being substantially free from other mammalian proteins.

46. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:

- (a) the nucleotide sequence of SEQ ID NO:37;
- (b) the nucleotide sequence of SEQ ID NO:37 from nucleotide 1031 to nucleotide 1252;
- (c) the nucleotide sequence of SEQ ID NO:37 from nucleotide 1100 to nucleotide 1252;
- (d) the nucleotide sequence of the full-length protein coding sequence of clone vc21\_1 deposited under accession number ATCC 98785;
- (e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vc21\_1 deposited under accession number ATCC 98785;
- (f) the nucleotide sequence of a mature protein coding sequence of clone vc21\_1 deposited under accession number ATCC 98785;
- (g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vc21\_1 deposited under accession number ATCC 98785;
- (h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:38;
- (i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:38, the fragment comprising eight contiguous amino acids of SEQ ID NO:38;
- (j) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g); and
- (k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO:37.

47. A protein comprising an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:38;
  - (b) the amino acid sequence of SEQ ID NO:38 from amino acid 29 to amino acid 74;
  - (c) a fragment of the amino acid sequence of SEQ ID NO:38, the fragment comprising eight contiguous amino acids of SEQ ID NO:38; and
  - (d) the amino acid sequence encoded by the cDNA insert of clone vc21\_1 deposited under accession number ATCC 98785;
- the protein being substantially free from other mammalian proteins.

48. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:

- (a) the nucleotide sequence of SEQ ID NO:39;
- (b) the nucleotide sequence of SEQ ID NO:39 from nucleotide 94 to nucleotide 1482;
- (c) the nucleotide sequence of SEQ ID NO:39 from nucleotide 214 to nucleotide 1482;
- (d) the nucleotide sequence of the full-length protein coding sequence of clone vc23\_1 deposited under accession number ATCC 98784;
- (e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vc23\_1 deposited under accession number ATCC 98784;
- (f) the nucleotide sequence of a mature protein coding sequence of clone vc23\_1 deposited under accession number ATCC 98784;
- (g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vc23\_1 deposited under accession number ATCC 98784;
- (h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:40;
- (i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:40, the fragment comprising eight contiguous amino acids of SEQ ID NO:40;
- (j) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g); and
- (k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees

C with 50% formamide, to any one of the polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO:39.

49. A protein comprising an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:40;
- (b) a fragment of the amino acid sequence of SEQ ID NO:40, the fragment comprising eight contiguous amino acids of SEQ ID NO:40; and
- (c) the amino acid sequence encoded by the cDNA insert of clone vc23\_1 deposited under accession number ATCC 98784;

the protein being substantially free from other mammalian proteins.

50. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:

- (a) the nucleotide sequence of SEQ ID NO:41;
- (b) the nucleotide sequence of SEQ ID NO:41 from nucleotide 153 to nucleotide 413;
- (c) the nucleotide sequence of SEQ ID NO:41 from nucleotide 264 to nucleotide 413;
- (d) the nucleotide sequence of the full-length protein coding sequence of clone vc25\_1 deposited under accession number ATCC 98784;
- (e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vc25\_1 deposited under accession number ATCC 98784;
- (f) the nucleotide sequence of a mature protein coding sequence of clone vc25\_1 deposited under accession number ATCC 98784;
- (g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vc25\_1 deposited under accession number ATCC 98784;
- (h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:42;
- (i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:42, the fragment comprising eight contiguous amino acids of SEQ ID NO:42;

(j) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g); and

(k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO:41.

51. A protein comprising an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO:42;

(b) a fragment of the amino acid sequence of SEQ ID NO:42, the fragment comprising eight contiguous amino acids of SEQ ID NO:42; and

(c) the amino acid sequence encoded by the cDNA insert of clone vc25\_1 deposited under accession number ATCC 98784;

the protein being substantially free from other mammalian proteins.

52. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:

(a) the nucleotide sequence of SEQ ID NO:43;

(b) the nucleotide sequence of SEQ ID NO:43 from nucleotide 87 to nucleotide 1409;

(c) the nucleotide sequence of SEQ ID NO:43 from nucleotide 156 to nucleotide 1409;

(d) the nucleotide sequence of the full-length protein coding sequence of clone vc26\_1 deposited under accession number ATCC 98784;

(e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vc26\_1 deposited under accession number ATCC 98784;

(f) the nucleotide sequence of a mature protein coding sequence of clone vc26\_1 deposited under accession number ATCC 98784;

(g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vc26\_1 deposited under accession number ATCC 98784;

(h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:44;

(i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:44, the fragment comprising eight contiguous amino acids of SEQ ID NO:44;

(j) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g); and

(k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO:43.

53. A protein comprising an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO:44;

(b) a fragment of the amino acid sequence of SEQ ID NO:44, the fragment comprising eight contiguous amino acids of SEQ ID NO:44; and

(c) the amino acid sequence encoded by the cDNA insert of clone vc26\_1 deposited under accession number ATCC 98784;

the protein being substantially free from other mammalian proteins.

54. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:

(a) the nucleotide sequence of SEQ ID NO:45;

(b) the nucleotide sequence of SEQ ID NO:45 from nucleotide 63 to nucleotide 428;

(c) the nucleotide sequence of SEQ ID NO:45 from nucleotide 156 to nucleotide 428;

(d) the nucleotide sequence of SEQ ID NO:45 from nucleotide 356 to nucleotide 1773;

(e) the nucleotide sequence of the full-length protein coding sequence of clone vc30\_1 deposited under accession number ATCC 98804;

(f) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vc30\_1 deposited under accession number ATCC 98804;

- (g) the nucleotide sequence of a mature protein coding sequence of clone vc30\_1 deposited under accession number ATCC 98804;
- (h) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vc30\_1 deposited under accession number ATCC 98804;
- (i) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:46;
- (j) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:46, the fragment comprising eight contiguous amino acids of SEQ ID NO:46;
- (k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(h); and
- (l) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(h), and that has a length that is at least 25% of the length of SEQ ID NO:45.

55. A protein comprising an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:46;
- (b) the amino acid sequence of SEQ ID NO:46 from amino acid 1 to amino acid 97;
- (c) a fragment of the amino acid sequence of SEQ ID NO:46, the fragment comprising eight contiguous amino acids of SEQ ID NO:46; and
- (d) the amino acid sequence encoded by the cDNA insert of clone vc30\_1 deposited under accession number ATCC 98804;

the protein being substantially free from other mammalian proteins.

56. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:

- (a) the nucleotide sequence of SEQ ID NO:47;
- (b) the nucleotide sequence of SEQ ID NO:47 from nucleotide 30 to nucleotide 1799;

- (c) the nucleotide sequence of SEQ ID NO:47 from nucleotide 90 to nucleotide 1799;
- (d) the nucleotide sequence of the full-length protein coding sequence of clone vd1\_1 deposited under accession number ATCC 98748;
- (e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vd1\_1 deposited under accession number ATCC 98748;
- (f) the nucleotide sequence of a mature protein coding sequence of clone vd1\_1 deposited under accession number ATCC 98748;
- (g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vd1\_1 deposited under accession number ATCC 98748;
- (h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:48;
- (i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:48, the fragment comprising eight contiguous amino acids of SEQ ID NO:48;
- (j) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g); and
- (k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO:47.

57. A protein comprising an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:48;
  - (b) a fragment of the amino acid sequence of SEQ ID NO:48, the fragment comprising eight contiguous amino acids of SEQ ID NO:48; and
  - (c) the amino acid sequence encoded by the cDNA insert of clone vd1\_1 deposited under accession number ATCC 98748;
- the protein being substantially free from other mammalian proteins.

58. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:

- (a) the nucleotide sequence of SEQ ID NO:49;
- (b) the nucleotide sequence of SEQ ID NO:49 from nucleotide 69 to nucleotide 443;
- (c) the nucleotide sequence of SEQ ID NO:49 from nucleotide 111 to nucleotide 443;
- (d) the nucleotide sequence of the full-length protein coding sequence of clone vd2\_1 deposited under accession number ATCC 98748;
- (e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vd2\_1 deposited under accession number ATCC 98748;
- (f) the nucleotide sequence of a mature protein coding sequence of clone vd2\_1 deposited under accession number ATCC 98748;
- (g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vd2\_1 deposited under accession number ATCC 98748;
- (h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:50;
- (i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:50, the fragment comprising eight contiguous amino acids of SEQ ID NO:50;
- (j) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g); and
- (k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO:49.

59. A protein comprising an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:50;
- (b) a fragment of the amino acid sequence of SEQ ID NO:50, the fragment comprising eight contiguous amino acids of SEQ ID NO:50; and
- (c) the amino acid sequence encoded by the cDNA insert of clone vd2\_1 deposited under accession number ATCC 98748;

the protein being substantially free from other mammalian proteins.



60. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:

- (a) the nucleotide sequence of SEQ ID NO:51;
- (b) the nucleotide sequence of SEQ ID NO:51 from nucleotide 176 to nucleotide 1249;
- (c) the nucleotide sequence of SEQ ID NO:51 from nucleotide 227 to nucleotide 1249;
- (d) the nucleotide sequence of the full-length protein coding sequence of clone vd3\_1 deposited under accession number ATCC 98804;
- (e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vd3\_1 deposited under accession number ATCC 98804;
- (f) the nucleotide sequence of a mature protein coding sequence of clone vd3\_1 deposited under accession number ATCC 98804;
- (g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vd3\_1 deposited under accession number ATCC 98804;
- (h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:52;
- (i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:52, the fragment comprising eight contiguous amino acids of SEQ ID NO:52;
- (j) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g); and
- (k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO:51.

61. A protein comprising an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:52;
- (b) a fragment of the amino acid sequence of SEQ ID NO:52, the fragment comprising eight contiguous amino acids of SEQ ID NO:52; and

(c) the amino acid sequence encoded by the cDNA insert of clone vd3\_1 deposited under accession number ATCC 98804; the protein being substantially free from other mammalian proteins.

62. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:

- (a) the nucleotide sequence of SEQ ID NO:53;
- (b) the nucleotide sequence of SEQ ID NO:53 from nucleotide 94 to nucleotide 1530;
- (c) the nucleotide sequence of SEQ ID NO:53 from nucleotide 145 to nucleotide 1530;
- (d) the nucleotide sequence of the full-length protein coding sequence of clone vd4\_1 deposited under accession number ATCC 98804;
- (e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vd4\_1 deposited under accession number ATCC 98804;
- (f) the nucleotide sequence of a mature protein coding sequence of clone vd4\_1 deposited under accession number ATCC 98804;
- (g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vd4\_1 deposited under accession number ATCC 98804;
- (h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:54;
- (i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:54, the fragment comprising eight contiguous amino acids of SEQ ID NO:54;
- (j) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g); and
- (k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO:53.

63. A protein comprising an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:54;
  - (b) a fragment of the amino acid sequence of SEQ ID NO:54, the fragment comprising eight contiguous amino acids of SEQ ID NO:54; and
  - (c) the amino acid sequence encoded by the cDNA insert of clone vd4\_1 deposited under accession number ATCC 98804;
- the protein being substantially free from other mammalian proteins.

64. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:

- (a) the nucleotide sequence of SEQ ID NO:55;
- (b) the nucleotide sequence of SEQ ID NO:55 from nucleotide 71 to nucleotide 1300;
- (c) the nucleotide sequence of SEQ ID NO:55 from nucleotide 182 to nucleotide 1300;
- (d) the nucleotide sequence of the full-length protein coding sequence of clone ve4\_1 deposited under accession number ATCC 98784;
- (e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone ve4\_1 deposited under accession number ATCC 98784;
- (f) the nucleotide sequence of a mature protein coding sequence of clone ve4\_1 deposited under accession number ATCC 98784;
- (g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone ve4\_1 deposited under accession number ATCC 98784;
- (h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:56;
- (i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:56, the fragment comprising eight contiguous amino acids of SEQ ID NO:56;
- (j) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g); and
- (k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO:55.

65. A protein comprising an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:56;
- (b) a fragment of the amino acid sequence of SEQ ID NO:56, the fragment comprising eight contiguous amino acids of SEQ ID NO:56; and
- (c) the amino acid sequence encoded by the cDNA insert of clone ve4\_1 deposited under accession number ATCC 98784;

the protein being substantially free from other mammalian proteins.

66. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:

- (a) the nucleotide sequence of SEQ ID NO:57;
- (b) the nucleotide sequence of SEQ ID NO:57 from nucleotide 57 to nucleotide 785;
- (c) the nucleotide sequence of SEQ ID NO:57 from nucleotide 147 to nucleotide 785;
- (d) the nucleotide sequence of the full-length protein coding sequence of clone ve8\_1 deposited under accession number ATCC 98804;
- (e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone ve8\_1 deposited under accession number ATCC 98804;
- (f) the nucleotide sequence of a mature protein coding sequence of clone ve8\_1 deposited under accession number ATCC 98804;
- (g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone ve8\_1 deposited under accession number ATCC 98804;
- (h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:58;
- (i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:58, the fragment comprising eight contiguous amino acids of SEQ ID NO:58;
- (j) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g); and
- (k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees

C with 50% formamide, to any one of the polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO:57.

67. A protein comprising an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:58;
- (b) a fragment of the amino acid sequence of SEQ ID NO:58, the fragment comprising eight contiguous amino acids of SEQ ID NO:58; and
- (c) the amino acid sequence encoded by the cDNA insert of clone ve8\_1 deposited under accession number ATCC 98804;

the protein being substantially free from other mammalian proteins.

68. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:

- (a) the nucleotide sequence of SEQ ID NO:59;
- (b) the nucleotide sequence of SEQ ID NO:59 from nucleotide 64 to nucleotide 1002;
- (c) the nucleotide sequence of SEQ ID NO:59 from nucleotide 139 to nucleotide 1002;
- (d) the nucleotide sequence of the full-length protein coding sequence of clone vf1\_1 deposited under accession number ATCC 98784;
- (e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vf1\_1 deposited under accession number ATCC 98784;
- (f) the nucleotide sequence of a mature protein coding sequence of clone vf1\_1 deposited under accession number ATCC 98784;
- (g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vf1\_1 deposited under accession number ATCC 98784;
- (h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:60;
- (i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:60, the fragment comprising eight contiguous amino acids of SEQ ID NO:60;

- (j) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g); and
- (k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO:59.

69. A protein comprising an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:60;
- (b) a fragment of the amino acid sequence of SEQ ID NO:60, the fragment comprising eight contiguous amino acids of SEQ ID NO:60; and
- (c) the amino acid sequence encoded by the cDNA insert of clone vf1\_1 deposited under accession number ATCC 98784;

the protein being substantially free from other mammalian proteins.

70. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:

- (a) the nucleotide sequence of SEQ ID NO:61;
- (b) the nucleotide sequence of SEQ ID NO:61 from nucleotide 588 to nucleotide 995;
- (c) the nucleotide sequence of SEQ ID NO:61 from nucleotide 750 to nucleotide 995;
- (d) the nucleotide sequence of the full-length protein coding sequence of clone vh1\_1 deposited under accession number ATCC 98804;
- (e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vh1\_1 deposited under accession number ATCC 98804;
- (f) the nucleotide sequence of a mature protein coding sequence of clone vh1\_1 deposited under accession number ATCC 98804;
- (g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vh1\_1 deposited under accession number ATCC 98804;
- (h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:62;

(i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:62, the fragment comprising eight contiguous amino acids of SEQ ID NO:62;

(j) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g); and

(k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO:61.

71. A protein comprising an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO:62;

(b) a fragment of the amino acid sequence of SEQ ID NO:62, the fragment comprising eight contiguous amino acids of SEQ ID NO:62; and

(c) the amino acid sequence encoded by the cDNA insert of clone vh1\_1 deposited under accession number ATCC 98804;

the protein being substantially free from other mammalian proteins.

72. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:

(a) the nucleotide sequence of SEQ ID NO:63;

(b) the nucleotide sequence of SEQ ID NO:63 from nucleotide 29 to nucleotide 1369;

(c) the nucleotide sequence of SEQ ID NO:63 from nucleotide 104 to nucleotide 1369;

(d) the nucleotide sequence of the full-length protein coding sequence of clone vi1\_1 deposited under accession number ATCC 98804;

(e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vi1\_1 deposited under accession number ATCC 98804;

(f) the nucleotide sequence of a mature protein coding sequence of clone vi1\_1 deposited under accession number ATCC 98804;

- (g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vi1\_1 deposited under accession number ATCC 98804;
- (h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:64;
- (i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:64, the fragment comprising eight contiguous amino acids of SEQ ID NO:64;
- (j) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g); and
- (k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO:63.


73. A protein comprising an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:64;
- (b) a fragment of the amino acid sequence of SEQ ID NO:64, the fragment comprising eight contiguous amino acids of SEQ ID NO:64; and
- (c) the amino acid sequence encoded by the cDNA insert of clone vi1\_1 deposited under accession number ATCC 98804;

the protein being substantially free from other mammalian proteins.



FIGURE 1A




**Plasmid name:** pED6dpc2

**Plasmid size:** 5374 bp

**Comments/References:** pED6dpc2 is derived from pED6dpc1 by insertion of a new polylinker to facilitate cDNA cloning. SST cDNAs are cloned between EcoRI and NotI. pED vectors are described in Kaufman et al.(1991), NAR 19: 4485-4490.

FIGURE 1B



**Plasmid name:** pNOTs

**Plasmid size:** 4529 bp

**Comments/References:** pNOTs is a derivative of pMT2 (Kaufman et al, 1989. Mol. Cell. Biol. 9:1741-1750). DHFR was deleted and a new polylinker was inserted between EcoRI and HpaI. M13 origin of replication was inserted in the ClaI site. SST cDNAs are cloned between EcoRI and NotI

## SEQUENCE LISTING

<110> Valenzuela, Dario  
 Yuan, Olive  
 Hoffman, Heidi  
 Hall, Jeff  
 Rapiejko, Peter  
 AlphaGene, Inc.

<120> SECRETED PROTEINS AND POLYNUCLEOTIDES ENCODING THEM

<130> GI 6900X

<140>

<141>

<160> 107

<170> PatentIn Ver. 2.0

<210> 1

<211> 2201

<212> DNA

<213> Homo sapiens

<400> 1

```

tccttcgcct cctgcacctt gggagccctg ggctactctt tcacggcccc tgttgccctg 60
tgatctgtag gtccttgagg acgcacagtt aagggtgccag gacatcctgg aagctgggaa 120
atgatatgta ttcatcttcc accaccgtag tggaagagat actatcccta tctttacaac 180
tgatagcatt tccaacagta agctgtgaga ttctgcttga aatcacctct caaacaaata 240
aaaaacagac cggggagaca tgctacgctc attctgctga agaaataggc atcatagctg 300
ggaaacggat tcacaagacc caggctgttc cctacatag tttcctcctc cgacatcagt 360
tcatcagtc aatcaagccat gtgagagtgg aggccttgta ttccctatta ttcttgggca 420
ctctactcca agtaggaaaa ggccaggagg tcctgttaaa ggatgcactc agagcccggg 480
ctccctaaca tatgagagt ctaaccagca ggtgtagact tttcaggagt gaagaatgag 540
gcaggcattc caaacctgga ccttcacac cttttgtttc atctcaagac aattctgagg 600
gactgttttg gagcgtgtct ggaaggtgaa ccttgaagaa gagtgtgggc tttgatgtga 660
ctcagttgag atctttcatg gggaggcagg aattcaatgc ccagaatctg ggctgggtgc 720
tttgagggtc gtaggtttgc tctttgtatc caagtccatt gttactaggt tggaggctgg 780
agattctaaa tggctttccag accatctctc tggtctctct tgggagatgg ggtctgaaag 840
acaatatcag tagtttttgg aaattctaga aagtgtgctt ggaaacgtgg gaagagctct 900
tgcctagtgc ctaaagtctc cttttgcagc tctagccaag tagatacttg gtaggtatag 960
agccgggttt gcgtttatat cagcaaaacc tatatcagag ttgaagaagt agtcaggaaa 1020
aagcgtcttg gtcgcaggcc ggggaacatc taaaagcaa acttctagcc tgctgactct 1080
tggcaatgag tgttgatcc tggctaaagt gccttgaatg cagcatgagg ccaatccatg 1140
aatccaactt ctcatggaga aatgttaata ttttttcagt ttgaatcaat cagggtgaaa 1200
ctaccatgct attggtttgc ttacttttta ttatttcatg taaaatctaa gacaaaatac 1260
attaaatgct tattgacata tgtatttatt cttcaccagg ctgataatat ctgcctaatt 1320
ttaaactttc ttccattttg taggtttcaa cttattctat tgtaagatac tgttaaattc 1380
aatagaggca ttgtcacttt tacgtataat tttattttat ttcataatatt tcctattggc 1440
tttttacatt taaattatgg agcacttcat catataaaaa acttcaatta tatttaaca 1500
gtaagtcttt ggattttttt gccttgtaat ttccatatta cataataatg agataaacat 1560
taatgttttc agggtaactt aaattttaga taattaacta ttgtattcat gtgaaatttg 1620
tttttactgc atgtgtgggt tggaggactg ttttcacttc tgattcatct ttactcttat 1680
ctcatcagag ctcatacctc ttgtagttgg gggattgcag ttataattc caataaatgg 1740
ggcaaatcca aatacaaatg agtttgaatg caggacaggc cttcaaagca 1800
tacacaacat gggcctacat atgtacaaca ataataattt ataagttact gtttggatgg 1860
aaagtaaaag tacagaaaat ttgttaaagg aaattaaaat ggagatcatg tctcaataat 1920
ctctgagcag acaaaattag ttaggtctca taagtgatct caacctogct tgatttgcaa 1980
atacaaaaca aacttacatt atttcttgta gctgcatatt gaaaaaagag aaatgaagct 2040

```

```

caaccagtca gaagtagcca acaaccttat ataaatagaa actgtccaac aaggtaaaca 2100
gacaaacaaa aaacaataaa aaaagttgtg ctaccaccaa aaaaaaaaaa aaaaaaaaaa 2160
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa a                2201

```

<210> 2  
 <211> 120  
 <212> PRT  
 <213> Homo sapiens

<400> 2  
 Met Tyr Ser Phe Pro Thr Thr Val Val Glu Glu Ile Leu Ser Leu Ser  
     1                    5                    10                    15  
 Leu Gln Leu Ile Ala Phe Pro Thr Val Ser Cys Glu Ile Leu Leu Glu  
                     20                    25                    30  
 Ile Thr Ser Gln Thr Asn Lys Lys Gln Thr Arg Glu Thr Cys Tyr Ala  
             35                    40                    45  
 His Ser Ala Glu Glu Ile Gly Ile Ile Ala Gly Lys Arg Ile His Lys  
       50                    55                    60  
 Thr Gln Ala Val Pro Tyr Ile Cys Phe Leu Leu Arg His Gln Phe Ile  
       65                    70                    75                    80  
 Ser Gln Ser Ser His Val Arg Val Glu Ala Leu Tyr Ser Leu Leu Phe  
                     85                    90                    95  
 Leu Gly Thr Leu Leu Gln Val Gly Lys Gly Gln Glu Val Leu Leu Lys  
             100                    105                    110  
 Asp Ala Leu Arg Ala Arg Ala Pro  
       115                    120

<210> 3  
 <211> 2498  
 <212> DNA  
 <213> Homo sapiens

<400> 3  
 ggtcgttttg atagtgatga acagaaaatt cagaatgata tcattgatat tttactgact 60  
 ttacacaaag gagttaatga aaaactcaca atctcagaag agactctggc caataataact 120  
 tggctcttaa tgtaaaaga agttctttct tcaatcttga aggttcctga aggatttttt 180  
 tctggactca tactcctttc agagctgctg cctcttccat tgcccatgca aacaactcag 240  
 gttattgagc cacatgatat atcagtggca ctcaacaccg gaaaattgtg gagcatgcac 300  
 ctcatgttc aagcaaagtt gctccaagaa atagttcgct ctttctctgg cacaacctgc 360  
 cagcccatcc aacatatggt acggcgctatt tgtgttcaat tgtgtgacct tgccctacca 420  
 actgcacttc tgattatgag aactgtgttg gatttgattg tagaagactt gcaaagcact 480  
 tcagaagata aagaaaaaca gtatactagc caaaccacca ggttgcttgc tcttcttgat 540  
 gctctggctt cacacaaagc ttgtaaatta gctattttgc atctaattaa tggaactatt 600  
 aaagggtgat aaagatatgc agagatatcc caggatcttt tagcttttgt gcggtctcct 660  
 ggagacagtg ttattcgcca acagtgtgtt gaatatgtca catccatttt gcagtctctc 720  
 tgtgatcagg acattgcact tatcttacca agctcttctg aaggttctat ttctgaactg 780  
 gagcagctct ccaattctct accaaataaa gaattgatga cctcaatctg tgactgtctg 840  
 ttggctacgc tagctaactc tgagagcagt tacaactgtt tactgacatg tgtcagaaca 900  
 atgatgtttc ttgcagagca tgattatgga ttatttcatt taaaaagttc ttttaaggaaa 960  
 aacagtagtg ctctgcatag tttactgaaa cgagtgggtc gcacatttag taaggacaca 1020  
 ggagagcttg catcttcatt tttagaattt atgagacaaa ttcttaactc tgacacaatt 1080  
 ggatgctgtg gagatgataa tggctctcatg gaagtagagg gagctcatac atcacggacg 1140

```

atgagtatta atgctgcaga gttaaaacag cttctacaaa gcaaagaaga aagtccagaa 1200
aatttgttcc ttgaactaga gaagcttggt ttggaacatt caaaagatga tgacaatctg 1260
gattctttgt tggacagtgt agttggactt aagcagatgc tggagtcac aggtgacct 1320
ttacctctca gtgaccagga tgtagaacca gtactttcag ctccagaatc tcttcagaat 1380
ctgtttaaca ataggactgc ctatgtgctt gctgatgtca tggatgatca gttgaaatct 1440
atgtggttca ctccatttca ggctgaagag atagatacag atctggattt ggtaaagggt 1500
gacttaattg aactctctga aaaatgctgt agtgactttg atttgcactc agaattagag 1560
cgctcatttt tgtcagaacc atcatctcca ggaagaacca agactactaa aggattcaaa 1620
cttggaagc acaagcatga gacctttata acgtcaagtg gaaaatctga atacattgaa 1680
cctgccaaaa gagctcatgt tgtgccacca ccaagaggaa ggggcagggg aggatttgga 1740
caggggtatac gacctcatga tatttttctg cagagaaaac agaacacaag tagaccacca 1800
tctatgcatg tggatgactt tgttgctgct gaaagtaaag aagtgggtcc tcaagatgga 1860
atactccac caaaacggcc actcaaagca tcacagaaga tttcttcccg tgggtgggtt 1920
tcaggcaata gaggaggacg ggggtgctttc cacagtcaga atagggtttt cacaccacct 1980
gcttcaaaag gaaactacag tcgtcgggaa ggaacaagag gctccagttg gagtgtcag 2040
aatactctc gaggaatta caatgaaagt cgtggaggcc agagcaattt taacagaggc 2100
cctctccac cattacgacc ccttagttct acaggttacc gcccaagtc tcgggaccgt 2160
gcttctagag gtcgtggggg acttgacact tcctgggcta gtgcaaata cggcagtggg 2220
ggctcaagag gaaagtttgt tagtgaggc agtggttag gtcgtcatgt acgctcctt 2280
acacgataaa aatccttttg ggaacatctt aactgtatat gaacatttca cgaggacaat 2340
aaaaataaga cattgaagga ccaattttag cttagcagtt atctggagac atctgagaga 2400
atatttttat ctgaagaaag cagaatttgt ttgataccta acaagatttc aataaaaaatc 2460
caaactttgt atgtaaaaaa aaaaaaaaaa aaaaaaaa 2498

```

&lt;210&gt; 4

&lt;211&gt; 719

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 4

```

Met Leu Lys Glu Val Leu Ser Ser Ile Leu Lys Val Pro Glu Gly Phe
  1                      5                      10                     15

Phe Ser Gly Leu Ile Leu Leu Ser Glu Leu Leu Pro Leu Pro Leu Pro
    20                      25                      30

Met Gln Thr Thr Gln Val Ile Glu Pro His Asp Ile Ser Val Ala Leu
    35                      40                      45

Asn Thr Arg Lys Leu Trp Ser Met His Leu His Val Gln Ala Lys Leu
    50                      55                      60

Leu Gln Glu Ile Val Arg Ser Phe Ser Gly Thr Thr Cys Gln Pro Ile
    65                      70                      75                      80

Gln His Met Leu Arg Arg Ile Cys Val Gln Leu Cys Asp Leu Ala Ser
    85                      90                      95

Pro Thr Ala Leu Leu Ile Met Arg Thr Val Leu Asp Leu Ile Val Glu
   100                      105                     110

Asp Leu Gln Ser Thr Ser Glu Asp Lys Glu Lys Gln Tyr Thr Ser Gln
   115                      120                     125

Thr Thr Arg Leu Leu Ala Leu Leu Asp Ala Leu Ala Ser His Lys Ala
   130                      135                     140

Cys Lys Leu Ala Ile Leu His Leu Ile Asn Gly Thr Ile Lys Gly Asp
   145                      150                     155                     160

```

Glu Arg Tyr Ala Glu Ile Phe Gln Asp Leu Leu Ala Leu Val Arg Ser  
 165 170 175  
 Pro Gly Asp Ser Val Ile Arg Gln Gln Cys Val Glu Tyr Val Thr Ser  
 180 185 190  
 Ile Leu Gln Ser Leu Cys Asp Gln Asp Ile Ala Leu Ile Leu Pro Ser  
 195 200 205  
 Ser Ser Glu Gly Ser Ile Ser Glu Leu Glu Gln Leu Ser Asn Ser Leu  
 210 215 220  
 Pro Asn Lys Glu Leu Met Thr Ser Ile Cys Asp Cys Leu Leu Ala Thr  
 225 230 235 240  
 Leu Ala Asn Ser Glu Ser Ser Tyr Asn Cys Leu Leu Thr Cys Val Arg  
 245 250 255  
 Thr Met Met Phe Leu Ala Glu His Asp Tyr Gly Leu Phe His Leu Lys  
 260 265 270  
 Ser Ser Leu Arg Lys Asn Ser Ser Ala Leu His Ser Leu Leu Lys Arg  
 275 280 285  
 Val Val Ser Thr Phe Ser Lys Asp Thr Gly Glu Leu Ala Ser Ser Phe  
 290 295 300  
 Leu Glu Phe Met Arg Gln Ile Leu Asn Ser Asp Thr Ile Gly Cys Cys  
 305 310 315 320  
 Gly Asp Asp Asn Gly Leu Met Glu Val Glu Gly Ala His Thr Ser Arg  
 325 330 335  
 Thr Met Ser Ile Asn Ala Ala Glu Leu Lys Gln Leu Leu Gln Ser Lys  
 340 345 350  
 Glu Glu Ser Pro Glu Asn Leu Phe Leu Glu Leu Glu Lys Leu Val Leu  
 355 360 365  
 Glu His Ser Lys Asp Asp Asp Asn Leu Asp Ser Leu Leu Asp Ser Val  
 370 375 380  
 Val Gly Leu Lys Gln Met Leu Glu Ser Ser Gly Asp Pro Leu Pro Leu  
 385 390 395 400  
 Ser Asp Gln Asp Val Glu Pro Val Leu Ser Ala Pro Glu Ser Leu Gln  
 405 410 415  
 Asn Leu Phe Asn Asn Arg Thr Ala Tyr Val Leu Ala Asp Val Met Asp  
 420 425 430  
 Asp Gln Leu Lys Ser Met Trp Phe Thr Pro Phe Gln Ala Glu Glu Ile  
 435 440 445  
 Asp Thr Asp Leu Asp Leu Val Lys Val Asp Leu Ile Glu Leu Ser Glu  
 450 455 460  
 Lys Cys Cys Ser Asp Phe Asp Leu His Ser Glu Leu Glu Arg Ser Phe  
 465 470 475 480

```
<210> 5
<211> 2054
<212> DNA
<213> Homo sapiens
```

<400> 5						
tgcagggccca	gggtgggggtg	tccagcacca	gccaaagctgg	tgctccagcg	cacctcccca	60
gagctccccc	cactgacggg	gctgcaggag	caggtgcagt	gggcgccac	actggccctg	120
cagtgatgca	gggcgggag	gagataagaa	gaccccgag	tcaagtggag	catggccctc	180
cctggctccc	tgtccctggg	ctcagcacga	ccacacagga	caccagcca	gggaattctg	240
aagaccagag	agcagcccac	gggcatcacg	agcgctctgc	tcctctctct	ggccctctgt	300
cttcccgaga	gctgccccca	aatcacagat	acctctgtgg	ctctctctct	gttcacgttt	360
acagagcata	aggctgtctt	ggatcccaac	agcacccag	ccctgcatgg	ggggagcctg	420
ggcctaataq	gcaccocctg	taactcaggc	tgtggcggga	gcagagtccc	cccctccggc	480

```

ccctcttctt  ttaccccttc  tcctccagca  gtggcacaag  ggtaggctct  agagccagca  540
caggctcactg  cctgacctgg  actaagaacc  ccacggcccc  actgtccaca  cactgcctcc  600
ccaccgcccc  cctcggtctg  taggcccctc  gcctggactg  gactggggag  ggaaagcgcc  660
ttttcctgca  gctcttcaga  gccacagacc  tcagggtgga  gtgagcccat  ggtgggcagt  720
gggcaaggcg  gtgggtggtg  ggcaagggtg  gacctcctgc  agcctggaaa  gaggagggag  780
gccaaaggcca  ttccctaact  ccctcctgcc  cctggtctga  ggaggaggga  ctctggagta  840
gcagaggggc  tgggaaagag  ggggcagggg  ctgctgggac  actgagcagg  agggaggcct  900
gagcacactg  ctttggaat  tattctaaac  aaaaaaagg  gaaagaaaat  gttatttctc  960
cctaagtcag  gagcatgcag  agctagccca  cctcatgtcc  agctgtccac  ttccatcct  1020
ggagaaagaa  cagtgtgcct  caaactcctg  ccctcccag  gcctctgggg  cccgctggaa  1080
agggctctga  cccctgggcc  cggccgggct  ctctagtgg  gatccggctc  attctctctg  1140
aagttggaag  cacaattttc  ccccaagtg  gaggaaaagg  aaagggcccc  agcctactga  1200
agaggtgttt  attttttaac  taacagcctc  ccacccatt  aagactcacc  aggagaggtc  1260
tgagggccat  tcagaaccca  ctccctgagt  ggtgggtggg  tgggactcag  tccagagacc  1320
taacattcag  aatatagcag  tggttgccta  ttttgagatg  gatttaatct  cccacagtat  1380
tcatgagacc  atctgatgga  atcagatccc  tgagccacct  tgcaggacgt  tttcccaac  1440
ctcttacacc  ctggatgtca  ctttggaac  caagcccttg  gaagcaagt  ggggtggcatg  1500
ggagagaagg  gaggaagggt  gcacaggtgg  tgagcttatg  tgtgggact  ctactgcctc  1560
acagaagcca  gccaaagtgc  aaggtcagct  tggctggtct  gaggccacct  tcttagccaa  1620
aaacctagg  ttcattttca  ggactttgat  aatgaacaac  aaaatgggga  cttctttggg  1680
cagatgctag  gtcagttgtt  ttcacctaat  atcctctttt  agctgcatgt  atatttattt  1740
ataattataa  ccctggtgga  ctgcagcctt  catctttatt  gggaatgagt  ttgttataaa  1800
tcagaaatgg  gtccatgatg  accactgttt  tccaaaccca  gtctgttccc  tgctccctcg  1860
ctggcaagcc  ccaccacaca  ggagtgaggc  caggggctag  gagttctaag  aacagaggct  1920
ggggtgagg  tggcaccag  gcagctgcat  ctggtctgtt  ttaatttaac  tgtatttaac  1980
ttgctttcaa  aattaaaagt  caatacagt  ttttaacagt  cctaaaaaaa  aaaaaaaaaa  2040
aaaaaaaaaa  aaaa  2054

```

<210> 6  
 <211> 117  
 <212> PRT  
 <213> Homo sapiens

<400> 6  
 Met Ala Leu Pro Gly Ser Leu Ser Leu Gly Ser Ala Arg Pro His Arg  
 1 5 10 15  
 Thr Pro Ser Gln Gly Ile Leu Lys Thr Arg Glu Gln Pro Thr Gly Ile  
 20 25 30  
 Thr Ser Ala Leu Leu Leu Ser Trp Ala Pro Ala Leu Pro Glu Ser Cys  
 35 40 45  
 Pro Gln Ile Arg His Thr Ser Val Ala Leu Leu Trp Phe Thr Phe Thr  
 50 55 60  
 Glu His Lys Ala Val Leu Asp Pro Asn Arg His Pro Ala Leu His Gly  
 65 70 75 80  
 Gly Ser Leu Gly Leu Ile Gly Thr Pro Cys Thr Ser Gly Cys Gly Gly  
 85 90 95  
 Ser Arg Val Pro Pro Ser Gly Pro Ser Ser Phe Thr Pro Ser Pro Pro  
 100 105 110  
 Ala Val Ala Lys Gly  
 115

<210> 7



<211> 724  
 <212> DNA  
 <213> Homo sapiens

<400> 7  
 gtggacctgt gctgtctcag tttgctctgg ggtctgggca gtctgtggt ttgggcagag 60  
 gcctcagagg gccctagggg cagactgacc caggctctgag cctcttggga gcgtgcggat 120  
 ggccggcctc agacaggcct ggttgtgggt ttgtcttcca aggggcacac gcgcactctg 180  
 gtgcttcttg gcattcagaa gagaatgggg aatccagaca tcaggccttc cttctccctg 240  
 ggaaggatgg cagggtgctg gagccaggcc tgtcttgaga gccagggctc tgggtcttcc 300  
 tcctccagtg cctgttcca cgccttcagt gcacaaagca cccccctcct gggatctctt 360  
 cagggatccc cggtatgcaa actggccagg gattagaatt ccacatttga gcaaacagac 420  
 tgagagtggg gaagcaccca gctggacatc ctctaggtgt tcctggcaga ggcccttgct 480  
 acttgtctgt gcccaaaggc cctagagggt cctagatgtg ggacaaggtc tcagcagggc 540  
 tccagtccca ggccctggaa cagctggggg tgggggaagc tggtgggtg ggtgtgggta 600  
 tcttttccca gcttgtggct cggaggtgac agaaccaatc tcaggaggct ttgtttgggt 660  
 aataaaatct actgaatggt ttaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 720  
 aaaa 724

<210> 8  
 <211> 128  
 <212> PRT  
 <213> Homo sapiens

<400> 8  
 Met Ala Gly Leu Arg Gln Ala Trp Leu Trp Val Cys Leu Pro Arg Gly  
 1 5 10 15  
 Thr Arg Ala Leu Trp Cys Phe Leu Ala Phe Arg Arg Glu Trp Gly Ile  
 20 25 30  
 Gln Thr Ser Gly Leu Pro Ser Pro Trp Glu Gly Trp Gln Val Leu Gly  
 35 40 45  
 Ala Arg Pro Val Leu Arg Ala Arg Ala Leu Gly Leu Pro Pro Pro Val  
 50 55 60  
 Pro Cys Ser Thr Pro Ser Val His Lys Ala Leu Pro Ser Trp Asp Leu  
 65 70 75 80  
 Phe Arg Asp Pro Arg Asp Ala Asn Trp Pro Gly Ile Arg Ile Pro His  
 85 90 95  
 Leu Ser Lys Gln Thr Glu Ser Gly Glu Ala Pro Ser Trp Thr Ser Ser  
 100 105 110  
 Arg Cys Ser Trp Gln Arg Pro Leu Leu Leu Val Cys Ala Gln Arg Pro  
 115 120 125

<210> 9  
 <211> 2685  
 <212> DNA  
 <213> Homo sapiens

<400> 9  
 acaccagctg ccacttcttt tgcctcatga agaactcttg ggccagccaa actgggaacc 60  
 taggtgtctg ggtcttgtga caaccaaagc actttgacac taccctctgc cgagagaaga 120  
 ggagtggatg agcctgcggg tttgcctcaa gaaacttcat gaggggtctct tactaactcc 180  
 attacactct ctctcctgga gcctcatctc catgtcaagc aggagggttaa agaagggaac 240

```

taagagcagg tctttcaagc cacaccccca cctgcggatg gatgggtttc tctgtaggcc 300
atgcaggcct ttgtcgcagc aaaccttccc agcagccctt gagccaagta aaaccagcac 360
aaccagccac cagtgtgttg tgaggcagtg cccacaaggc tcatgttgta tgcccttgat 420
aaggccatct tggctttgag tagcagtgtt cctcgtcacc cttttcccc tcaggattac 480
aacacctgct atcaaatcat ctaagctgaa aacatgagat gcgcttgga aggccctagtc 540
agaagccatt tcctcttata atttccctct cctatgcacc agtaaggccc gtccagagcc 600
ccagcaggga gtgggacctg agtccacact gtccctgagt gatccaggag gctgcccaca 660
tccccacatg tgcactgttg ttccagtgtg gctgctgtga gccactgcc actgcctcag 720
aaggagacca ctgtgaacct ctcgagtggc tccaaagagc agtggctttt tgagaatggc 780
ccatacttct ggcccggtcg gatgaaggga atgccgaccc tttggcctct cccctcctt 840
ccatctcttc tctctcttgc cctatctctc tttctacttc agaaaaaaaa aaaaaaaaaa 900
agcctgtcat tcacttttta acactttatc ccaaataaga tccctgtgta attctgaagc 960
tggatgacca cttggaattg tagatagttt caggaagctc ctgcagggct gtccaccgtt 1020
ggtgtgtgcc tcagtatttg gacttccgaa actgaaagtg aaagtgtctt tataggagag 1080
aaacgcacatg tgcctcttgg ctctttctgt ccaacttttc tagaaatgac tcaaagtcca 1140
ttaagatttg tgaatatgtg ataaattagc atgggaaagt agcaggtcag atggaaaatt 1200
ctttccaca gccctgctct ccgcctccct ccatcttagg agcgctgcc tcaattcctc 1260
gtcaactgct ttgctccact ccatccaca ggtgtgagtg gggaagtgtt ttcattagga 1320
atacagtcctg cgtgacatgg agaattggatg gagggagctt tgctactctg ctcttgcat 1380
gactccagga ttttttctg gaatccaacc tctgtcctct taggagaagg aacctgtcct 1440
tgggtcagat ggctggcat gaggaggaaa atttccatta gtgtagaaaa gtgctggaca 1500
gaatccggtt tgaaaaatta caaatccagt tggtaaaaat aggccatttc ctatgtgtga 1560
cctattcgtg gtatgccaac tggactgctt cctaaacagg acgaggaaaag tgaggaatat 1620
ttttatatga aagccttagc ctgtctggca cccatgaaaa aaactattta tgcactccta 1680
ctttcacctg ctttttgcct tctctatttg tagcacaaca gagttgaatg ccacaaaaca 1740
ccccgtttat agtgagctgt tttcagtgc caatatcaga aggaggcttg cttctggact 1800
agcctcacta attgccagca gccaccattt tccatggaat ggcttgga cagatgtcac 1860
ctctgttatg gggctcta ataggaaagaga atgttttttc ccttcctatg atcaatactg 1920
caaattattg ctgctcacag cttttatagg atttcccaa ctgaaagtgt cagcattttt 1980
ctgtccctgt gcacagtag taacaaaaga cagcctcacc aagtctgtat atttgaacag 2040
aggcaagtta attcatcccc ccgtgtcaga gccacaggca tgttgagggg gttgatacgt 2100
agcactggac cagggcgcaa agcccagata gtccagcca tgagaggaga gcacaagaat 2160
gctctgcact ctgcactcag caccatcttg ggtctgctt gccagatga gggaccacta 2220
acaaccttct cagcacatgt gaatgtggac tgatttttaa atgcattcat tctgctagga 2280
ttgggctgga agctggaaca gtgagagtac ttttctgct cctagtcac tccctttctc 2340
agcgtgacat cctcctgcag caagcctagt atcactagca gtagttcctg cgactcttag 2400
caacacaacc cgaatatttg ctccctgcct ctgggtcctc caccaggatg ggctgcgca 2460
tctgcattgc tgtacagaca aacaggcctt ttaatttaca tctccttta attctcatta 2520
aaatgcagg gtttttgtt gaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 2580
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 2640
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaa 2685

```

&lt;210&gt; 10

&lt;211&gt; 103

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 10

```

Met Ser Leu Arg Val Cys Leu Lys Lys Leu His Glu Gly Leu Leu Leu
  1                      5                      10                      15

```

```

Thr Pro Leu His Ser Leu Ser Trp Ser Leu Ile Ser Met Ser Ser Arg
          20                      25                      30

```

```

Arg Val Lys Lys Gly Thr Lys Ser Arg Ser Phe Lys Pro His Pro His
          35                      40                      45

```

```

Leu Arg Met Asp Gly Phe Leu Cys Arg Pro Cys Arg Pro Leu Ser Gln
          50                      55                      60

```

Gln Thr Phe Pro Ala Ala Leu Glu Pro Ser Lys Thr Ser Thr Thr Ser  
 65 70 75 80

His Gln Trp Leu Val Arg Gln Cys Pro Gln Gly Ser Cys Cys Met Pro  
 85 90 95

Leu Ile Arg Pro Ser Trp Leu  
 100

<210> 11  
 <211> 1760  
 <212> DNA  
 <213> Homo sapiens

<400> 11  
 ggcggggcct cgcacacccc aagaaccatc tttcacccca gcaaggggggt gcgacgccac 60  
 aggtgccatc cccctgttgt cgttttgact cccccgggg gccacctcca ccccggtctg 120  
 gtctgctagg tgctctcatg gctgaggatg gggtagagagg gtctccacca gtgccctctg 180  
 ggccccccat ggaggaagat ggactcaggt ggactccaaa gtctcctctg gaccctgact 240  
 cgggcctcct ttcattgtact ctgcccacag gttttggggg acaatctggg ccagaagggg 300  
 agcgcagctt ggcaccccct gatgccagca tctcatcag caatgtgtgc agcatcgggg 360  
 accatgtggc ccaggagctt tttcagggtc cagatttggg catggcagaa gaggcagaga 420  
 ggccctgggg gaaagccggc cagcacagcc ccctgcgaga ggagcatgtg acctgcgtac 480  
 agagcatcct ggacgaattc cttcaaacgt atggcagcct catacccctc agcactgatg 540  
 aggtagtaga gaagctggag gacattttcc agcaggagtt ttccaccctc tccaggaagg 600  
 gcctgggtgt gcagctgatc cagtcttacc agcggatgcc aggcaatgcc atgggtgagg 660  
 gcttccgagt ggcttataag cggcacgtgc tgaccatgga tgacttgggg accttgatat 720  
 gacagaactg gctcaatgac caggtgatga acatgtatgg agacctgggtc atggacacag 780  
 tccctgaaaa ggtgcatttc ttcaatagtt tcttctatga taaactccgt accaagggtt 840  
 atgctggggg gaaaagggtg accaaaaacg tggacatcct caataaggag ctactgctaa 900  
 tccccatcca cctggaggtg cattgggtccc tcatctctgt tgatgtgagg cgacgcacca 960  
 tcacctattt tgactcgcag cgtaccctaa accgccgtg ccctaagcat attgccaagt 1020  
 atctacaggc agaggcggta aagaaagacc gactggattt ccaccagggc tggaaagggt 1080  
 acttcaaaat gaatgtggcc aggcagaata atgacagtga ctgtgtgtgt tttgtgttgc 1140  
 agtactgcaa gcatctggcc ctgtctcagc cattcagctt caccagcag gacatgcca 1200  
 aacttcgtcg gcagatctac aaggagctgt gtcactgcaa actcactgtg tgagcctcgt 1260  
 accccagacc ccaagcccat aaatgggaag ggagacatgg gagtcccttc ccaagaaact 1320  
 ccagttcctt tctctctctg cctcttccca ctcaactccc tttgggtttt catattttaa 1380  
 tgtttcaatt tctgtatttt tttttctttg agagaatact tgttgatttc tgatgtgcag 1440  
 ggggtggcta cagaaaagcc cctttcttcc tctgtttgca ggggagtgtg gccctgtggc 1500  
 ctgggtggag cagtcacctt ccccttccc cgtgcaggga gcaggaaatc agtgcctggg 1560  
 gtgggtggcg gacaatagga tcaactgctg ccagatcttc aaacttttat atatatatat 1620  
 atatatatat atatatatat atatatatat atatatatat ataaaaatgc caccgtcctg 1680  
 ctctgggtcaa taaaggatcc tttgttgata aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 1740  
 aaaaaaaaaa aaaaaaaaaa 1760

<210> 12  
 <211> 371  
 <212> PRT  
 <213> Homo sapiens

<400> 12  
 Met Ala Glu Asp Gly Val Arg Gly Ser Pro Pro Val Pro Ser Gly Pro  
 1 5 10 15

Pro Met Glu Glu Asp Gly Leu Arg Trp Thr Pro Lys Ser Pro Leu Asp  
 20 25 30

Pro Asp Ser Gly Leu Leu Ser Cys Thr Leu Pro Asn Gly Phe Gly Gly

35					40					45						
Gln	Ser	Gly	Pro	Glu	Gly	Glu	Arg	Ser	Leu	Ala	Pro	Pro	Asp	Ala	Ser	
50					55					60						
Ile	Leu	Ile	Ser	Asn	Val	Cys	Ser	Ile	Gly	Asp	His	Val	Ala	Gln	Glu	
65					70					75					80	
Leu	Phe	Gln	Gly	Ser	Asp	Leu	Gly	Met	Ala	Glu	Glu	Ala	Glu	Arg	Pro	
85					90					95						
Gly	Glu	Lys	Ala	Gly	Gln	His	Ser	Pro	Leu	Arg	Glu	Glu	His	Val	Thr	
100					105					110						
Cys	Val	Gln	Ser	Ile	Leu	Asp	Glu	Phe	Leu	Gln	Thr	Tyr	Gly	Ser	Leu	
115					120					125						
Ile	Pro	Leu	Ser	Thr	Asp	Glu	Val	Val	Glu	Lys	Leu	Glu	Asp	Ile	Phe	
130					135					140						
Gln	Gln	Glu	Phe	Ser	Thr	Pro	Ser	Arg	Lys	Gly	Leu	Val	Leu	Gln	Leu	
145					150					155					160	
Ile	Gln	Ser	Tyr	Gln	Arg	Met	Pro	Gly	Asn	Ala	Met	Val	Arg	Gly	Phe	
165					170					175						
Arg	Val	Ala	Tyr	Lys	Arg	His	Val	Leu	Thr	Met	Asp	Asp	Leu	Gly	Thr	
180					185					190						
Leu	Tyr	Gly	Gln	Asn	Trp	Leu	Asn	Asp	Gln	Val	Met	Asn	Met	Tyr	Gly	
195					200					205						
Asp	Leu	Val	Met	Asp	Thr	Val	Pro	Glu	Lys	Val	His	Phe	Phe	Asn	Ser	
210					215					220						
Phe	Phe	Tyr	Asp	Lys	Leu	Arg	Thr	Lys	Gly	Tyr	Asp	Gly	Val	Lys	Arg	
225					230					235					240	
Trp	Thr	Lys	Asn	Val	Asp	Ile	Phe	Asn	Lys	Glu	Leu	Leu	Leu	Ile	Pro	
245					250					255						
Ile	His	Leu	Glu	Val	His	Trp	Ser	Leu	Ile	Ser	Val	Asp	Val	Arg	Arg	
260					265					270						
Arg	Thr	Ile	Thr	Tyr	Phe	Asp	Ser	Gln	Arg	Thr	Leu	Asn	Arg	Arg	Cys	
275					280					285						
Pro	Lys	His	Ile	Ala	Lys	Tyr	Leu	Gln	Ala	Glu	Ala	Val	Lys	Lys	Asp	
290					295					300						
Arg	Leu	Asp	Phe	His	Gln	Gly	Trp	Lys	Gly	Tyr	Phe	Lys	Met	Asn	Val	
305					310					315					320	
Ala	Arg	Gln	Asn	Asn	Asp	Ser	Asp	Cys	Gly	Ala	Phe	Val	Leu	Gln	Tyr	
325					330					335						
Cys	Lys	His	Leu	Ala	Leu	Ser	Gln	Pro	Phe	Ser	Phe	Thr	Gln	Gln	Asp	
340					345					350						
Met	Pro	Lys	Leu	Arg	Arg	Gln	Ile	Tyr	Lys	Glu	Leu	Cys	His	Cys	Lys	

355

360

365

Leu Thr Val  
370

&lt;210&gt; 13

&lt;211&gt; 1299

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 13

```

agtgctctta aagttccgta cagataaagg aagagatccc agttctgata catatgagga 60
agattctgag ttgttgctcc agatacgaag tgatgtgctt gactcactgg gtattagtcc 120
tgacctgctt cctgaggact ttgtcaggta ctgcttctcc gagatggccc cagtgtgtgc 180
ggtggttga gggatttttg cacaggaaat tgtgaaggcc ctgtctcagc gggaccctcc 240
tcacaacaac ttcttcttct tcgatggcat gaagggaat gggattgtgg agtgccttgg 300
ccccaagtga actcaagatt tggcagcccc agagatgcca actgcagcat gccacctgt 360
attcctgtc ccttctcttc atgaaggcat ctccaggcaa ggaaaactga agtcattggc 420
ccgatacaaa acatttcctg caacgaagga ggtggtgccg acgtgctgct tcccatcacc 480
agcagctgct cgacaagggy cgcagggtgg ctgtctttgt tccagcactg ttcaggctgc 540
ctgtcatccc gggcctgcca gctcccctga gtgatgagca cttccaagca cccctctgcc 600
ctttctctgt ccttatgtcg tcccggctcg ccagccctct ggggcattgt gggagatgcc 660
tgccaggaat gagcaagctc tgttgctcgg gagcctcttg tcacctctt ggacttattc 720
cccacctgat accttataga gaaaagtgtg aattcagggt gagagtaggc ccaggcccca 780
tgaggcacca gtggaagcac agctccaagt tcagacaggt gcccttagag aggaaaacca 840
tgacaggcaa atgcatttcc tctggagttt gagaccctga caaacaacag gtggcatctg 900
gtgtgctgtt cttgagtttt cgtttaggat tagttgagtt ccagctgggt tttgggagaa 960
aggagatgct accaagtctt ggatgttagg gcgagaccct gcaagttgag tattagagag 1020
cttgtctttc aaggcagggt cctggggctt cagggttagg agggaggagc ctgccctttt 1080
aacagaacc cagtcacatg cggctcaagt cactcagagg ctgttgcat tccagggtat 1140
gttggtcctt tgtttacctc ctaaaccaca gctgtttgtg tttcacatat gttgtgaatt 1200
ttccttggtt ctttttaaaag gaatgataat aaagttactt gctttaggaa aaaaaaaaaa 1260
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 1299

```

&lt;210&gt; 14

&lt;211&gt; 85

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 14

```

Met Leu Ser Arg Leu Ala Ser Pro Leu Gly His Cys Gly Arg Cys Leu
  1                      5                      10                      15

Pro Gly Met Ser Lys Leu Cys Cys Ser Gly Ala Ser Cys His Leu Leu
          20                      25                      30

Gly Leu Ile Pro His Leu Ile Pro Tyr Arg Glu Lys Cys Glu Phe Arg
          35                      40                      45

Trp Arg Val Gly Pro Gly Pro Met Arg His Gln Trp Lys His Ser Ser
          50                      55                      60

Lys Phe Arg Gln Val Pro Leu Glu Arg Lys Thr Met Thr Gly Lys Cys
          65                      70                      75                      80

Ile Ser Ser Gly Val
          85

```

&lt;210&gt; 15

&lt;211&gt; 2996

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 15

```

atttccagct cgcacccggg ctccgatcgc tcgccccgct cctctcgtc tgetcctggc 60
cggggctgcg ggttcgggtcc gggcgccggg gcgctcctgc cggctcctgt gcccgggact 120
ccgggtcccc gcgggctgct gcgcacgatg aagctggccc tgctcctgcc ctgggcgtgt 180
tgctgcctct cggggtcggc gctggccact ggctttctct atcccttctc ggccgcagct 240
ctgcagcagc acggctaccc cgagcccggc gccggctccc ctggcagcgg ctacgcgagc 300
cgccggcact ggtgccatca cacagtgaca cggacgggtgt cctgccaggt gcagaatggc 360
tcggagacgg tgggtccagcg cgtgtaccag agctgccggg gccggggggc ctgcgccaac 420
ctcgtaaagt acaggactct gatcagaccc acctacagag tgctcctacc caggtgacg 480
gtgctggagt ggagatgctg ccctggcttc accgggagca actgtgatga ggaatgcatg 540
aactgcaccg ggctcagtga catgagttag cgactgacca cactggaggc caaggtcctc 600
ctgctagaag cagcagaacg gccctccagc ccggacaacg acctgccagc ccccgagagc 660
actccgcca cctggaatga ggacttcttc cccgacgcca tccctcttgc tcacctgtg 720
ccacgacaga gaaggcccac gggcccagcc gggcccccg ggacagacag accaccagg 780
cctgcaggcc cccccgggtc taaagggtgac cgaggccaga caggagagaa ggggtccagc 840
gggcccgtcg ggtcctcggg gcctccaggg ccccgctggg ttctcggaga gatggggcgc 900
cccgccccc caggaccacc cgcccagca ggcaaccag gccctcacc aaacagcccc 960
cagggcgccc tctactcct gcagccgcct acagacaaag acaatggaga ctcaaggctg 1020
gcctctgcca tcgtggcac agtgcctggc ggtgtccag gacccgggg tccccctgt 1080
ccaccaggtc cccctgggcc tcgaggtccc ccaggacccc caggaacacc tggatcccag 1140
ggcctggctg gagagcgagg cacagtggg cgtctggtg aacctggcgt gaagggggaa 1200
gaaggagaga aagccgccac tgcagagggc gagggggtgc agcagctgag agaggccctg 1260
aagatcctgg cagagcgagt cctcatcctg gagcacatga ttgggatcca cgatcccctg 1320
gcctcccagc agggaggttc tggccaggat gctgccctga gagccaacct caagatgaag 1380
aggggtggcg cccaaccgca tggggctcct gctgccctgc ttggggccga ccctggacag 1440
aagagcgtgg accaggccag cagcaggaag tgagagcca ctgctccagg acacctgtc 1500
ctgctagtag acccagcccc agaggcctga ccgcgcgtg tttcctaaag atgccccag 1560
gggaactggg ctccaggcgt ggatgattgt gaggacatgg ggggctttgg ggacagataa 1620
tgtctccagg ggcagggtct ggaggggcca acacctcat cagagccctc ctctggcctg 1680
tcccctccc taccctcact cccggtgga gacggggtct ggtgggctg ggtgctggga 1740
atgagaataa toctaatac catcatttat tgagtccctg ctgtaactgg ccctgtccag 1800
ggaactttcg ttacgttgtc tcattattta acccttagga ggtaagctta ttatccccac 1860
ttcacaaggg gaccgaggct cagacggtag aaataaccct ctcttgcca ccagatcacg 1920
ggtggcaggg gcaggatttg aaccagggac ctcagttcc tgaagccatg ttctcttgac 1980
cctgccagct tcccctcttc gagagaaaac tcagacaggg agggcgagg gccagaacgg 2040
ctccttaagg caggcagggc tgcggggagg ctgggccagc cagcctgagg gggtaggcag 2100
ggtcctgcag ggctggggc tccccttct catccccct cccactggc tcggggagca 2160
gcctggactg cagctctcag aggccaggga gacctgaat aaatcactgc cagccatac 2220
gacttgagga ccttgagaga gaagcatttg ggtgcaagg gtcccccaa ccagataggc 2280
atccctggcc actgcctccc agtcttgctg agcccacccg ctctctctg gtccatccca 2340
tccttgagcc aggggaggca gcatttcatg ggcattgtct cagaggtgg gacttgacg 2400
ctctgcccc cgagtttgct tctcagtgga ctctataggt ttgctacttt tgcatgacac 2460
agcaagccca gtgtccctt tgcaagctgc agagagggaa acagagtccc aggcctgctg 2520
ggaagagatg ctctgcctc ccacctcca gacttgggg cctggcaggc tccatggcag 2580
gcaccaggtc ctagcagcc cagaacagct ctgactggag ccctcaagg ctctggggc 2640
agggctctcc tgatcagctc agccctggtg ttctctctt gctgggctgg gacctgggac 2700
acagccacgg cagcaaactc agagaattga aggtgctggc gccaccctgg ggcactctgt 2760
cttcacagca ggagtgactg tctccagtgc tcttggtact cctgtttggc tgtggcctg 2820
tccctctggg ccctgggatc ttcttgaggc ggtctggaga ggcagtctc 2880
gtcttcatgg aggggtggtc agaggcgggc gggaccacca gcctgtagcg ttattattat 2940
atgtgacaat aaagggtgct tccccacaaa aaaaaaaaa aaaaaaaa 2996

```

&lt;210&gt; 16

&lt;211&gt; 441

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 16

Met Lys Leu Ala Leu Leu Leu Pro Trp Ala Cys Cys Cys Leu Cys Gly  
 1 5 10 15  
 Ser Ala Leu Ala Thr Gly Phe Leu Tyr Pro Phe Ser Ala Ala Ala Leu  
 20 25 30  
 Gln Gln His Gly Tyr Pro Glu Pro Gly Ala Gly Ser Pro Gly Ser Gly  
 35 40 45  
 Tyr Ala Ser Arg Arg His Trp Cys His His Thr Val Thr Arg Thr Val  
 50 55 60  
 Ser Cys Gln Val Gln Asn Gly Ser Glu Thr Val Val Gln Arg Val Tyr  
 65 70 75 80  
 Gln Ser Cys Arg Trp Pro Gly Pro Cys Ala Asn Leu Val Ser Tyr Arg  
 85 90 95  
 Thr Leu Ile Arg Pro Thr Tyr Arg Val Ser Tyr Arg Thr Val Thr Val  
 100 105 110  
 Leu Glu Trp Arg Cys Cys Pro Gly Phe Thr Gly Ser Asn Cys Asp Glu  
 115 120 125  
 Glu Cys Met Asn Cys Thr Arg Leu Ser Asp Met Ser Glu Arg Leu Thr  
 130 135 140  
 Thr Leu Glu Ala Lys Val Leu Leu Leu Glu Ala Ala Glu Arg Pro Ser  
 145 150 155 160  
 Ser Pro Asp Asn Asp Leu Pro Ala Pro Glu Ser Thr Pro Pro Thr Trp  
 165 170 175  
 Asn Glu Asp Phe Leu Pro Asp Ala Ile Pro Leu Ala His Pro Val Pro  
 180 185 190  
 Arg Gln Arg Arg Pro Thr Gly Pro Ala Gly Pro Pro Gly Gln Thr Gly  
 195 200 205  
 Pro Pro Gly Pro Ala Gly Pro Pro Gly Ser Lys Gly Asp Arg Gly Gln  
 210 215 220  
 Thr Gly Glu Lys Gly Pro Ala Gly Pro Pro Gly Leu Leu Gly Pro Pro  
 225 230 235 240  
 Gly Pro Arg Gly Leu Pro Gly Glu Met Gly Arg Pro Gly Pro Pro Gly  
 245 250 255  
 Pro Pro Gly Pro Ala Gly Asn Pro Gly Pro Ser Pro Asn Ser Pro Gln  
 260 265 270  
 Gly Ala Leu Tyr Ser Leu Gln Pro Pro Thr Asp Lys Asp Asn Gly Asp  
 275 280 285  
 Ser Arg Leu Ala Ser Ala Ile Val Asp Thr Val Leu Ala Gly Val Pro  
 290 295 300

Gly Pro Arg Gly Pro Pro Gly Pro Pro Gly Pro Pro Gly Pro Arg Gly  
 305 310 315 320  
 Pro Pro Gly Pro Pro Gly Thr Pro Gly Ser Gln Gly Leu Ala Gly Glu  
 325 330 335  
 Arg Gly Thr Val Gly Pro Ser Gly Glu Pro Gly Val Lys Gly Glu Glu  
 340 345 350  
 Gly Glu Lys Ala Ala Thr Ala Glu Gly Glu Gly Val Gln Gln Leu Arg  
 355 360 365  
 Glu Ala Leu Lys Ile Leu Ala Glu Arg Val Leu Ile Leu Glu His Met  
 370 375 380  
 Ile Gly Ile His Asp Pro Leu Ala Ser Pro Glu Gly Gly Ser Gly Gln  
 385 390 395 400  
 Asp Ala Ala Leu Arg Ala Asn Leu Lys Met Lys Arg Gly Gly Ala Gln  
 405 410 415  
 Pro Asp Gly Val Leu Ala Ala Leu Leu Gly Pro Asp Pro Gly Gln Lys  
 420 425 430  
 Ser Val Asp Gln Ala Ser Ser Arg Lys  
 435 440

<210> 17  
 <211> 850  
 <212> DNA  
 <213> Homo sapiens

<400> 17  
 cgagggcggtt cctgtcgggg ctgcagcggc gggaggggagc ccagtggagg cgccctcccg 60  
 aagcgccact gccatgctg accacccagc cctccggctg ctgatgtcat gagtaacacc 120  
 actgtgccca atgcccccca ggccaacagc gactccatgg tgggctatgt gttggggccc 180  
 ttcttctca tcaccctggt cggggtggtg gtggctgtgg taatgtatgt acagaagaaa 240  
 aagcgggtgg accggctgcg ccatcacctg ctcccatgt acagctatga ccagctgag 300  
 gaactgcatg aggctgagca ggagctgctc tctgacatgg gagaccccaa ggtggtacat 360  
 ggctggcaga gtggctacca gcacaagcgg atgccactgc tggatgtcaa gacgtgacct 420  
 gaccccttg cccacccctt cagagcctgg ggtcctggac tgcctggggc cctgccatct 480  
 gcttcccctg ctgtcacctg gctccccctg ctgggtgctg ggtctccatt tctccctcca 540  
 cccaccctca gcagcatctg cttcccatgc cctcaccatc acctcactgc cccaggcct 600  
 tctgcccttt gtgggtggtg agctcaccgc ccacccacag gcactcatgg gaagaggctt 660  
 tccttctggg atggcggcgg ctggtagaca cctttgcttt ctctagccct cctgggctgg 720  
 gcttgggcac aaatccccag gcaggctttg gagttgttct catgggtgatg gggccagatg 780  
 tatagtattc agtatatatt ttgtaaataa aatgttttgt ggctaaaaaa aaaaaaaaaa 840  
 aaaaaaaaaa 850

<210> 18  
 <211> 102  
 <212> PRT  
 <213> Homo sapiens

<400> 18  
 Met Ser Asn Thr Thr Val Pro Asn Ala Pro Gln Ala Asn Ser Asp Ser  
 1 5 10 15

Met Val Gly Tyr Val Leu Gly Pro Phe Phe Leu Ile Thr Leu Val Gly



20 25 30

Val Val Val Ala Val Val Met Tyr Val Gln Lys Lys Lys Arg Val Asp  
35 40 45

Arg Leu Arg His His Leu Leu Pro Met Tyr Ser Tyr Asp Pro Ala Glu  
50 55 60

Glu Leu His Glu Ala Glu Gln Glu Leu Leu Ser Asp Met Gly Asp Pro  
65 70 75 80

Lys Val Val His Gly Trp Gln Ser Gly Tyr Gln His Lys Arg Met Pro  
85 90 95

Leu Leu Asp Val Lys Thr  
100

<210> 19  
<211> 1108  
<212> DNA  
<213> Homo sapiens

<400> 19  
ataaaactccc agggccccgcc cagccccgc cggggcctta tcctggaccc gggatccccgc 60  
gcgcctggag acaggttcca gatctgcctc gagcccctcg aaaccaggac tccagcacct 120  
ctgggtccccgc cctcaccggg acccctggcc ctccagctctc ctccagggat ggcgctggcg 180  
gctttgatga tcgccctcgg cagcctcggc ctccacacct ggcaggccca ggctgttccc 240  
accatcctgc ccctgggcct ggctccagac acctttgacg atacctatgt gggttgtgca 300  
gaggagatgg aggagaaggc agccccctg ctaaaggagg aaatggccca ccatgccctg 360  
ctgcgggaat cctgggaggc agcccaggag acctgggagg acaagcgtcg agggcttacc 420  
ttgccccctg gcttcaaagc ccagaatgga atagccatta tggctctacac caactcatcg 480  
aacaccttgt actgggagtt gaatcaggcc gtgcggacgg gcggaggctc ccgggagctc 540  
tacatgaggc actttccctt caaggccctg catttctacc tgatccgggc cctgcagctg 600  
ctgcgaggca gtgggggctg cagcagggga cctggggagg tgggtgttccg aggtgtgggc 660  
agccttcgct ttgaacccaa gaggtctggg gactctgtcc gcttgggcca gtttgctcc 720  
agctccctgg ataaggcagt ggcccacaga tttggggaga agaggcgggg ctgtgtgtct 780  
gcgccaggag ccctgggaac ggggtacctt catatgacga agaggcacct ccagcagcct 840  
tgagaagcaa gaacatggtt ccggaccag ccctagcagc cttctcccca accaggatgt 900  
tggcctgggg aggccacagc agggctgagg gaactctgct atgtgatggg gacttcctgg 960  
gacaagcaag gaaagtactg aggcagccac ttgattgaac ggtgttgcaa tgtggagaca 1020  
tggagtttta ttgaggtagc tacgtgatta aatggtattg cagtgtggaa aaaaaaaaaa 1080  
aaaaaaaaa aaaaaaaaaa aaaaaaaaaa 1108

<210> 20  
<211> 224  
<212> PRT  
<213> Homo sapiens

<400> 20  
Met Ala Leu Ala Ala Leu Met Ile Ala Leu Gly Ser Leu Gly Leu His  
1 5 10 15

Thr Trp Gln Ala Gln Ala Val Pro Thr Ile Leu Pro Leu Gly Leu Ala  
20 25 30

Pro Asp Thr Phe Asp Asp Thr Tyr Val Gly Cys Ala Glu Glu Met Glu  
35 40 45

Glu Lys Ala Ala Pro Leu Leu Lys Glu Glu Met Ala His His Ala Leu

50                                      55                                      60  
 Leu Arg Glu Ser Trp Glu Ala Ala Gln Glu Thr Trp Glu Asp Lys Arg  
 65                                      70                                      75                                      80  
 Arg Gly Leu Thr Leu Pro Pro Gly Phe Lys Ala Gln Asn Gly Ile Ala  
                                     85                                      90                                      95  
 Ile Met Val Tyr Thr Asn Ser Ser Asn Thr Leu Tyr Trp Glu Leu Asn  
                                     100                                      105                                      110  
 Gln Ala Val Arg Thr Gly Gly Gly Ser Arg Glu Leu Tyr Met Arg His  
                                     115                                      120                                      125  
 Phe Pro Phe Lys Ala Leu His Phe Tyr Leu Ile Arg Ala Leu Gln Leu  
                                     130                                      135                                      140  
 Leu Arg Gly Ser Gly Gly Cys Ser Arg Gly Pro Gly Glu Val Val Phe  
 145                                      150                                      155                                      160  
 Arg Gly Val Gly Ser Leu Arg Phe Glu Pro Lys Arg Leu Gly Asp Ser  
                                     165                                      170                                      175  
 Val Arg Leu Gly Gln Phe Ala Ser Ser Ser Leu Asp Lys Ala Val Ala  
                                     180                                      185                                      190  
 His Arg Phe Gly Glu Lys Arg Arg Gly Cys Val Ser Ala Pro Gly Ala  
                                     195                                      200                                      205  
 Leu Gly Thr Gly Asp Leu His Met Thr Lys Arg His Leu Gln Gln Pro  
                                     210                                      215                                      220

&lt;210&gt; 21

&lt;211&gt; 1589

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 21

tctgaacctg tcttgctcctg ggtcctccag ttgttggaag ccactctttt ccccaacct 60  
 gctgaaatgc cacctttacc acacactgat gtcttacata gacttagatc tatttctgga 120  
 acttctcttc tcttcgctta cttgggtgtc tcactctggca ccagccatac aattttaact 180  
 attgtcaatt tctaatgtct tattatgtgg tgggatgagt cccttcaactc ttcttttaca 240  
 aaatttccta gttattctct cacatctatt ctccacata aactttaaat tgtgccagt 300  
 cctccacccc ctgtcccatc cccaccccga aattctgggc tctgtcattc cctgtgccat 360  
 catcttcccc ccattgtaat tactgtccac tcagggtctgt gaaatagact atgttctata 420  
 aagagggaca aaaaggcatc cctgatcttg agagaagcct gctgttcttc ccatcatttc 480  
 acctgcccc taagcccagg agttgtcatg agaggtcacc agggccccac tcaatctcag 540  
 cttgggaacc aaagtcaccc accttggttg tgttggttg gaccgcccac ctgtccctgg 600  
 tccagacgag aaagaggagt ctctcctagg cctggagctg ggaaagaatg tgtggcccag 660  
 ttgtctgcac ttctaattct catcatggag aaacctttat tcctatctcc ctttcttgaa 720  
 ctggtttttt gttgtttttt tttcattttt ttttgggggg atagtttctt gctctttaat 780  
 ttggagtctc cagtaccttt gggatgcagg cagttcttgc ctgggccttc tcggaaccct 840  
 cactccccta gccactctt gcgtacctg caggaggctg ccaacctggt gcattctgac 900  
 aagcctccca cccaaatctc tctcctgcca ttgtgtocaa aatcccacca ttagaggctc 960  
 ttgtagggaa gagcgtttct tgaaggcttt taggccttcc agagccagga gggaagtcag 1020  
 acaatagcag gaagtcccca ggccttttca aagttccaaa ccaagctctc ctgattttta 1080  
 tgtagagatc ataccaaccc aggtggggga ggagggtccc cagccccagg cagcagccat 1140  
 cccccctcc actgaaaaca atattggagg ctgctttggg actgcccttc tcagccccct 1200  
 aagtctgttt tgtaatgcct gtggtgctct ccctcctgga ccttctctct cgggggtcac 1260

```

cacactttgc taactcttgt gtgcacatat tttataatag agtagcgagg gaatggtgcc 1320
gctccagct tccgtaagct gcccgggctc tggggggctc tgggacaatc ggggctggga 1380
agtgactgtg ctcttattgt acactcttta tttctgtgta tctttggctt gtgctctttg 1440
taattaatgg gatttgtctg ccttttcaac actatactga gcaataacaa taaatgcaca 1500
cgtggaaatg cagacacggt acacatcaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 1560
aaaaaaaaa aaaaaaaaaa aaaaaaaaaa
1589

```

&lt;210&gt; 22

&lt;211&gt; 148

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 22

```

Met Arg Gly His Gln Ala Pro Thr Gln Ser Gln Leu Gly Asn Gln Ser
  1              5              10              15

His Pro Pro Trp Leu Cys Trp Gly Gly Pro Ala Ile Cys Pro Trp Ser
      20              25              30

Arg Arg Glu Arg Gly Val Ser Pro Arg Pro Gly Ala Gly Lys Glu Cys
      35              40              45

Val Ala Gln Leu Ser Ala Leu Leu Ile Leu Ile Met Glu Lys Pro Leu
      50              55              60

Phe Leu Ser Pro Phe Pro Glu Leu Val Phe Cys Cys Phe Cys Phe Ile
      65              70              75              80

Leu Phe Trp Gly Asp Ser Phe Leu Leu Phe Asn Leu Glu Ser Pro Val
      85              90              95

Pro Leu Gly Cys Arg Gln Phe Leu Pro Gly Pro Ser Arg Asn Pro His
      100             105             110

Ser Pro Ser Pro Leu Leu Arg Tyr Leu Gln Glu Ala Ala Asn Leu Val
      115             120             125

His Ser Asp Lys Pro Pro Thr Gln Ile Ser Leu Leu Pro Leu Cys Pro
      130             135             140

Lys Ser His His
145

```

&lt;210&gt; 23

&lt;211&gt; 2538

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 23

```

aaaggttgta taccctgaaa taccatctga taaaacctgc agaaaggata atttttagttc 60
ataaatgtga ccttcattgt tggcgcatca gtgagatggg agagaacagg ctgagtcaaaa 120
ggagatgata ctcccagctg cccccaccca actgttactt ctctgtagat caagaagtga 180
tgtggcacag gctctgggtt cagattctag cttctccact cacttggtgc atggctacat 240
caagttactt actgtctcta cgctttcatg ttatcttcaa aattgggata atatgattcc 300
atcagtggtt atcgtttttt taatatggcc cagagacctc ctgaaattag acatgggttg 360
caatttatth tgttttggga ttcagaaagg aaacatttgt aaaactgtgc tcaaggatca 420
aaaatcctgc agttattttg actgttacaa cctccttatt aatgctacca aggcatttca 480
gagagtgtct tcctgaagtg actccattca tctgagctct gtggtgttcc gtcataatat 540
gtggtgagct ttaatcttcc ctttcagctc aggaagctgt gagtcattta tctacttgtg 600

```

```

caaagaggac agagacatcc tatctcttat gttcatcagt ttgttcagat ctatagtggg 660
tgtattggag aaacctggct gttatccaaa agggtaggtt ggaagaggct taccacacac 720
attgaatata tttcttaaaag ctgctatgga aataaagtga tgtcaccttc taccctaata 780
ttgcatgtgg ctggaatctc tgaggcatgg gtttgccctt cccaccctcc tgtgcgttgg 840
tgtctcagac ttgtaatctt gcttggtgaa gaagtcattc tttgtttttt tgggtagatg 900
gaaatgggtg gcccaaagtg tacctctaaa ctcatatctg cttgctccca ctggttaggga 960
gatgtctaga cacggagaaa agggcttggt aattaattga ctttgggaaa ttccacttaa 1020
aagtagagat acaatttttt ttattttata aaatatttca acaaagagg aaattggaag 1080
agtaataata cacacacatg tatatgtaaa agttactgac tatatatgcc aagggccatt 1140
ttgagtttct aagaggggtga atatagattg tgatatttac atatttggtg gacttttttc 1200
tagagcatct ttcctttggg atacattttg ggaaatattg gtttataatt tattttcttg 1260
gtgggaaaga catggataag tatctatacc ttgagataaa taactaaaac tgcataatta 1320
aagaaataag ttgtcaagtg aatttcacaa gcacaaggga gagttaaagt gttgtagtgg 1380
gtcatataag ctttgacata tttttctca taaagctgat aactcttcag tattgagttt 1440
ctaaaaaagg aagtatttcc tgtggtaaat tttcacttgt gtatctgtga ataccattat 1500
tgtgtgtgaa acttaaaaac tggtagagaa cactaccttt ctcaataaat cagtaccac 1560
gatgggtcta gtgtggaaga caggagggtg tgggaagtgt tgttgtaaca gaatttaaaa 1620
gtgccaaggg agaagaaatt cacaaggtgt ttatatccag gaaagtgtat ttaataatgt 1680
tttttacatt ctctaagaaa aaaagattga aaatatcagg agagtctcaa tgaaaagaac 1740
atacaaaaag aacataccag gattctagga ctgatacatt ttctgtcaac gctattgcta 1800
ttacaagtaa agggattaag cacttgtgaa tgttgatacc atgtataata actctaattg 1860
gatattgttc aacgtttatt tccatattac ccaatattta gtgcattgta actaatagaa 1920
ggccctcata gccaacctta cttgatcttc ttgataacct tgagaggtgg atattattat 1980
ccccatttta tagatgtgta aaataagcct cagagaagaa tagaagtttc tgttgaaaaa 2040
tatatatgaa gaattttata ccaaatgaca gatatttgtc aaacatttca gaaaacattt 2100
ggagaccggc agagtttttt aaataattga aataattgga attggtacct aagcagcaaa 2160
ggaaatttaa ggagaaagaa tattttgaag taaattataa attaaacaat gtgaaatata 2220
gttttcatag gttgtcataa atgctttcat gtagtttgtg catgctttgc aactcagctg 2280
caagtgccta cagaaactaa ttttttattt ttaacaattt tttgcaagtt tttgaaaatg 2340
ttttgattgt caggttcata gacttctaac tcaaaactaa tgtaacaaaa tattagaaaa 2400
agtggaaaaa ttagaaaggg gatcttagaa tttataaaaa taaatatctg aagagtacct 2460
atttgaaaaa atgtagtctt gttttatcat atattagtta cagtaaaaaa tatcaaaaaa 2520
aaaaaaaaa aaaaaaaa 2538

```

&lt;210&gt; 24

&lt;211&gt; 123

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 24

```

Met Ile Leu Pro Ala Ala Pro Thr Gln Leu Leu Leu Leu Cys Arg Ser
  1                      5                      10                      15

```

```

Arg Ser Asp Val Ala Gln Ala Leu Gly Ser Asp Ser Ser Phe Ser Thr
                20                      25                      30

```

```

His Leu Leu His Gly Tyr Ile Lys Leu Leu Thr Val Ser Thr Leu Ser
    35                      40                      45

```

```

Cys Tyr Leu Gln Asn Trp Asp Asn Met Ile Pro Ser Val Ala Ile Val
    50                      55                      60

```

```

Phe Leu Ile Trp Pro Arg Asp Leu Leu Lys Leu Asp Met Gly Gly Asn
    65                      70                      75                      80

```

```

Leu Phe Cys Phe Gly Ile Gln Lys Gly Asn Ile Cys Lys Thr Val Leu
                85                      90                      95

```

```

Lys Asp Gln Lys Ser Cys Ser Tyr Phe Asp Cys Tyr Asn Leu Leu Ile
    100                      105                      110

```

Asn Ala Thr Lys Ala Phe Gln Arg Val Ala Ser  
115 120

<210> 25  
<211> 4466  
<212> DNA  
<213> Homo sapiens

<400> 25  
gttgcgagaga acctacaagt ctccgctccg gcatgcgcgg cgcgcccaaa tcaggaagac 60  
ttctgcctct aatagggctg tgcgagagag gcagatgctc tgcgcgcagc tggcctctgc 120  
gggcacgggg ccttgcccag tgcattccagc ttccaacggg actagtcacg cgccagccct 180  
gctgccccga gcacggaatc ttttaagaatc cgccagcact tggtagcgctc tgcagccacc 240  
caggtagcat acgctctttg ctgtgtagaa gaaatgccc tacgacagct ttgcccctgt 300  
ttgaagacct ccttctttgc ctctccagac gtgttcccc aggagatctt ccttccgtcc 360  
ttcctggcgc cctgggtgac caccttgccc tgcttctct tacgtgctag ctttgtacct 420  
atcgctcact gcatgctcgc ctccctcttg ctggcatccc ggctgtttc aatgactacc 480  
gctctgtac ttaggcacag ggactccgcc gcacgctgac ggaccacgag ggctgacccc 540  
ttccagcctg acttggttca tggaggctcc tactctgcc tctccaagct cccctggcgg 600  
ctccccacct ggttgcccag ttctattga tgagctctgg acagaaagat gcccgtttg 660  
ccaggctggt ggcttgatgg gtgtacctgg agaggggggtc tggcttctct cccaagatgc 720  
ctccagccc tgcaggggc cgggtgcagc ggcaggggc catctgtgct gtagtggtcg 780  
agtgtgctg gcaaggagcg tagttctgcc atgtctgggg gccagggtcc actctgcaca 840  
tgaatatgca gctctggagg ccctactgct catactggga aggaccaatg ttgcacctct 900  
gttaatgcct gacttcagct gctgggtgtc tgatggagcc agaggcttgg ggaatctgga 960  
acttgctgc taaataaggt catggtggac tctcagccat tgggcaggctc tatcaggctg 1020  
caggttccca cacaccacg cctgaggggc atagcaggct aagggtggat accagcgact 1080  
ccctttgctg cccaggatct ccattggcag tgcacagcg gctgatgctc agtcaactct 1140  
gcttctaccc cctgtcactg atggcgagcc ttgcccagct tgagacctgt tccatctctc 1200  
attcaggctg catgtggcct tcaactgagc cctgcagcca cccacgcacc atctgtgggt 1260  
ctccaaaggc accttgtagc atgtactccc cgtgcctggg caatcagatg ggctgccttt 1320  
gtccaaggga aaacagactc ccttcgggaa acatccttaa gcacttaagg ccgggggggg 1380  
gtgtctgcct ctggcaaccc agccagggtc ttggtggcat ttgtaaaagc aaagagctgt 1440  
ggactgccgt ggtcctagt tgggtgacaat gcagcactgg catgcatgtc cttctgaagg 1500  
acctcatcct tctctacagg cggatgacca agaaatcatt ttgtggctgg gtttggccac 1560  
gccctttgga ctgtgctgtt ccgccatatt tcaatgccaa atgaaccaca ttgacatgac 1620  
ctggaccata gggcttctca tctgggctc agctgcccct gtctgaaggg tctggttg 1680  
attgcagaag gacaacctcc gcaccacct aaagacatgt atatgtcttg ggaatccaga 1740  
gattgggtcc ttgggcctgg cttcttaaga gttttgatga tgctgggaaa agtgactgctg 1800  
attctgaaga accgctgcct tgcaagggtc aggcatttca gtggttgcct gggctccgag 1860  
actactgcca cccactcacc atcaactctg ttagcccaat tgcctgctg aacaactgcc 1920  
tgaatacagg ctttaggttc ccctggactc cagccaaggc tgttcagggt ggaccatggt 1980  
gctctttaag cgtgatcgga gggaagacac acagcagggc caccattcca tgaatgggag 2040  
gtgtacagat cactttctct ttgtgctcag ttctctctct tctccagcag ctatattggt 2100  
aagactagta cctgccaggg agaggtgccc ccaagtgaag ggttacagt gcacctggga 2160  
aaaggcacct ggaaggtttc catgtggccc agcccagcat ggaagcaggg tgggaactct 2220  
gctgtgctgc cagccctcac tctactcaag tggctttttg agagccctgc catgtctgtg 2280  
tcaggcctgt gctgcttcac accctacagc tgctgggaa aggcgggcca cgctccctgt 2340  
ccacacactc cctgtccaca cactccctgt ccacaactgc agccgggccc tctgcctatg 2400  
ggcacccaat ccaagcagct gctccacctt tgtttggcat ggtgatttgt gttttttctc 2460  
ttggtgctta tgtgtgtggg cttgggacga gtgctggtat gcacttagga cttctctgat 2520  
agctccctgc actttggaac acggagcaga tgagagaggg tcaggggctt gccctccacc 2580  
ttggacttgg aagaagccca cattggagag gtgaggacct catggtggct ctagtggag 2640  
atacgttagt ctccagctaa ggaggatgag gcgcagcccc agaggagagac ctcaagtata 2700  
ggggatcagg ctacgaaagt gggggaaggg agatgctttg tacatatatt ggggttataa 2760  
tttctctaaa ttttaggaga acgggtattg attgataaaa gggacaggca gtagtggtca 2820  
acagtgcagt tgaaggaaag ttctgttttc catgggtttg acattctttg gactgtattg 2880  
tgactgctgt ctggtccaca tgggtaccct ttggtaagta ggcttcagt cataccaggg 2940

```

tattcactgga gatgggagtt agtgaagggg tgactccctg gcctagtata gtgtgaccct 3000
gggacaactt aatgtcctaa agcatttttg tgacttctag ggaatagcaa agacctattt 3060
cattgtcccc aggttaagtat gtgatgagca atgaggagga gtggaaaaca aaaccagaa 3120
agtgcggcag gaccagcctg acgcacacgc tcctgttggtc atggcagaca gccgccttgg 3180
gtgggcacca ccctggcagt tccagcctgt aggggagtga agggacatgg ctgagctggg 3240
catgtgctga ggttgactta ggggaacaagc cctgggattg gacaaaaggg cccatgctgc 3300
agccactgac tgggggcaga gctctgggtg gaagagggaa gagatcctaa tggaggcgcc 3360
tccatctgca accacagttg taaggctcat ggcacctctg cttggaaagc actggttttag 3420
ggacttagag aggttaggcac aaggtgggtc tcctgggtag ggaagcaaga gcagactggt 3480
gggccaacag gagaagctcc ccagagtagg ggagaagggt ggggtgtagg gccttcacg 3540
tggaacagac agcccctgtg tctctgtctc ttggggacct gattttgggt ggggtggcag 3600
ttggcacagc gcagatgcgg tagagatggg aggaaacca gctcctcact tccgtgtgcc 3660
tcatgccttt gcatacacia gcaccaaacc tactagggtc tctcattacc catgtaaacc 3720
acatgttaga taaatttttg caagtagagg aaagaaggaa ataaaacatc acattttggt 3780
gtctctcagg ctttcccccc caactatggt ttctttgctt tttgttttaa catagttttg 3840
ttgctgtctt ctgtaatgat acagttttgt gcagctgttt tcacttagca tatcgtgggc 3900
atctccccct atgattacta aatattttat tttggagtgg ctgtgtactc tccattgac 3960
tagatggacc attgtgccag ttgccaatca ctaatgctgt tactaacttt tcagttataa 4020
attgatgaat atctttgtgc acaggctgtt tcccaatgtc aagttattag ggtagactcc 4080
aggaggtggg attcttcaac taaagaatat gaaaacctt gaggtttta ctacatattg 4140
acaaaatggt ttccggaaat atttgtatcc cttacactg ccaccagcaa ggataaacat 4200
gtccatcttg ccgtatttg gaattatcat ctggctaaat atttgctaat ttgataatga 4260
aaaaatagca tcgtgtttca gttggcattt cactgacttc tagcacggtt gaacatcttt 4320
catgtggagc gattgtattt cctcctttgt ggattgtcag tgcctttgc tctatcttct 4380
ggggtcagat aaatttgtat gagctcggtt tatattaaag atattaacct ggtgtgtgtc 4440
ataaaaaaaa aaaaaaaaaa aaaaaa 4466

```

&lt;210&gt; 26

&lt;211&gt; 125

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 26

```

Met Arg Gly Ala Pro Lys Ser Gly Arg Leu Leu Pro Leu Ile Gly Leu
  1             5             10             15

```

```

Cys Glu Arg Gly Arg Cys Ser Ala Ala Ser Trp Pro Leu Arg Ala Arg
      20             25             30

```

```

Gly Leu Ala Gln Cys Ile Gln Leu Pro Thr Gly Leu Val Gln Arg Gln
      35             40             45

```

```

Pro Cys Leu Pro Glu His Gly Ile Phe Lys Asn Pro Pro Ala Leu Gly
      50             55             60

```

```

Ser Val Cys Ser His Pro Gly Ser Ile Arg Ser Leu Leu Cys Arg Arg
      65             70             75             80

```

```

Asn Ala His Thr Thr Ala Leu Pro Leu Phe Glu Asp Leu Pro Ser Cys
      85             90             95

```

```

Leu Ser Arg Arg Val Pro Arg Gly Asp Leu Pro Ser Val Leu Pro Gly
      100            105            110

```

```

Ala Leu Val Ala His Leu Ala Val Leu Pro Leu Thr Cys
      115            120            125

```

&lt;210&gt; 27

&lt;211&gt; 2667

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 27

```

gtccctggg acccatgggc cttctgggtg tgtgtagggg acagcgctg gattaagcca 60
gggaagtaag gacttgatt gttaagaaac agcctcttg ctgctgtggg gaaccaggga 120
aggcagcttg gagccttctc cagggccctg gctggcgga cagggggctg ctccatgtc 180
caggaccctg gaaggaccca ggaggtgtg gacagggccg gtagcccgag gtgactggg 240
atgggggctc tgcattgtg tgaaggtggc agcgtcagg cacagcttct cgccccctc 300
tcacccacac ggaagagcag cgaggaggcc atgcgggagc gacagcagg ggtgtccctg 360
gccgccatgc gggagcccag cctgctgagg ttctacgtgt ccgcgagtg gctcaacaag 420
ttcaaacctc tcgcagagcc agggcccatc accaaccaga ccttctcttg ctccacgga 480
ggtgaggcgc cccctgtggg gggagagcag ggtgggcagc tgggcccagc cacagcttcg 540
ctccctgtac cttcttccca ggcattccgc cccacaaata ccactacatc gacgacctg 600
tggtcattct gcccagaac gtctgggagc acctgtacaa cagattcggg ggtggccccg 660
ccgtgaacca cctgtactgt tgctccatct gccagggtga gatcgaggca ctggccaagc 720
gcaggaggat cgagatcgac accttcatca agttgaacaa ggccttccag gccgaggagt 780
cgccggcgct catctactgc atcagcatgc agtgggttcc ggagtgggag gcttctgtca 840
aggggaagga caacgagccc cccgggccc tggacaacag caggattgca caggtaaaag 900
gaagcgccca tgtccagctg aagcaggagg ctgactacgg gcagatttcg gaggagacct 960
ggacctacct gaacagcctg tatggaggtg gcccagagat tgccatccgc cagagtgttg 1020
cgacccgct gggcccagag aacctgcacg gggagcagaa gatcgaagcc gagacgggg 1080
ccgtgtgatc tgctgggcta gtctgtaagt cggcccggtt ggtccctcca tggcactctg 1140
ggtcctctcc tactctcca gagacctca catgtcctt tgaacatcca aagagcagg 1200
ccctgaaagc accttctctg aggatgtggg agtggccttg acatggccc gcccactgc 1260
tgagtgcctg tgtcccaca gcccattgtg cccacccc cgggaaggcg gtttgtgccc 1320
agaagagagg cgggctgtc gcagaacccc gccgtgtaaa gaggcagaaa agttggtttg 1380
gtttgcagta acgctgcaac tagaaaatat atgcacttca ggcttgttga aacgaccaag 1440
actctgtgac gttaatttgg gtctttgtcc tggcagtgcc tctgccagtc actgtcatc 1500
ttgtgtcccc cacaactgtc ctcttgctag ctggcccag ctttgtccct ggagcccgat 1560
gctacccttg tcagacagag gctgcggcct gggccagagt cagggagtag ctgctgcttc 1620
acggcgtctc cactgtgcga ttggcccgga gcccgaaga ctggaggga gctgctcagg 1680
gccgtgagc gcagccagaa gccctggcca gtgaggagct cacaggctc cctgggtgg 1740
ccgcgcgac ctctgcatct cctgggcgtc accaggaagg ctctgaagtc ccgggctgct 1800
ctcagcactt ctctgcaga ctgaagactc tggactcatt gctgattgga acaccaggag 1860
gaggttgat ttctgccagt gggggatgtt tctggaggca gctgggtccc cacaccgct 1920
cctgtgagc ctgccccctg gattggctgt aatttgctc gaagttcagc agttcatct 1980
catgggaaat ttgctgagcc cccaccaggg aaccggatga tgaaacaggg atacctcaca 2040
gcttggccat ttgaggcaaa ggcagcttcc cgagctgatg cttaaagaaga cagactttcc 2100
cttctccca gcagcagcag tgcagagccc gctggagg atgtgggggc tgtgcagggt 2160
gcagcgctca ggtggatcct gggaagcagc ctctggatgc tgagtggagg gagccactga 2220
gcacagcaag gcaccaaagc ccctggagaa accgccaggg cgaggtgcga ccatcatcag 2280
gatcaaagca gacggggcgt ggggtgggaa ggggctctgg gaccagacc cccactac 2340
tgcgtctttg tttctatcag tctttgtaga agcaggtggt ggtggaaatt ccagcagg 2400
ggtcccgag aggcctgag gcctcacttt tcggatcttc tgtcccagat cctgtccct 2460
cctgtctgag cctggggttc ccctggcatt ggcccagcc ttctgaaagc cggcgtgca 2520
gccagaggcc gcacgtgca ctgtcgcgac gcagagaggc ttctgtgcag gctgggagct 2580
ggcccatgt ctgtgtgtc tagtttgtgt tcaaatgtc agaataaaca cagaataaat 2640
gttaaaaaaa aaaaaaaaaa aaaaaaa 2667

```

&lt;210&gt; 28

&lt;211&gt; 232

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 28

```

Met Ser Arg Thr Arg Glu Gly Pro Arg Arg Trp Trp Thr Gly Pro Val
1           5           10           15

```

```

Ala Arg Gly Ala Leu Gly Trp Gly Leu Cys Met Cys Leu Lys Val Ala

```

20 25 30  
 Ala Val Arg His Ser Phe Ser Pro Pro Pro His Pro Thr Gly Arg Ala  
 35 40 45  
 Ala Arg Arg Pro Cys Gly Ser Asp Ser Arg Trp Cys Pro Trp Pro Pro  
 50 55 60  
 Cys Gly Ser Pro Ala Cys Cys Gly Ser Thr Cys Pro Ala Ser Gly Ser  
 65 70 75 80  
 Thr Ser Ser Thr Pro Ser Gln Ser Gln Ala Pro Ser Pro Thr Arg Pro  
 85 90 95  
 Ser Ser Ala Pro Thr Glu Val Arg Arg Pro Leu Trp Trp Glu Ser Arg  
 100 105 110  
 Val Gly Ser Trp Ala Glu Pro Gln Leu Arg Ser Leu Tyr Leu Leu Pro  
 115 120 125  
 Arg His Pro Ala Pro Gln Ile Pro Leu His Arg Arg Pro Gly Gly His  
 130 135 140  
 Pro Ala Pro Glu Arg Leu Gly Ala Pro Val Gln Gln Ile Arg Gly Trp  
 145 150 155 160  
 Pro Arg Arg Glu Pro Pro Val Arg Val Leu His Leu Pro Gly Gly Asp  
 165 170 175  
 Arg Gly Thr Gly Gln Ala Gln Glu Asp Arg Asp Arg His Leu His Gln  
 180 185 190  
 Val Glu Gln Gly Leu Pro Gly Arg Gly Val Ala Gly Arg His Leu Leu  
 195 200 205  
 His Gln His Ala Val Val Pro Gly Val Gly Gly Val Arg Gln Gly Glu  
 210 215 220  
 Gly Gln Arg Ala Pro Arg Ala His  
 225 230

&lt;210&gt; 29

&lt;211&gt; 2699

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 29

agaaattgcc gtggatattg taaaacatgc ctttattact aaatccatga cattactgca 60  
 gatgtctaca gtgaatatag agccagtctt gcttttgacc ttgttagcag ccgacagaaa 120  
 aatgcataca ctgattacag tgactctgta gcacggagga tgggctttat tcctctccca 180  
 ctactgtgtt tactcatcag agttgtaaca agctcaatta aagtgcagg aatcctgtct 240  
 tatgcctgtg tcatactctt ctattttggg ttgatatccc tgaaagtact taatagcatc 300  
 gtgctgttgg ggaaatcgtg ccagtatgtg aaggaagcca aaatggaaga gaagctgtcg 360  
 aatcctcccc caacctgcac tccaggcaag ccgtccagta aatcacagaa caaatgtaaa 420  
 ccctctcaaag gcctttccac agaagaaaac ctgtctgcct ccacaccaa acaacctatt 480  
 catcaaaagg aaaatatcat accattactt gtgacaagca attctgatca gtttttgaca 540  
 actccagatg gtgacgagaa ggacataacg caggacaatt ctgaattaaa acacagatcc 600  
 tcaaagaaag atttgttaga gatagacagg ttcacaattt gtggaaaccg aattgactga 660  
 atctgtggct tcatgcgctg aagaagctgg gtcctggggc aacaagtgtg gtgttgccag 720



```

gacaaataga tgctaaacat ggcacttaaa tatttatTTa aaaacttaaa ttattattgg 780
caagcaaadc ttagtatctt tcttccagta atatggcctg gctgagggtc agaccacagg 840
acaggagcga cctccggcct tgactgtctg ggaagcttga tggattataa aacttcctcc 900
tgcttgccca agcagcagca tcatttccag gacccaacaa aggcaacatc aaaatctgtt 960
ttgctttgtc agtctgggct tccagaatgt tgaatttgcc tcaaggcctc ttcagtataa 1020
ggaaatacct ggaaaactgt gaaactttta ccacgacgta atctttccag tctcatacta 1080
ttttcacaaa cagttttcaa acgttacttc atctgccaaa gcattaaaaa aattaaacat 1140
aagtcaagat aaatgttctt accaccagaa taacccttaa agatgtatct taattaatca 1200
gaataaaagg ctaccttaaa taagacatga tgaatagtag cattttgtag ggttaaaaaa 1260
aaatgctaaa ctagtattat tattaaaaaa ataattaatg aaggctatgc attactggga 1320
aaaatccttc ataatttttc agtttactct ttaaagcaaa atgtgagctg tatgtcattt 1380
aattgggtga taaaacaaat ttccttacia aagggcactt tttacaccaa ggaagcagag 1440
cagtgttaac tttaagggtat acttaactga ttttgcttta aaactaatta cttcataaat 1500
tattacagct aaaaggattc gatgttgaac aggcgtgaaa attgtcaatg tacaaaattc 1560
aaaactgtca actttaactg taaagtaaat gctccaagtg tgtagacag catcatcttg 1620
cttgggctta ccaaatgcat tagtctttgt gtttgggtcg acagcgagtg tgcctgtgtc 1680
ggggcagggt gtgtgttctg tgggagggtg tctgtgggga tgtgactatc aggggtgggc 1740
tgtgtgtggg atggggcagg cctgggtctg gagaggattt tgtgtgaaag taaatggggt 1800
gtttgaggcg tatgggtggc tgttggtgtg gggaggcatc tgtgtatggc tgttgggaac 1860
agcaaccaa aggtgctttt tggttttatt tgagatgaag attgtgtttc cgcttaatta 1920
ctagtttgtg gtctatatca tagaagttat ttccacccc attttatctt gacaaccgtg 1980
tttgcatctt tgtaaaactt ctacaacttc tgggtgcaga actgtccaga agatgggtact 2040
gttaactgtt atttcctttg atgttttgat ttgaagttt agctctcatg caaatgtttc 2100
aggcgtagat acataggcag aaagcaattt ttaggtgatt tgtctgttct ttggatgaaa 2160
tataaagcaa gctttaatgt tctgacttgt tcatttgaaa tacaaaaaag taagtgaatt 2220
ttaatgtttt gcattaacta aagaaatctg aagattaatg ttgaggaaat tgtatggaca 2280
tgcttttgtg aaaccaggaa gtattttaag ttaaaaatga aaaaggtttt aattgctttg 2340
tgtgtgtttt aatggagccc cattttagaa ttatttttct catctccctt taccaacaaa 2400
aggaacaatg ccaccgtgaa tggaaatagt tggggaaagc tttgccaaac acaaccctga 2460
tttcagagca ggaacatggt ttggatagat cttcagttcc gcttgaatta ttctgttact 2520
gcgctgtcat ttccagaaga ttccatttcc ttgcagatg ctggtgggag ttcgggatta 2580
tgttcatttc ttctgtttta atggcattca gtactaattt tataagtga tcttgtgtga 2640
atctcaataa attcagtttt gtaatcttaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 2699

```

&lt;210&gt; 30

&lt;211&gt; 166

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 30

```

Met Gly Phe Ile Pro Leu Pro Leu Ala Val Leu Leu Ile Arg Val Val
  1                      5                      10                     15

```

```

Thr Ser Ser Ile Lys Val Gln Gly Ile Leu Ser Tyr Ala Cys Val Ile
      20                      25                     30

```

```

Leu Phe Tyr Phe Gly Leu Ile Ser Leu Lys Val Leu Asn Ser Ile Val
      35                      40                     45

```

```

Leu Leu Gly Lys Ser Cys Gln Tyr Val Lys Glu Ala Lys Met Glu Glu
      50                      55                     60

```

```

Lys Leu Ser Asn Pro Pro Ala Thr Cys Thr Pro Gly Lys Pro Ser Ser
      65                      70                     75                     80

```

```

Lys Ser Gln Asn Lys Cys Lys Pro Ser Gln Gly Leu Ser Thr Glu Glu
      85                      90                     95

```

```

Asn Leu Ser Ala Ser Ile Thr Lys Gln Pro Ile His Gln Lys Glu Asn
      100                     105                    110

```

Ile Ile Pro Leu Leu Val Thr Ser Asn Ser Asp Gln Phe Leu Thr Thr  
 115 120 125

Pro Asp Gly Asp Glu Lys Asp Ile Thr Gln Asp Asn Ser Glu Leu Lys  
 130 135 140

His Arg Ser Ser Lys Lys Asp Leu Leu Glu Ile Asp Arg Phe Thr Ile  
 145 150 155 160

Cys Gly Asn Arg Ile Asp  
 165

<210> 31  
 <211> 1300  
 <212> DNA  
 <213> Homo sapiens

<400> 31  
 tctccccccg ggctccgccc accccacgcc gggaacccac gggggccact acaagcccgc 60  
 ccttttctac gtctgggtcca gtcggtcttc ctccggcccg ggccctggcc cagctagccg 120  
 gccatggaag tgaagaaaat gtttggaagc tctgtgaata catcaaaaac catgaccagt 180  
 atcctttaga agaattgtat gctgtcttca tatctaata gaggaagatg atacctatct 240  
 ggaaacaaca gccgagacct ggagatggac ctgtgatctg ggattaccat gttgttttgc 300  
 ttcattgttc aagtggagga cagagcttca tttatgatct cgatactgtc ttgccatttc 360  
 cctgcctctt tgacacttat gtagaagatg ccattaagtc tgatgatgac attcaccac 420  
 agtttaggag gaaatttaga gtgatctgtg cagattcata tttgaagaac tttgcttctg 480  
 accgatctca catgaaagac tccagtggga attggagaga gcctccgccc ccatatccct 540  
 gcattgagac tggagattcc aaaatgaacc tgaacgattt catcagtatg gatcccaagg 600  
 taggatgggg cgccgtctac acactatccg aatttacaca tcggtttggc agtaaaaact 660  
 ctggaacttg gcctcaagat gtggaactgt ggagaaatc taggacatga acaagctatc 720  
 ctttcatcga ggacagcaaa cattatggta cagttggctt ggaattatgt ctttctcttt 780  
 taatttgatt gagtggaaat ctgagttagt acaaataata atgaacaaca taaaaacttt 840  
 tgttttgaca tgtcaaattg aaacttgata aagtgcgtac ttgctaagat attcctgttg 900  
 ctcatgcgtt acaacacgag gacttaagcc agtaatcgtt tttgttcaga tagaggtgtg 960  
 gaggtagagc cagcccctca tgtctgttct ggatgttttg tgtctctcca gctacactgt 1020  
 aagttccttg agggcagggc catggcccat tgctctgtga atctcaaag cccataaaag 1080  
 gtgcccataa aatgttttct tgaacatttg aatgtgctgt tgtctggaaa ggggtaatat 1140  
 tgtgagctga atcagcaata agtattagtc tttttgact atggtattgt taaaaagact 1200  
 gcagccctct cagacttgag cgtaatttg cttatttatt tatggcttta aataaaatcg 1260  
 atttaacgtt aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 1300

<210> 32  
 <211> 145  
 <212> PRT  
 <213> Homo sapiens

<400> 32  
 Met Ile Pro Ile Trp Lys Gln Gln Ala Arg Pro Gly Asp Gly Pro Val  
 1 5 10 15

Ile Trp Asp Tyr His Val Val Leu Leu His Val Ser Ser Gly Gly Gln  
 20 25 30

Ser Phe Ile Tyr Asp Leu Asp Thr Val Leu Pro Phe Pro Cys Leu Phe  
 35 40 45

Asp Thr Tyr Val Glu Asp Ala Ile Lys Ser Asp Asp Asp Ile His Pro  
 50 55 60

Gln Phe Arg Arg Lys Phe Arg Val Ile Cys Ala Asp Ser Tyr Leu Lys  
65 70 75 80

Asn Phe Ala Ser Asp Arg Ser His Met Lys Asp Ser Ser Gly Asn Trp  
85 90 95

Arg Glu Pro Pro Pro Pro Tyr Pro Cys Ile Glu Thr Gly Asp Ser Lys  
100 105 110

Met Asn Leu Asn Asp Phe Ile Ser Met Asp Pro Lys Val Gly Trp Gly  
115 120 125

Ala Val Tyr Thr Leu Ser Glu Phe Thr His Arg Phe Gly Ser Lys Asn  
130 135 140

Cys  
145

<210> 33

<211> 1256

<212> DNA

<213> Homo sapiens

<400> 33

```
ctcgcttcta actggactgc acgttggtga cagcgtccca agctgggtgac agaccactc 60
tgtaactttc agctagattc agccaccaga tcccagaaac atgacccttg ctgcctacaa 120
agagaagatg aaggagctcc cgctgggtgtc cttgttctgc tcctgcttcc tggccgatcc 180
cctgaataag tcgtcctaca aatatgaagc agacacggtg gacctgaatt ggtgcgtcat 240
ttccgacatg gaagtcacgc agctgaacaa atgcacctcg ggccaatcct ttgaagtcac 300
cctgaagcca cctcctttg atgggggttc cgagttcaac gcctccctgc caaggcggcg 360
agaccatcc ctggaagaga tccagaagaa actagaagcg gctgaggagc gaaggaagta 420
ccaggaagcg gagctcctga aacacctagc agagaaacgg gaacatgaga gagaggtgat 480
ccaaaaggcc attgaggaaa acaacaactt catcaagatg gctaaggaaa aactggccca 540
gaagatggaa tccaacaagg agaacaggga ggcccacctc gccgccatgt tggaacggct 600
gcaagagaag gacaagcacg ccgaggaggt gcggaaaaac aaggagctga aggaagaggc 660
ctccaggtaa agcctagagg ccaaagaact ttccagggtc gccggacagc tccagcagct 720
ccacgttcca ggcagcctcg cccgccggct gcgctcccag cactgggggt tggggggagg 780
ggggtggcca aggggcgttt cctctgcttt tgggtgttgt acatgttaag aattgaccag 840
tgaagccatc ctatttgttt ccggggaaca atgaccgggt gggagagggg agaggagaga 900
gtttgggaaa gggagatgga gaagaactca aggacattgc aacctgccc gccgcagatc 960
tgattttcac atctctacct ggacattgag cctccaggca ccatgttgag gagagatgaa 1020
aaccaggcgc gtagaacttc aggggtgaag acagagtcct ggggtgggca gcggctgcag 1080
ggcgaccagc agaaccagc cagagggggt gtgagtacca gtggtgttgc ttccaccctg 1140
cagcaggtgg gatgaggtct gtgtgtgtgt gtgaaccatc attttttgat catcatgacc 1200
aatgaaacat tgaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaa 1256
```

<210> 34

<211> 189

<212> PRT

<213> Homo sapiens

<400> 34

Met Thr Leu Ala Ala Tyr Lys Glu Lys Met Lys Glu Leu Pro Leu Val  
1 5 10 15

Ser Leu Phe Cys Ser Cys Phe Leu Ala Asp Pro Leu Asn Lys Ser Ser  
20 25 30

Tyr Lys Tyr Glu Ala Asp Thr Val Asp Leu Asn Trp Cys Val Ile Ser  
 35 40 45  
 Asp Met Glu Val Ile Glu Leu Asn Lys Cys Thr Ser Gly Gln Ser Phe  
 50 55 60  
 Glu Val Ile Leu Lys Pro Pro Ser Phe Asp Gly Val Pro Glu Phe Asn  
 65 70 75 80  
 Ala Ser Leu Pro Arg Arg Arg Asp Pro Ser Leu Glu Glu Ile Gln Lys  
 85 90 95  
 Lys Leu Glu Ala Ala Glu Glu Arg Arg Lys Tyr Gln Glu Ala Glu Leu  
 100 105 110  
 Leu Lys His Leu Ala Glu Lys Arg Glu His Glu Arg Glu Val Ile Gln  
 115 120 125  
 Lys Ala Ile Glu Glu Asn Asn Asn Phe Ile Lys Met Ala Lys Glu Lys  
 130 135 140  
 Leu Ala Gln Lys Met Glu Ser Asn Lys Glu Asn Arg Glu Ala His Leu  
 145 150 155 160  
 Ala Ala Met Leu Glu Arg Leu Gln Glu Lys Asp Lys His Ala Glu Glu  
 165 170 175  
 Val Arg Lys Asn Lys Glu Leu Lys Glu Glu Ala Ser Arg  
 180 185

&lt;210&gt; 35

&lt;211&gt; 1783

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 35

aaggataatg gcctccagct cagatggaat atctctatca tatagacctg ttgttacagg 60  
 gcaggatcgg atgatggaca ctgaagtcct cagcttgcta agttcagttg ctctccctag 120  
 cctccttttg gcttcagagt cttttgattc catctatcct ggtatttttt gtgtgctgat 180  
 gtttagttct ggattggttt cagctgtgct aataggaagg gcgttgctct ttcaagcaat 240  
 cttaaaagggt ggtcaatcaa aaggccagag tctgaatccc ttctgtggct taaataattt 300  
 gaggatcaag tccagtgtct tgttaatccc tgttctactg tgccagacac tatcttgaat 360  
 gcttttatat gttcaggttc aaaatcgctc tttcatacca ggggatgata gtaacgtgta 420  
 acttgcaata gattccttca tcttagtaat aagatgatca gtctagttag gacaaaatag 480  
 agattgaata aattaacttt tccaagtta cagagtaaaa atgagcagat ctctgctgg 540  
 tttgtgaaa aagagttagc actggtaaat agaataattc tactoctaca ccattctttc 600  
 agtatatcat cactgaagac aggaagatag gcacacagat tcttctcgt agtaattcat 660  
 agtgcaactag gtgaaagaga tgaagtatgt attaaaagta caatgtgatg gcatttatta 720  
 ttcagataat ccaggattc tagaagaaaa taaagaagag tgacagttca gttaggggtg 780  
 gaacttccag aggagcactg cttaagctga acttgagagc attgtgcaaa agcacagtag 840  
 tctgttaaga actagaaata acctagcttg tgccacttcg ggagtattaa gacataagcc 900  
 tagaaaggta ggcaaagggt agatcttaga ctgtcttgta tttttctcat tcctgttgat 960  
 tacctacctc aaaattgaat atgttttttc ctctgcctaa cacaaaacta ccaagggca 1020  
 gaaatttaaa ttcttccttg gtgtatgtgc aaagaagggt gaatatattc atgcctacct 1080  
 tattttggac taggaataca gtagtatact ttccgaagac ttgcctgaat agtatataag 1140  
 gtggaggcaa ctgactagtt aggtcagtat ttttagaaac tcttaatagc tcatactctt 1200  
 gataccaaaa gcagccctga ttgttaaagc acacacctgc acaagaagca gtgatgggtg 1260  
 catttacatt tcctgggtgc acaaaaaaaaa attctcaaaa agcaaggact tacgcttttt 1320  
 gcaaaagcctt tgagaagtta ctggatcata ggaagcttat aacaagaatg gaagattctt 1380

```

aaataactca ctttcttttg tatccagtaa cagtagatgt tcaaaatatg tagctgatta 1440
ataccagcat tgtgaacgct gtacaacctt gtggttatta ctaagcaagt tactactagc 1500
ttctgaaaag tagcttcata attaatgtta ttatacact gccttccatg acttttactt 1560
tgccctaagc taatctccaa aatctgaaat gctactccaa taccagaaaa aaagggggag 1620
gtggaattat atttcctgtg attttaagag tacagagaat catgcacatc tctgattagt 1680
tcataatagt ctagtgtgta ataaaagtca agatgaactc tcaaaaaaaaa aaaaaaaaaa 1740
aaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaa 1783

```

&lt;210&gt; 36

&lt;211&gt; 116

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 36

```

Met Ala Ser Ser Ser Asp Gly Ile Ser Leu Ser Tyr Arg Pro Val Val
  1             5             10             15

```

```

Thr Gly Gln Asp Arg Met Met Asp Thr Glu Val Leu Ser Leu Leu Ser
          20             25             30

```

```

Ser Val Ala Leu Pro Ser Leu Leu Leu Ala Ser Glu Ser Phe Asp Ser
          35             40             45

```

```

Ile Tyr Pro Gly Ile Phe Cys Val Leu Met Phe Ser Ser Gly Leu Val
          50             55             60

```

```

Ser Ala Val Leu Ile Gly Arg Ala Leu Ser Phe Gln Ala Ile Leu Lys
          65             70             75             80

```

```

Gly Gly Gln Ser Lys Gly Gln Ser Leu Asn Pro Phe Cys Gly Leu Asn
          85             90             95

```

```

Asn Leu Arg Ile Lys Ser Ser Val Leu Leu Ile Pro Val Leu Leu Cys
          100             105             110

```

```

Gln Thr Leu Ser
          115

```

&lt;210&gt; 37

&lt;211&gt; 1725

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 37

```

ggttggtaat aggaaatgga ggggctgctg aggtcctgtg aatgtttctg tcattgtact 60
ttcttccaga agcctgcaga gaatggaagc atcttcttta ttgtcctttc ctggcatgtc 120
catccttatt gtcactacgt tgcaactgga gtttgatttg gatctgggtt taaaattctt 180
ctgtgcaata gatgggtttg aggatttagc ggccctgatg tcttggtcat agcctggtaa 240
gaatgtccat gctgaggagc cagatgttgt atttctaact gcctgagtca cacagaatag 300
ggtaagagcc tgaccccat ctgtaaatca gaaagcaagg atggagaccc tttcctgctg 360
ctattattgg ctctctttga ggaagtggga ggtaaggaa ggaacttggt tgtttccgta 420
tacgactcct tcttctctct agttcagtc tccagccagtc cagcgctctc ttccacactt 480
cagagccctc tcagagaaaag cattagcagg aatgagacaa ggcagagctg cagtgcctcc 540
tgaggcttcc acacatcttt ctgaatatta tttttcaagt aacaagggca gggacagcgg 600
aaacagctgc ccaccccccc catcccagca gctcagctaa gccctgatga gaatgaagcc 660
acaggagtgt tctgaggtga acccagccgc tcagccacac atggaagcca ttgcctttgc 720
acatagttct tgggttcttt ttcttaaaaa ggtaaggagc tgaggtgtgt gggtttttta 780
tattaagaat atataatgga aaacacacga ctgacgctca ggcatcttcc cctactcccc 840
aacagatccc cagaagacag cgtggaaggc agtgtagaca gtaaactcggg cttcagttct 900

```

```

atagccaaga agagatcagc tgctgaaacc accagtgggt accccaggcc acctgccttt 960
gaacttgggg atttgccatg tctgatcttg tcacatactt gctttttttac aagatgaact 1020
ctttgtatatt atgatttggg gggcaatgaa aggttgcatt caggaactgc tgctgccgag 1080
ctcgcgtggtc acatgggggt gccaggcggg attctggaaa accagtgcac ttaaactgat 1140
cctgaagaga gctgtcccag cactctggcc accaggaggg ccagattccc cagaaactac 1200
cttttgccca aagaacatgc tcagtatttg gggcatttcc tcccacaaac cctgactgct 1260
tctgttacct cagggccttg gtacctggat actgccacag aattggggcg ggtgggggag 1320
gggcctatatt ttaataaaaa taactgttca aagttggggg ttttttaaaa aattaagaaa 1380
aaggaaagct attctgtatt gcaccttttc acaatttaat acattttctt acattttcct 1440
gtgattttcg aaactaaacc attgtgtgtc ctgtagtggt ctgggttagc tgccgctcag 1500
cagcttcctc ggggggattt ggaacacctg tgtctgtcgc cgcactgcct gtgggagggg 1560
cccagagggc tgctgggact ggcgtctgta cacacttggt tggccttttc tgtagttagt 1620
gctgtaaact ctatggcttt ttaaaaaacg tttcatgttt ttatttagta ttggaaatcc 1680
aatacacttt tttatccaa tcaaaaaaaaa aaaaaaaaaa aaaaaa 1725

```

&lt;210&gt; 38

&lt;211&gt; 74

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 38

```

Met Ile Trp Gly Ala Met Lys Gly Ala Met Gln Glu Leu Leu Leu Pro
  1             5             10            15

Ser Ser Leu Val Thr Trp Gly Cys Gln Ala Gly Phe Trp Lys Thr Ser
          20             25            30

Ala Leu Lys Leu Ile Leu Lys Arg Ala Val Pro Ala Leu Trp Pro Pro
  35             40            45

Gly Gly Pro Asp Ser Pro Glu Thr Thr Phe Cys Pro Lys Asn Met Leu
  50             55            60

Ser Ile Trp Gly Ile Ser Ser His Lys Pro
  65             70

```

&lt;210&gt; 39

&lt;211&gt; 1953

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 39

```

gcccttcagg ctctgtctct gtggagactg ggctttggga gggagaaaga gggacctagc 60
gcgggccgcg caggcgcacg gtgggcagct gcaatggcgc tgcgtgtgtac ccttaacagg 120
tatctgctcc tcatggcgca ggagcatctg gagttccgcc tgccggaaat aaagtctttg 180
cttttgcttt ttggaggtca gtttgccagc agtcaagaaa cttatggaaa gtcaccattt 240
tggtattctta gcattccctc tgaagatatt gcaagaaatt tgatgaaacg gacagtgtgt 300
gccaagtcta tttttgaact atgggggtcat ggacaatctc ctgaggagct gtacagttct 360
cttaaaaact accctgtgga gaagatgggt ccattttctac attcggactc tacatataaa 420
ataaagattc acacttttaa taagacattg acacaagaag agaaaatcaa gcgaatagat 480
gcacttgaat ttctgccatt tgaaggaaaa gtgaatttaa agaaaccgca acatgtattt 540
tctgttttgg aggattatgg tttagaccga aactgcatcc ctgagaatcc acataatatt 600
tattttggta gatggattgc agatggacag agagagctta ttgagtcata cagtgtcaaa 660
aagagacact ttattggaaa tacaagtatg gatgctgggt tgtcattcat tatggctaac 720
catggaaaag tgaaagaaaa tgatattgtc tttgatccat ttgttggaac aggtggcctg 780
ctgatagcat gtgctcattt tgggtgcatat gtgtatggga cagacataga ctacaacaca 840
gttcattggc tgggaaaggc tactaggaaa aaccagaagt ggagaggacc agatgaaaac 900
attagggcca atctctgtca atatggttta gagaagtatt accttgatgt cctggtttca 960
gatgcatcta aaccttcctg gaggaagggc acatattttg atgcaatcat tactgatcct 1020

```

```

ccatatggta tcagagaatc tacaagaaga acaggttcac agaaggagat accaaagggg 1080
atagaaaaat gggaaaaaatg tccagaaagc catgttcctg tttccttgag ttatcatctg 1140
agtgatatgt ttcttgacct gttaaacttc gcagctgaga ccctcgtttt aggtggaaga 1200
ctagtctatt ggttaccggg gtatacgcca gaatacactg aagagatggg gccttgggcac 1260
ccttgccctgg aactcgttag caactgcgag cagaagcttt ccagtcacac atcaaggcgc 1320
ttgatcacaa tggaaaaggt gaagaaattht gagaatcggg accagtattc acatctgcta 1380
agtgatcatt ttctgccata ccaaggtcat aattccttcc gtgagaaata ttttagtggg 1440
gtaacaaaaa gaattgccaa ggaagaaaaa tccaccaggg aatgaaaatt aagattttga 1500
caatgaagaa agaataagaa tttgatttaa aaagacatct ggatgtgaac tttcatgtat 1560
gatccagaaa ataggtacgg ttttaaaata ttttatatag aaaagctaca aagtaaattg 1620
agcaatgctt ttaaagttat ctttgtttta tagacttttt tgttgatgtg attacagtct 1680
ttataatctt atttaatgta ttttggtact ttcaagtact gatggagata gactcaaac 1740
agttatTTTT ttacaattaa tctacaaagg gaattaatat tgttgacttt taaaacatct 1800
gctggatata ttatatgcaa ttaatagtag ttaagaattht attcatttgg tagatatgtt 1860
tatttggttt ttggtgtgca tcgattttaca ttgccactaa taaaccatat tgagaatttc 1920
taaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaa 1953

```

<210> 40

<211> 463

<212> PRT

<213> Homo sapiens

<400> 40

```

Met Ala Leu Ser Cys Thr Leu Asn Arg Tyr Leu Leu Leu Met Ala Gln
  1              5              10              15

```

```

Glu His Leu Glu Phe Arg Leu Pro Glu Ile Lys Ser Leu Leu Leu Leu
      20              25              30

```

```

Phe Gly Gly Gln Phe Ala Ser Ser Gln Glu Thr Tyr Gly Lys Ser Pro
      35              40              45

```

```

Phe Trp Ile Leu Ser Ile Pro Ser Glu Asp Ile Ala Arg Asn Leu Met
      50              55              60

```

```

Lys Arg Thr Val Cys Ala Lys Ser Ile Phe Glu Leu Trp Gly His Gly
      65              70              75              80

```

```

Gln Ser Pro Glu Glu Leu Tyr Ser Ser Leu Lys Asn Tyr Pro Val Glu
      85              90              95

```

```

Lys Met Val Pro Phe Leu His Ser Asp Ser Thr Tyr Lys Ile Lys Ile
      100             105             110

```

```

His Thr Phe Asn Lys Thr Leu Thr Gln Glu Glu Lys Ile Lys Arg Ile
      115             120             125

```

```

Asp Ala Leu Glu Phe Leu Pro Phe Glu Gly Lys Val Asn Leu Lys Lys
      130             135             140

```

```

Pro Gln His Val Phe Ser Val Leu Glu Asp Tyr Gly Leu Asp Pro Asn
      145             150             155             160

```

```

Cys Ile Pro Glu Asn Pro His Asn Ile Tyr Phe Gly Arg Trp Ile Ala
      165             170             175

```

```

Asp Gly Gln Arg Glu Leu Ile Glu Ser Tyr Ser Val Lys Lys Arg His
      180             185             190

```

```

Phe Ile Gly Asn Thr Ser Met Asp Ala Gly Leu Ser Phe Ile Met Ala

```

195	200	205
Asn His Gly Lys Val Lys Glu Asn Asp Ile Val Phe Asp Pro Phe Val 210 215 220		
Gly Thr Gly Gly Leu Leu Ile Ala Cys Ala His Phe Gly Ala Tyr Val 225 230 235 240		
Tyr Gly Thr Asp Ile Asp Tyr Asn Thr Val His Gly Leu Gly Lys Ala 245 250 255		
Thr Arg Lys Asn Gln Lys Trp Arg Gly Pro Asp Glu Asn Ile Arg Ala 260 265 270		
Asn Leu Arg Gln Tyr Gly Leu Glu Lys Tyr Tyr Leu Asp Val Leu Val 275 280 285		
Ser Asp Ala Ser Lys Pro Ser Trp Arg Lys Gly Thr Tyr Phe Asp Ala 290 295 300		
Ile Ile Thr Asp Pro Pro Tyr Gly Ile Arg Glu Ser Thr Arg Arg Thr 305 310 315 320		
Gly Ser Gln Lys Glu Ile Pro Lys Gly Ile Glu Lys Trp Glu Lys Cys 325 330 335		
Pro Glu Ser His Val Pro Val Ser Leu Ser Tyr His Leu Ser Asp Met 340 345 350		
Phe Leu Asp Leu Leu Asn Phe Ala Ala Glu Thr Leu Val Leu Gly Gly 355 360 365		
Arg Leu Val Tyr Trp Leu Pro Val Tyr Thr Pro Glu Tyr Thr Glu Glu 370 375 380		
Met Val Pro Trp His Pro Cys Leu Glu Leu Val Ser Asn Cys Glu Gln 385 390 395 400		
Lys Leu Ser Ser His Thr Ser Arg Arg Leu Ile Thr Met Glu Lys Val 405 410 415		
Lys Lys Phe Glu Asn Arg Asp Gln Tyr Ser His Leu Leu Ser Asp His 420 425 430		
Phe Leu Pro Tyr Gln Gly His Asn Ser Phe Arg Glu Lys Tyr Phe Ser 435 440 445		
Gly Val Thr Lys Arg Ile Ala Lys Glu Glu Lys Ser Thr Gln Glu 450 455 460		

&lt;210&gt; 41

&lt;211&gt; 1605

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 41

```

agggagattc ctcgaaacta gtgtgtgttt attaaaagga gaaaggataa caatagaatg 60
ttctaaaacc agaagtccaa gtgcgtgtct acttatggga ccaataaata aagaacagac 120
atttgatttg aggtgaggta aaagcctgaa acatggaatg gcattctggt ttgatggatt 180

```



```

ttcattttctt cgcactttctg agacggcaaa gccaacccact tagaagcctt ccacatcttt 240
gtcacctgcc tggctcctgc tctctgatgt acctctgggt agtgagatgg aaatggtgcc 300
tgcagaagtt ggggagaagg atacttttgc acagcctcca tgatgtcttt attgcaaata 360
tggatgacaa ggtgtctctgt tacaggggcc tcagagcacc ttcgtttctc ctctagacca 420
gggacaggtg tagagataag gactggcaac cagagcctca gcatccaaag atggactgaa 480
gtgggatggc tgacaggcac ataacttacg ggaaagggaa tttcatacat acgattttttg 540
ttttgtgggt aggagggctt atcatcaaca ctgattttat aatctgacaa taaatgtctt 600
tcattaaaga gtttacctaa atgatgttcg attatatgta taatttataa aatatttatg 660
tatagtttgt ttattcaggt atatgtataa tttattgaac acctactatg tcccagcata 720
tctacaaaac tgggtacata catactgtct aactgctaata ccacatttcc agtcttataa 780
aggacataat gattagttaa gccctaattt agatttgagg aaactgaagc tgagagaggg 840
ttaagtaaat tacccaaagt acagctaata agaccagaa tctcagtctc actccttggg 900
atcctgtgta tttccctgag tcttctaaca tatgaaaatt catatctaaa tcaacaagtg 960
actgtaatct ggtactataa atactaaata aacacttctt cataaactg taccaattca 1020
gcttttaaat tttattactt tgctttcctg tcctttgcca actcttaacc tagttaatcc 1080
tagttctggt gacattggac caggctcagt aaataaacga atggatttcc agcctttttt 1140
tcccactgtg tctgtctttt agtctctga atctgcttct tttcttactg ctgctttatt 1200
ttacagtgat tttgtcaaac atagaatata ggactaaaaa tgcaaagaaa ttgggtctgt 1260
gtttaatttt gatgtttcaa attttgagct tccaagtctt tgtggccacc caatgaagtt 1320
tgagtctgcc tgttcagatg tgaaaggtaa gggctgcagc aggtttaagg gtggcccttc 1380
accacctgtg tgtcacctgc acaggcactc cccatttgc agatgaagaa atgttcagag 1440
aagaaaaatg atggacaaa cgtctgtttg cacaattgaa actctaccag tggactattc 1500
tattttcaca gctacctagt ttctgccgat gattttttta aatgtgaaat aaacagtgat 1560
acttttaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaa 1605

```

&lt;210&gt; 42

&lt;211&gt; 87

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 42

```

Met Glu Trp His Ser Val Leu Met Asp Phe His Phe Phe Ala Leu Leu
  1             5             10             15

```

```

Arg Arg Gln Ser Gln Pro Leu Arg Ser Leu Pro His Leu Cys His Leu
          20             25             30

```

```

Pro Gly Ser Cys Ser Leu Met Tyr Leu Trp Val Val Arg Trp Lys Trp
          35             40             45

```

```

Cys Leu Gln Lys Leu Gly Arg Arg Ile Leu Leu His Ser Leu His Asp
          50             55             60

```

```

Val Phe Ile Ala Asn Met Asp Asp Lys Gly Leu Cys Tyr Arg Gly Leu
          65             70             75             80

```

```

Arg Ala Pro Ser Phe Leu Leu
          85

```

&lt;210&gt; 43

&lt;211&gt; 1936

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 43

```

agaaactccc atctccctca ccagccggaa agtacgagtc ggctcagcct ggagggaccc 60
aaccagagcc tggcctggga gccaggatgg ccatccacaa agccttggtg atgtgcctgg 120
gactgcctct cttcctgttc ccaggggcct gggcccaggg ccatgtccca cccggctgca 180
gccaaaggcct caacccctg tactacaacc tgtgtgaccg ctctggggcg tggggcatcg 240

```

```

tcctggaggc cgtggctggg gcgggcattg tcaccacgtt tgtgctcacc atcatcctgg 300
tggccagcct cccctttgtg caggacacca agaaacggag cctgctgggg acccaggtat 360
tcttccttct ggggaccctg ggcctcttct gcctcgtgtt tgctgtgtg gtgaagcccg 420
acttctccac ctgtgcctct cggcgcttcc tctttggggg tctgttcgcc atctgcttct 480
cttgtctggc ggctcacgtc tttgccctca acttcttggc ccggaagaac cacgggcccc 540
ggggctgggt gatcttcaact gtggctctgc tgcctgacct ggtagaggtc atcatcaata 600
cagagtgggt gatcatcacc ctgggttcggg gcagtggcga gggcggccct cagggcaaca 660
gcagcgcagg ctggggccgtg gcctccccct gtgccatcgc caacatggac tttgtcatgg 720
cactcatcta cgtcatgctg ctgctgctgg gtgccttctt gggggcctgg cccgccctgt 780
gtggccgcta caagcgtgtg cgtaagcatg ggtctttgt gctcctcacc acagccacct 840
ccgttgccat atgggtgggt tggatcgtca tgtatactta cggcaacaag cagcacaaca 900
gtccacactg ggatgacccc acgctggcca tcgccctcgc cgccaatgcc tgggccttcg 960
tctcttctta cgtcatcccc gaggtctccc aggtgaccaa gtccagccca gagcaaagct 1020
accaggggga catgtacccc acccggggcg tgggctatga gaccatcctg aaagagcaga 1080
agggtcagag catgttcgtg gagaacaagg ccttttccat ggatgagccg gttgcagcta 1140
agaggccggt gtcaccatac agcgggtaca atgggcagct gctgaccagt gtgtaccagc 1200
ccactgagat ggccctgatg cacaagttc cgtccgaagg agcttacgac atcatcctcc 1260
cacggggcac cgccaacagc caggtgatgg gcagtgccaa ctcgacctg cgggctgaag 1320
acatgtactc ggcccagagc caccaggcgg ccacaccgcc gaaagacggc aagaactctc 1380
aggtctttag aaacccttac gtgtgggact gagtcagcgg tggcgaggag aggcggtcgg 1440
atttggggag ggccctgagg acctggcccc gggaaggga ctctccaggc tcctcctccc 1500
cctggcaggc ccagcaacat gtgccccaga tgtggaaggg cctccctctc tgccagtgtt 1560
tgggtgggtg tcatgggtgt cccacccac tcctcagtgt ttgtggagtc gaggagccaa 1620
ccccagctc ctgcccaggat cacctcggcg gtcacactcc agccaaatag tgttctcggg 1680
gtggtggctg ggcagcgct atgtttctct ggagattcct gcaacctcaa gagacttccc 1740
aggcgctcag gcctggatct tgctcctctg tgaggaacaa ggggtgcctaa taaatacatt 1800
tctgctttaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 1860
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 1920
aaaaaaaaaa aaaaaa 1936

```

&lt;210&gt; 44

&lt;211&gt; 441

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 44

```

Met Ala Ile His Lys Ala Leu Val Met Cys Leu Gly Leu Pro Leu Phe
  1              5              10             15

Leu Phe Pro Gly Ala Trp Ala Gln Gly His Val Pro Pro Gly Cys Ser
      20              25              30

Gln Gly Leu Asn Pro Leu Tyr Tyr Asn Leu Cys Asp Arg Ser Gly Ala
      35              40              45

Trp Gly Ile Val Leu Glu Ala Val Ala Gly Ala Gly Ile Val Thr Thr
      50              55              60

Phe Val Leu Thr Ile Ile Leu Val Ala Ser Leu Pro Phe Val Gln Asp
      65              70              75              80

Thr Lys Lys Arg Ser Leu Leu Gly Thr Gln Val Phe Phe Leu Leu Gly
      85              90              95

Thr Leu Gly Leu Phe Cys Leu Val Phe Ala Cys Val Val Lys Pro Asp
      100             105             110

Phe Ser Thr Cys Ala Ser Arg Arg Phe Leu Phe Gly Val Leu Phe Ala
      115             120             125

```

```

Ile Cys Phe Ser Cys Leu Ala Ala His Val Phe Ala Leu Asn Phe Leu
130                      135                      140

Ala Arg Lys Asn His Gly Pro Arg Gly Trp Val Ile Phe Thr Val Ala
145                      150                      155                      160

Leu Leu Leu Thr Leu Val Glu Val Ile Ile Asn Thr Glu Trp Leu Ile
165                      170                      175

Ile Thr Leu Val Arg Gly Ser Gly Glu Gly Gly Pro Gln Gly Asn Ser
180                      185                      190

Ser Ala Gly Trp Ala Val Ala Ser Pro Cys Ala Ile Ala Asn Met Asp
195                      200                      205

Phe Val Met Ala Leu Ile Tyr Val Met Leu Leu Leu Leu Gly Ala Phe
210                      215                      220

Leu Gly Ala Trp Pro Ala Leu Cys Gly Arg Tyr Lys Arg Trp Arg Lys
225                      230                      235                      240

His Gly Val Phe Val Leu Leu Thr Thr Ala Thr Ser Val Ala Ile Trp
245                      250                      255

Val Val Trp Ile Val Met Tyr Thr Tyr Gly Asn Lys Gln His Asn Ser
260                      265                      270

Pro Thr Trp Asp Asp Pro Thr Leu Ala Ile Ala Leu Ala Ala Asn Ala
275                      280                      285

Trp Ala Phe Val Leu Phe Tyr Val Ile Pro Glu Val Ser Gln Val Thr
290                      295                      300

Lys Ser Ser Pro Glu Gln Ser Tyr Gln Gly Asp Met Tyr Pro Thr Arg
305                      310                      315                      320

Gly Val Gly Tyr Glu Thr Ile Leu Lys Glu Gln Lys Gly Gln Ser Met
325                      330                      335

Phe Val Glu Asn Lys Ala Phe Ser Met Asp Glu Pro Val Ala Ala Lys
340                      345                      350

Arg Pro Val Ser Pro Tyr Ser Gly Tyr Asn Gly Gln Leu Leu Thr Ser
355                      360                      365

Val Tyr Gln Pro Thr Glu Met Ala Leu Met His Lys Val Pro Ser Glu
370                      375                      380

Gly Ala Tyr Asp Ile Ile Leu Pro Arg Ala Thr Ala Asn Ser Gln Val
385                      390                      395                      400

Met Gly Ser Ala Asn Ser Thr Leu Arg Ala Glu Asp Met Tyr Ser Ala
405                      410                      415

Gln Ser His Gln Ala Ala Thr Pro Pro Lys Asp Gly Lys Asn Ser Gln
420                      425                      430

Val Phe Arg Asn Pro Tyr Val Trp Asp
435                      440

```

<210> 45  
 <211> 1773  
 <212> DNA  
 <213> Homo sapiens

<400> 45  
 cgcgcgcgcg cttccccctgc aaggatgcgg ccctctgcgc ctacgcggtc acctacacag 60  
 cgatgtacgt gactctcgtg ttccgcgtga agggctcccc cctgggtcaaa ccctcgtctt 120  
 gcctggcctt gctgtgcccg gccttcctgg tgggcgtggt ccgcgtggcc gagtaccgaa 180  
 accactgggtc ggacgtgctg gctggcttcc tgacaggggc ggccatcgcc accttttttg 240  
 tcacctgcgt tgtgcataac tttcagagcc ggccaccctc tggccgaagg ctctctccct 300  
 gggaggacct gggccaagcc cccaccatgg atagccccct cgaaaagaac ccgaggtctg 360  
 caggccgcat tcgacaccgg cacggctcac cccatccaag tcgcagaact gcgcccgcgg 420  
 tggccacctg atccccagct gtgtctcctc caggggccca gccatgtgtt cgctgccccg 480  
 tgtgccccgt cctcgattga ggtctgagcc gacgcccttg cccctgcccc taccctgcc 540  
 agcggccacc cccagccagg gcccctcgcc ttctccctt ggacctgggg ggccaggcgg 600  
 ggggtgggtga cgtggccgga agctgctgct gccacgccc ctgctgcggg acctgtacac 660  
 cctgagtggga ctctatccct ccccttcca cggggacaac ttcagccctt acctgtttgc 720  
 cagccgtgac cacctgctgt gaggcccgac caccaccca gaatctgcc agtccccact 780  
 tcttccctgc cagcgtgtg tgtgcgtgtg ccacgtgagt gccaaagtcc cctgcccccc 840  
 aagccagcca gaccagaca ttagtaagat ggctagaagg acatttagga gacatctgcc 900  
 tctctggccc tctgagatat cccgatgggc acaaatggaa ggtgcgcaact tgcccctact 960  
 attgcccttt taaggccaa agcttgacct cattggccat tgctggcta atgagaacct 1020  
 ctggttctca gaattttaac caaaaggagt tggctccaac caatgggagc cttccccctc 1080  
 cttcttagaa tcctctgca agagggcaac tccagccagt gttcagcgac tgaacagcca 1140  
 ataggagccc ttggtttcca gaatttctag agtgggtggg catgattcca gtcaatgggg 1200  
 gaccgcccgt gtctaagcat gtgcaaagga gaggaggag atgaggtcat tgtttgcac 1260  
 tgagtcttct ctcagaatca gcgagcccag ctgtagggtg gggggcaggc tcccccatgg 1320  
 cagggtcctt ggggtacccc ttttctctc agcccctccc tgtgtgcggc ctctccacct 1380  
 ctcacccact ctctcctaat cccctactta agtagggctt gcccacttc agagggtttg 1440  
 ggggtcaggg tgctgtgtct ccccttgct gtgccaggc catcccaaac cttctgttta 1500  
 tttattaggg ctgtgggaag ggtttttctt ctttttcttg gaacctgcc ctgtttctta 1560  
 cactgcccc catgcctcag cctcatacag atgtgccatc atggggggca tgggtggagc 1620  
 agaggggctc cctcaccctg ggcaggcaaa ggcagtgggt agaggaggca ctgccccct 1680  
 ttctgcccc ctctcatct ttaataaaga cctggcttct catctttaat aaagacctgt 1740  
 ttgtaacaga aaaaaaaaaa aaaaaaaaaa aaa 1773

<210> 46  
 <211> 122  
 <212> PRT  
 <213> Homo sapiens

<400> 46  
 Met Tyr Val Thr Leu Val Phe Arg Val Lys Gly Ser Arg Leu Val Lys  
 1 5 10 15  
 Pro Ser Leu Cys Leu Ala Leu Leu Cys Pro Ala Phe Leu Val Gly Val  
 20 25 30  
 Val Arg Val Ala Glu Tyr Arg Asn His Trp Ser Asp Val Leu Ala Gly  
 35 40 45  
 Phe Leu Thr Gly Ala Ala Ile Ala Thr Phe Leu Val Thr Cys Val Val  
 50 55 60  
 His Asn Phe Gln Ser Arg Pro Pro Ser Gly Arg Arg Leu Ser Pro Trp  
 65 70 75 80  
 Glu Asp Leu Gly Gln Ala Pro Thr Met Asp Ser Pro Leu Glu Lys Asn

85

90

95

Pro Arg Ser Ala Gly Arg Ile Arg His Arg His Gly Ser Pro His Pro  
 100 105 110

Ser Arg Arg Thr Ala Pro Ala Val Ala Thr  
 115 120

<210> 47  
 <211> 1974  
 <212> DNA  
 <213> Homo sapiens

<400> 47  
 tctgcatect tccccacatt cccagcaata tgcattcttg acgtctgggc ggctcctgct 60  
 ccctccttct gctactgggg gccctgtctg gatggggcgg cagcgatgac cccattgaga 120  
 aggtcattga agggatcaac cgagggtgga gcaatgcaga gagagaggtg ggcaaggccc 180  
 tggatggcat caacagtggg atcacgcatg ccggaaggga agtggagaag gttttcaacg 240  
 gacttagcaa catggggagc cacaccggca aggagttgga caaaggcgct caggggctca 300  
 accacggcat ggacaagggt gcccatgaga tcaaccatgg tattggacaa gcaggaaagg 360  
 aagcagagaa gcttggccat ggggtcaaca acgctgctgg acagggtggg aaggaggcag 420  
 acaaaactgat ccatcatggg gtccatcacg gggccaacca ggccgggaagt gaggcaggga 480  
 agtttggcca gggagtcgac aatgctgcag ggcaggctgg aaatgaggct gggagggttg 540  
 gccagggagt ccaccatgct gcaggggcag ccggaaatga ggctgggagg tttggccagg 600  
 gagtccacca tgctgcaggg caggccggaa atgaggctgg gagatttggc cagggggccc 660  
 accatggtct cagtggggc tggaaggaga cagagaagtt tggccagggg atccaccatg 720  
 ctgccggtca ggttgggaag gaggcagaga agtttggcca gggggcccac catgctgcgg 780  
 ggcaggccgg aaatgaggca gggagatttg gccagggggt ccaccatggt ctcatgtagg 840  
 gctggaagga gacagagaag tttggccagg ggggtccacca tactgctggt cagggttggg 900  
 aggaggcaga gaagtgtggc cagggggccc accatgctgc ggggcaggcc ggaaatgagg 960  
 caggagagatt tggccagggg gccaccatg ctgcggggca ggccggaaat gaggctggga 1020  
 ggtttggcca ggggggtccac catggtctca gtgagggtg gaaggagaca gagaagtttg 1080  
 gccagggggt ccaccatgct gccagtcagt ttgggaagga aacagagaag ctccggccatg 1140  
 ggggtccacca tggggttaat gaggcctgga aggaagcaga gaagtgtggc caggggtgtcc 1200  
 accatgctgc ctgcaggtg gggaaggagg aagacagagt ggtccaaggc ctccatcatg 1260  
 gcgttagtca ggctggaagg gagggggggc agtttggcca cgacattcac cacacagcag 1320  
 ggcaggctgg gaaagaggga gacatagcag ttcattggtg ccaacctggg gtccacgagg 1380  
 ccgggaagga ggcaggcgag tttggccagg gacttcacca tacccttgaa caggccggga 1440  
 aggaagcaga caaagcggtc caagggttcc acactggggt ccaccaggct gggaagggaag 1500  
 cagagaaact tggccaaggg gtcaaccatg ctgctgacca ggctggaaag gaagtggaga 1560  
 agcttggcca aggtgcccac catgctgctg gccaggccgg gaaggagctg cagaatgctc 1620  
 ataattgggt caaccaagcc agcaaggagg ccaaccagct gctgaatggc aaccatcaaa 1680  
 gcggtatctc cagccatcaa ggaggggcca caaccacgcc gttagcctct ggggcctcag 1740  
 tcaacacgcc ttatcatcaac cttcccggcc tgtggaggag cgtcgccaac atcatgccct 1800  
 aaactggcat ccggccttgc tgggagaata atgtcgccgt tgtcacatca gctgacatga 1860  
 cctggagggg ttgggggtgg gggacagggt tctgaaatcc ctgaaggggg ttgtactggg 1920  
 atttgtgaat aaacttgata cactatgctg tcaaaaaaaaa aaaaaaaaaa aaaa 1974

<210> 48  
 <211> 590  
 <212> PRT  
 <213> Homo sapiens

<400> 48  
 Met His Leu Ala Arg Leu Val Gly Ser Cys Ser Leu Leu Leu Leu Leu  
 1 5 10 15  
 Gly Ala Leu Ser Gly Trp Ala Ala Ser Asp Asp Pro Ile Glu Lys Val  
 20 25 30

Ile Glu Gly Ile Asn Arg Gly Leu Ser Asn Ala Glu Arg Glu Val Gly  
 35 40 45  
 Lys Ala Leu Asp Gly Ile Asn Ser Gly Ile Thr His Ala Gly Arg Glu  
 50 55 60  
 Val Glu Lys Val Phe Asn Gly Leu Ser Asn Met Gly Ser His Thr Gly  
 65 70 75 80  
 Lys Glu Leu Asp Lys Gly Val Gln Gly Leu Asn His Gly Met Asp Lys  
 85 90 95  
 Val Ala His Glu Ile Asn His Gly Ile Gly Gln Ala Gly Lys Glu Ala  
 100 105 110  
 Glu Lys Leu Gly His Gly Val Asn Asn Ala Ala Gly Gln Val Gly Lys  
 115 120 125  
 Glu Ala Asp Lys Leu Ile His His Gly Val His His Gly Ala Asn Gln  
 130 135 140  
 Ala Gly Ser Glu Ala Gly Lys Phe Gly Gln Gly Val Asp Asn Ala Ala  
 145 150 155 160  
 Gly Gln Ala Gly Asn Glu Ala Gly Arg Phe Gly Gln Gly Val His His  
 165 170 175  
 Ala Ala Gly Gln Ala Gly Asn Glu Ala Gly Arg Phe Gly Gln Gly Val  
 180 185 190  
 His His Ala Ala Gly Gln Ala Gly Asn Glu Ala Gly Arg Phe Gly Gln  
 195 200 205  
 Gly Ala His His Gly Leu Ser Glu Gly Trp Lys Glu Thr Glu Lys Phe  
 210 215 220  
 Gly Gln Gly Ile His His Ala Ala Gly Gln Val Gly Lys Glu Ala Glu  
 225 230 235 240  
 Lys Phe Gly Gln Gly Ala His His Ala Ala Gly Gln Ala Gly Asn Glu  
 245 250 255  
 Ala Gly Arg Phe Gly Gln Gly Val His His Gly Leu Ser Glu Gly Trp  
 260 265 270  
 Lys Glu Thr Glu Lys Phe Gly Gln Gly Val His His Thr Ala Gly Gln  
 275 280 285  
 Val Gly Lys Glu Ala Glu Lys Phe Gly Gln Gly Ala His His Ala Ala  
 290 295 300  
 Gly Gln Ala Gly Asn Glu Ala Gly Arg Phe Gly Gln Gly Ala His His  
 305 310 315 320  
 Ala Ala Gly Gln Ala Gly Asn Glu Ala Gly Arg Phe Gly Gln Gly Val  
 325 330 335  
 His His Gly Leu Ser Glu Gly Trp Lys Glu Thr Glu Lys Phe Gly Gln  
 340 345 350

Gly Val His His Ala Ala Ser Gln Phe Gly Lys Glu Thr Glu Lys Leu  
 355 360 365  
 Gly His Gly Val His His Gly Val Asn Glu Ala Trp Lys Glu Ala Glu  
 370 375 380  
 Lys Phe Gly Gln Gly Val His His Ala Ala Ser Gln Val Gly Lys Glu  
 385 390 395 400  
 Glu Asp Arg Val Val Gln Gly Leu His His Gly Val Ser Gln Ala Gly  
 405 410 415  
 Arg Glu Gly Gly Gln Phe Gly His Asp Ile His His Thr Ala Gly Gln  
 420 425 430  
 Ala Gly Lys Glu Gly Asp Ile Ala Val His Gly Val Gln Pro Gly Val  
 435 440 445  
 His Glu Ala Gly Lys Glu Ala Gly Gln Phe Gly Gln Gly Val His His  
 450 455 460  
 Thr Leu Glu Gln Ala Gly Lys Glu Ala Asp Lys Ala Val Gln Gly Phe  
 465 470 475 480  
 His Thr Gly Val His Gln Ala Gly Lys Glu Ala Glu Lys Leu Gly Gln  
 485 490 495  
 Gly Val Asn His Ala Ala Asp Gln Ala Gly Lys Glu Val Glu Lys Leu  
 500 505 510  
 Gly Gln Gly Ala His His Ala Ala Gly Gln Ala Gly Lys Glu Leu Gln  
 515 520 525  
 Asn Ala His Asn Gly Val Asn Gln Ala Ser Lys Glu Ala Asn Gln Leu  
 530 535 540  
 Leu Asn Gly Asn His Gln Ser Gly Ser Ser Ser His Gln Gly Gly Ala  
 545 550 555 560  
 Thr Thr Thr Pro Leu Ala Ser Gly Ala Ser Val Asn Thr Pro Phe Ile  
 565 570 575  
 Asn Leu Pro Ala Leu Trp Arg Ser Val Ala Asn Ile Met Pro  
 580 585 590

&lt;210&gt; 49

&lt;211&gt; 923

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 49

gagagctgga tccttgaaaa tctactctat cagctgctgt ggttgccacc attctcagga 60  
 ccctcgccat gaaagccctt atgctgctca ccctgtctgt tctgctctgc tgggtctcag 120  
 ctgacattcg ctgtcactcc tgctacaagg tccctgtgct gggctgtgtg gaccggcagt 180  
 cctgccgcct ggagccagga cagcaatgcc tgacaacaca tgcatacctt ggtaagatgt 240  
 gggttttctc caatctgcgc tgtggcacac cagaagagcc ctgtcaggag gccttcaacc 300  
 aaaccaaccg taagctgggt ctgacatata acaccacctg ctgcaacaag gacaactgca 360  
 acagcgcagg accccggccc actccagccc tgggccttgt cttecttacc tccttggtg 420

```

gccttgccct ctggctgctg cactgagact cattccattg gctgcccctc ctcccacctg 480
ccttgccctg agcctctctc cctgtgtctc tgtatcccct ggctttacag aatcgtctct 540
ccctagctcc catttcttta attaaacact gttccgagtg gtctcctcat ccgtccttcc 600
cacctcacac ccttcactct cctttttctg ggtcccttcc cacttccttc caggacctcc 660
attggctcct agaagggtc cccactttgc ttctataact ctgctgtccc ctacttgagg 720
agggattggg atctggggcc tgaaatggg cttctgtgtt gtccccagtg aaggctccca 780
caaggacctg atgacctcac tgtacagagc tgactcccca aatccaggct cccatatgta 840
ccccatcccc catactcacc tctttccatt ttgagtaata aatgtctgag tctgaaaaaa 900
aaaaaaaaaa aaaaaaaaaa aaa 923

```

&lt;210&gt; 50

&lt;211&gt; 125

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 50

```

Met Lys Ala Leu Met Leu Leu Thr Leu Ser Val Leu Leu Cys Trp Val
  1              5              10              15

```

```

Ser Ala Asp Ile Arg Cys His Ser Cys Tyr Lys Val Pro Val Leu Gly
      20              25              30

```

```

Cys Val Asp Arg Gln Ser Cys Arg Leu Glu Pro Gly Gln Gln Cys Leu
      35              40              45

```

```

Thr Thr His Ala Tyr Leu Gly Lys Met Trp Val Phe Ser Asn Leu Arg
      50              55              60

```

```

Cys Gly Thr Pro Glu Glu Pro Cys Gln Glu Ala Phe Asn Gln Thr Asn
      65              70              75              80

```

```

Arg Lys Leu Gly Leu Thr Tyr Asn Thr Thr Cys Cys Asn Lys Asp Asn
      85              90              95

```

```

Cys Asn Ser Ala Gly Pro Arg Pro Thr Pro Ala Leu Gly Leu Val Phe
      100              105              110

```

```

Leu Thr Ser Leu Ala Gly Leu Gly Leu Trp Leu Leu His
      115              120              125

```

&lt;210&gt; 51

&lt;211&gt; 1493

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 51

```

ggagaagccc aggcagttga ggacaggaga gagaaggctg cagacccaga gggagggagg 60
acagggagtc ggaaggagga ggacagagga gggcacagag acgcagagca agggcggcaa 120
ggaggagacc ctggtgggag gaagacactc tggagagaga gggggctggg cagagatgaa 180
gttccagggg cccctggcct gcctcctgct ggccctctgc ctgggcagtg gggaggctgg 240
ccccctgcag agcggagagg aaagcactgg gacaaatatt ggggaggccc ttggacatgg 300
cctgggagac gccctgagcg aaggggtggg aaaggccatt ggcaaagagg ccggaggggc 360
agctggctct aaagtccagt aggcccttgg ccaagggacc agagaagcag ttggcactgg 420
agtcaggcag gttccaggct ttggcgtagc agatgctttg ggcaacaggg tcggggaagc 480
agcccatgct ctgggaaaca ctgggcacga gattggcaga caggcagaag atgtcattcg 540
acacggagca gatgctgtcc gcggctcctg gcagggggtg cctggccaca atggtgcttg 600
ggaaacttct ggaggccatg gcatcttttg ctctcaaggt ggccttgagg gccagggcca 660
gggcaatcct ggaggtcttg ggactccgtg ggtccacgga taccgccgaa actcagcagg 720
cagctttgga atgaatcctc agggagctcc ctggggtcaa ggaggcaatg gagggccacc 780

```



```

aaactttggg accaacactc agggagctgt ggcccagcct ggctatggtt cagtgaagagc 840
cagcaaccag aatgaagggt gcacgaatcc cccaccatct ggctcaggtg gaggctccag 900
caactctggg ggaggcagcg gctcacagtc gggcagcagt ggcagtggca gcaatggtga 960
caacaacaat ggcagcagca gtggtggcag cagcagtggc agcagcagtg gcggcagcag 1020
tggcggcagc agtgggtggca gcagtggcaa cagtgggtggc agcagaggtg acagcggcag 1080
tgagtccctc tggggatcca gcaccggctc ctccctccggc aaccacggtg gagcggcgga 1140
ggaaatggac ataaacccgg gaactctgag acgtctcctg ggatgtttaa ctttgacact 1200
ttctggaaga attttaaatc caagctgggt ttcataact gggatgccat aaacaaggac 1260
cagagaagct ctgcacatccc gtgacctcca gacaaggagc caccagattg gatgggagcc 1320
cccacactcc ctcccttaaaa caccaccctc tcataactaa tctcagccct tgcccttgaa 1380
ataaacctta gctgccccac aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 1440
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaa 1493

```

<210> 52

<211> 358

<212> PRT

<213> Homo sapiens

<400> 52

```

Met Lys Phe Gln Gly Pro Leu Ala Cys Leu Leu Leu Ala Leu Cys Leu
  1                      5                      10                      15

```

```

Gly Ser Gly Glu Ala Gly Pro Leu Gln Ser Gly Glu Glu Ser Thr Gly
          20                      25                      30

```

```

Thr Asn Ile Gly Glu Ala Leu Gly His Gly Leu Gly Asp Ala Leu Ser
          35                      40                      45

```

```

Glu Gly Val Gly Lys Ala Ile Gly Lys Glu Ala Gly Gly Ala Ala Gly
          50                      55                      60

```

```

Ser Lys Val Ser Glu Ala Leu Gly Gln Gly Thr Arg Glu Ala Val Gly
          65                      70                      75                      80

```

```

Thr Gly Val Arg Gln Val Pro Gly Phe Gly Val Ala Asp Ala Leu Gly
          85                      90                      95

```

```

Asn Arg Val Gly Glu Ala Ala His Ala Leu Gly Asn Thr Gly His Glu
          100                     105                     110

```

```

Ile Gly Arg Gln Ala Glu Asp Val Ile Arg His Gly Ala Asp Ala Val
          115                     120                     125

```

```

Arg Gly Ser Trp Gln Gly Val Pro Gly His Asn Gly Ala Trp Glu Thr
          130                     135                     140

```

```

Ser Gly Gly His Gly Ile Phe Gly Ser Gln Gly Gly Leu Gly Gly Gln
          145                     150                     155                     160

```

```

Gly Gln Gly Asn Pro Gly Gly Leu Gly Thr Pro Trp Val His Gly Tyr
          165                     170                     175

```

```

Pro Gly Asn Ser Ala Gly Ser Phe Gly Met Asn Pro Gln Gly Ala Pro
          180                     185                     190

```

```

Trp Gly Gln Gly Gly Asn Gly Gly Pro Pro Asn Phe Gly Thr Asn Thr
          195                     200                     205

```

```

Gln Gly Ala Val Ala Gln Pro Gly Tyr Gly Ser Val Arg Ala Ser Asn
          210                     215                     220

```

Gln Asn Glu Gly Cys Thr Asn Pro Pro Pro Ser Gly Ser Gly Gly Gly  
225 230 235 240

Ser Ser Asn Ser Gly Gly Gly Ser Gly Ser Gln Ser Gly Ser Ser Gly  
245 250 255

Ser Gly Ser Asn Gly Asp Asn Asn Asn Gly Ser Ser Ser Gly Gly Ser  
260 265 270

Ser Ser Gly Ser Ser Ser Gly Gly Ser Ser Gly Gly Ser Ser Gly Gly  
275 280 285

Ser Ser Gly Asn Ser Gly Gly Ser Arg Gly Asp Ser Gly Ser Glu Ser  
290 295 300

Ser Trp Gly Ser Ser Thr Gly Ser Ser Ser Gly Asn His Gly Gly Ala  
305 310 315 320

Ala Glu Glu Met Asp Ile Asn Pro Gly Thr Leu Arg Arg Leu Leu Gly  
325 330 335

Cys Leu Thr Leu Thr Leu Ser Gly Arg Ile Leu Asn Pro Ser Trp Val  
340 345 350

Ser Ser Thr Gly Met Pro  
355

<210> 53

<211> 1897

<212> DNA

<213> Homo sapiens

<400> 53

```
acagaggagg gcacagagac gcagagcaag ggcggaagg aggagaccct ggtgggagga 60
agacactctg gagagagagg gggctgggca gagatgaagt tccaggggcc cctggcctgc 120
ctcctgtctg cctctgcct gggcagtggg gaggtggcc cctgcagag cggagaggaa 180
agcactggga caaatattgg ggaggccctt ggacatggcc tgggagacgc cctgagcgaa 240
ggggtgggaa aggccattgg caaagaggcc ggaggggag ctggctctaa agtcagttag 300
gcccttggcc aaggaccag agaagcagtt ggcactggag tcaggcaggt tccaggcttt 360
ggcgtagcag atgctttggg caacagggtc ggggaagcag cccatgctct gggaaacact 420
gggcacgaga ttggcagaca ggcagaagat gtcattcgac acggagcaga tgctgtccgc 480
ggctcctggc aggggtgccc tggccacaat ggtgcttggg aaacttctgg aggccatggc 540
atctttggct ctcaaggtgg ccttggaggg cagggccagg gcaatcctgg aggtctgggg 600
actccgtggg tccacggata ccccgaaac tcagcaggca gctttggaat gaatcctcag 660
ggagctccct ggggtcaagg aggcaatgga gggccaccaa actttgggac caacactcag 720
ggagctgtgg ccagcctgg ctatggttca gtgagagcca gcaaccagaa tgaagggtgc 780
acgaatcccc caccatctgg ctacagtgga ggctccagca actctggggg aggcagcggc 840
tcacagtggg gcagcagtgg cagtggcagc aatggtgaca acaacaatgg cagcagcagt 900
ggtggcagca gcagtggcag cagcagtggc ggcagcagtg gcggcagcag tgggtggcagc 960
agtggcaaca gtggtggcag cagaggtgac agcggcagtg agtcctcctg gggatccagc 1020
accggtcct cctccggcaa ccacgggtgg agcggcgagg gaaatggaga taaaccggg 1080
gggcaagggt cgagctgggg cagtggagga ggtgacgctg ttggtggagt caatactgtg 1140
aactctgaga cgtctcctgg gatgtttaac tttgacactt tctggaagaa ttttaaatac 1200
aagctgggtt tcatcaactg ggatgccata aacaagaacc aggtcccgcc cccagcacc 1260
cgagccctcc tctacttcag ccgactctgg gaggatttca aacagaacac tcctttctc 1320
aactggaag caattattga ggggtgcggac gcgtcatcac tgcagaaacg tgcaggcaga 1380
gccgatcaga actacaatta caaccagcat gcgtatccca ctgcctatgg tgggaagtac 1440
tcagtcaaga cccctgcaaa ggggggagtc tcaccttctt cctcggttc cgggtgcaa 1500
```

```

cctggcctgc tgcagtgggt gaagttttgg taggcaattt cttgcaacca ccaccgaggc 1560
cccgaaaagc actggtcgtc agggagctcc tccccttggc cccagcctg tgccagccct 1620
ggccccggctg ccacacctct gtttcctagg ctggggaccc agcttggtctc tccttggttc 1680
ttcccaactgc actgtggtgc ttcagtggcc accagcctcg tcacatacac cagcatcttt 1740
ctgtacctcc tcccttttgt gacctgaagt cactgtgaca gttctccagg aaggaggagc 1800
ttcctacttt tgagtttctc tgtggaaata aaacatgaat cttgtttccc taaaaaaaaa 1860
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaa 1897

```

&lt;210&gt; 54

&lt;211&gt; 479

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 54

```

Met Lys Phe Gln Gly Pro Leu Ala Cys Leu Leu Leu Ala Leu Cys Leu
  1             5             10             15

```

```

Gly Ser Gly Glu Ala Gly Pro Leu Gln Ser Gly Glu Glu Ser Thr Gly
      20             25             30

```

```

Thr Asn Ile Gly Glu Ala Leu Gly His Gly Leu Gly Asp Ala Leu Ser
      35             40             45

```

```

Glu Gly Val Gly Lys Ala Ile Gly Lys Glu Ala Gly Gly Ala Ala Gly
      50             55             60

```

```

Ser Lys Val Ser Glu Ala Leu Gly Gln Gly Thr Arg Glu Ala Val Gly
      65             70             75             80

```

```

Thr Gly Val Arg Gln Val Pro Gly Phe Gly Val Ala Asp Ala Leu Gly
      85             90             95

```

```

Asn Arg Val Gly Glu Ala Ala His Ala Leu Gly Asn Thr Gly His Glu
      100            105            110

```

```

Ile Gly Arg Gln Ala Glu Asp Val Ile Arg His Gly Ala Asp Ala Val
      115            120            125

```

```

Arg Gly Ser Trp Gln Gly Val Pro Gly His Asn Gly Ala Trp Glu Thr
      130            135            140

```

```

Ser Gly Gly His Gly Ile Phe Gly Ser Gln Gly Gly Leu Gly Gly Gln
      145            150            155            160

```

```

Gly Gln Gly Asn Pro Gly Gly Leu Gly Thr Pro Trp Val His Gly Tyr
      165            170            175

```

```

Pro Gly Asn Ser Ala Gly Ser Phe Gly Met Asn Pro Gln Gly Ala Pro
      180            185            190

```

```

Trp Gly Gln Gly Gly Asn Gly Gly Pro Pro Asn Phe Gly Thr Asn Thr
      195            200            205

```

```

Gln Gly Ala Val Ala Gln Pro Gly Tyr Gly Ser Val Arg Ala Ser Asn
      210            215            220

```

```

Gln Asn Glu Gly Cys Thr Asn Pro Pro Pro Ser Gly Ser Gly Gly Gly
      225            230            235            240

```

```

Ser Ser Asn Ser Gly Gly Gly Ser Gly Ser Gln Ser Gly Ser Ser Gly

```

245										250					255				
Ser	Gly	Ser	Asn	Gly	Asp	Asn	Asn	Asn	Gly	Ser	Ser	Ser	Gly	Gly	Ser				
			260						265					270					
Ser	Ser	Gly	Ser	Ser	Ser	Gly	Gly	Ser	Ser	Gly	Gly	Ser	Ser	Gly	Gly				
		275					280					285							
Ser	Ser	Gly	Asn	Ser	Gly	Gly	Ser	Arg	Gly	Asp	Ser	Gly	Ser	Glu	Ser				
		290				295					300								
Ser	Trp	Gly	Ser	Ser	Thr	Gly	Ser	Ser	Ser	Gly	Asn	His	Gly	Gly	Ser				
305					310					315					320				
Gly	Gly	Gly	Asn	Gly	His	Lys	Pro	Gly	Gly	Gln	Gly	Ser	Ser	Trp	Gly				
			325					330						335					
Ser	Gly	Gly	Gly	Asp	Ala	Val	Gly	Gly	Val	Asn	Thr	Val	Asn	Ser	Glu				
			340					345					350						
Thr	Ser	Pro	Gly	Met	Phe	Asn	Phe	Asp	Thr	Phe	Trp	Lys	Asn	Phe	Lys				
		355					360					365							
Ser	Lys	Leu	Gly	Phe	Ile	Asn	Trp	Asp	Ala	Ile	Asn	Lys	Asn	Gln	Val				
		370				375					380								
Pro	Pro	Pro	Ser	Thr	Arg	Ala	Leu	Leu	Tyr	Phe	Ser	Arg	Leu	Trp	Glu				
385					390				395						400				
Asp	Phe	Lys	Gln	Asn	Thr	Pro	Phe	Leu	Asn	Trp	Lys	Ala	Ile	Ile	Glu				
			405					410						415					
Gly	Ala	Asp	Ala	Ser	Ser	Leu	Gln	Lys	Arg	Ala	Gly	Arg	Ala	Asp	Gln				
			420					425					430						
Asn	Tyr	Asn	Tyr	Asn	Gln	His	Ala	Tyr	Pro	Thr	Ala	Tyr	Gly	Gly	Lys				
		435					440					445							
Tyr	Ser	Val	Lys	Thr	Pro	Ala	Lys	Gly	Gly	Val	Ser	Pro	Ser	Ser	Ser				
		450				455					460								
Ala	Ser	Arg	Val	Gln	Pro	Gly	Leu	Leu	Gln	Trp	Val	Lys	Phe	Trp					
465				470						475									

&lt;210&gt; 55

&lt;211&gt; 1532

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 55

```

gaagagcccc tgcggccggg cgcgaaaatg gggcgggcgg cgacggccgg gcgctcctga 60
agcagcagtt atggagcttc cctcagggcc ggggcccggag cggctctttg actcgcaccg 120
gcttccgggt gactgcttcc tactgctcgt gctgctgctc tacgcgccag tcgggttctg 180
cctcctcgtc ctgcgcctgt ttctcgggat ccacgtcttc ctggtcagct gcgcgctgcc 240
agacagcgtc cttcgcagat tcgtagtgcg gaccatgtgt gcggtgctag ggctcgtggc 300
ccggcaggag gactccggac tccgggatca cagtgtcagg gtcctcattt ccaaccatgt 360
gacacctttc gaccacaaca tagtcaattt gcttaccacc tgtagcacc ctctactcaa 420
tagtccccc agctttgtgt gctgggtctcg gggcttcatg gagatgaatg ggcgggggga 480
gttggtggag tcaactcaaga gattctgtgc ttccacgagg cttcccccca ctctctgtct 540

```

```

gctattccct gaggaagagg ccaccaatgg cggggagggg ctctgcgct tcagttcctg 600
gccattttct atccaagatg tgggtacaacc tcttaccctg caagttcaga gaccctgggt 660
ctctgtgacg gtgtcagatg cctcctgggt ctcagaactg ctgtgggtcac ttttcgtccc 720
tttcacggtg tatcaagtaa ggtggcttcg tctgtttcat cgccaactag gggaagcgaa 780
tgaggagttt gactccgtg tacaacagct ggtggccaag gaattgggcc agacagggac 840
acggctcact ccagctgaca aagcagagca catgaagcga caaagacacc ccagattgcg 900
ccccagtcga gccagctctt ctttcctctc ctcctctggt ccttctcctg atgtgcaact 960
ggcaactctg gctcagagag tcaaggaagt tttgccccat gtgccattgg gtgtcatcca 1020
gagagacctg gccaaagactg gctgtgtaga cttgactatc actaatctgc ttgagggggc 1080
cgtagctttc atgcctgaag acatcaccaa gggaactcag tccctaccca cagcctctgc 1140
ctccaagttt cccagctctg gcccgggtgac ccctcagcca acagccctaa catttgccaa 1200
gtcttctctg gcccggcagg agagcctgca ggagcgcaag caagcactat atgaatacgc 1260
aagaaggaga ttcacagaga gacgagccca ggaggtgac tgagctcaaa ggaacaggat 1320
ggcaccacaga gccgcaggac ggagactggg ggcagccctc acccaactca caacaggctg 1380
gatgggtggg tggtaaaaaa ggaaggatga ggctcccca atgtcacatt aaattcatgg 1440
ttttcattca aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 1500
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aa 1532

```

&lt;210&gt; 56

&lt;211&gt; 410

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 56

```

Met Glu Leu Pro Ser Gly Pro Gly Pro Glu Arg Leu Phe Asp Ser His
  1                      5                      10                      15

Arg Leu Pro Gly Asp Cys Phe Leu Leu Leu Val Leu Leu Leu Tyr Ala
      20                      25                      30

Pro Val Gly Phe Cys Leu Leu Val Leu Arg Leu Phe Leu Gly Ile His
      35                      40                      45

Val Phe Leu Val Ser Cys Ala Leu Pro Asp Ser Val Leu Arg Arg Phe
      50                      55                      60

Val Val Arg Thr Met Cys Ala Val Leu Gly Leu Val Ala Arg Gln Glu
      65                      70                      75                      80

Asp Ser Gly Leu Arg Asp His Ser Val Arg Val Leu Ile Ser Asn His
      85                      90                      95

Val Thr Pro Phe Asp His Asn Ile Val Asn Leu Leu Thr Thr Cys Ser
      100                      105                      110

Thr Pro Leu Leu Asn Ser Pro Pro Ser Phe Val Cys Trp Ser Arg Gly
      115                      120                      125

Phe Met Glu Met Asn Gly Arg Gly Glu Leu Val Glu Ser Leu Lys Arg
      130                      135                      140

Phe Cys Ala Ser Thr Arg Leu Pro Pro Thr Pro Leu Leu Leu Phe Pro
      145                      150                      155                      160

Glu Glu Glu Ala Thr Asn Gly Arg Glu Gly Leu Leu Arg Phe Ser Ser
      165                      170                      175

Trp Pro Phe Ser Ile Gln Asp Val Val Gln Pro Leu Thr Leu Gln Val
      180                      185                      190

```

Gln Arg Pro Leu Val Ser Val Thr Val Ser Asp Ala Ser Trp Val Ser  
 195 200 205  
 Glu Leu Leu Trp Ser Leu Phe Val Pro Phe Thr Val Tyr Gln Val Arg  
 210 215 220  
 Trp Leu Arg Pro Val His Arg Gln Leu Gly Glu Ala Asn Glu Glu Phe  
 225 230 235 240  
 Ala Leu Arg Val Gln Gln Leu Val Ala Lys Glu Leu Gly Gln Thr Gly  
 245 250 255  
 Thr Arg Leu Thr Pro Ala Asp Lys Ala Glu His Met Lys Arg Gln Arg  
 260 265 270  
 His Pro Arg Leu Arg Pro Gln Ser Ala Gln Ser Ser Phe Pro Pro Ser  
 275 280 285  
 Pro Gly Pro Ser Pro Asp Val Gln Leu Ala Thr Leu Ala Gln Arg Val  
 290 295 300  
 Lys Glu Val Leu Pro His Val Pro Leu Gly Val Ile Gln Arg Asp Leu  
 305 310 315 320  
 Ala Lys Thr Gly Cys Val Asp Leu Thr Ile Thr Asn Leu Leu Glu Gly  
 325 330 335  
 Ala Val Ala Phe Met Pro Glu Asp Ile Thr Lys Gly Thr Gln Ser Leu  
 340 345 350  
 Pro Thr Ala Ser Ala Ser Lys Phe Pro Ser Ser Gly Pro Val Thr Pro  
 355 360 365  
 Gln Pro Thr Ala Leu Thr Phe Ala Lys Ser Ser Trp Ala Arg Gln Glu  
 370 375 380  
 Ser Leu Gln Glu Arg Lys Gln Ala Leu Tyr Glu Tyr Ala Arg Arg Arg  
 385 390 395 400  
 Phe Thr Glu Arg Arg Ala Gln Glu Ala Asp  
 405 410

&lt;210&gt; 57

&lt;211&gt; 2093

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 57

cgcgtttcag cgaagtcgca cgtgaaggat agcagtggcc tgagaaagac ccagtcatgg 60  
 cagcctccag catcagttca ccatggggaa agcatgtgtt caaagccatt ctgatgggtcc 120  
 tagtggccct taccctcctc cactcagcat tggcccagtc ccgtcgagac tttgcaccac 180  
 caggccaaca gaagagagaa gccccagttg atgtcttgac ccagataggt cgatctgtgc 240  
 gagggacact ggatgcctgg attgggccag agaccatgca cctgggtgtca gagtcttcgt 300  
 cccaagtgtt gtgggccatc tcatcagcca tttctgtggc cttctttgct ctgtctggga 360  
 tcgccgcaca gctgctgaat gccttgggac tagctggtga ttacctcgcc cagggcctga 420  
 agctcagccc tggccaggtc cagaccttcc tgctgtgggg agcaggggcc ctggtcgtct 480  
 actggctgct gtctctgctc ctcggttggt tcttggcctt gctggggcgg atcctgtggg 540  
 gcctgaagct tgtcatcttc ctggccggct tcgtggccct gatgaggtcg gtgcccagac 600  
 cttccacccg ggcctgctta ctctggcct tgctgatcct ctacgcctg ctgagccggc 660

```

tcaactggctc ccgagcctct ggggcccacac togaggccaa ggtgagagg ctggaacgcc 720
aggtggagga gctgcgctgg cgccagaggg gagcgcccaa gggggcccg agtgaggagg 780
aggagtggag cggtatgccc acacaccggc agtgatcatac caaagagctg agctgcttcg 840
gggcatgca gccctcctgc cagccccctg cccctttctt gccctgtctc tgaaccttca 900
gaacattgat ccttgccgca gcccactag ccaagagaaa cagagaaaga ccattcccc 960
tgctgtctct tgcggccctg tcttctgagg ttctctgtct ggggttggt ctcttaaccc 1020
tttctctgct cccagcctgc ctcaccaggg aagggttgag gggcctccct ctggcttctg 1080
catctgcgcc agcaaacatc actgccgttg gtctctcatg acttaactgg cttccctctg 1140
ctgctgcctt ggcttcctcc taatgctcgt gctctcctgt cctctgaag ttgctcctt 1200
gccaaatctc cagctccctt cttgttttcc tcatcctcct accctgtact cccaccaaac 1260
catggtcctt taaggcacgc tcctgtctc ctcattgccc agcagtaggg aggggcagg 1320
gtaaggggac ctgaggataa aggggtggga aacagggtcc cctgaggcct gtgggggctg 1380
caggggagga ggatgtacct tgtgtctct tcaagtgcct taatccgagc cagcagggcc 1440
ttctgcttgc ctgctgccat actgtatgta ggaaagtgt ctgtggctgc tttgtgtcaa 1500
gaaaagagca gtcactctca gaatcttgat tccccatcag ccaaagcaaa agatggctgc 1560
tgctttgtag gcatgtgcct gcaagtggga ccttgctggg cattatatgc cctgtggggg 1620
tttcagagac cctgaaagag gagggaggac ccgctcctt gtctgcacaa ctgcatgcac 1680
ttctctcccc atcgctccac aacctgaaac cgagaaggag ttgctgacca gtccccacc 1740
cggcagcccg ggaggaacac aggcagctcc tttcccttca cgtggtctgc agagagcagg 1800
gtgagctgcc agctgccct ctcaccagg gtaccctgtc ttggtggtta ggggccactt 1860
ttcctttgag gctctagtgg aggtggatgt ccttctctgc caggcttggc acatgatgtg 1920
aagaataaat gcccaattct tactgttcag gtttgatgtg gaatcacagc tgcagtata 1980
tatatttttt atcagtgcct ggttggtttt aaataaagt cagctattt tattatctt 2040
ttctgaataa aatgtattta ctccaaaaa aaaaaaaaa aaaaaaaaa aaa 2093

```

&lt;210&gt; 58

&lt;211&gt; 243

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 58

```

Met Ala Ala Ser Ser Ile Ser Ser Pro Trp Gly Lys His Val Phe Lys
  1                      5                      10                      15

```

```

Ala Ile Leu Met Val Leu Val Ala Leu Ile Leu Leu His Ser Ala Leu
      20                      25                      30

```

```

Ala Gln Ser Arg Arg Asp Phe Ala Pro Pro Gly Gln Gln Lys Arg Glu
      35                      40                      45

```

```

Ala Pro Val Asp Val Leu Thr Gln Ile Gly Arg Ser Val Arg Gly Thr
      50                      55                      60

```

```

Leu Asp Ala Trp Ile Gly Pro Glu Thr Met His Leu Val Ser Glu Ser
      65                      70                      75                      80

```

```

Ser Ser Gln Val Leu Trp Ala Ile Ser Ser Ala Ile Ser Val Ala Phe
      85                      90                      95

```

```

Phe Ala Leu Ser Gly Ile Ala Ala Gln Leu Leu Asn Ala Leu Gly Leu
      100                      105                      110

```

```

Ala Gly Asp Tyr Leu Ala Gln Gly Leu Lys Leu Ser Pro Gly Gln Val
      115                      120                      125

```

```

Gln Thr Phe Leu Leu Trp Gly Ala Gly Ala Leu Val Val Tyr Trp Leu
      130                      135                      140

```

```

Leu Ser Leu Leu Leu Gly Leu Val Leu Ala Leu Leu Gly Arg Ile Leu
      145                      150                      155                      160

```

Trp Gly Leu Lys Leu Val Ile Phe Leu Ala Gly Phe Val Ala Leu Met  
 165 170 175

Arg Ser Val Pro Asp Pro Ser Thr Arg Ala Leu Leu Leu Leu Ala Leu  
 180 185 190

Leu Ile Leu Tyr Ala Leu Leu Ser Arg Leu Thr Gly Ser Arg Ala Ser  
 195 200 205

Gly Ala Gln Leu Glu Ala Lys Val Arg Gly Leu Glu Arg Gln Val Glu  
 210 215 220

Glu Leu Arg Trp Arg Gln Arg Arg Ala Ala Lys Gly Ala Arg Ser Val  
 225 230 235 240

Glu Glu Glu

<210> 59  
 <211> 1372  
 <212> DNA  
 <213> Homo sapiens

<400> 59  
 atcggcgtcc gcagcgggcg gctgctgagc tgccttgagg tgcagtgttg gggatccaga 60  
 gccatgtcgg acctgctact actgggcctg attggggggcc tgactctctt actgctgctg 120  
 acgctgctgg cctttgcccgt gtactcaggg ctactggctg ggggtggaagt gagtgctggg 180  
 tcacccccca tccgcaacgt cactgtggcc tacaagttcc acatggggct ctatggtgag 240  
 actgggcggc ttttctactga gagctgcagc atctctccca agctccgctc catcgctgtc 300  
 tactatgaca acccccacat ggtgccccct gataagtgcc gatgtgcogt gggcagcatc 360  
 ctgagtgaag gtgaggaatc gccctccccct gagctcatcg acctctacca gaaatttggc 420  
 ttcaaggtgt tctccttccc ggcaaccagc catgtggtga cagccacctt cccctacacc 480  
 accattctgt ccatctggct ggctaccgc cgtgtccatc ctgccttggg cacctacatc 540  
 aaggagcggg agctgtgtgc ctatctcgg ctggagatct accaggaaga ccagatccat 600  
 ttcatgtgcc cactggcagc gcagggagac ttctatgtgc ctgagatgaa ggagacagag 660  
 tggaaatggc gggggcttgt ggaggccatt gacaccagg tggatggcac aggagctgac 720  
 acaatgagtg acacgagttc tgtaagtctg gaagtgagcc ctggcagccg ggagacttca 780  
 gctgccacac tgtaacctgg ggcgagcagc cgtggctggg atgacgggtga caccgcagc 840  
 gagcacagct acagcgagtc aggtgccagc ggctcctctt ttgaggagct ggacttggag 900  
 ggcgaggggc ccttagggga gtcacggctg gaccctggga ctgagcccct ggggactacc 960  
 aagtggctct gggagcccac tgcccctgag aagggcaagg agtaacccat ggcctgcacc 1020  
 ctctctcagt gcagttgctg aggaactgag cagactctcc agcagactct ccagccctct 1080  
 tctccttcc tctgggggag gaggggttcc tgagggacct gacttcccct gctccaggcc 1140  
 tottgctaag ccttctctc actgccctt aggtctccag ggcagagga gccagggact 1200  
 attttctgca ccagccccca gggctgccgc cctgttgtg tctttttttc agactcacag 1260  
 tggagcttcc aggaccaga ataaagccaa tgatttactt gtttcacctg gaaaaaaaaa 1320  
 aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aa 1372

<210> 60  
 <211> 313  
 <212> PRT  
 <213> Homo sapiens

<400> 60  
 Met Ser Asp Leu Leu Leu Leu Gly Leu Ile Gly Gly Leu Thr Leu Leu  
 1 5 10 15

Leu Leu Leu Thr Leu Leu Ala Phe Ala Gly Tyr Ser Gly Leu Leu Ala



<210> 61  
<211> 1529  
<212> DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 61

```

gggctgcctg gtccaggaag ggggtgcggc tctgtcagga aacctggact ctcaaggccc 60
accagcctct ccgtgagtgt tagaaatcac agatacagta tatacttaat tacactaaat 120
tattgtctggg attccttata agcactaatt atacctgatt atagggttaa atattttatt 180
tgtcaaaata ttttcttggg aatgtgttta accctttctg cgttcattgt tgctgagatg 240
tgaaaactaa ccattccctc ctgcctacct ttttggccac tgggcggcag agaatggcgc 300
tatgtgcagt tgggccccctg gcacctggg cctttggcct gcctgctgca gactagccct 360
gcctgggcag tctccaggca ctgagcaggc catctgtggc caggctgaga gaatgactgg 420
ctcgcttacc agcgtgcatg ggacaaggag ctttggagcc tcaaggggtt gttgctggcc 480
tgggctagag ggaaagggtg ccattcgtct gtctcctgt ctttctatta gcgcctccat 540
gtgagtgatg gtgccttggg tcaactagcct tccccacca cccaccatg ccacctggtg 600
gtcttggggc ctgtgctgtc actccagccc ctggggagga gaggaccag cccggagagt 660
tggggcaagg gctccacatg gcccaggggc aacagatgct cgcagggcag ctgctgccga 720
tgctcacgct cctgcccccc tcttcccgc tgcacaccc caccctgggc cccgcagac 780
acgcatctct aactcagttg ggcccagcct tctggatggc ttggggtagg ccattggccc 840
acctggggcc agggcagccc ctggggcagc tctggaagag cagtgtggag gaggacttgc 900
ttgcagcctg gcttcagcct ctggcactgc tggagtggc cctgggagct tctgactgt 960
cggctttggg gacgtctcac ccacttgggt tacagtaggc cttccccacc cagagagaag 1020
tgtttccacc ccagagacat tgtctgtcag cccctgaagt gctcgccctc cccagtggcc 1080
gtcaccagcc cttcctatct gtgggttcca agtcaggctt cccctgcggc caccagccat 1140
agggagcagc catcagcccc cgagtcagaa ctgcttctgt ctgtccatac ctccaggctc 1200
tcccggagag ggggacggat atttatttcc taaagtgtgc acttaattgt gaggattctc 1260
aggattgttg ggggctactg aaaagaggaa tgtgttgaat gtcgcgtttg ctgtccactc 1320
gtcctagaag tttagtgttt ttgtcactgt catgtgtttc tgtgggcaga gctggttctg 1380
gagggtgggt cagtgcaccc gaggtcaga gcatccatcc acccactgg ccctccttc 1440
agataccctc tctctaattg ggttcttgca tgtaaaatac tccacaataa ataaataatt 1500
gaacaaaaaa aaaaaaaaaa aaaaaaaaaa 1529

```

&lt;210&gt; 62

&lt;211&gt; 136

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 62

```

Met Pro Pro Gly Gly Leu Gly Ala Cys Ala Val Thr Pro Ala Pro Gly
  1              5              10              15

Glu Glu Arg Thr Gln Pro Gly Glu Leu Gly Gln Gly Leu His Met Ala
      20              25              30

Gln Gly Gln Gln Met Leu Ala Gly Gln Leu Leu Pro Met Leu Thr Leu
      35              40              45

Leu Pro Pro Ser Phe Pro Leu Pro His Pro Thr Leu Gly Pro Arg Arg
      50              55              60

His Ala Ser Leu Thr Gln Leu Gly Pro Ala Phe Trp Met Ala Trp Gly
      65              70              75              80

Arg Pro Trp Ala His Leu Gly Pro Gly Gln Pro Leu Gly Gln Leu Trp
      85              90              95

Lys Ser Ser Val Glu Glu His Leu Leu Ala Ala Trp Leu Gln Pro Leu
      100             105             110

Ala Leu Leu Glu Trp Ser Leu Gly Ala Ser Ala Leu Ser Ala Leu Gly
      115             120             125

```

Thr Ser His Pro Leu Gly Leu Gln  
130 135

<210> 63  
<211> 2242  
<212> DNA  
<213> Homo sapiens

<400> 63  
gagctgaggt ggcagtgggt ccaccaacat ggagctctcg cagatgtcgg agctcatggg 60  
gctgtcgggtg ttgcttgggc tgctggccct gatggcgacg gggcggttag cgcgggggtg 120  
gctgcgcgcg ggggaggaga ggagcgccg gccgcctgc caaaaagcaa atggatttcc 180  
acctgacaaa tcttcgggat ccaagaagca gaaacaatat cagcggattc ggaaggagaa 240  
gcctcaacaa cacaacttca cccaccgcct cctggctgca gctctgaaga gccacagcgg 300  
gaacatatct tgcattggact ttagcagcaa tggcaaatac ctggctacct gtgcagatga 360  
tcgcaccatc cgcattctgga gcaccaagga ctctctgcag cgagagcacc gcagcatgag 420  
agccaacgtg gagctggacc accccaccct ggtgcgcttc agccctgact gcagagcctt 480  
catcgtctgg ctggccaacg gggacaccct cctgtctctc aagatgacca agcggggagga 540  
tgggggctac accttcacag ccacccaga ggacttccct aaaaagcaca aggcgcctgt 600  
catcgacatt ggcattgcta acacaggga gtttatcatg actgcctcca gtgacaccac 660  
tgtcctcatc tggagcctga aggttcaagt gctgtctacc atcaacacca accagatgaa 720  
caacacacac gctgctgtat ctccctgtgg cagatttcta gcctcgtgtg gcttcacccc 780  
agatgtgaag gtttgggaag tctgcttgg aaagaagggg gagttccagg aggtggtgcg 840  
agccttcgaa ctaaagggcc actccgcggc tgtgcactcg tttgctttct ccaacgactc 900  
acggaggatg gcttctgtct ccaaggatgg tacatggaaa ctgtgggaca cagatgtgga 960  
atacaagaag aagcaggacc cctacttgct gaagacaggc cgctttgaag aggcggcggg 1020  
tgccgcgcgc tgccgcctgg cctctctccc caacgcccag gtcttggcct tggccagtgg 1080  
cagtagtatt catctctaca ataccgcgcg gggcgagaag gaggagtgtt ttgagcgggt 1140  
ccatggcgag tgtatcgcca acttgtcctt tgacatcact ggccgctttc tggcctcctg 1200  
tggggaccgg gcggtgcggc tgtttcacia cactcctggc caccgagcca tgggtggagga 1260  
gatgcagggc cactgaagc gggcctccaa cgagagcacc cgccagaggc tgcagcagca 1320  
gctgacccag gcccaagaga ccctgaagag cctgggtgcc ctgaagaagt gactctggga 1380  
gggcccggcg cagaggattg aggaggaggg atctggcctc ctcatggcac tgctgccatc 1440  
tttctcccca ggtggaagcc tttcagaagg agtctcctgg ttttcttact ggtggccctg 1500  
cttcttccca ttgaaactac tcttgtctac ttaggtctct ctcttcttgc tggctgtgac 1560  
tcctccctga ctagtggcca aggtgctttt ctctctccca ggcccagtgg gtggaatctg 1620  
tccccacctg gcactgagga gaatggtaga gaggagagga gagagagaga gaatgtgatt 1680  
tttggccttg tggcagcaca tctctacacc caaagaagtt tgtaaagtgt ccagaacaac 1740  
ctagagaaca cctgagtact aagcagcagt tttgcaagga tgggagactg ggatagcttc 1800  
ccatcacaga actgtgttcc atcaaaaaga cactaaggga tttccttctg ggcctcagtt 1860  
ctatttgtaa gatggagaat aatcctctct gtgaactcct tgcaaagatg atatgaggct 1920  
aagagaatat caagtcccca ggtctggaag aaaagtagaa aagagttagta ctattgtcca 1980  
atgtcatgaa agtggtaaaa gtgggaacca gtgtgctttg aaaccaaatt agaaacacat 2040  
tccttgggaa ggcaaagttt tctgggactt gatcatacat tttatatggt tgggacttct 2100  
ctcttcggga gatgatctct tgtttaagga gacctctttt cagttcatca agttcatcag 2160  
atatttgagt gccactctg tgcccaaata aatatgagct ggggattaaa tacgaaaaaa 2220  
aaaaaaaaa aaaaaaaaaa aa 2242

<210> 64  
<211> 447  
<212> PRT  
<213> Homo sapiens

<400> 64  
Met Glu Leu Ser Gln Met Ser Glu Leu Met Gly Leu Ser Val Leu Leu  
1 5 10 15  
Gly Leu Leu Ala Leu Met Ala Thr Ala Val Ala Arg Gly Trp Leu  
20 25 30

Arg Ala Gly Glu Glu Arg Ser Gly Arg Pro Ala Cys Gln Lys Ala Asn  
 35 40 45  
 Gly Phe Pro Pro Asp Lys Ser Ser Gly Ser Lys Lys Gln Lys Gln Tyr  
 50 55 60  
 Gln Arg Ile Arg Lys Glu Lys Pro Gln Gln His Asn Phe Thr His Arg  
 65 70 75 80  
 Leu Leu Ala Ala Ala Leu Lys Ser His Ser Gly Asn Ile Ser Cys Met  
 85 90 95  
 Asp Phe Ser Ser Asn Gly Lys Tyr Leu Ala Thr Cys Ala Asp Asp Arg  
 100 105 110  
 Thr Ile Arg Ile Trp Ser Thr Lys Asp Phe Leu Gln Arg Glu His Arg  
 115 120 125  
 Ser Met Arg Ala Asn Val Glu Leu Asp His Ala Thr Leu Val Arg Phe  
 130 135 140  
 Ser Pro Asp Cys Arg Ala Phe Ile Val Trp Leu Ala Asn Gly Asp Thr  
 145 150 155 160  
 Leu Arg Val Phe Lys Met Thr Lys Arg Glu Asp Gly Gly Tyr Thr Phe  
 165 170 175  
 Thr Ala Thr Pro Glu Asp Phe Pro Lys Lys His Lys Ala Pro Val Ile  
 180 185 190  
 Asp Ile Gly Ile Ala Asn Thr Gly Lys Phe Ile Met Thr Ala Ser Ser  
 195 200 205  
 Asp Thr Thr Val Leu Ile Trp Ser Leu Lys Gly Gln Val Leu Ser Thr  
 210 215 220  
 Ile Asn Thr Asn Gln Met Asn Asn Thr His Ala Ala Val Ser Pro Cys  
 225 230 235 240  
 Gly Arg Phe Val Ala Ser Cys Gly Phe Thr Pro Asp Val Lys Val Trp  
 245 250 255  
 Glu Val Cys Phe Gly Lys Lys Gly Glu Phe Gln Glu Val Val Arg Ala  
 260 265 270  
 Phe Glu Leu Lys Gly His Ser Ala Ala Val His Ser Phe Ala Phe Ser  
 275 280 285  
 Asn Asp Ser Arg Arg Met Ala Ser Val Ser Lys Asp Gly Thr Trp Lys  
 290 295 300  
 Leu Trp Asp Thr Asp Val Glu Tyr Lys Lys Lys Gln Asp Pro Tyr Leu  
 305 310 315 320  
 Leu Lys Thr Gly Arg Phe Glu Glu Ala Ala Gly Ala Ala Pro Cys Arg  
 325 330 335  
 Leu Ala Leu Ser Pro Asn Ala Gln Val Leu Ala Leu Ala Ser Gly Ser  
 340 345 350

Ser Ile His Leu Tyr Asn Thr Arg Arg Gly Glu Lys Glu Glu Cys Phe  
 355 360 365

Glu Arg Val His Gly Glu Cys Ile Ala Asn Leu Ser Phe Asp Ile Thr  
 370 375 380

Gly Arg Phe Leu Ala Ser Cys Gly Asp Arg Ala Val Arg Leu Phe His  
 385 390 395 400

Asn Thr Pro Gly His Arg Ala Met Val Glu Glu Met Gln Gly His Leu  
 405 410 415

Lys Arg Ala Ser Asn Glu Ser Thr Arg Gln Arg Leu Gln Gln Gln Leu  
 420 425 430

Thr Gln Ala Gln Glu Thr Leu Lys Ser Leu Gly Ala Leu Lys Lys  
 435 440 445

<210> 65  
 <211> 21  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> oligonucleotide

<400> 65  
 aagtgatctc aacctcgctt g 21

<210> 66  
 <211> 21  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> oligonucleotide

<400> 66  
 gtcagaacca tcattctccag g 21

<210> 67  
 <211> 18  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> oligonucleotide

<400> 67  
 cagtcagtc caggcgag 18

<210> 68  
 <211> 18  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> oligonucleotide

<400> 68  
aggaagcacc agagtgcg 18

<210> 69  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> oligonucleotide

<400> 69  
ccatctgacc tgctactttc c 21

<210> 70  
<211> 18  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> oligonucleotide

<400> 70  
gctgatgagg atgctggc 18

<210> 71  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> oligonucleotide

<400> 71  
ctcaggaagc aggtcaggac 20

<210> 72  
<211> 19  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> oligonucleotide

<400> 72  
ctctgatgag ggtggtggc 19

<210> 73  
<211> 19  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> oligonucleotide

<400> 73  
cacaggcact catgggaag 19

<210> 74

<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> oligonucleotide

<400> 74  
ctggagacag ggtccagatc 20

<210> 75  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> oligonucleotide

<400> 75  
tggaagaata gatgtgagag 20

<210> 76  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> oligonucleotide

<400> 76  
tcagagagtt gcttcctgaa g 21

<210> 77  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> oligonucleotide

<400> 77  
gctcctactc tgccctctcc 20

<210> 78  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> oligonucleotide

<400> 78  
gaaggtctgg ttggtgatgg 20

<210> 79  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>

<223> oligonucleotide

<400> 79  
cagttctgac accagaagtt g 21

<210> 80  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> oligonucleotide

<400> 80  
tttcatcgag gacagcaaac 20

<210> 81  
<211> 19  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> oligonucleotide

<400> 81  
aggacagagt cctgggtgg 19

<210> 82  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> oligonucleotide

<400> 82  
cagagatgtg catgattccc 20

<210> 83  
<211> 19  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> oligonucleotide

<400> 83  
agcgtggaag gcagtgtag 19

<210> 84  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> oligonucleotide

<400> 84  
ccaaggcacc atctcttcag 20



<210> 85  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> oligonucleotide

<400> 85  
aatcagtgtt gatgataagc c 21

<210> 86  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> oligonucleotide

<400> 86  
tggactttgt catggcactc 20

<210> 87  
<211> 18  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> oligonucleotide

<400> 87  
ttctgcgact tggatggg 18

<210> 88  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> oligonucleotide

<400> 88  
ggaaggaggc agagaagttt g 21

<210> 89  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> oligonucleotide

<400> 89  
gctcaccctg tctgttctgc 20

<210> 90  
<211> 18  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> oligonucleotide

<400> 90  
ccagggtctc ctccttgc 18

<210> 91  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> oligonucleotide

<400> 91  
ggaacttcat ctctgcccag 20

<210> 92  
<211> 19  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> oligonucleotide

<400> 92  
ccagctttgt gtgctggtc 19

<210> 93  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> oligonucleotide

<400> 93  
gccaacagaa gagagaagcc 20

<210> 94  
<211> 19  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> oligonucleotide

<400> 94  
tcctggaagc tccactgtg 19

<210> 95  
<211> 19  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> oligonucleotide

<400> 95  
aggtaggcag gagggaatg 19

<210> 96  
 <211> 21  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> oligonucleotide

<400> 96  
 tcctctctgt gaactccttg c

21

<210> 97  
 <211> 85  
 <212> PRT  
 <213> Homo sapiens

<400> 97  
 Met Tyr Ser Phe Pro Thr Thr Val Val Glu Glu Ile Leu Ser Leu Ser  
   1                  5                  10                  15  
 Leu Gln Leu Ile Ala Phe Pro Thr Val Ser Cys Glu Ile Leu Leu Glu  
                   20                  25                  30  
 Ile Thr Ser Gln Thr Asn Lys Lys Gln Thr Arg Glu Thr Cys Tyr Ala  
           35                  40                  45  
 His Ser Ala Glu Glu Ile Gly Ile Ile Ala Gly Lys Arg Ile His Arg  
       50                  55                  60  
 Pro Arg Leu Phe Pro Thr Tyr Val Ser Ser Ser Asp Ile Ser Ser Ser  
       65                  70                  75                  80  
 Val Asn Gln Ala Met  
                   85

<210> 98  
 <211> 161  
 <212> PRT  
 <213> Homo sapiens

<400> 98  
 Met Trp Pro Gly Arg Ile Met Thr Val Thr Val Val Leu Leu Cys Cys  
   1                  5                  10                  15  
 Ser Thr Ala Ser Ile Trp Pro Cys Leu Ser His Ser Ala Ser Pro Ser  
       20                  25                  30  
 Arg Thr Cys Pro Asn Phe Val Gly Arg Ser Thr Arg Ser Cys Val Thr  
       35                  40                  45  
 Ala Asn Ser Leu Cys Glu Pro Arg Thr Pro Asp Pro Lys Pro Ile Asn  
       50                  55                  60  
 Gly Lys Gly Asp Met Gly Val Pro Ser Gln Glu Thr Pro Val Pro Phe  
       65                  70                  75                  80  
 Leu Ser Cys Leu Phe Pro Leu Thr Ser Leu Trp Phe Phe Ile Phe Lys  
           85                  90                  95

Cys Phe Asn Phe Cys Ile Phe Phe Ser Leu Arg Glu Tyr Leu Leu Ile  
 100 105 110  
 Ser Asp Val Gln Gly Val Ala Thr Glu Lys Pro Leu Ser Ser Ser Val  
 115 120 125  
 Cys Arg Gly Val Trp Pro Cys Gly Leu Gly Gly Ala Val Ile Leu Pro  
 130 135 140  
 Leu Pro Arg Ala Gly Ser Arg Lys Ser Val Leu Gly Val Val Gly Gly  
 145 150 155 160  
 Gln

&lt;210&gt; 99

&lt;211&gt; 159

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 99

Met Tyr Arg Arg Lys Ser Gly Trp Thr Gly Cys Ala Ile Thr Cys Ser  
 1 5 10 15  
 Pro Cys Thr Ala Met Thr Gln Leu Arg Asn Cys Met Arg Leu Ser Arg  
 20 25 30  
 Ser Cys Ser Leu Thr Trp Glu Thr Pro Arg Trp Tyr Met Ala Gly Arg  
 35 40 45  
 Val Ala Thr Ser Thr Ser Gly Cys His Cys Trp Met Ser Arg Arg Asp  
 50 55 60  
 Leu Thr Pro Leu Pro His Pro Ser Glu Pro Gly Val Leu Asp Cys Leu  
 65 70 75 80  
 Gly Pro Cys His Leu Leu Pro Leu Leu Ser Pro Gly Ser Pro Cys Trp  
 85 90 95  
 Val Leu Gly Leu His Phe Ser Leu His Pro Pro Ser Ala Ala Ser Ala  
 100 105 110  
 Ser His Ala Leu Thr Ile Thr Ser Leu Pro Pro Gly Leu Leu Pro Phe  
 115 120 125  
 Val Gly Val Glu Leu Thr Ala His Pro Gln Ala Leu Met Gly Arg Gly  
 130 135 140  
 Phe Pro Ser Gly Met Ala Ala Ala Gly Arg His Leu Cys Phe Leu  
 145 150 155

&lt;210&gt; 100

&lt;211&gt; 54

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 100

Met Ser Pro Phe Thr Leu Leu Leu Gln Asn Phe Leu Val Ile Leu Ser  
 1 5 10 15  
 His Leu Phe Phe His Ile Asn Phe Lys Leu Cys Pro Val Leu His Pro  
 20 25 30  
 Leu Ser His Ser His Pro Gln Ile Leu Gly Ser Val Ile Pro Cys Ala  
 35 40 45  
 Ile Ile Phe Pro Pro Leu  
 50

<210> 101  
 <211> 212  
 <212> PRT  
 <213> Homo sapiens

<400> 101  
 Met Val Leu Phe Lys Arg Asp Arg Arg Glu Asp Thr Gln Gln Gly His  
 1 5 10 15  
 His Ser Met Asn Gly Arg Cys Thr Asp His Phe Leu Phe Val Leu Ser  
 20 25 30  
 Ser Leu Leu Ser Pro Ala Ala Ile Leu Val Arg Leu Val Pro Ala Arg  
 35 40 45  
 Glu Arg Cys Pro Gln Val Lys Gly Tyr Ser Gly Thr Trp Glu Lys Ala  
 50 55 60  
 Pro Gly Arg Phe Pro Cys Gly Pro Ala Gln His Gly Ser Arg Val Gly  
 65 70 75 80  
 Thr Leu Leu Cys Arg Gln Pro Ser Leu Tyr Ser Ser Gly Phe Leu Arg  
 85 90 95  
 Ala Leu Pro Cys Leu Cys Gln Ala Cys Ala Ala Ser His Pro Thr Ala  
 100 105 110  
 Ala Trp Glu Arg Pro Ala Thr Leu Pro Val His Thr Leu Pro Val His  
 115 120 125  
 Thr Leu Pro Val His Asn Cys Ser Arg Ala Leu Cys Leu Trp Ala Pro  
 130 135 140  
 Asn Pro Ser Ser Cys Ser Thr Phe Val Trp His Gly Asp Leu Cys Phe  
 145 150 155 160  
 Phe Ser Trp Cys Leu Cys Val Trp Ala Trp Asp Glu Cys Trp Tyr Ala  
 165 170 175  
 Leu Arg Thr Phe Leu Ile Ala Pro Cys Thr Leu Glu His Gly Ala Asp  
 180 185 190  
 Glu Arg Gly Ser Gly Ala Cys Pro Pro Pro Trp Thr Trp Lys Lys Pro  
 195 200 205  
 Thr Leu Glu Arg  
 210

&lt;210&gt; 102

&lt;211&gt; 73

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 102

```

Met Glu Asn Thr Arg Leu Thr Leu Arg His Leu Pro Leu Leu Pro Asn
 1              5              10              15

Arg Ser Pro Glu Asp Ser Val Glu Gly Ser Val Asp Ser Lys Ser Gly
          20              25              30

Phe Ser Ser Ile Ala Lys Lys Arg Ser Ala Ala Glu Thr Thr Ser Gly
          35              40              45

Tyr Pro Arg Pro Pro Ala Phe Glu Leu Gly Asp Leu Pro Cys Leu Ile
          50              55              60

Leu Ser His Thr Cys Phe Phe Thr Arg
          65              70

```

&lt;210&gt; 103

&lt;211&gt; 302

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 103

```

Met Ala Ile His Lys Ala Leu Val Met Cys Leu Gly Leu Pro Leu Phe
 1              5              10              15

Leu Phe Pro Gly Ala Trp Ala Gln Gly His Val Pro Pro Gly Cys Ser
          20              25              30

Gln Gly Leu Asn Pro Leu Tyr Tyr Asn Leu Cys Asp Arg Ser Gly Ala
          35              40              45

Trp Gly Ile Val Leu Glu Ala Val Ala Gly Ala Gly Ile Val Thr Thr
          50              55              60

Phe Val Leu Thr Ile Ile Leu Val Ala Ser Leu Pro Phe Val Gln Asp
          65              70              75              80

Thr Lys Lys Arg Ser Leu Leu Gly Thr Gln Val Phe Phe Leu Leu Gly
          85              90              95

Thr Leu Gly Leu Phe Cys Leu Val Phe Ala Cys Val Val Lys Pro Asp
          100              105              110

Phe Ser Thr Cys Ala Ser Arg Arg Phe Leu Phe Gly Val Leu Phe Ala
          115              120              125

Ile Cys Phe Ser Cys Leu Ala Ala His Val Phe Ala Leu Asn Phe Leu
          130              135              140

Ala Arg Lys Asn His Gly Pro Arg Gly Trp Val Ile Phe Thr Val Ala
          145              150              155              160

```

Leu Leu Leu Thr Leu Val Glu Val Ile Ile Asn Thr Glu Trp Leu Ile  
 165 170 175  
 Ile Thr Leu Val Arg Gly Ser Gly Glu Gly Gly Pro Gln Gly Asn Ser  
 180 185 190  
 Ser Ala Ala Gly Pro Trp Pro Pro Pro Val Pro Ser Pro Thr Trp Thr  
 195 200 205  
 Leu Ser Trp His Ser Ser Thr Ser Cys Cys Cys Cys Trp Val Pro Ser  
 210 215 220  
 Trp Gly Pro Gly Pro Pro Cys Val Ala Ala Thr Ser Ala Gly Val Ser  
 225 230 235 240  
 Met Gly Ser Leu Cys Ser Ser Pro Gln Pro Pro Pro Leu Pro Tyr Gly  
 245 250 255  
 Trp Cys Gly Ser Ser Cys Ile Leu Thr Ala Thr Ser Ser Thr Thr Val  
 260 265 270  
 Pro Pro Gly Met Thr Pro Arg Trp Pro Ser Pro Ser Pro Pro Met Pro  
 275 280 285  
 Gly Pro Ser Ser Ser Ser Thr Ser Ser Pro Arg Ser Pro Arg  
 290 295 300

&lt;210&gt; 104

&lt;211&gt; 114

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 104

Met Ala Gly Ser Leu Gly Tyr Pro Phe Ser Ser Gln Pro Leu Pro Val  
 1 5 10 15  
 Cys Gly Leu Ser Thr Ser His Pro Leu Phe Leu Ile Pro Tyr Leu Ser  
 20 25 30  
 Arg Ala Cys Pro Thr Ser Glu Val Leu Gly Phe Arg Val Leu Cys Leu  
 35 40 45  
 Pro Leu Pro Val Pro Arg Ser Ser Gln Thr Leu Leu Leu Phe Ile Arg  
 50 55 60  
 Ala Val Gly Arg Val Phe Leu Leu Phe Leu Gly Thr Cys Pro Cys Ser  
 65 70 75 80  
 Ser His Cys Pro Pro Cys Leu Ser Leu Ile Gln Met Cys His His Gly  
 85 90 95  
 Gly His Gly Trp Ser Arg Gly Ala Pro Ser Pro Arg Ala Gly Lys Gly  
 100 105 110  
 Ser Gly

&lt;210&gt; 105

<211> 18  
 <212> PRT  
 <213> Homo sapiens

<400> 105  
 His His Ala Ala Gly Gln Ala Gly Asn Glu Ala Gly Arg Phe Gly Gln  
 1 5 10 15

Gly Val

<210> 106  
 <211> 369  
 <212> PRT  
 <213> Homo sapiens

<400> 106  
 Met Lys Phe Gln Gly Pro Leu Ala Cys Leu Leu Leu Ala Leu Cys Leu  
 1 5 10 15

Gly Ser Gly Glu Ala Gly Pro Leu Gln Ser Gly Glu Glu Ser Thr Gly  
 20 25 30

Thr Asn Ile Gly Glu Ala Leu Gly His Gly Leu Gly Asp Ala Leu Ser  
 35 40 45

Glu Gly Val Gly Lys Ala Ile Gly Lys Glu Ala Gly Gly Ala Ala Gly  
 50 55 60

Ser Lys Val Ser Glu Ala Leu Gly Gln Gly Thr Arg Glu Ala Val Gly  
 65 70 75 80

Thr Gly Val Arg Gln Val Pro Gly Phe Gly Val Ala Asp Ala Leu Gly  
 85 90 95

Asn Arg Val Gly Glu Ala Ala His Ala Leu Gly Asn Thr Gly His Glu  
 100 105 110

Ile Gly Arg Gln Ala Glu Asp Val Ile Arg His Gly Ala Asp Ala Val  
 115 120 125

Arg Gly Ser Trp Gln Gly Val Pro Gly His Asn Gly Ala Trp Glu Thr  
 130 135 140

Ser Gly Gly His Gly Ile Phe Gly Ser Gln Gly Gly Leu Gly Gly Gln  
 145 150 155 160

Gly Gln Gly Asn Pro Gly Gly Leu Gly Thr Pro Trp Val His Gly Tyr  
 165 170 175

Pro Gly Asn Ser Ala Gly Ser Phe Gly Met Asn Pro Gln Gly Ala Pro  
 180 185 190

Trp Gly Gln Gly Gly Asn Gly Gly Pro Pro Asn Phe Gly Thr Asn Thr  
 195 200 205

Gln Gly Ala Val Ala Gln Pro Gly Tyr Gly Ser Val Arg Ala Ser Asn  
 210 215 220



Gln Asn Glu Gly Cys Thr Asn Pro Pro Pro Ser Gly Ser Gly Gly Gly  
 225 230 235 240  
 Ser Ser Asn Ser Gly Gly Gly Ser Gly Ser Gln Ser Gly Ser Ser Gly  
 245 250 255  
 Ser Gly Ser Asn Gly Asp Asn Asn Asn Gly Ser Ser Ser Gly Gly Ser  
 260 265 270  
 Ser Ser Gly Ser Ser Ser Gly Gly Ser Ser Gly Gly Ser Ser Gly Gly  
 275 280 285  
 Ser Ser Gly Asn Ser Gly Gly Ser Arg Gly Asp Ser Gly Ser Glu Ser  
 290 295 300  
 Ser Trp Gly Ser Ser Thr Gly Ser Ser Ser Gly Asn His Gly Gly Ser  
 305 310 315 320  
 Gly Gly Gly Asn Gly His Lys Pro Gly Asn Ser Glu Thr Ser Pro Gly  
 325 330 335  
 Met Phe Asn Phe Asp Thr Phe Trp Lys Asn Phe Lys Ser Lys Leu Gly  
 340 345 350  
 Phe Ile Asn Trp Asp Ala Ile Asn Lys Asp Gln Arg Ser Ser Arg Ile  
 355 360 365

Pro

<210> 107  
 <211> 74  
 <212> PRT  
 <213> Homo sapiens

<400> 107  
 Met Gly Pro Pro Gly Ala Arg Pro Ala Pro Gly Ala Ala Leu Glu Glu  
 1 5 10 15  
 Gln Cys Gly Gly Ala Leu Ala Cys Ser Leu Ala Ser Ala Ser Gly Thr  
 20 25 30  
 Ala Gly Val Val Pro Gly Ser Phe Cys Thr Val Gly Phe Gly Asp Val  
 35 40 45  
 Ser Pro Thr Trp Val Thr Val Gly Leu Pro His Pro Glu Arg Ser Val  
 50 55 60  
 Ser Thr Pro Glu Thr Leu Ser Val Ser Pro  
 65 70

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US99/08504

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : C07H 21/04; C07K 14/435; C12N 1/20; C12P 21/02; A61K 38/00  
US CL : 536/23.5; 530/351; 435/252.3, 69.5; 514/2

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 536/23.5; 530/351; 435/252.3, 69.5; 514/2

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)  
Please See Extra Sheet.

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	Database Medline on STN, pir60: Accession No:C434597; reference No:A35796. GERSHON, P. D. and MOSS, B. Early transcription factor subunits are encoded by vaccinia virus late genes. Proc. Natl. Acad. Sci. U.S.A. 1990, Vol. 87, pages 4401-4405. Amino Acids LQVGKGQEV.	9
X	Database Medline on STN, swiss-prot37. Accession No:P49682. LOETSCHER et al. Chemokine receptor specific for IP10 and mig: structure, function, and expression in activated T-lymphocytes. 1996. J. EXP. MED. Vol. 184, pages 963-969. Amino acids: ALYSLFL.	9



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
*A* document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
*B* earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*G* document member of the same patent family
*O* document referring to an oral disclosure, use, exhibition or other means	
*P* document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

08 JULY 1999

Date of mailing of the international search report

30 AUG 1999

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

EILEEN E. O'HARA

Telephone No. (703) 308-0196

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US99/08504

## C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	Database Medline on STN, EST: Accession No:T35343. ADAMS et al. EST83120 Homo sapiens cDNA 5' end similar to None. Initial assesment of human gene diversity and expression patterns based upon 52 million basepairs of cDNA sequence. Available in database Sept. 6, 1995. 100% sequence match over 297 nucleotide bases, corresponding to nucleotides 156 to 453 of SEQ ID NO:1.	1-11

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US99/08504

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
  
2. ☐ Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
  
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
  
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

1-11

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.  
☐ No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US99/08504

## B. FIELDS SEARCHED

Electronic data bases consulted (Name of data base and where practicable terms used):

SEQUENCE DATA BASE MPSRCH: GenEmbl, EST, N\_Geneseq\_34, Issued\_Patents\_NA, PIR\_58, SwissProt\_36, STREMBL\_8, A\_Geneseq\_34, Issued\_Patents\_AA, pir60, SwissProt\_37,pir\_60, sptrembl19, a-geneseq35, a-issued

## BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for all inventions to be searched, the appropriate additional search fees must be paid.

Group I, claims 1-11, drawn to polynucleotides comprising SEQ ID NO:1, the protein encoded by that polynucleotide comprising SEQ ID NO:2, host cells containing said polynucleotides, a recombinant process for producing protein, and a pharmaceutical composition comprising the protein.

Group II, claims 12 and 13, drawn to a polynucleotide comprising SEQ ID NO: 3 and a protein comprising SEQ ID NO: 4.

Group III, claims 14 and 15, drawn to a polynucleotide comprising SEQ ID NO: 5 and a protein comprising SEQ ID NO: 6.

Group IV, claims 16 and 17, drawn to a polynucleotide comprising SEQ ID NO: 7 and a protein comprising SEQ ID NO.

Group V, claims 18 and 19, drawn to a polynucleotide comprising SEQ ID NO: 9 and a protein comprising SEQ ID NO: 10.

Group VI, claims 20 and 21, drawn to a polynucleotide comprising SEQ ID NO: 11 and a protein comprising SEQ ID NO: 12.

Group VII, claims 22 and 23, drawn to a polynucleotide comprising SEQ ID NO: 13 and a protein comprising SEQ ID NO: 14.

Group VIII, claims 24 and 25, drawn to a polynucleotide comprising SEQ ID NO: 15 and a protein comprising SEQ ID NO: 16.

Group IX, claims 26 and 27, drawn to a polynucleotide comprising SEQ ID NO: 17 and a protein comprising SEQ ID NO: 18.

Group X, claims 28 and 29, drawn to a polynucleotide comprising SEQ ID NO: 19 and a protein comprising SEQ ID NO: 20.

Group XI, claims 30 and 31, drawn to a polynucleotide comprising SEQ ID NO: 21 and a protein comprising SEQ ID NO: 22.

Group XII, claims 32 and 33, drawn to a polynucleotide comprising SEQ ID NO: 23 and a protein comprising SEQ ID NO: 24.

Group XIII, claims 34 and 35, drawn to a polynucleotide comprising SEQ ID NO: 25 and a protein comprising SEQ ID NO: 26.

Group XIV, claims 36 and 37, drawn to a polynucleotide comprising SEQ ID NO: 27 and a protein comprising SEQ ID NO: 28.

Group XV, claims 38 and 39, drawn to a polynucleotide comprising SEQ ID NO: 29 and a protein comprising SEQ ID NO: 30.

Group XVI, claims 40 and 41, drawn to a polynucleotide comprising SEQ ID NO: 31 and a protein comprising SEQ ID NO: 32.

Group XVII, claims 42 and 43, drawn to a polynucleotide comprising SEQ ID NO: 33 and a protein comprising SEQ ID NO: 34.

Group XVIII, claims 44 and 45, drawn to a polynucleotide comprising SEQ ID NO: 35 and a protein comprising SEQ ID NO: 36.

Group XIX, claims 46 and 47, drawn to a polynucleotide comprising SEQ ID NO: 37 and a protein comprising SEQ ID NO: 38.

Group XX, claims 48 and 49, drawn to a polynucleotide comprising SEQ ID NO: 39 and a protein comprising SEQ ID NO: 40.

Group XXI, claims 50 and 51, drawn to a polynucleotide comprising SEQ ID NO: 41 and a protein comprising SEQ ID NO: 42.

Group XXII, claims 52 and 53, drawn to a polynucleotide comprising SEQ ID NO: 43 and a protein comprising SEQ ID NO: 44.

Group XXIII, claims 54 and 55, drawn to a polynucleotide comprising SEQ ID NO: 45 and a protein comprising SEQ ID NO: 46.

Group XXIV, claims 56 and 57, drawn to a polynucleotide comprising SEQ ID NO: 47 and a protein comprising SEQ

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US99/08504

ID NO: 48.

Group XXV, claims 58 and 59, drawn to a polynucleotide comprising SEQ ID NO: 49 and a protein comprising SEQ ID NO: 50.

Group XXVI, claims 60 and 61, drawn to a polynucleotide comprising SEQ ID NO: 51 and a protein comprising SEQ ID NO: 52.

Group XXVII, claims 62 and 63, drawn to a polynucleotide comprising SEQ ID NO: 53 and a protein comprising SEQ ID NO: 54.

Group XXVIII, claims 64 and 65, drawn to a polynucleotide comprising SEQ ID NO: 55 and a protein comprising SEQ ID NO: 56.

Group XXIX, claims 66 and 67, drawn to a polynucleotide comprising SEQ ID NO: 57 and a protein comprising SEQ ID NO: 58.

Group XXX, claims 68 and 69, drawn to a polynucleotide comprising SEQ ID NO: 59 and a protein comprising SEQ ID NO: 60.

Group XXXI, claims 70 and 71, drawn to a polynucleotide comprising SEQ ID NO: 61 and a protein comprising SEQ ID NO: 62.

Group XXXII, claims 72 and 73, drawn to a polynucleotide comprising SEQ ID NO: 63 and a protein comprising SEQ ID NO: 64.

The inventions listed as Groups I-XXXII do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: Pursuant to 37 C.F.R. § 1.475 (b-d), the ISA/US considers that where multiple processes are claimed, the main invention shall consist of the first invention of the category first mentioned in the claims and the first recited invention of each of the other categories related thereto. Accordingly, the main invention (Group I) comprises the first recited product, a polynucleotide comprising SEQ ID NO:1, the polypeptide it encodes comprising SEQ ID NO:2, vectors comprising the polynucleotides, host cells containing the polynucleotides and methods of producing the polypeptide. Further pursuant to 37 C.F.R. § 1.475(b-d), the ISA/US considers that any feature which the subsequently recited products and methods share with the main invention does not constitute a special technical feature within the meaning of PCT Rule 13.2 and that each of such products and methods accordingly defines a separate invention.